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ABSTRACT 
 
Bovine herpesvirus-1 (BoHV-1) causes recurrent respiratory and genital infections in cattle; and 
infection of cattle with this virus predisposes them to lethal secondary bacterial infections.  A 
primary strategy to prevent and reduce the severity of disease associated with BoHV-1, and to 
reduce the virus’ transmission, is to vaccinate cattle against the virus.  Problems associated with 
the current commercially available vaccines against BoHV-1, which are either modified live 
(MLV) or killed (KV/inactivated), include that the vaccines are expensive to produce, can cause 
disease (MLV) or may be ineffective (KV).  Development of an effective, non-viral vaccine for 
BoHV-1 has the potential to address these shortcomings. 
 
DNA vaccines are non-viral. They are economical to produce, and they are safe.  The amount of 
antigen expressed after DNA immunization is small (picogram to nanogram range) however, and 
this presents a problem with respect to successful immunization of large animals such as cattle.  
Since only dendritic cells (DCs) can prime immune responses, it is sensible to think that a more 
robust response to a DNA vaccine could be initiated by engineering the vaccine, the DNA in the 
vaccine, or the DNA’s expressed antigen in such a way as to attract DCs.  One way to achieve 
this would be to incorporate a peptide that is chemotactic for DCs to bring the DCs to the site of 
vaccination where the antigen is being produced.  Research suggests a role for beta (β)-
defensins; peptides that are released by cells in response to injury or infection, in attracting 
immature DCs (iDCs) to the site of vaccination and the subsequent induction of immune 
responses. Accordingly, I hypothesized that:  1) bovine β-defensins would be chemotactic for 
bovine iDCs; 2) using a bovine β-defensin in a DNA vaccine could attract iDCs to the site of 
DNA vaccination and that this attraction would effectively target the DNA-encoded BoHV-1 
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antigen truncated glycoprotein D (tgD) to the DC; and 3) the enhanced priming by targeted DC 
would improve humoral and cell-mediated immune responses (CMI) and subsequently protect 
cattle upon challenge with BoHV-1. 
 
In the first study I characterized the immature state of the bovine DC and then these bovine iDC 
were used to screen the panel of synthesized bovine β-defensins for chemotactic activity. 
Previous to this work, neither an iDC nor the chemotactic nature of any of the β-defensins, had 
been described for cattle; thus both parts of this study were novel in nature. I showed that bovine 
monocytes (Mo), positively selected from peripheral blood by magnetic-activated cell sorting 
(MACS), differentiated to iDCs within only 3 days (DC3). Phenotypically, only expression of 
the mannose receptor (MMR), and functionally, only endocytosis of dextran were defining 
characteristics of the most immature stage for bovine DCs. Additionally, chemotaxis to the 
fourteen synthesized bovine β-defensins peptides was almost two-fold higher by the immature 
DC3 than by day 6 monocyte-derived-DC (DC6) . Through further studies and analysis of the 
DC3 chemotaxis data I discovered and confirmed that bovine neutrophil β-defensin (BNBD) 3, 
BNBD9 and enteric β-defensin  (EBD) were equally the most chemotactic of the fourteen 
synthesized peptides. Because BNBD3 was highly chemotactic for iDC and since it is also the 
most abundant of the thirteen BNBDs in the bovine neutrophil, I chose BNBD3 as the peptide I 
would use for the rest of the project. To address concerns regarding the correct folding and fold-
related functionality of the synthesized peptides, I compared three synthesized variants of 
BNBD3 with native BNBD3 (nBNBD3) using comparative high-performance liquid 
chromatography (HPLC) and iDC chemotaxis. I showed that all three synthesized BNBDs were 
equally chemotactic as the nBNBD3 for bovine iDCs. Since this functionality is fold-related, the 
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chemotactic equivalency observed strongly supported the conclusion that the BNBD3 
synthesized peptides were correctly folded and by extension, that all synthesized peptides used in 
this study were correctly folded. Lastly, the synthesized analog BNBD3 (aBNBD3), was tested 
for in vivo iDC chemotactic activity by injecting it into the skin of cattle. Cluster of 
differentiation (CD) 1
+
 DCs infiltrated in response to aBNBD3 injection proving that BNBD3 
could attract bovine iDCs in the skin. 
 
In the second study, I constructed plasmids that expressed the selected peptide, BNBD3; either 
alone or as an N-terminal fusion construct with the BoHV-1 antigen tgD, and then tested the 
effects of the plasmids as vaccines in both mice and cattle.  pMASIA-tgD, pMASIA-BNBD3 and 
pMASIA-BNBD3-tgD were successfully constructed with all plasmids correctly expressing their 
respectively encoded genes. In mice, inclusion of BNBD3 on a separate plasmid (pMASIA-
BNBD3 + pMASIA-tgD) improved cell-mediated immunity (CMI) but did not improve humoral 
response. Inclusion of BNBD3 in the DNA vaccine as a fusion construct (pMASIA-BNBD3-
tgD) was unable to improve the humoral response and did not increase but rather modulated CMI 
through enhanced induction of tgD-specific cytotoxic T lymphocytes (CTLs) and induction of an 
interesting population of CD3
- 
CD8
+
  interferon gamma (IFN-γ)+ cells that may have been 
splenic DCs. 
 
In cattle, BNBD3 delivered as a separate plasmid was unable to improve either CMI or humoral 
responses, whereas inclusion of BNBD3 in the DNA vaccine as a fusion construct improved 
CMI but did not improve humoral response. After challenge with BoHV-1, the addition of 
BNBD3 to tgD as a fusion construct vaccine improved the CMI response as observed in 
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increased magnitude of the IFN-γ response, improved induction of tgD-specific CD8+ T cells, 
and increased proportion of CD25
+
 CTLs in the CD8
+
 T cell subset; yet was unable to improve 
the humoral response, although the immunoglobulin (Ig) G and virus neutralizing (VN) antibody 
responses were maintained. Clinically, cattle vaccinated with either pMASIA-BNBD3-tgD or 
pMASIA-tgD showed comparable reduction in virus shedding, rectal temperature and weight 
loss. Thus both vaccines were equally protective. Given that humoral immunity was not 
enhanced, and that inefficient humoral immune responses have been implicated in a lack of 
protection from BoHV-1 challenge, these results suggested that the humoral immune responses 
were not high enough and that the improved cellular immunity induced by BNBD3 was not 
sufficient to result in enhanced protection from BoHV-1. Thus successful DNA vaccination 
strategies for BoHV-1 will likely need to improve the humoral response while maintaining 
strong cellular immunity.  
 
The third study was designed to assess an alternate strategy to improve humoral responses to 
pMASIA-tgD by utilizing BNBD3 in its peptide form, as a complex with the DNA vaccine. The 
rationale for this work came from the discovery that when a small cationic peptide fused to a 
short antigenic epitope was complexed at a low peptide to DNA ratio (125:1) with a DNA 
vaccine encoding for a full length antigen, the humoral immune response to the DNA-encoded 
antigen could be improved without loss of CMI responses. After establishing bio-activity of the 
synthesized peptide aBNBD3, I investigated whether vaccine complexes of the positively 
charged aBNBD3 peptide and the negatively charged pMASIA-tgD DNA could enhance 
humoral responses of mice to tgD encoded by pMASIA-tgD. Although Low and High peptide to 
DNA ratio vaccines were also evaluated, only the vaccine consisting of 0.1875 nmol aBNBD3, 
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complexed with 5 μg (0.0015 nmol) of pMASIA-tgD at the Medium nanomolar peptide to DNA 
ratio of 125:1 increased humoral responses of mice. CMI was not only maintained relative to 
pMASIA-tgD, but was modulated to more of a Th1-type response as evidenced by induction of 
IFN-γ+ cells and antibody of the IgG2a isotype. To discern the potential mechanism of the 
complexed vaccine I then examined the effect of BNBD3 on maturation/activation of mouse 
bone marrow derived dendritic cells (BMDCs). BNBD3 induced phenotypic and functional 
maturation/activation of in vitro treated mouse BMDCs. This is an important aspect of any DC-
based vaccine strategy, since after antigen-uptake, the DCs must “mature” in order to traffic 
(antigen-loaded) from the site of vaccination to the draining lymph node where induction of 
antigen-specific responses takes place. 
 
With regard to the project hypothesis, I show enhanced efficacy of the humoral responses while 
maintaining robust cell-mediated responses to a DNA vaccine by the addition of a medium 
concentration of the synthesized peptide aBNBD3 as a complex with the DNA vaccine; a 
characteristic of the immune response that was not induced previously by vaccination with the 
DNA vaccine fusion construct encoding BNBD3 with tgD. I saw induction of IFN-γ secreting 
cells and an increase in IgG2a antibody production, both of which are desirable. Since both 
robust antibody and CMI responses of a Th1-type are desired for protection from BoHV-1 
infection, and this strategy does result in both, the results of this study are supportive of our 
project hypothesis and indicate a future direction for a DNA vaccination strategy using 
complexed vaccines that might be more effective to protect cattle from challenge with BoHV-1.   
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1. INTRODUCTION AND LITERATURE REVIEW 
 
1.1 Herpesviruses  
 
Herpesviruses are found in a diversity of species, from mammals to fish to oysters [1]. These 
viruses tend to be species-specific, which is surprising given the similarities in their structural 
[2], biological and infectious characteristics [1]. To be classified as a member of the family 
Herpesviridae, these viruses must share a common architecture. In general, they are large (from 
120 to 260 nm), complex, enveloped, double-stranded DNA viruses that replicate in the nucleus 
of their host cells. The mature virion has at its’ centre a core that contains the linear double-
stranded viral DNA. Surrounding the core is the symmetrical icosohedral viral capsid. Wrapping 
the capsid is an asymmetrical, historically less well defined area called the tegument [3]. The 
tegument contains numerous viral proteins that effectively manage the newly infected host cell 
environment to the benefit of the virus [4, 5]. Finally, on the exterior of the virion is the 
envelope; a layer that is made up of mostly of host-cell membrane and with viral glycoproteins 
embedded [1]. Perhaps the most defining characteristic of all the herpesviruses, and certainly the 
most challenging from the perspective of the vaccinologist, is their ability to evade the clearing 
action of their hosts’ immune system by their ability to persist in the latent state in their natural 
host. The Herpesviridae family is further divided into the sub-families Alphaherpesvirinae, 
Gammaherpesvirinae, and Betaherpesvirinae. 
 2 
1.1.1 Alphaherpesviruses  
Alphaherpesviruses are commonplace and pervasive pathogens with a broad host range, a 
relatively short reproductive cycle, and a lytic action on primary infected cells [1]. Three of the 
four genera of Alphaherpesvirinae (Simplexviruses, Varicelloviruses and Iltoviruses) are 
neuroinvasive meaning that the virus can invade or spread to cells (sensory/peripheral neurons) 
that were not directly exposed to virus inoculation with the end result of a lifelong latent 
infection [6]. Although these viruses can infect cells in vitro from a wide variety of species, 
latent infections are typically established in and limited to, the natural host [7, 8]. In humans, two 
common alphaherpesviruses, namely herpes simplexvirus (HSV/HHV) -1 and HSV-2, of the 
genus Simplexvirus, currently infect more than two-thirds of the world’s population [9, 10]. The 
other common alphaherpesvirus that infects humans is Varicella-zoster virus (VZV/HHV3), of 
the genus Varicellovirus [11]. VZV is the causative agent of chickenpox as the primary infection 
and of shingles as the reactivation of the latent infection [12]. Equine herpes virus 1 and 4 (EHV-
1, -4) in horses, pseudorabies (PRV/SuHV-1) in pigs, and bovine herpesvirus 1 (BoHV-1) in 
cattle, are important veterinary alphaherpesviruses, and they also belong to the genus 
Varicellovirus [11, 13].  Other ruminant alphaherpesviruses that are closely related to BoHV-1 
by way of common antigenic properties and serological relationships, and for which there exists 
some risk of cross-species infection to cattle, include bubaline herpesvirus 1 (water buffalo), 
caprine herpesvirus 1 (goat), cervid herpesviruses 1 and 2 (deer), and elk herpesvirus 1 [14]. 
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1.1.1.1 Classification of Alphaherpesviruses  
The order Herpesvirales contains three subfamilies: the Alloherpesviridae, the 
Malacoherpesviridae and finally the Herpesviridae (Table 1.1). The family Herpesviridae is the 
largest with 90 formal species sharing common features and is composed of three subfamilies: 
the beta-, gamma- and alpha- herpesvirinae. Besides common morphological properties, viruses 
in this family also share several biological properties such as a lytic primary infection followed 
by the establishment of latency in a specific cell type(s) and thus lifelong latent infections in their 
natural host. These characteristics have historically formed the basis for classification [15, 16]. 
The alphaherpesvirinae are neurotropic viruses, in that they establish latency in specific 
neuronal cell populations. Beta- and gammaherpesvirinae establish latency in lymphocytes and 
consequently persist in lymphoid organs. Gammaherpesvirinae establish early latency, often 
with little lytic infection and tend to be associated with non-lymphoid cancers and/or 
lymphoproliferative diseases [15].  
 
As new methods have become available, studies using immunological methods to detect 
similarities through antigenic relationships, and using molecular methods such as nucleic acid 
sequencing to reveal genetic similarities have allowed for further refining of the classification 
into genera [16]. Classification of the alphaherpesvirinae subfamily was recently updated in 
2012 by the International Committee on Taxonomy of Viruses [17] such that it now has five 
assigned genera that include Iltovirus, Mardivirus, Scutavirus Simplexvirus and Varicellovirus. 
Within the genus Varicellovirus are found VZV (human natural host), PRV (swine), EHV-1 and 
2 (equine), CvHV-1and 2 (deer), CpHV-1 (goat), BuHV-1 (water buffalo), and BoHV-1 (cattle).  
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Table 1.1 Classification and nomenclature of alphaherpesviruses 
Order Family Subfamily Genus Species 
(natural host) 
Informal 
name 
H
er
p
es
vi
ra
le
s 
Malacoherpesviridae     
Alloherpesviridae     
H
er
p
es
vi
ri
d
a
e 
Gammaherpesvirinae    
Betaherpesvirinae    
A
lp
h
a
h
er
p
es
vi
ri
n
a
e 
Iltovirus Gallid herpesvirus 1 
(chickens) 
Infectious 
laryngo-
tracheitis 
virus 
   
Mardivirus Gallid herpesvirus 2 
 
Marek 
disease 
HV 1 
 Gallid herpesvirus 3 Marek 
disease 
HV 2 
   
Simplexvirus Human herpesvirus 1 
 
HSV-1 
 Human herpesvirus 2 HSV-2 
   
Varicellovirus Bovine herpesvirus 1 
(cattle) 
 
IBR/IPV 
 Bubaline herpesvirus 1 
(water buffalo) 
 
 
 Caprine herpesvirus 1 
(goat) 
 
 
 Cervid herpesvirus 1 
(deer) 
 
 
 Cervid herpesvirus 2 
 
 
 Elk herpesvirus 1 
a 
 
Elk HV 
b 
 Equine herpesvirus 1 
(horses) 
 
 
 Equine herpesvirus 4 
 
 
 Human herpesvirus 3 
 
VZV 
 Suid herpesvirus 1 
(pigs) 
PRV 
 
(Adapted from Pellett and Roizman (2007)  [15]  and Pellet and Roizman (2013)  [18]).  The naming 
of elk herpesvirus as 
a
elk herpesvirus 1 from Thiry et al. (2006)  [14] and as
 b
ElkHV from Deregt et 
al. (2000) [19]. BoHV-1 classification is shown by grey areas and the reference species are in bold. 
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1.1.1.2 Virion Structure   
Much of what is known regarding the structure of the alphaherpesvirus virion has been drawn 
from studies of the prototypical alphaherpesvirus, HSV-1. As described above for herpesviruses, 
alphaherpesvirus virions are composed of four structural elements, a core containing the double-
stranded DNA genome, an icosohedral capsid around the core, the tegument that surrounds the 
capsid, and the viral envelope containing viral membrane glycoproteins [20]. The core of a 
typical herpesvirus is composed of a single molecule of viral nonchromatinized linear dsDNA 
wrapped around a fibrous torus (donut)-shaped, spool-like core [21, 22]. The torus of some 
herpesvirions appears suspended by fibrils passing through the center of the spool and attaching 
to the inner side of the capsid [18]. In HSV-1, the DNA is known to be packed tightly and 
effectively pressurized to facilitate injection of the viral genome into the nucleus of the host cells 
[10], and a small amount of viral DNA may exist in circular form [23].  
 
Around the core is the capsid which is an 100-nm T=16 icosahedron composed of many copies 
of four conserved capsid proteins viral protein (VP) 5 / unique long (UL ) 19, VP26/UL35, 
VP23/UL18, VP19C/UL38) [23], that with the UL6 gene product, make up a portal complex 
(through which the viral genomic DNA is loaded into or released from the capsid), 150 
hexomeric (faces and edges) and 11 pentametric (vertices) capsomeres connected in groups of 
three [23, 24]. Studies with HSV-1 show that the portal complex is created with a dodecameric 
ring of UL6 encoded protein at one vertex of the capsid and the portal capping protein of the 
mature capsid is formed by the UL25 gene product [25]. These two proteins are considered 
capsid proteins and are products of genes conserved among the herpesviruses [18]. Lytically 
infected cells harbour capsids in three forms that represent stable intermediates or end products 
 6 
of herpesvirus capsid assembly: capsids with no core structure (A capsids); capsids with an 
assembly scaffold but no genome (B capsids); and capsids that contain the genomic DNA core, 
no scaffold proteins and a portal capping protein (C capsids) [18, 24].  
 
Surrounding the capsid is the tegument which makes up approximately 40% of the virion protein 
mass [26], and which has been described as an amorphous proteinaceous layer of varying 
thickness [18]. The tegument is an ordered structure made up of more than 20 different virally 
encoded proteins; some of which are acquired in the nucleus and make up the inner tegument, 
and others located at the periphery that interact with envelope glycoproteins [18]. The tegument 
proteins provide the virus with a supply of pre-made proteins that can manipulate the host cell 
environment to assist in both viral replication/propagation as seen with the transcriptional 
activator VP16 of HSV-1 [24] and the UL82 encoded transcriptional activator of human 
cytomegalovirus (HCMV/HHV5) pp71 [27]; and in evasion of host cell defences as observed by 
the action of the HSV-1 virion host shut-off protein (vhs) UL41 that degrades host cell mRNA 
[28] and the HCMV UL83 encoded pp65 protein that blocks major histocompatibility class I 
molecule (MHC I) presentation of viral proteins [29] and inhibits induction of host interferon 
(IFN) responses [30].  
 
The outermost layer of the virion is the viral envelope that has been described as a lipid bilayer 
[31] with a trilaminar appearance [18]. The envelope is compositionally similar to the organelle 
and cellular membranes through which the viral particle has passed on its way out of the infected 
host cell and thus consists of lipids, proteins (host cell and viral) and viral glycoproteins that are 
embedded in the envelope and protrude in a spike-like manner [18, 24]. Importantly, some of 
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these viral glycoproteins are involved in, and essential for, viral entry into the host cells [32]. 
Among herpesviruses the number of glycoproteins encoded varies, few are conserved with the 
exceptions of gB and gH/gL [31], and not all that are encoded are actually found present in the 
virion [24]. In HSV-1, 20 glycoproteins are encoded and 11 are found present in the virion [33]. 
Envelope glycoproteins of the HSV virions include: gB (VP7 and VP8.5, encoded by the UL27 
gene), gC (VP8, UL44), gD (VP17 and VP19, unique short (US6)), gE (VP12.3 and VP12.6, 
US8), gG (US4), gH (UL22), gI (US7), gK (UL53), gL (UL1), and gM (UL11) (reviewed in [23]). 
For the alphaherpesviruses HSV-1, PRV and BoHV-1, binding of virus to cells is primarily by 
gC [34], and for entry and infection of cells gB, gD, gH and gL are required [34, 35]. Thus gB, 
gC, gD, gH and gL are targets for adaptive immunity, and in HSV they may also be involved in 
initiating the early innate immune response to the virus [35].  
 
Glycoprotein D (gD) is a type I membrane glycoprotein that is involved in virus entry into the 
host cell by its interaction with one of several potential entry receptors in the case of HSV-1 
(reviewed in [35]), or only nectin-1 (poliovirus receptor-related protein 1) and poliovirus 
receptor (Pvr) in the case of BoHV-1 [36]. Cellular expression of gD may inhibit subsequent 
infection by BoHV-1 as has been described by Dasika and Letchworth (1999) for gD of 
homologous BoHV-1 strain [37]. Superinfection, defined as “infection occurring after or on top 
of an earlier infection” [38, 39], is of concern in vaccine development for several reasons; one 
because the protective response to the first infection may lessen protection against subsequent 
infection by the superinfecting virus [40], and two because of the risk of recombination between 
a vaccination strain (ie marker vaccine or MLV) and a field strain [41]. Recombination can occur 
between different strains of the same alphaherpesvirus species when 1) two viruses infect the 
 8 
same cell at the same time (co-infection) [42], or 2) two viruses infect the same cell as 
consecutive infections as would be more likely under natural field conditions, and when the two 
viruses have common target cells [41]. In a comparative in vitro study of full length versus 
truncated gD, it was found that homologous and heterologous superinfection was inhibited by 
expression of full-length gD, but bovine cells that expressed the truncated, soluble and secreted 
form tgD were fully susceptible to infection by BoHV-1 [43]. These findings provide support to 
the hypothesis of a common gD receptor as interference against heterologous viruses suggests a 
common receptor pathway for entry [43]. The significance of these findings on the protective 
ability of tgD in a BoHV-1 vaccine regimen in the face of field challenge is unclear. Meurens et 
al (2004) importantly point out that all these observations were carried out in vitro with gD- or 
tgD-expressing cell lines and not in situations of natural superinfection; thus it may not possible 
to attribute the interference of superinfection to that of gD expression by the lytically infected 
cells [41].  Most significantly to practical purposes, when comparing gD and tgD as DNA 
vaccine antigens, cattle immunized intradermally with a vaccine encoding tgD were afforded 
protection against BoHV-1 challenge whereas the cattle immunized with the gD encoding 
vaccine were not [44]. Thus it does not appear that transfection of cells by either plasmid had any 
effect on superinfection or susceptibility to infection by BoHV-1, even if the plasmid vaccine 
and BoHV-1 virus were found to target the same cells.  
 
Glycoprotein D is particularly interesting with respect to development of adaptive immunity and 
vaccine design. Findings from studies with HSV-1 show that gD is a major component of the 
virion envelope and also stimulates the production of high titers of neutralizing antibodies [45], 
therefore it is an attractive vaccine antigen candidate. Although the presence of BoHV-1 gD in 
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wild-type virus was found to induce apoptotic cell death in PBMCs, affinity-purified gD (up to 
5μg/ml) did not induce apoptosis [46]. Since gD alone without other virion components does not 
activate the apoptotic process, gD and tgD should be able to be used safely as a vaccine antigen. 
 
1.1.1.3 Virion Replication   
The replication cycle of the alphaherpesviruses has been mostly determined through studies of 
HSV, and in particular HSV-1, as the prototypical alphaherpesvirus. Figure 1.1 shows the HSV-1 
replication cycle. As such, primary infection of the host normally begins with entry of the 
 
Figure 1.1 Replication cycle of herpes simplexvirus 1.   
Reprinted by permission from Lippincott, Williams & Wilkins Fields’ Virology (p. 1836). Roizman, B., 
Knipe, D.M., Whitley, R. (2013) [23].  
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virion into the host which occurs typically by inhalation of virus-laden droplets and then 
engagement/attachment of the virus to epithelial cells of the respiratory mucosa. Next, the virus 
tethers to the host cell by binding to cell surface molecules of heparin sulphate proteoglycans 
[23, 35]. Tethering/binding of HSV-1, PRV and BoHV-1 is typically mediated by the viral 
envelope glycoprotein gC, although this function can also be carried out by gB or gD, both of 
which also contribute to stable binding [34]. Following tethering, entry can occur by cell-type 
dependent endocytosis (reviewed in [23]), or by fusion. Fusion of the virion envelope with the 
host cell plasma membrane is mediated by engagement of the viral glycoproteins gB, gD, gH and 
gL with their receptors. Specifically, engagement of gD triggers a conformational change that 
results in recruitment and heterodimerization of gH/gL and activation of gB that enables fusion 
[23, 34, 35]. Fusion results in the release of the viral nucleocapsid (capsid and tegument proteins) 
into the cytoplasm. Endocytosed virus that escapes from the endosome is also released as a 
nucleocapsid to the cytoplasm. Once in the cytoplasm, the capsids follow a network of 
microtubules that facilitate their movement to the nuclear envelope where they bind to nuclear 
pores and then release their viral DNA into the nucleus leaving the tegument proteins and empty 
capsids behind in the cytoplasm [4, 23].  
 
The tegument vhs protein causes degradation of host messenger RNAs in the cytoplasm and the 
alpha trans-inducing protein VP16 (UL48) moves from the cytoplasm into the nucleus where, 
upon circularization of the viral DNA, VP16 facilitates transcription of the immediate-early (IE) 
or α-genes by host RNA polymerase II to give alpha(α)-mRNAs. Translation of mRNA occurs in 
the cytoplasm and resultant proteins are either transported back to the nucleus, or to cellular 
organelle membranes, or they remain in the cytoplasm. Translation of the α-mRNAs results in 
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six IE proteins, five of which act to regulate viral gene expression in the nucleus including 
inhibition of further transcription of α-mRNA [23]. Interestingly, cholesterol as a component of 
lipid rafts is essential in early replication and particularly for virus entry into the host cells for a 
number of alphaherpesviruses, including BoHV-1 [47], HSV-1 [48], VZV [49] and PRV [50]. 
This IE phase occurs from about 2-5 hours (h) post-infection (p.i.) [51]. Next, IE proteins 
transactivate beta (β) gene transcription. Translated β-mRNA early (E) proteins, including the 
viral DNA polymerase, are involved in replicating the viral DNA and in stimulating gamma (γ) 
gene expression. Replication of viral DNA signals the end of the early phase (about 5 h p.i.) and 
the beginning of the late phase of infection [51]. Translated γ-mRNA late (L) proteins include 
the structural capsid proteins and the envelope glycoproteins. Late proteins are involved in 
assembling the capsid in the nucleus and in modifying the host cellular membranes for the final 
step from particle to fully enveloped infectious virion during virus egress [4]. Thus from 5 h p.i. 
until total cell lysis at 10-20 h p.i., the late phase is dominated by viral DNA replication, 
synthesis of structural proteins and assembly of viral particles [51]. 
 
Capsid assembly takes place in the nucleus where the late proteins form capsomeres that are 
assembled into capsids, and that process and package the viral DNA into the capsid [4, 23]. The 
first step in nuclear egress is primary envelopment, whereby capsids are wrapped in the inner 
nuclear membrane. In HSV [4] and PRV [52], this requires that capsids obtain a nuclear 
envelopment complex (NEC) containing the viral proteins pUL31 (nuclear phosphoprotein) and 
pUL34 (type II integral membrane protein). In HSV, pUL31 and pUL34 also promote the 
recruitment of pUS3, a multifunctional serine-threonine protein kinase that, in the function of 
egress of capsids from the nucleus, serves to alter the structure of the nuclear membranes to 
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enable budding of capsids into [23], and out of [53], the perinuclear space  [23]. Capsids acquire 
a subset of tegument proteins (VP1-2/pUL36, pUL37, vhs, VP22, VP16); and then bud from the 
nucleus to the cytoplasm utilizing a process that preferentially selects for C-capsids and requires 
a nuclear envelopment (NEC) complex around the capsid. Capsids progress through membranes 
of cytosolic structures by sequential envelopment and de-envelopment. Tegument proteins are 
added at several locations throughout the process of egress and viral envelope glycoproteins are 
added during secondary envelopment in the trans-Golgi network (TGN) [4, 23]. Interestingly, a 
few of the glycoproteins of HSV (gJ, gK, and gN) that are rarely recruited to the sites of 
secondary envelopment are also rarely found in extracellular virions [54]. This suggests some 
importance to the process of selection and sorting of viral glycoproteins by the secondary 
envelopment sites. Lastly, enveloped virions within TGN-derived membrane vesicles are 
exocytosed by the cell following fusion of the TGN-derived membrane to the host cell plasma 
membrane and most enveloped virus particles are found attached to the outer surface of the cell 
plasma membrane as opposed to being fully released from the cell. This puts the infectious 
virions in close contact with adjacent cells and encourages cell-to-cell spread [4, 23].  
 
1.1.2 Bovine Herpesvirus 
Bovine herpesvirus-1 (BoHV-1) is classified as an alphaherpesvirus, genus Varicellovirus, and is 
considered a serious pathogen in cattle [55].  BoHV-1 causes recurrent respiratory and genital 
infections in cattle, and predisposes to lethal secondary infections [56].  Like other 
alphaherpesviruses BoHV-1 causes not only initial, but recurring disease due to the virus’ ability 
to establish latency [57]. 
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1.1.2.1 Molecular Aspects of BoHV1 
As mentioned above, the BoHV-1 genome is a double-stranded linear DNA molecule that is 
relatively long at 135-136.9-140 kilobase pairs (kbp) [18, 58-61] and has a relatively high 
guanine and cytosine content of 72% [18]. The BoHV-1 genome structure is that of a D-class 
herpesvirus, characteristic of the genus Varicellovirus, a structure that is also demonstrated in 
PRV, VSV and EHV-1 and 4 [18, 58]. As such it is comprised of a unique long segment UL (103 
kbp), an internal inverted repeat IR (11 kbp), a unique short segment US (10 kbp), and a terminal 
inverted repeat TR (11 kbp) [62]. DNA replication begins following formation of a circular 
molecule as a result of ligation of the termini of the linear genome. Replication by rolling circle 
model from this circular DNA molecule results in recombinational events [58] and the 
accumulation of many concatemers (complex concatemeric intermediates), which are multiple 
copies of the genome linked end-to-end, in the cells [58, 62, 63]. At the time of DNA replication 
(in the concatemer) the US segment inverts relative to the UL segment resulting in two isomers 
where the UL segment is fixed and the US is in either of two orientations called the prototype (P) 
orientation [58, 62]. The UL segment can also invert, giving rise to four isomers, although 
genomes with this inverted UL segment (IL orientation) are only found within the concatemeric 
DNA. Cleavage of DNA concatemers favors the two isomers with the P orientation and this 
results in predominantly equimolar amounts of two isomers of the linear double-stranded DNA 
molecule packaged into virions [58, 62]. The 73 open reading frames encoded by the BoHV-1 
genome are homologous to genes of other alphaherpesviruses and are thus labelled relative to 
those of HSV-1 with the exception of the BoHV-1-specific gene, UL0.5, and a few other genes 
specific to BoHV-1 [61] or to varicelloviruses. These genes and their corresponding proteins are 
reviewed very nicely in table form comparatively with the genome of BoHV-5 [64] and also in 
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relation to the timing of their production in the viral life cycle (immediate early, IE; early, E; 
late, L) and their essentiality with regard to in vitro  viral replication [65]. The UL region of the 
genome encodes proteins involved in viral replication and processing, and also proteins that 
make up the capsid, tegument, and six envelope glycoproteins, gK (UL53), gC (UL44), gB 
(UL27), gH (UL22), gM (UL10), and gL (UL1) [61, 64]. The gene that encodes gN, UL49.5, is  
also within the UL region [64], but as this protein is not glycosylated in BoHV-1, it is considered 
a “false protein” even though it functions in a conserved manner by forming a disulfide-linked 
heteroduplex with gM (reviewed in [59]). The US region similarly encodes both non-structural 
and structural proteins including the remaining four envelope glycoproteins, gG (US4), gD (US6), 
gI (US7), and gE (US8) [61, 64].  
 
1.1.2.2 Infectious Nature of BoHV-1 and Immune Responses to BoHV-1 Infection 
1.1.2.2.1 BoHV-1 Primary Infection 
BoHV-1 has evolved strategies to evade clearance and ensure survival that involve modulation 
of itself and modulation of the host immune system.  BoHV-1 modulates host responses by 
transiently suppressing the immune system in a number of ways that support viral infection, 
often through impairment of the normal functioning of the immune system.  The first way is by 
compromising the first line of defence, the integrity of the respiratory tract. The respiratory form 
of BoHV-1 infects epithelial cells of the upper respiratory tract. Lytic replication ensues where 
infected epithelial cells increase in size, develop intranuclear inclusions, and ultimately necrotize 
or undergo apoptosis (releasing large numbers of progeny virus) in what is known as the 
cytopathic effect (CPE) of BoHV-1 lytic infection [59].  As well as direct CPE, BoHV-1 
interferes with repair of the airway epithelium by inhibiting the migration of new epithelial cells 
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to injured areas [66].  The high numbers of virus particles that are shed via the nasal mucus, and 
the fast replication cycle of the virus result in rapid spread of infection within a cattle herd [67]. 
Damage to the epithelial cells of the upper respiratory tract thus disrupts the first line of defense 
against bacterial colonization of the lung by impairing ciliary activity with a resulting loss of 
function of the mucociliary escalator. Resident, commensal bacteria of the nasopharynx (ie. M. 
haemolytica) [68-70], that would normally be coated in mucus and then expelled by the constant 
upward movement of the epithelial cilia, can then migrate or be inhaled such as to gain access to 
the lower respiratory tract where they multiply rapidly.  BoHV-1 also triggers a 
bronchoconstriction that further traps secretions and bacteria in the lungs [71]. BoHV-1 can then 
gain access to the central nervous system by penetrating nerve endings present in the infected 
epithelia of the upper respiratory tract [72].   
 
The second line of defense is the innate or non-specific inflammatory and cellular reactions to 
BoHV-1 infection. These include (but are not limited to) release of the type I-IFNs (IFNα and β) 
from infected cells that result in recruitment of alveolar macrophages (aMΦ), neutrophils and 
large granular lymphocytes (natural killer cells (NKs)). These effector cells in turn release more 
of these early cytokines in the infected epithelium which attract cells of the innate (DCs) and the 
adaptive immune system (T helper-cells), including CD8+ CTLs (MHC I-restricted cytotoxic 
lymphocytes), and activate MΦs  and CTLs to kill virus-infected cells [59].  Cattle are able to 
mount a strong and effective innate response to eliminate virus, but in addition to latency that 
makes it impossible to completely eliminate the virus, BoHV-1 encodes two proteins that inhibit 
the innate immune response and favour viral replication [59, 73].  Bovine infected-cell protein 0 
(bICP0) increases transcription of viral proteins and inhibits transcription of interferons (IFNs) - 
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in particular IFNα [59, 73].  The subsequent lower numbers of recruited alveolar MΦs and their 
severely reduced activity interferes with an important part of lung defense (alveolar MΦ 
phagocytosis and killing of engulfed bacteria) and favours infection by bacteria. Glycoprotein G 
binds lymphocyte-attracting chemokines, effectively reducing their numbers at the site of 
infection that would reduce CTL killing of infected cells and impair development of a robust 
adaptive immune response [59, 73]. 
 
BoHV-1 strategies that interfere with the development of the adaptive immune response impair 
the third line of defense.  BoHV-1 infects leukocytes that can spread the virus systemically 
whereupon it has been suggested that infection of distant organs [59, 74] can occur.  As well, 
infection of lymphocytes causes suppression of their proliferative ability  [75, 76].  Infection by 
BoHV-1 causes CD4+ cells to lose their CD4 molecules which induces apoptosis of the CD4+ T 
helper cells [77].  Thus the number of CD4+ Th cells is reduced as they apoptose and are 
effectively removed from the circulation.  With reduced numbers, T helper cell function and 
cytokine production is impaired which in turn lowers humoral and cell mediated responses. Viral 
protein UL41.5 (gN) blocks assembly of peptide-MHC I complexes thus inhibiting recognition 
and subsequent killing of infected cells by CD8+ CTLs [78].    
 
The bacteria implicated in bovine respiratory disease (BRD) subsequent to BoHV-1 infection 
also have the ability to negatively impact the immune response. M. haemolytica produces 
leukotoxin, an exotoxin that attaches to CD18 expressed on all leukocytes and induces cytolysis, 
thus reducing the number of both innate and adaptive immune system cells [79]. Leukotoxin also 
down-regulates expression of MHC II molecules on  MΦs and DCs, thus reducing antigen 
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presentation [80]. The polysaccharide capsules of M. haemolytica make the bacteria less 
susceptible to complement-mediated serum killing, and reduce phagocytosis by neutrophils and 
MΦs  [81]. Thus while BoHV-1 immune evasion strategies seek to increase viral replication and 
survival, these viral strategies additionally perpetuate an environment favourable for the bacteria; 
and while the immune modulating activities of the bacteria serve to lessen the potency of the 
immune response against the bacteria themselves, these strategies result in an environment 
beneficial to both bacteria and BoHV-1. 
 
Infection with BoHV-1 is responsible for a wide range of disease manifestations that are not 
limited to respiratory disease of feedlot cattle, but also include respiratory and reproductive 
disease in dairy and beef breeding herds [82]. Clinical symptoms of the respiratory form, also 
known as infectious bovine Rhinotracheitis (IBR) include rapid breathing, loss of appetite, fever, 
coughing, nasal discharge, foamy salivation, open-mouth breathing, severe inflammation of the 
nasal passages and tissue surrounding the eyes (conjunctivitis), and loss of weight and condition. 
In calves under 4 months of age, sequelae of infection can include meningitis or fatal systemic 
disease leading to death. In the breeding herd, cows exposed between 5-7 months gestation may 
abort, and in dairy animals milk yield may be reduced [83]. Infectious pustular vulvovaginitis 
(IPV) and Infectious balanoposthitis (IBP) diseases manifest in cows and bulls respectively and 
the symptoms include fever, genital tract lesions (plaques) and genital discharge. Less 
frequently, BoHV-1 has also been reported to cause digestive tract disease (enteritis), dermatitis 
and lesions of the interdigital space, and a catarrhal type of mastitis [84]. 
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1.1.2.2.2 BoHV-1 Latency 
BoHV-1 has evolved strategies to evade clearance and ensure survival that involve modulation 
of itself and modulation of the host immune system. The most important viral modulation, and a 
characteristic of alphaherpesviruses, is the ability to establish latency. BoHV-1 is thought to gain 
access to the central nervous system by penetrating nerve endings present in the infected 
epithelia of the upper respiratory tract [72]. In the absence of BoHV-1 lesions, it is unlikely the 
virus would have access to these nerve termini. The virus is then transported along the 
microtubules of the axons to the nucleus in the body of the trigeminal and sacral ganglions where 
it establishes latency [59]. In the neuron, BoHV-1 transcript expression is modified such that 
only two proteins are translated and expressed.   High levels of the latency related gene product, 
that serves to turn off viral expression and inhibit apoptosis of the neuron [85], and the open 
reading frame (ORF) -E gene product, that enhances neuronal health [86] are expressed. Due to 
their abundance, these gene products are thought to be actively involved in the maintenance of 
latency [59]. Natural stressors that lead to increased secretion of corticosteroid (or experimental 
administration of cortisol) and/or immune suppression can initiate reactivation from latency [59]. 
Once reactivated, there is a reversing of the above-described events with viral gene expression 
occurring in the sensory/peripheral neurons and infectious virus shed from the nose and eyes [87, 
88]. BoHV-1 can be repeatedly reactivated throughout the animal’s productive lifetime causing 
recurrent infection, viral shedding, and spread of the virus to naïve animals [70].   
 
1.1.2.3 Bovine Respiratory Disease  
Bovine respiratory disease complex (BRDC) is multifactorial, resulting from interactions among 
bovine viral and bacterial pathogens at times of stress [70, 71, 89].  Viruses that are present in 
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feedlot cattle and that have been implicated in BRDC include BoHV-1, bovine respiratory 
syncytial virus (BRSV), bovine viral diarrhea virus (BVDV) and parinfluenza-3 virus (BPIV3).  
BoHV-1 is the causative agent of IBR [55, 90].  Infection by BoHV-1 leading to IBR causes a 
transient immune system suppression that predisposes cattle to secondary bacterial infection 
characteristic in BRDC [71]. In Canada and the US, the causative bacteria are Mannheimia 
haemolytica and Mycoplasma bovis [71, 73]. Other bacteria that infect the bovine respiratory 
tract of cattle are Histophilus (Haemophilus) somni and Pasteurella multocida [73, 91]. 
Secondary bacterial infection by these organisms causes pneumonia and it is the pneumonia 
subsequent to the viral infection (BRD) that leads to morbidity and death of affected feedlot 
cattle [90].    
 
BRDC results in animal pain and suffering, and a loss of revenue to the to the feeder cattle 
industry. Economic losses are due to mortality, cost of treatment, and reduced growth 
performance resulting from BRDC. Using industry data from the United States feedlot and meat 
industry, industry economic losses of $3 billion (US) each year (USDA:NASS, Cattle on Feed 
2002), and feedlot mortality of 1.4%, with 2/3 of those deaths attributable to BRD [92] have 
been reported. In Canada, BRD accounted for 66% of mortality in Ontario feedlots between the 
years 1978-1980 [93], and 10-57% of mortality in a large commercial Western Canadian feedlot 
between the years 1985-88 [89]. In fact, the economic losses attributed to IBR in the cattle 
industry worldwide [83], are considered so severe, that IBR eradication programmes utilizing 
BHV-1 glycoprotein E-negative vaccines (to differentiate immunized versus infected animals) 
were started more than a decade ago in a number of European countries [94].    
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It should be noted that not all cases of infection by BoHV-1 (IBR) are complicated by secondary 
bacterial infection with progression to pneumonia and death.  The course of the disease varies 
among animals and outbreaks, and many animals are able to recover [71, 89].  How well they 
recover depends on care during illness [93], and ability to clear the virus [95].  A relatively long 
period of low level immune suppression is seen even after the lesions have resolved [95].  This 
can translate to long term lower weight gains and poor performance in the feedlot [93].  In 
unvaccinated feedlot cattle, morbidity is usually high (20-30 and as high as 100%) and mortality 
rate is low (1% and as high as 10%) [71]. Stresses associated with weaning, mixing of cattle at 
sale yards and feedlots, and shipping tend to increase the severity of IBR and the likelihood of 
pneumonic BRD [71, 89].  Mortality data over 4 years from a commercial feedlot study showed 
a rise in mortality due to BRD 14-16 days after arrival at the feedlot (25
th
 percentile), this peaked 
at 15-19 days (19-22d median), and gradually decreased out to 29-42 days (75
th
 percentile) [89].  
The reported incubation period for development of IBR after BHV-1 exposure varies from 1-6 
days after experimental challenge to 10-20 days after new cattle are introduced in a field setting 
[71].  The timing of incubation to mortality supports the association between BoHV-1 infection, 
stress (mixing and shipping) and development of BRD. It has been suggested that control of 
BRD involve a combination of vaccination with improved management practices that minimize 
stress of cattle upon arrival at the feedlot [59, 70, 93].   
 
1.1.2.4 Control of BoHV-1 Infection 
Methods to control BoHV-1 typically involve animal management practices to minimize stress 
and basic biosecurity measures that minimize opportunities for animal to animal transmission. 
Beyond these very important considerations, the adoption of specialized biosecurity, vaccination 
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and/or eradication programs tends to differ by country and continent. For example, in many 
European countries, eradication programs have been in place, and may include strictly 
serological identification with culling of infected animals, or may additionally include 
vaccination of animals with a gE deleted marker vaccine (DIVA vaccine) to differentiate 
vaccinated from infected animals [59].  Interestingly, only the countries that have practiced 
culling of infected animals while prohibiting vaccination have achieved BoHV-1/IBR-free status 
(Austria, Denmark, Finland, Norway, Sweden, and Switzerland). The economic loss of otherwise 
healthy animals through culling would appear to limit practicality of this approach to only those 
countries with low incidence at the outset of the eradication program [96] or with low animal 
numbers or concentrations. In the case of the DIVA strategy, the relatively low sensitivity (70%) 
of the diagnostic ELISA test for BoHV-1 gE antibody presents both a risk of infected animals 
going undetected, and an economic cost of unnecessary culling of false positive animals 
(reviewed in [59]). Additionally, establishment of latency and the potential for BoHV-1 
recombinants are biosafety concerns with the MLV gE-deleted DIVA vaccines [59, 97]. For 
eradication in particular and control in general, additional biosecurity measures are 
recommended that include ensuring breeding stock, embryos and semen are BoHV-1 free; 
physical separation of positive and negative animals; and knowledge of transmissibility of 
BoHV-1 through feed that dictate feedstuff contamination control measures in the feedlot 
(reviewed in [96]). In North America, relatively high seroprevalence [98], differences in 
geography, climate, animal numbers and concentrations dictate practices that are, by necessity, 
quite different. Here also though, it has been suggested that control of BoHV-1/IBR/BRDC 
involve a combination of vaccination with improved management practices that minimize stress 
of cattle upon arrival at the feedlot [59, 70, 93].  An area that is often ignored is management of 
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cattle that are already in the feedlot, past the time of highest risk for IBR. A recently reported 
increase in IBR outbreaks in vaccinated feeder cattle points to a need for attention to this group. 
Reversion to virulence of modified live vaccines, or emergence of a new BoHV-1 strain have 
been suggested as possible reasons for these outbreaks [99, 100]. Other possibilities to consider 
are changes in the genetics of cattle currently on feed (more Angus than the traditional 
Hereford/Charolais/Limousine influence) that may not respond as well to vaccine strains or that 
might require different management. Also, a move to year-round receiving of cattle from many 
sources into feedlots (this is different than the traditional entry of newly weaned cattle in the fall) 
means that cattle currently in the feedlot have an increased chance of exposure to pathogens 
carried by newly received cattle at a time when protective immunity of the vaccine given to 
resident cattle at the time of entry may be declining. Thus establishment of long-term 
immunological memory may be an important consideration for BoHV-1 vaccines for North 
American cattle. 
 
In Canada and the United States, current strategies to control BoHV-1 emphasize and include 
vaccination with commercial MLV or KV BoHV-1 vaccines. These commercial vaccines do not, 
however, completely protect cattle from infection with BoHV-1 [101]. Additionally, the safety 
and effectiveness of these commercial vaccines are still of concern. As mentioned above, 
eradication programs using deletion marker vaccines fall short of ideal also [102]. Vaccination of 
neonates, particularly in the face of maternal antibody, is another area of difficulty that might be 
overcome with improved vaccines. Recently it has been reported that a combination of adjuvant 
with a BoHV-1 MLV resulted in enhanced  immunogenicity and protective effect [103].  
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Obviously, the shortcomings of current commercial vaccines point to a need for, and drive the 
development of, a better vaccine for BoHV-1.  
 
1.2 Dendritic Cells 
1.2.1 Dendritic Cells in the Induction of Immune Responses 
DCs are unique antigen presenting cells (APCs) as they are the only ones that are able to induce 
primary immune responses and the subsequent establishment of immunological memory [104, 
105]. Dendritic cells are also potent initiators of a cell-mediated response [106]. In a MLR, only 
one DC is needed to turn on 100-3,000 T cells [106], and in mice, ex vivo-activated DCs can 
prime recipient animals to respond to an antigenic challenge in an antigen-specific manner 
within a week [107]. DCs can process exogenous antigen for presentation on both MHC I and 
MHC II molecules, thus inducing both CD8 (CTL) and Th mediated immunity [108]. Non-
replicating antigen is limited, in most APCs, to presentation on MHC class II molecules with 
subsequent presentation to, and activation of, Th cells [106]. DCs, however, are able to transport 
phagocytosed/endocytosed antigens from the endocytic compartment to the cytosol [109, 110]. 
This unique characteristic, called “cross-presentation”, allows DCs to present exogenous antigen 
on MHC I molecules, leading to induction of CD8 T-cell immunity [111].  DCs are able, 
therefore, to simultaneously present exogenous antigen on both MHC I and MHC II molecules. 
The subsequent immune response after presentation to T cells is balanced, resulting in the 
generation of antibody, Th and CTL cells. If a BoHV-1 vaccine could be targeted to DCs, then 
this characteristic of DCs could be exploited to induce effective immunity to viral infection.   
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1.2.2 Types of Dendritic Cells 
Dendritic cells are non-dividing cells [112] whose precursors originate from CD34+ 
haematopoietic stem cells within the bone marrow [113]. As shown in Figure 1.2, they are a 
heterogeneous population with respect to phenotype and function but essentially develop along a 
pathway from a common precursor belonging to one of two lineages [113, 114]. The first lineage 
is that of the myeloid cells. These include Mo, MΦs, DCs and granulocytes that arise from a 
common myeloid progenitor (CMP). The second lineage is that of the lymphoid cells including T 
cells, B cells, NK, and a certain subset of DC that arise from a common lymphoid progenitor 
(CLP) [115]. There is some question, however, as to whether the plasmacytoid DCs (pDCs) 
actually do arise from a CLP, or whether they derive from a myeloid origin common DC 
precursor (CDP) [116], or both [117, 118]. Beyond ontogeny, DCs are grouped as either 
conventional DCs (cDCs), monocyte-derived DCs (MoDC) or plasmacytoid DCs (pDCs). There 
is also some debate as to whether the activated MoDCs, termed by some as “inflammatory” DCs, 
and the activated interstitial cDCs (derived from the CLA
-
 CDP) are in vivo functional 
equivalents [119]. If so, then the MoDCs would also be grouped as a cDC. DCs are further 
described as either migratory or lymphoid tissue-resident, based on whether they stay in one 
place or not. Migratory DCs are present in the blood at low frequencies, and in peripheral tissues 
and in lymphoid tissues at high frequencies. Upon antigen-uptake, activation and maturation, 
they migrate to the draining lymph node (LN). In contrast, the lymphoid tissue-resident DCs 
perform all the same DC functions of antigen-uptake, activation and maturation, but they remain 
within the lymphoid tissue [120, 121]. The most recent work on DC lineages and DC subtypes 
aligns mouse and human DCs into four subsets irrespective of their location. In mice, they all 
derive from a Lin
-
CX3CR1
+
 CD11b
-
 CD115
+
 cKit
+
 CD135
+  
macrophage-DC precursor (MDP) 
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that derive from the CMP [116], and the subsets correspond to Xcr1+ cDC, CD11b+ cDC, 
MoDC, and pDC [122]. Regardless of whether they are migratory or resident, notably, it is the 
cDCs and the MoDCs [123] that have the ability to prime naïve T cells [117].  
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Figure 1.2 DC lineage and development of DC subsets. 
CLA, cutaneous lymphocyte antigen; MoDC, monocyte-derived dendritic cell; GM-CSF, 
granulocyte macrophage colony-stimulating factor 
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The pDCs are referred to as IFN producing cells or natural IFN producing cells as when 
activated, they produce massive amounts (10-100 times more than any other type of cell) of type 
I IFN [124]. pDCs differ from cDCs in that they are found mainly in the blood and are poor 
antigen presenting cells (APCs). They are, however, considered the main antiviral innate 
immune response effector cell due to their virus-activated IFN production [125]. In general, 
cDCs are of the myeloid lineage and pDCs are of the lymphoid lineage [114, 126]. For the 
remainder, this review will focus on DCs of the myeloid lineage. 
 
1.2.3 Life-cycle of a Dendritic Cell (DC) 
1.2.3.1 Immature DCs 
Myeloid immature DCs (iDCs) are derived successively from bone-marrow CD34+ progenitor 
cells and precursor cells as described above. The precursor DCs travel through the bloodstream 
and migrate to tissues where they reside as immature DCs at body surfaces and interstitial 
spaces; thus they are typically found in peripheral tissues where they monitor their environment 
[105, 106, 114]. They can be resident cells such as Langerhans cells of the skin that derive from 
CD14
-
CD11c
+
  blood precursors, or they can be infiltrating iDCs or pre-DCs that derive from 
CD14
+
CD11c
+
  blood precursors [114]. iDCs are poor stimulators of T cells. iDCs are further 
characterized by their endocytic ability that allows them to continuously sample from their 
environment, expression of uptake receptors, abundant MHC II products within intracellular 
compartments for complexing processed peptide from the antigen that gets taken up [127], 
expression of  chemokine receptors, chemokine receptor (CCR) 1, CCR5 and CCR6  that allow 
them to selectively home to areas within the tissues of infection and inflammation where 
chemokines, chemokine ligand (CCL) 3 (MIP-1α), CCL4 (MIP-1β), CCL20 (MIP-3α), and 
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chemokine (CXCL motif) ligand (CXCL) 10 (IP-10), are secreted  in response to pathogens or  
inflammatory signals from resident tissue cells [128] and from the iDCs [129]. iDCs very 
capably internalize particles, viruses, bacteria apoptotic and necrotic cell fragments by 
phagocytosis [130, 131], they sample extracellular fluids and solutes in their immediate 
environment into large pinocytic vesicles by macropinocytosis [132], and  they express 
adsorptive uptake receptors such as the type-1 transmembrane C-type lectin receptors like the 
macrophage mannose receptor (MMR/CD206) [132] and DEC-205 (CD205) [133, 134], as well 
as fragment crystalizable (Fc) γ and Fcε receptors [132]. Thus the immature state of DCs can be 
identified by functional assessment of proliferative and phagocytic ability and phenotypic 
assessment for expression of chemokine and uptake receptors.  
 
1.2.3.2 Mature DCs 
Maturation of DCs is a continuous process initiated at the site of infection and completed in the 
LN whereby iDCs undergo phenotypic and functional changes that result in their transition from 
antigen capturing cells at the periphery to antigen processing and presenting cells at the LN [135, 
136]. During maturation (Figure 1.3) expression of CCR1, CCR5 and CCR6 are down-regulated 
and expression of CCR7 is up-regulated. Expression of CCR7’s ligand, SLC (CCL 21) on the 
endothelium of the afferent lymphatic system, and by the stromal cells in the T-cell zone directs 
migration of the maturing DC out of the tissue and toward the LN [137]. In the LN, mature 
antigen-presenting DCs stimulate naïve T-cells through up-regulation of their surface 
costimulatory molecules CD80 (B7.1), CD86 (B7.2), and CD40, which bind to CD28 and 
CD40L (CD154) respectively on T-cells. T-cell recognition of the presented antigen leads to T 
cell-mediated terminal maturation of DCs, a process characterized by further up-regulation 
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Figure 1.3 Maturation process of DCs. Signals in the environment such as pathogen-associated 
molecular patterns (PAMPs) or damage-associated molecular patterns (DAMPS) activate pattern 
recognition receptors (PRRs) of iDCs, and along with antigen uptake, initiate the maturation 
process. Expression of iDC chemokine receptors is down-regulated and expression of the LN 
homing receptor CCR7 is up-regulated. Maturing DCs migrate to the LN where they present 
antigen to CD4
+
 and CD8
+
 T cells. DCs  are activated through CD40:CD40L interaction by the 
CD4
+
 T cells which then licence the DCs. Licenced DCs upregulate costimulatory molecules 
such as CD137L. Priming of CD8+ T cells causes upregulation of CD137 by the CD8+ T cell; 
and engagement results in CD8+ T cell activation, proliferation, effector function and memory. 
(Adapted from De Haes et al. (2012) [138]). 
 
of co-stimulatory molecules and the release of IL-1 and IL-12 by DCs and IFN-γ by T-cells 
[139]. Engagement of CD40 by CD40L of antigen activated CD4 T cells induces mature DC to 
differentiate further in a step known as “licensing” [138]. Licencing of DCs by CD4+ T cells 
provides a form of T cell help that amplifies the DCs activity and allows for induction of potent 
cytotoxic CD8+ T cell responses in the absence of a very strong inflammatory stimulus [140]. 
Licenced DCs up regulate additional cell-surface molecules such as CD137L, CD70, 
CD252/OX40L and glucocorticoid-induced TNF receptor-related protein ligand (GITRL). 
Priming of CD8+ T cells by MHC class I-restricted peptides causes upregulation of the 
corresponding molecules CD137 [138], CD27, CD134/OX40, and GITR respectively by the 
CD8+ T cell; and engagement of these molecules with their cognate ligands results in robust 
L 
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CD8+ T cell activation, proliferation and effector function, as well as the induction and 
maintenance of memory [141].  
 
Whether T-cells of the Th2 subtype release IL-4 during terminal maturation of DCs, and what 
effect this would have on terminal maturation of DCs, is currently not clear. However, it has 
been shown that IL-4 secreted by Th2 cells can strongly enhance the production of bioactive IL-
12p70 heterodimer by CD40L-stimulated DC and can synergize with IFN-γ [142]. Theoretically, 
this increase in IL-12 may amplify the signal to DC to terminally mature; or it may be that the 
CD40 (DC):CD40L (T-cell) interaction is the critical factor. The presence of B cells and their 
secretory Ig molecules may also be important for development of fully functional DCs. Splenic 
cDCs were unable to crosspresent soluble antigen in the absence of T and B cells (lymphopenic 
mice) and this DC cross presentation was found to be dependent on serum Ig. It was further 
hypothesized that Ig, either as immune complexes or via Fc receptors, acts through C-type lectin 
receptors (CD205, CD206/MMR, DC-SIGN) expressed by the DCs [143]. This idea that 
terminal maturation, given the presence of other activating factors, occurs as a result of 
CD40:CD40L interaction between the DC and the T-cell is supported by the results of another 
study whereby cell-free supernatants from activated T-cells that contained sCD40L and IFN-γ 
could induce terminal differentiation of DC [144]. Thus it may be through the action of CD40 
ligation, in combination with the bioactive IL-12p70 heterodimer and IFN-γ synergy, that Th2 or 
Th1 cells mediate terminal maturation of DCs.   
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1.2.4 Implications of Infection on DC Function and Subsequent Immune Response 
In a natural infection, the host is invaded at the periphery and the virus gains access to host cells 
by breaking through the physical defences of skin and mucosal surfaces [106]. DCs, the 
specialized cells that capture and carry antigen from the site of infection to the LN whereupon 
they orchestrate the adaptive immune response, are found at a high frequency in the peripheral 
tissues, where they are influenced by the action of virus infection on the local environment [106, 
108]. Viruses are obligate parasites; to survive they must enter (infect) the cells of the host where 
they then utilize the host cell machinery to produce the viral structural and non-structural 
proteins, RNA and DNA (DNA virus) they require to replicate [145]. To prevent such a hostile 
takeover, the mammalian system has devised ways to protect itself from infection, but at the 
same time, viruses and in particular, herpesviruses such as HSV-1, have evolved ways to get 
around these protective systems [5] including infection and impairment of the DC itself [146].  
 
Infection of iDCs is mediated by interaction of DC-SIGN (DC-specific C-type lectin) with gB 
and gC of the virus. DC-SIGN also captures HSV-1 for transmission to permissive cells [147]. 
Earlier studies showed that only iDCs could support production of infectious HSV-1 viral 
particles, whereas in infected mature DC (mDC) only IE and E transcripts were generated. 
Additionally, maturation of DCs is interfered with by HSV-1 infection as was observed by 
complete ICP0-dependent proteosome-mediated degradation of the maturation marker CD83 
[148] and an  inhibitory effect on the induction of antiviral T cell responses and DC-mediated T 
cell proliferation [146].  To control the immediate infection and limit replication of the invading 
virus, the  non-specific innate immune system of the host recognizes pathogen associated 
molecular patterns (PAMPs) of the virus  [149]. The infected cells and innate-system cells such 
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as MΦs, pre-DCs and iDCs continually sample their surroundings to detect the presence of 
invading pathogens through pattern-recognition receptors (PRRs).  
 
Recognition of PAMPs by PRRs of the infected cells initiates a cascade of signalling that results 
in the production of Type I inflammatory cytokines IFN-α and IFN-β  to help the cells defend 
against infection or to limit viral replication even if this means death (apoptosis) of infected host 
cells. In addition to acting for the benefit of the infected cells themselves, these inflammatory 
cytokines are also released into the local environment and alert the surrounding cells to the 
presence of infection [150]. Secreted type I IFNs, IFN-α/β, activate the same antiviral 
mechanisms in the neighbouring cells, helping them to resist virus infection. As these responses 
are amplified by cells in the area, a local inflammatory antiviral state is established [151, 152]. 
HSV-1 infection can interfere with the induction of an antiviral state by reducing IFN-α secreted 
by DCs. This was observed in a mouse model where HSV-1 infection resulted in reduced ability 
for IFN-α secretion by otherwise high secreting plasmacytoid DCs [153].  
 
Additionally, although expression of maturation/activation molecules of all the CD11c+ DC 
subsets was unaffected by in vivo infection of mice with HSV-1, the ability of these DCs to 
induce allo-T cell proliferation, and to secrete the Th1-type cytokine IFN-γ, particularly with 
respect to CD8+ cell secretion, was reduced yet Th2-type cytokine secretion was unaffected. 
Thus, through its action on the DC, HSV-1 infection induced a Th2-type response as opposed to 
the more desirable antiviral Th1-type response [153]. HSV-1 infection also blocked IFN-γ 
signalling in mDCs by impairment of the interferon-γ-induced, signal transducer and activator of 
transcription 1 (STAT1) signalling pathway. This was executed by down-regulation of the IFN-γ 
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receptor alpha chain (IFNGR1) mRNA (thus reducing expression of IFNGR1 on the cell 
surface), inhibition of STAT1 phosphorylation in response to IFN-γ, and the subsequent 
inhibition of downstream activation of the IFN-γ inducible interferon regulatory factor 1 (IRF-1) 
[154]; a molecule that as a transcription factor activates expression of IFN-β and that also 
functions as a transcriptional activator or repressor of genes involved in IFN-γ-mediated host 
response and immunity including MHC I antigen processing [154], regulation of apoptosis, 
tumor suppression, and DNA damage. 
 
 HSV-1 also could hamper DC induction of the antiviral response by interfering with migration 
of antigen-loaded DC from infected tissue to the secondary lymphoid organs. CCR7 and CXCR4 
are receptors that are usually expressed by mDCs and that induce trafficking to their ligands 
CCL19 and CCL12 in the LN. Infection of mDCs with HSV-1, or of iDCs prior to maturation, 
caused either down-regulation of CCR7 and CXCR4 from the mDCs or failure of iDCs to up-
regulate CCR7 and CXCR4 following maturation [155]. Chemokines are also secreted in 
response to virus and these provide the signals that recruit circulating MΦs, PMNs, natural killer 
cells (NK cells) and γδT cells to the site of infection [137]. Stimulation of these cells by the 
combination of  IFN-α/β and PRR signalling promote sustained release of pro-inflammatory 
cytokines IL-1, TNF-α, and IL-6 [108]. NK cells recognize and kill virus-infected cells and 
release IFN-γ [156]. Chemokines such as CCL3 (MIP-1α), CCL4 (MIP-1β), CCL20 (MIP-3α) 
and CXCL10 (IP-10) are ligands for receptors (CCR1, CCR5, and CCR6) that are highly 
expressed by iDCs. Thus release of these chemokines serves to attract iDCs to the very site 
where viral proteins are being released from apoptotic infected cells [106]. Within this “stew” of 
inflammatory molecules and signals, iDCs are taking up antigenic viral proteins, processing them 
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and being influenced as to the type of adaptive response they will ultimately induce [106]. Thus 
any interference by the virus on the DCs’ ability to secrete or be stimulated by cytokines 
ultimately interferes with the effectiveness of the immediate antiviral response and the 
subsequent adaptive response. Fortunately, although this initial delay in the generation of 
immune responses to HSV at peripheral sites is accomplished by viral disruption of DC function, 
it is ultimately overcome by bystander DC maturation (soluble factors secreted by DCs after 
infection induced DC maturation of the surrounding uninfected DCs) [157] and the ability of 
non-infected and specialized subsets (ie. CD8α) of DCs to cross-present exogenous viral antigen 
on MHCI molecules--a method by which CD8 T cell responses can be induced/achieved, viral 
immune evasion mechanisms notwithstanding [157, 158].    
 
1.2.5 Modulation of Immune Response by DCs 
Influenced by the local inflammatory antiviral state, iDCs undergo maturation and secrete 
successive waves of cytokines that recruit Mo, lymphocytes and more NK cells to the area [159]. 
Viral infection typically results in sufficient inflammation that strong recruitment of lymphocytes 
and NKs occurs, and these infiltrating cells then begin secreting large amounts of IFN-γ. In this 
environment of IFN-γ, maturing DCs develop; travel to the LN and up-regulate the co-
stimulatory molecules that enable them to prime an adaptive immune response. For most viral 
infections including herpesviruses, this involves  priming naive T cells and driving CD4
+
 cells 
toward an antiviral Th type I (Th1) phenotype [106]. In the absence of these signals, anergy or 
tolerance is induced (not desired for an adaptive antiviral response) [160]. Induction of CD8+ 
CTLs requires Th1 assistance, so induction of sufficient Th1 cells is critically important for an 
anti-viral CD8+ response [161]. Mature DCs (described above) provide the signals that activate 
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naïve B cells to plasma cells (IL-12, IL-6/soluble IL-6Rα), and CD40-activated memory B cells 
(IL-6/soluble IL-6Rα) to IgG-secreting cells [162, 163]. When antigen-specific CD4 T cells and 
antigen-specific B cells interact with mature DCs through BAFF/Blys-L (on DC and T-cells); B 
cells proliferate and antibody is produced and secreted [164, 165]. Mature DCs readily prime Th 
cells. Thus Th activated by mature DCs complete the immune response by interacting with B 
cells (antibody production), MΦs (activate them), and infected cells (lysis) [137].  
 
1.3 Bovine Beta-Defensins 
 
1.3.1 Host Defense Peptides 
Host defense peptides (HDPs) are small mostly cationic molecules that participate in the early 
host defence response against microorganisms. Since the primary function of these peptides was 
originally considered to be their antimicrobial activity, they are also known as antimicrobial 
peptides (AMPs). HDPs are molecules of innate immunity, so called because they are gene-
encoded, quickly expressed or delivered anti-infection tools of the host. AMPs of plants 
(thionins), that were toxic when injected in animals, were isolated in the 1970s and since then 
non-toxic plant AMPs called plant defensins were discovered and characterized [166, 167]. 
Similar peptides have been described in insects [168], arthropods  and molluscs [169], fish and 
amphibians [170] and vertebrate animals [170, 171]. More than 2000 of these natural peptides 
have been found in eukaryotes and bacteria [172], and over 700 AMPs have been isolated from 
mammalian tissues [173]. HDPs possess direct antimicrobial as well as anti-infective, anti-tumor 
or immunomodulatory properties [172, 174] and are divided into two main groups: (1) 
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cathelicidins and (2) the α- defensins and β-defensins [175]. The diversity of functions fulfilled 
by some of the mammalian α- and β-defensins in host defense are illustrated in Figure 1.4. 
 
 
 
Figure 1.4 Functions of defensins. In addition to antimicrobial activity, defensins participate in 
host defence by carrying out a variety of functions that contribute to the innate and adaptive 
immune response. (Adapted by permission from Macmillan Publishers Ltd.: Nature Reviews 
Microbiology, Lehrer (2004) [176]. http://www.nature.com/nrmicro/index.html) 
 
1.3.1.1 Cathelicidins 
Cathelicidins are a diverse family of small (12-100 aa) cationic amphipathic peptides that derive 
their name due to the homology of their evolutionarily conserved pro-sequence to the porcine 
neutrophil protein cathelin. They are produced as precursor, with an N-terminal signal peptide, a 
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highly conserved cathelin domain, and a variable (sequence and structure) C-terminus that is 
cleaved off to give the mature peptide [177, 178]. Once the signal peptide has targeted the 
cathelicidin to storage granules or to the exterior of the cell it is cleaved off.  Further processing 
to form two disulfide bridges yields a storage form holoprotein or “pro-protein”. When the cell is 
activated, proteolytic cleavage of the holoprotein at a cleavage site between the cathelin domain 
and C-terminal peptide occurs; and the active mature peptide is released [179, 180]. The four 
possible structures of mature C-terminal cathelicidin peptides and an example of each are: α-
helical (human LL-337), proline-rich (bovine Bac-5), disulfide bonds and/or β-sheets (bovine 
Protegrin) and tryptophan-rich (bovine Indolicidin) [177, 180]. 
 
1.3.1.2 Alpha-Defensins 
Mammalian defensins are a family of secreted cationic and highly disulfide-bonded peptides. 
They are divided into three subfamilies α-, β-, and Ө defensins based on the linear location and 
spacing of their cysteine residues and disulfide pairing of their six conserved residues [175]. The 
disulphide-paired cysteines of the α-defensins are linked Cys [1-6], Cys [2-4], and Cys [3-5]; and 
for the β-defensins they are linked Cys [1-5], Cys [2-4] and Cys [3-6]. The Ө-defensins are 
structurally dissimilar and derived from mutated α-defensin genes. As such they are backbone 
cyclic octadecapeptides that are stabilized by three disulfide bonds [181]. In Table 1.2 some of 
the known mammalian α- and β-defensins are listed with their characteristics described [182-
185]. The first α-defensins were discovered in rabbit aMΦ and they had microbicidal activity and 
antiviral activity toward HSV [186, 187]. The same peptides could not be found in rabbit 
peritoneal MΦs [188], but were isolated from rabbit neutrophils and so were renamed NP-1 and 
NP-2. With the additional four peptides that were discovered in rabbit peritoneal neutrophils, a 
 38 
total of six α-defensins (NP1-6) were isolated and characterized from rabbit [189]. Currently 
there are six known human α-defensins (HNP1-6). HNPs1-4 derive from the cytoplasmic 
granules of polymorphonuclear leukocytes (PMN; neutrophils), and have HSV-1 antiviral and 
broad spectrum antimicrobial activities [190]. HDP5 and 6 are expressed in the small intestinal 
Paneth cells (specialized secretory cells at the base of the small intestinal crypts) [191], as well 
as in epithelial cells of the female genital tract and are known mediators of antimicrobial defense 
[192]. Mouse α-defensins (cryptidins) are also expressed by small intestinal Paneth cells [193, 
194] but not by PMNs [195]. Mouse cryptidins 1-6 have potent antimicrobial activity against 
specific microorganisms that is initiated by the microbially stimulated release of their cryptidin-
containing granules from the Paneth cells to the lumen of the crypts of Lieberkhun in the small 
intestine, where the α-defensins also influence mucosal immunity [193, 196, 197]. Interestingly, 
neither α-defensins nor the genes encoding for them have been found in cattle [198]. 
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Table 1.2 Mammalian α- and β-defensins: sources, expression, and immune functions 
       Activity relevant to 
immunity 
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HNP1-3 α Human N, 
CD8 T 
C 
I 
D 
S 
C/EBPa *Microbicidal 
*Antiviral 
*Chemotactic 
*Promote 
phagocytosis 
*Mast cell 
degranulation 
*Stimulate 
cytokine, 
chemokines 
*Regulate 
complement 
activation 
*Inhibit 
ACTH 
receptor and 
glucocorticoi
d production 
*Recruiting 
immune cells 
 
*Inducing 
cytokines 
 
*Enhancing Ag-
specific 
humoral and 
cellular IRs 
 
*Resistence to 
bacterial 
invasion 
HNP4 α  “  “ “     “ C/EBPa 
HD5 α  Paneth 
cells/GI, GU 
tract 
C D NF IL-6 
HD6 α  “  “ C D NF IL-6 
Cryptdins α Mouse 
Rat 
Paneth 
cells/GI tract 
C D ND
a
 
NP1-2 α Rabbit aMΦ C D ND 
HBD1 β Human K, EC/GI, 
GU,OM,P, 
Ki,Co,L,T,  
Sk, Ear, Si 
C 
I 
S ND *Microbicidal 
*Chemotactic 
via CCR6 
(HBD2, 
mBD2) 
*Mast cell 
degranulation 
*Stimulate 
cytokine, 
prostaglandin 
*DC 
maturation 
via TLR4 
(mBD2) 
*Enhancing Ag-
specific 
humoral and 
cellular IRs 
 
*Resistence to 
bacterial 
invasion 
HBD2-4 β Human K, EP/,L,T,  
Sk, Eye, Si 
I S NF-кB 
mBD1 β Mouse Gut,H,Ki,L,a
MΦ,U 
C - ND 
mBD2 β Mouse K,U,H,A I - ND 
mBD3 β Mouse Si,L,Li I - ND 
pBD1 β Pig A,GI,OM,To C - ND - - 
sBD1 β Sheep GI,T ND - ND - - 
sBD2 β Sheep GI ND - ND -  
TAP β Cow EC/T, aMΦ I S NF-Кb, 
NF IL-6 
 
*Microbicidal 
 
- 
LAP β Cow To,T I S NF-Кb, 
NF IL-6 
- 
EBD β Cow Si I S NF IL-6 - 
BNBD1-3, 
6-11 
β Cow N C D - - 
BNBD4 β Cow N, aMΦ,  T, 
dSi, L Sp 
C D - - 
BNBD5 β Cow N, aMΦ C D - - 
BNBD12,13 β Cow N,T,C,dSi C D - - 
N= neutrophil, C= constitutive, I= inducible, D= degranulation, S= secretion, C/EBPA= CCAAT/Enhancer-
binding protein, GI= gastrointestinal, GU= genitourinary, NF= nuclear factor, K= keratinocyte, EC= 
epithelial cell, OM= oral mucosa,  P= pancreas, Ki= kidney, Co= colon, L= lung, T= trachea, Sk= skin, Si= 
small intestine, dSI= distal Si, H= heart, U= uterus/female reproductive organs, A= airway, Li= liver, To= 
tongue, Sp= spleen, 
a 
Not determined, - Not known 
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(Adaped from Diamond and Bevins (1998) [185], Kaiser and Diamond (2000) [182], Ganz 
(2003) [184], Yang ( 2004) [183]). 
 
1.3.2 Beta-Defensins 
β-defensins are cationic, membrane active, antimicrobial proteins of the innate immune system 
that participate in defense against microbiological pathogens [199]. They are 38 to 42 amino 
acids in length (cattle), with three intra-molecular disulphide bridges [199-201]. As mentioned 
above, they differ from the α-defensins by their disulfide pairing and they are linked Cys [1-5], 
Cys [2-4] and Cys [3-6]. Also, where biosynthesis of the α-defensins involves cleavage of a 
signal peptide from the prepro-α-defensin to produce a pro-α-defensin, and this pro-peptide has 
little or no antimicrobial activity in vitro due to the nature of the pro-piece that is large (about 40 
aa) and anionic [202]; the β-defensins have a much shorter pro-piece separating the signal and 
mature peptide. This would result in a pro-β-defensin with a more cationic nature and would be 
expected to result in a different way of trafficking within the cell as compared to a pro-α-
defensin [175]. β-defensins are evolutionarily older than the α-defensins and it is thought that the 
β-and the α-defensins evolved from a common β-defensin ancestor [203]. From the common 
ancestor it is postulated that α-defensins came about by repeated gene duplication of β-defensin 
coupled with positive diversifying selection which is the evolutionary response to the changing 
makeup of microbes in the host habitat [204, 205]. Perhaps the above explain why β-defensins 
are found in a much broader range of species [188] and expressed in a wider variety of tissues 
than are α-defensins [175, 182, 184].  
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1.3.2.1 Human Beta-Defensin  
Although a large number of new human β-defensin genes have been reported [206], there are 
currently six known β-defensins and the first four, namely human β-defensin 1 (hBD1), human 
β-defensin 2 (hBD2), human β-defensin 3 (hBD3), and human β-defensin 4 (hBD4) have been 
characterized in detail. hBD1, hBD2 and hBD3 are mainly expressed in the skin and in the 
epithelial lining of the urinary and respiratory tracts although hBD3 is also expressed in non-
epithelial cells of the heart, liver and placenta [207, 208]. hBD4 and the more recently 
discovered human β-defensin 5 (hBD5) and human β-defensin 6 (hBD6) [209, 210] are primarily 
expressed in the testis and epididymis [208]. All human β-defensins characterized have the 
ability to kill or inhibit in vitro bacteria and fungi although much of this ability is salt- and 
plasma protein-sensitive. Additionally antiviral effects have been reported, particularly with 
respect to in vitro  inhibition of human immunodeficiency virus (HIV) -1 by hBD2 and hBD3 
[211, 212]. HIV-1 induced expression of hBD2 and hBD3 in human oral epithelial cells [212] 
and hBD3 was able to induce maturation and Th1 skewing in human langerhans cell-like DCs 
(LC-DC) [213]. Thus it is tantalizing to think that a β-defensin might have been part of the 
soluble factors secreted from DCs after HSV-1 infection that had the ability to induce maturation 
and increase IL-12 secretion of uninfected iDCs [157]. In addition to effects on maturation, 
human β-defensins can also contribute to the induction of acquired immune responses by 
recruiting immune cells to sites of inflammation. Human β-defensin 2 was chemotactic for iDCs 
and memory T cells through its interaction with CCR6 expressed by the cells [214] and hBD3 
was chemotactic for CCR2-expressing cells such as Mo, MΦs and neutrophils [215]. 
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1.3.2.2 Murine Beta-Defensin 
Many β-defensins have also been described in the mouse [185], and this been particularly useful 
to study and predict the effects of β-defensins in human and other species. Murine β-defensin 4 
(mBD4) and  Murine β-defensin 14 (mBD14), the reported orthologs for hBD2 and hBD3 
respectively, interact with CCR2 and induce chemotaxis of human Mo and mouse peritoneal 
exudates cells [215]. Much work was done to establish the immunomodulatory effects of murine 
β-defensin 2 (mBD2) at the time when it was thought to be the homolog for hBD2. In a toll-like 
receptor (TLR) 4-dependent manner, mBD2 increased activation and maturation of mouse iDCs 
as evidenced by upregulation of costimulatory molecules and CCR7 with an increased Th1-
polarizing proinflammatory cytokine profile [216]. mBD3 was chemotactic for murine bone 
marrow-derived DCs, and induced protective anti-tumor immunity in mice immunized 
intradermally with an mBD2/ tumor antigen fusion construct [217]. In a murine model, 
intradermal (ID) DNA immunization with an mBD2/gp120 fusion construct induced antiviral 
responses including mucosal CTL and neutralizing antibody to the HIV-1 envelope glycoprotein 
gp120 [218].  
 
Immunomodulatory characteristics such as the ability to chemo-attract iDC and to activate and 
mature iDC to mDC have not been established for the majority of β-defensins of large animals 
(ie cattle). If it was shown that β-defensin could attract iDCs of large mammals and subsequently 
mature them to boost immune responses, then β-defensin would have potential as an adjuvant in 
vaccines for cattle and other large animals. 
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1.3.2.3 Bovine Beta-Defensin 
In cattle, sixteen β-defensins have been discovered, thirteen are produced by bovine neutrophils 
(BNBD 1-13) [219]; one is produced by tracheal epithelial cells (TAP) [199]; another is 
produced by squamous epithelial cells of the tongue (LAP) [200]; and one is produced by the 
epithelial cells of the intestine (EBD) [201]. As with all other mammalian β-defensins, the 
bovine β-defensins are cationic and antimicrobial, but the mechanism has not yet been 
elucidated. Additionally, the β-defensin genes have two exons. The first exon encodes the 5’UTR 
and leader domain of the pre-pro-peptide. The second exon encodes the mature peptide [220, 
221]. Expression of bovine β-defensin is inducible by endotoxin, LPS and TNF-α [222-224]. An 
overview of α- and β-defensin translation and post-translational processing is shown in Figure 
1.5. Similar to the cathelicidins, the translation product is an inactive precursor (pre-pro-peptide) 
with an N-terminal signal sequence, a short pro-piece and a C-terminal mature peptide that is 
released as an active peptide when it has been cleaved by proteolytic processing [225]. BNBDs 
1-13 are constitutively expressed (produced and stored) by the neutrophil during the 
promyelocyte stage, and are released in response to inflammatory mediators (LPS etc.) [185]. 
The epithelial β-defensins TAP, LAP and EBD, are inducibly expressed under conditions of 
infection and inflammation [200, 201, 226].  
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Figure 1.5 A schematic of translation and post-translational processing of defensins. 
Defensins are translated as larger precursor polypeptides consisting of the prepiece, the propiece 
(often anionic), and the mature peptide. The prepiece is a highly hydrophobic signal peptide that 
is proteolytically cleaved in the Golgi body. The prepro region is proteolytically removed as a 
post-translational modification (hBDs, TAP, LAP, EBD) . Cleavage of the propiece differs for 
different defensins. For HNPs (and BNBDs) the propiece is proteolytically removed in the Golgi 
body, and the mature peptide is sorted to the primary granules of neutrophils for storage. HNP5 
is stored in granules of Paneth cells and is released as the proform. Interestingly, removal of the 
propiece of HD5 and cryptidins occurs extracellularly and is mediated by trypsin and matrilysin 
respectively. The enzyme(s) responsible for the removal of the propiece of β-defensin is 
unknown. Both α- and β-defensin peptides can be further processed by removal of individual 
amino acids from the N-terminus of the mature peptide. This variable processing can generate 
multiple forms of the mature peptide, and likely contributes to biological diversity. (Adapted 
from Yang et al. (2004) [183]). 
 
Based on gene structure characteristics such as site of expression, elements of regulation, intron 
size, and sequence similarity, bovine β-defensins are grouped with the epithelially-expressed 
human β-defensin 2 (hBD-2) [185]. Recently, bovine β-defensin genes were screened for 
molecular evolution. EBD and TAP were unchanged, and thus are considered subject to 
stabilizing negative selection (removal of changes/alleles that would be detrimental), while 
BNBD5 and BNBD9 were evolving under positive selection. Even with variances, or under 
positive selection pressure, all the peptides conserved the β-defensin consensus characteristics: 
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the triple-stranded β-sheet, the general fold, and the short amino terminal α-helix [227]. 
Interestingly, a novel β-defensin-like gene called bBD1 gene was found using primers designed 
to clone cDNA of an AMP expressed in bovine mammary epithelial cells that would be similar 
to hBD1. The cDNA predicted a 69 amino acid pro-peptide similar to hBD1. Gene organization 
study showed that the novel bBD1-gene had one long intron (8547 base pairs (bp)) as does the 
human β-defensin 1 (hBD1) gene (6962 bp) whereas the other bovine β-defensins had intron 
lengths of approximately 1500 bp. There was 57% similarity in sequence between bBD1 and 
hBD1, but only 34% when compared to LAP; whereas LAP showed 78, 86, and 89% similarity 
to BNBD4, EBD and TAP, respectively. The bBD1 transcript was detected in the teat, mucosa, 
kidney, vagina, ovary, oviduct and colon and a synthetic bBD1 peptide had antibacterial activity 
against E. coli. [228]. The results of this study suggest a homology in structure and function of β-
defensins between species and additionally suggest that more bovine β-defensins might exist, 
although isolation of the mature peptide from tissue still should be required as proof-positive. 
 
1.3.2.3.1 Bovine Beta-Defensin 3 
BNBD3 is one of thirteen bovine neutrophilic β-defensins that were numbered according to their 
increasing retention times on RP-HPLC. Based on the original isolation and characterization of 
these peptides from bovine neutrophils, BNBD3 is a mature 42-residue peptide with an N-
terminal pyroglutamyl residue and a calculated molecular weight of 4809 (UniprotKB/Swiss-
Prot accession number P46161). The peptide conforms to the β-defensin consensus that consists 
of 27 residue positions including the 11 absolutely conserved residues, the 16 residues where 
substitutions are conservative or limited, and the 3 disulphide bonds specified Cys [1-5], Cys [2-
4] and Cys [3-6]. BNBD3 is the most abundant of the 13 neutrophilic β-defensins, present at 
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approximately 2.2 mg / 4.9 mg (equals 10
10
)  neutrophils or 45%. It has antimicrobial activity 
against E. coli ML35 and S. aureus 502A [219]. It is a basic peptide with a predicted pI of 11.71 
and a net charge of 10
+
.  
 
1.3.3 Beta-Defensins In Immune Modulation 
Protective immunity to pathogens depends on accurate yet flexible immune responses tailored to 
the type of pathogen and the infected tissue. One of the very first steps to accomplishing 
immunity is to get the required immune cells to where they are needed. Defensins are potently 
chemotactic for a variety of immune cells, perhaps due their structural similarity to cytokines 
[229]. Specifically, hBD2 can recruit iDCs and the memory subset of peripheral blood 
(CD4+/CD45RO+) T cells [214]. hBD2-3 can recruit neutrophils and mast cells and induce mast 
cell degranulation [230-233]. Few receptors for immune cell recruitment by β-defensins are 
known with the exception of CCR6 for iDC and (CD4+/CD45RO+) T cells by hBD2 [214], and 
CCR2 for Mo by hBD3 [215]. Glycosaminoglycans may serve as a type of receptor to enhance 
chemotaxis of cells to β-defensins [234]. Production and release of β-defensin by cells in 
response to infection or trauma encourages migration of immature dendritic cells (iDC) from the 
circulation to the tissue [217, 218]. As more iDCs migrate into the area, it becomes more likely 
that a pathogen will be taken up by iDCs. Also, β-defensin peptides may form complexes with 
proteins, peptides and dying cells from infection and effectively target them to the iDC resulting 
in improved trafficking through cellular compartments, processing and presentation that includes 
cross presentation on MHC I molecules [161].  
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β-defensin also induces cells to express pro-inflammatory cytokines and chemokines [217, 235]. 
Treatment of keratinocytes with hBD3 induced CCL2 (MCP-1), CCL20  (MIP-3α),  and 
CXCL10  (IP10) [236]. Treatment of Mo with hBD3 induced IL-8, IL-6, and IL-1β through Toll 
like receptors (TLRs) 1 and 2 [237]. The murine β-defensin mBD2 acts directly on iDCs as an 
endogenous ligand for TLR 4 causing up-regulation of costimulatory molecules and maturation 
of DCs [216]. LL37 and several other cell-penetrating cationic peptides were recently found to 
enhance signalling by TLR3 and enable TLR3 to respond to dsRNA stimulation [238]. TLR3 
was expressed by the CD8α DCs that were involved in priming HSV-1 CD8 T cells; and in that 
study, for priming to occur, there had to be co-expression of TLR3 and the MHC class I-
restriction element by the presenting CD8α DC [239]. It is intriguing to think that β-defensins 
might also be acting on TLR3 of CD8α DCs and that this might explain at least in part, the 
stimulatory ability and Th1-polarized responses of DC treated with the cationic defensin peptide 
mBD2 [216], and the potent in vivo MHCI-restricted primary T cell responses primed in mice by 
vaccines encoding mBD2 [161].  
 
The influence of these substances on the iDC induces maturation, and the DCs become licenced 
to migrate from the tissue to the LN where they present antigen to prime naïve T-cells [137]. 
Sufficient signals are critical to maturation. Without these, anergy and/or tolerance result [240]. 
Mature antigen presenting DCs are potent, and uniquely capable of initiating both humoral and 
cell mediated primary immune responses through cross presentation of antigen on both MHC I 
and MHC II molecules [110, 114, 217].  β-defensin has potential to provide both the chemotactic 
impetus and the maturation signal and thus satisfy the above requirements in a DC targeting 
immunization strategy for BoHV-1 that mimics natural infection. 
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1.4 DNA Vaccines 
 
A DNA vaccine is described as an antigen encoding plasmid that, when introduced into the body, 
results in in vivo expression of the antigen, with a subsequent antigen-specific immune response 
[241]. DNA vaccines consist of a recombinant foreign gene cloned into a double-stranded, 
closed-circular bacterial plasmid vector. The plasmid generally contains an origin of replication 
(for amplification in bacteria), a bacterial antibiotic resistance gene (to allow for selection), the 
gene(s) of interest under the transcriptional control of a (viral) promoter and enhancer sequences 
(to obtain strong expression in mammalian cells) followed by a mRNA polyadenylation 
sequence (to stabilize the mRNA transcripts) [242].  
 
1.4.1 Benefits of DNA Vaccines 
Compared to other types of vaccines, DNA vaccines are cost-effective; they can be designed, 
manufactured and stored with relative ease [241]. They are non-infectious and do not promote 
inflammation at the site of immunization; important factors in vaccinations for food animals 
[243]. DNA vaccines can be used as marker vaccines to differentiate vaccinated and infection-
exposed animals in eradication programs [243]. They also have potential to initiate immunity in 
neonates born to immune mothers [244]. DNA vaccines stimulate both humoral and cellular 
immunity, and thus promote development of a balanced immune response [108, 243]. In the 
induction of humoral and cellular immune responses, DNA vaccines seem to mimic the effects 
of natural infection (or live attenuated vaccines) in at least two ways: they are able to induce 
MHC class I-restricted  CD8 T-cell (CTL) responses [241, 245]; and, they have the ability to 
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generate neutralizing antibodies to epitopes formed by non-contiguous regions which suggests 
that antigen expressed in vivo after DNA vaccination can assume a native configuration [246].  
 
1.4.2 Immune Responses Induced by DNA Vaccines 
In 1990, Wolff et al showed that injection of pure plasmid or “naked” DNA into the muscles of 
mice resulted in long-term expression of encoded reporter genes [247].  Induction of antigen-
specific immune responses with plasmid DNA was first reported by Tang et al, when mice 
immunized with plasmid encoding human growth hormone (hGH) developed an immune 
response specific for the hGH [248].  Since then, there have been more than 600 reports of 
successful induction of immune responses in animals given DNA vaccines [249]. Although 
many of these studies used the mouse as an experimental model, and results with large animals 
have not been as encouraging [243], DNA immunization has shown efficacy in primates and 
veterinary species [250], and human clinical evaluations have been initiated for HIV, hepatitis B 
virus (HBV) and influenza viruses [108]. The successes in induction of appropriate and 
protective immune responses in mice as a result of  DNA vaccination, have not been equalled 
when the technology has been transferred to large animals [249]. It has been suggested that a 
more robust response could be obtained by targeting the DNA vaccine or its expressed antigen to 
professional APCs such as DCs [242, 251]
 
. 
 
1.4.2.1 Antibody Responses 
DNA vaccines tend to induce less potent antibody responses in many different animal models 
than they do cellular responses [252]. This may be due to the encoded antigen getting expressed 
from within the transfected cell; thus as an “in-cell” antigen, it may be more likely to be 
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processed via the endogenous pathway with the subsequent peptides loaded onto and presented 
by MHC I molecules. It is only when antigen is released outside the cell, or when taken up from 
a dying cell, that it becomes available as exogenous antigen to the MHC II pathway (induction of 
required Th cells) or to the B cell receptor. Perhaps humoral responses are limited by this 
consequent limited availability of free antigen. This would seem sensible as secreted antigen is 
more likely to become “free” antigen, and humoral responses to DNA-encoded secreted antigens 
are higher than to their cell-associated counterparts [44, 253, 254]. Yet it has also been reported 
that DNA vaccination induction of CTLs has led to enhanced humoral responses [255] which 
suggest a possible synergistic generation of both humoral and cellular arms of adaptive immune 
responses. Protective antibody responses have also been observed after immunization with a 
HBV DNA vaccine that also induced antigen-specific Th cells and CD8 T cells [256]. Peak 
antibody responses occur 4-12 weeks after DNA vaccination which is relatively slow, but the 
response tends to be of long duration [257], and the antibody tends to be of good neutralizing 
ability, and to have good avidity (reviewed in [241]). In comparative studies, humoral responses 
have been greater in response to immunization with a sub-lethal dose of live virus [258], or to a 
protein based vaccine [259], than to the antigen-equivalent DNA vaccine. Antibody subtypes of 
IgB, IgA and IgG are generated in response to DNA vaccination and the subclass is typically 
influenced by the Th1 cytokine bias of DNA vaccines such that in mice antibody of subclass 
IgG2a/b was more commonly observed than was IgG1 [260]. Secreted DNA-encoded antigen 
tends to induce antibody of the IgG1 subclass [253], as does vaccination via gene gun [260]. 
Intradermal delivery by gene gun could be modified to induce a balanced IgG1 and IgG2 
response by providing additional immunostimulatory signals either by co-delivery of cytokine or 
by increasing immunostimulatory DNA  [261]. 
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Interestingly, how the DNA vaccine is given also influences the type of immune response and 
this may be related to the type and location of cell that is transfected and subsequently expresses 
the antigen. In mice, intramuscular (IM) injection induced mainly humoral responses to DNA-
encoded antigen, that were not dependent on expression of antigen by the muscle tissue at the 
injection site; whereas humoral responses from gene gun delivery were lower and required 
expression of antigen by transfected cells in the skin. Thus skin cells at the site of immunization 
(gene-gun delivery), but not muscle cells at the site of immunization (IM delivery) were 
important for DNA-raised responses  [262]. In large animals such as cattle and pigs, ID delivery 
has been shown to be more effective than IM (reviewed in [263]). In cattle naked/unadjuvanted 
DNA vaccines delivered ID to the ear improved antibody responses when compared to IM 
delivery [44]. Also, the effect of gene gun delivery of DNA vaccines on humoral responses of 
cattle is less clear. In one study, no improvements in humoral responses were attained when 
cattle were primed with a DNA vaccine delivered by gene gun to the genital mucosa 
(intravulvomucosally) [264]. When the effects of ID (to the skin of the hip) versus 
intravulvomucosal gene-gun delivery of a DNA vaccine were compared, humoral responses were 
low in both groups, although intravulvomucosal delivery was able to prime humoral responses 
[265]. However, in another study, humoral responses after gene gun delivery of a DNA vaccine 
to the skin were determined to be of sufficient magnitude, were long lasting and followed a 
general pattern of being primarily Th2 biased (predominantly IgG1 over IgG2) [263].  
 
1.4.2.2 Cellular Responses 
How cellular responses are induced by DNA vaccines can be likened to how they are induced by 
infection by virus or intracellular bacteria. In both cases, pathogen or DNA-encoded proteins are 
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produced within the host cell. Thus DNA vaccine-encoded proteins have a propensity for 
processing via the endocytic host cell pathway with subsequent loading to and presentation by 
MHC I molecules. There are however, three ways that antigen encoded by a DNA vaccine can be 
obtained and this has an effect on how it is processed and presented and thus an effect on the 
type of immune response elicited: (1) Direct priming by somatic cells that occurs when 
transfected resident tissue cells produce the DNA vaccine-encoded antigen; process the antigen 
through the endogenous pathway, and present antigen on MHCI molecules to specific CD8+ T 
cells. This type of  “priming” does not prime naïve CD8+ T cells since the somatic cells lack the 
co-stimulatory molecules required to initiate an immune response [266, 267], but continued 
expression of antigen by somatic cells most likely serves to augment or maintain the immune 
response after DNA vaccination [268]. (2) Direct transfection of professional APCs (bone-
marrow derived cells such as DCs) that occurs when DCs at either the vaccination site or the (LN 
are transfected, produce and process the antigen through the endogenous pathway and present 
antigen on MHC I molecules. There is also evidence that the endogenous antigen can enter the 
exogenous pathway by cytosolic degradation or antigen regurgitation and thus be presented on 
MHC II [241, 269]. These DCs when mature express the co-stimulatory molecules CD80, CD86, 
CD40 and thus by presenting on MHC I they can prime naïve CD8
+
 T cells including induction 
of CTLs [270, 271], or by presenting on MHCII they can prime naïve CD4
+
 Th cells [269]. (3) 
Acquisition of exogenous antigen that occurs when DCs take up the DNA encoded antigen that 
has been secreted from transfected somatic cells (exogenous antigen) or when DCs phagocytose 
transfected dying cells. In this case antigen is normally processed through the exogenous 
pathway and presented on MHC II but DCs have a specialized ability to “cross-present” and by 
this method, the antigen can escape or is released from the endosome to the cytosol where it is 
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processed through the endogenous pathway and presented on MHC I [111, 272]. Additionally, 
antigen-loaded MHC I molecules obtained from the dying cells can be recycled, allowing for 
peptide exchange in the MHC II compartments (MIICs) [273] or can be “cross-dressed” [274] 
and expressed on the surface of the DC. Thus, acquisition of exogenous antigen by DCs can 
result in priming of both naïve CD4
+ 
Th cells and naïve CD8
+
 T cells including CTLs dependent 
on whether the antigen is presented on MHC II or MHC I molecules respectively. In the case of 
cross-dressed antigen, this mechanism does not prime naïve cells, but rather activates and thus 
boosts the response of memory CD8+ T cells [274]. 
 
1.4.3 DC-Mediated DNA Vaccines 
Live attenuated viral vaccines, and vaccines consisting of a related but less virulent strain, can 
mimic natural infection, and effectively induce a protective, balanced immune response [242]. In 
the induction of humoral and cellular immune responses, DNA vaccines also seem to mimic the 
effects of natural infection [241, 245]. Despite these benefits, DNA vaccination typically 
requires large amounts of DNA. Additionally, in outbred, large animal species DNA vaccination 
has not always been successful [243]. Since very small amounts of antigen are produced as a 
result of DNA vaccination, and transfection is an inefficient process, efforts to increase the 
likelihood and the magnitude of an appropriate immune response are rational. It is possible that a 
robust response could be obtained by engineering the DNA vaccine so that its’ expressed antigen 
will attract iDCs. The transfected and antigen-loaded DCs would then act as adjuvants to 
generate an immune response and consequent resistance to infection [106, 275]. 
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1.4.4 Vaccination Strategies for BoHV1 
Currently available MLV and KV BoHV-1 vaccines have been shown to reduce clinical 
symptoms but do not afford adequate protection from infection [98, 99, 276]. Of the two types, 
the MLVs are considered more effective, as they stimulate not only humoral immunity, as is the 
case with KVs, but also CMI [277, 278].  Disadvantages of the current MLVs include: 1) a 
requirement for proper storage and handling (cold chain), 2) they can cause abortions and 
therefore cannot be used for all cattle, 3) vaccinated animals may shed infectious virus and 4) 
there is a risk of development of latency [242, 279] . 
 
1.4.5 Use of Defensin In a BoHV-1 DNA Vaccine to Modulate Immune Response 
The events that lead to the induction of immune responses after inoculation with a DNA vaccine 
are not fully understood [241, 242], but there is increasing evidence that DCs act as adjuvants to 
initiate immune responses to DNA immunization [108, 241, 269, 275, 280].  Steinman et al., 
2006, identified three “intricate and innate” properties of DCs that account for their roles as 
sentinels and sensors in the immune system: 1) special mechanisms for antigen capture and 
processing, 2) the capacity to migrate to defined sites in lymphoid organs to initiate immunity, 
and 3) their rapid differentiation or maturation in response to a variety of stimuli [281]. These are 
the very properties that make them desirable vaccine targets.  
 
Primary antigen-specific, CMI responses are characterized by activation and expansion of T cells 
to Th and CTLs, and only occur when antigen is presented to T cells by professional APCs such 
as DCs in the context of additional immunostimulatory signals [241, 242, 282].  Because the 
quantity of antigen produced in vivo after DNA vaccination is very small (picogram to nanogram 
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range), the APC responsible for initiating an immune response must display great efficiency in 
antigen capture, processing and presentation [241, 283]. As these are characteristics that are 
inherent in DCs, and given the iDC chemotactic nature of human and mouse β-defensins, it 
follows that bovine β-defensin, if chemotactic for bovine iDC, might have potential to increase 
iDC-uptake of the encoded antigen of a DNA vaccine in cattle. By providing the required 
maturation signal, the β-defensin would effect maturation to result in DC priming of naïve T 
cells. It makes sense then, to explore this possibility by designing a DNA vaccine with β-
defensin in such a way that iDCs will be attracted, and that the vaccine and/or its expressed 
antigen will effectively be “targeted” to the iDC and will provide co-stimulatory signals for DC 
maturation.  
 
At each step, the expected impact/benefit of the β-defensin on DC function and subsequent 
immune response to DNA vaccination is depicted in Figure 1.6, and could be described as 
follows. (1) After vaccination, plasmid would be internalized by resident skin cells and the 
encoded antigen synthesized in transfected local cells would be released or obtained by 
phagocytosis of dying skin cells [108, 241]. At this step, if an iDC chemotactic bovine β-
defensin was complexed to the DNA vaccine, we would expect infiltration of greater numbers of 
iDC and perhaps pre-DC with subsequent increased uptake of the plasmid by these cells. If 
encoded by the DNA vaccine, we would expect iDC to be attracted to the site by expressed  
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Figure 1.6 Enhancing immune responses with an iDC-attracting defensin in a DNA 
vaccine. Physical damage from delivery of the vaccine induces release of damage-associated 
molecular patterns (DAMPs) by resident cells. DNA vaccines, by their very nature, contain 
pathogen-associated molecular patterns (PAMPs), and the addition of β-defensin to the DNA 
increases the “danger signal” provided by the vaccine. These PAMPs and DAMPs are detected 
directly by pattern-recognition receptors (PRRs) and chemokine receptors expressed by dendritic 
cells (DCs), and stimulation of these encourages first in-migration of iDCs, followed by antigen 
uptake, DC activation, maturation and migration to the lymph nodes. The chemotactic effect of 
the defensin will encourage migration of greater numbers of pre-DCs and iDCs to the area and 
then the stimulatory effect of the defensin serves to induce maturation/activation and to orient 
and shape DC response. In the lymph nodes, the activated DCs present antigens with co-
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stimulatory signals to prime naïve CD4+ and CD8+ T cells, and evoke their differentiation. 
CD4+ T cells differentiate into various T helper (Th) cell subtypes. Th cells may also acquire a T 
follicular helper (TFH) cell phenotype and foster the development of B cells to  plasma cells or 
the germinal centre pathway. In addition, the cytokine expression profile of TFH cells can dictate 
B cell isotype switching. β-defensin containing DNA vaccines tend to promote IgG2a isotype 
antibody, indicative of a Th1 type response. Migratory DCs will also “pass” antigen to the 
resident splenic DCs that are very efficient at cross presentation. Depending on the balance 
between activating cytokines (Th1-derived IL-2 and other cytokines—see Figure 1.3 legend), 
activated CD8+ T cells differentiate into effector and memory CD8+ T cells. (Adapted by 
permission from MacMillan Publishers Ltd: Nature Reviews Immunology (Desmet and Ishii, 
2012) [284]).  
 
β-defensin and consequently acquire the vaccine antigen. The chances of acquisition of plasmid 
from transfected and/or dying skin cells by iDC would also be increased.  (2) By providing a 
danger signal to the surrounding cells [137], we would expect that β-defensin would  trigger 
increased release of  chemokines CCL3 (MIP-1α), CCL4 (MIP-1β), CCL20 (MIP-3α) and 
CXCL10 (IP-10)  Since iDCs express receptors (CCR1, CCR5, and CCR6 ) for these 
chemokines, more of these cells could be attracted to the site where the vaccine has been placed 
and/or where the encoded antigen is being produced by resident skin cells [106, 137].  (3) As 
with responses of local cells to invading pathogens, β-defensin in the vaccine might be expected 
to trigger increased secretion of cytokines, granulocyte-macrophage colony-stimulating factor 
(GM-CSF) and pro-inflammatory cytokines such as IL-1 and  tumor necrosis factor alpha (TNF-
α) [108]. These cytokines encourage highly phagocytic iDCs to capture dying cells and released-
antigen efficiently using phagocytosis, macropinocytosis and receptor-mediated endocytosis 
[131, 132].  (4) Capture of antigen along with the influence of cytokines in the local 
microenvironment serves to induce maturation of antigen-loaded DCs [106]. CpG motifs present 
in the backbone of the DNA vaccine plasmid also provide a stimulus for DC maturation [285]. 
Maturation down-regulates CCR1, CCR5 and CCR6 expression, and up-regulates expression of 
CCR7. Antigen is processed and DCs undergo phenotypic and functional changes that result in 
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their transition from antigen capturing to antigen processing and presenting cells [135]. During 
this time, expression of CCR7’s ligand, CCL21 (SLC) on the endothelium of the afferent 
lymphatic system, and by the stromal cells in the T-cell zone, direct migration of the maturing 
DC out of the tissue at the periphery and to the LN [137].   
 
In many cases however, there are insufficient signals in the vaccine for maturation of DCs to 
occur. Without expression of CCR7, insufficiently matured DCs cannot properly traffic to the 
LN and thus would be unable to undertake the next steps that lead to induction of an efficient 
antiviral immune response. As an agent of maturation, β-defensin at this step should ensure 
upregulation of CCR7 with subsequent trafficking of the DCs to the LN. (5) The “licensing” of 
DCs, which is mediated by pathogen-derived signals and characterized by expression of CCR7, 
is followed by full maturation of DCs which takes place in the LN and may also be driven by 
CCL19 (MIP3-β/ELC) and CCL21 (6Ckine/SLC) [286]. In the LN, mature antigen-presenting 
DCs stimulate naïve T-cells through up-regulation of their surface costimulatory molecules 
CD80 (B7.1), CD86 (B7.2), and CD40, which bind to CD28 and CD40L (CD154) respectively 
on T cells. Expression of costimulatory molecules is a critical step in the DC maturation process 
and is required for T cell recognition of the presented antigen and subsequent T cell-mediated 
terminal maturation of DCs, a process characterized by further up-regulation of co-stimulatory 
molecules and the release of IL-1 and IL-12 by DCs and IFN-γ by T cells [139]. At this step the 
positive effect of β-defensin in the vaccine would be to assure maturation of the DC. As detailed 
previously (section 1.2.5), in the induction of humoral responses, mature DCs activate naïve B 
cells to plasma cells, and stimulate CD40-activated memory B cells to IgG-secreting cells [162, 
163]. Antigen-specific CD4 T-cells and antigen-specific B-cells interact with mature DCs, B-
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cells proliferate and antibody is produced and secreted [164, 165]. Obviously, DC maturation is 
critical for the inductive steps of DNA vaccine-induced immunity as outlined above, but in 
addition, antigen-presentation by an un-matured DC is known to induce tolerance to the antigen; 
a response that would be completely undesirable. Thus β-defensin may act to both improve 
induction of appropriate antiviral immune response and prevent unintentional induction of 
tolerance to the vaccine antigen.  
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2. HYPOTHESIS AND OBJECTIVES 
 
I hypothesized that attracting iDCs to the site of DNA vaccination with β-defensin would result 
in improved uptake, processing and presentation of tgD by DCs leading to strong humoral and 
cell-mediated immune responses that would subsequently protect cattle upon challenge with 
BoHV-1. 
 
Objective 1:   Assess the chemotactic activity of bovine β-defensins for iDCs (in vitro and in 
vivo) and select the most chemotactic. 
Objective 2:   Construct plasmids that express the chemotactic β-defensin(s) alone and in 
combination with the BoHV-1 antigen tgD. Assess the immune and protective responses induced 
by intradermal DNA vaccination of mice and cattle using the plasmid treatment(s) with the most 
chemotactic β-defensin. 
 Objective 3:   Determine the potential of a BNBD3/DNA complexed vaccine to improve 
humoral immune responses of mice and maintain robust cell-mediated responses, and to assess 
the immunomodulatory effects of BNBD3 in vitro on murine bone marrow derived DCs. 
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3. THE SYNTHETIC PEPTIDES BOVINE ENTERIC ß-DEFENSIN (EBD), BOVINE 
NEUTROPHIL ß-DEFENSIN (BNBD) 9 AND BNBD3 ARE CHEMOTACTIC FOR 
IMMATURE BOVINE DENDRITIC CELLS 
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Third Chapter Transition/Overview 
In this chapter/manuscript I addressed the first objective of the project which was to assess the 
chemotactic activity of bovine β-defensins for iDCs (in vitro and in vivo) and select the most 
chemotactic. Bovine iDCs were generated from bovine monocytes and were defined 
phenotypically at day 3 of culture by the expression of DC-specific receptors, and functionally 
by phagocytosis, proliferation and chemotaxis assays. Fourteen of the sixteen known bovine β-
defensins were correctly synthesized. Using chemotaxis assays I screened these synthetic 
peptides for their ability to attract bovine iDCs.  Bovine iDCs were consistently and equally 
attracted to BNBD3, BNBD9 and bovine EBD in vitro. Of the three peptides, BNBD3 was 
selected as the best peptide to be used for the rest of the project because 1) it was the peptide 
with chemotactic activity for iDCs from all animals tested; 2) it had the greatest chemotactic 
activity for iDCs at the lowest concentrations; 3) it was the peptide with the least complicated 
coding sequence for the mature form of the peptide, thus it was straightforward to encode in the 
DNA construct (s); 4) it was one of the simplest peptides to synthesize and gave good yields of 
correctly folded peptide; and 5) it is the most abundant (60%) of the 13 BNBDs in the bovine 
neutrophil [219]. The in vivo activity of BNBD3 was verified by increased migration of CD205
+
 
DCs in response to ID injection of BNBD3 to the skin These novel findings into the chemotactic 
nature of bovine β-defensins are a first step into exploration of their use in new iDC-targeting 
vaccination strategies. The iDC-chemotactic bovine β-defensin, BNBD3, was used for the 
studies in the subsequent chapters. 
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3.1 Abstract 
 
Human and murine immature DCs (iDCs) are highly efficient in antigen capture and processing, 
while as mature cells they present antigen and are potent initiators of cell-mediated immune 
responses. Consequently, iDCs are logical targets for vaccine antigens.  Originally discovered for 
their antimicrobial activity, and thought of as strictly part of the innate immune system, studies 
with defensins such as human β (beta)-defensin 2 (hBD2) and murine β-defensin 2 (mBD2) have 
shown that they can function as chemo-attractant for iDCs and, in vaccination strategies, can 
enhance antigen-specific adaptive immune responses. Most studies to date have been conducted 
in mice. In contrast, little is known about defensins in cattle. To expand our understanding of the 
role of defensins in modulating immune responses in cattle, DCs were generated from bovine 
monocytes and the immature state of these bovine DCs was characterized phenotypically and 
through functional assays. By day three (DC3), bovine monocyte-derived DCs stained positively 
for DC-specific receptors CD1, CD80/86, CD205, DC-Lamp and MMR. When compared to 
conventional six-day DC cultures or DCs cultured for ten days with and without maturation 
factors, these DC3 were functionally at their most immature stage. Fourteen of the sixteen known 
bovine β-defensins were synthesized and the synthetic peptides were screened for their ability to 
attract bovine iDCs. Bovine DC3 were consistently attracted to BNBD3, an analog of BNBD3 
(aBNBD3), BNBD9 and bovine EBD in vitro and to aBNBD3 in vivo.  These results are the first 
to describe chemotactic ability of synthetic bovine β-defensins for immature bovine monocyte-
derived DCs. 
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3.2 Introduction 
 
Beta-defensins are small (3.5 - 4.5 kDa), cysteine-rich, cationic peptides characterized by an N-
terminal α-helix, and six conserved cysteine residues that form three disulfide bonds, and are 
released upon stimulation by microbial invasion and inflammation [214, 287].  They are either 
made by or released from cells primarily located in skin or mucosa [183, 222], and thus are in a 
good position to alert and recruit the cells of the adaptive immune system [183]. Dendritic cells 
are antigen presenting cells that are unique in their ability to induce primary immune responses 
and subsequently establish immunological memory [104-106, 288]. Thus DCs are desirable 
targets to increase vaccine success (reviewed in ref. [289]).  As immature cells they capture and 
process antigens. They are also mobile and selectively express receptors for inflammatory 
chemokines such as CCR1, CCR2, CCR5, CCR6 that direct them to sites of inflammation [290, 
291]. Recruitment of iDCs followed by their maturation at the site of infection is deemed critical 
for induction of appropriate adaptive immune responses to a number of pathogens and to 
vaccination [183, 292].  Immature (but not mature) DCs derived from human bone marrow 
CD34+ DC progenitors are chemo-attracted by human β-defensin 2 (hBD2) [214]. Similarly, 
mBD2 is selectively chemotactic for iDCs generated from mouse bone marrow progenitor cells 
[217]. Currently it is known that hBD2 and mBD2 can attract cell types other than iDCs, and that 
other β-defensins share this ability. In addition to iDCs, hBD2 chemoattracts memory T-cells 
[214], activated neutrophils [232] and mast cells [231].  Recently, hBD1 was found to be 
chemotactic for human monocyte-derived iDCs [293].  Human β-defensin 3 and its mouse 
orthologue mBD14 were reported to chemoattract  iDC-mimicking (CCR6-expressing) cells 
[294] and Mo [215] as were hBD2 and its mouse orthologue mBD4 [215, 295]. Since monocytes 
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do not express CCR6 it was subsequently shown that these β-defensins exert their chemotactic 
effect via a different Gi protein-coupled-receptor, namely CCR2 [215].  Both CCR2 and CCR6 
are expressed by iDC [217, 296] so theoretically, migration of iDC to hBD2 could be mediated 
by both receptors. Audaciously, a new report suggests that migration of iDC to hBD2 may not be 
even be receptor-mediated or alternatively may be only partially receptor-mediated.  Morgera et 
al. (2011) reported chemotactic activity of hBD2 due to hBD2-induced membrane variations that 
correlate with increased cellular motility [297]. They found poor correlation of chemotaxis to 
hBD2 with surface expression of CCR6 by human peripheral blood monocyte-derived DCs in 
contrast to highly correlated expression of CCR6 with chemotaxis to MIP3α, the natural ligand 
of CCR6. Since only CCR6 was investigated and iDC were not pre-treated with pertussis toxin to 
test for involvement of Gi-protein-coupled receptors, it is not known whether CCR2 may have 
been involved in the non-CCR6-mediated chemotaxis to hBD2, or whether cell membrane 
mechanisms are predominant or are only involved when CCR6 and or CCR2 are not present 
[297]. Monocyte chemotaxis to hBD2 is also controversial. With respect to hBD2, the persuasive 
findings of Rohrl et al. (2010) [215] are contradicted by the earlier finding of Yang et al. (1999) 
[214] who reported that neither native hBD2 from psoriatic skin, nor recombinant or 
synthetically produced hBD2 were chemotactic for human peripheral blood monocytes. An 
explanation for this discrepancy was not found in the more current publication [215]. Whereas 
the in vivo observations of Vanbervliet et al. (2002) suggested that pre-DC and DC would be 
recruited to a site of infection through the orderly and sequential action of different chemokines 
via different receptors [298], this finding of Rohrl et al. (2010a) would suggest that the same 
chemotactic peptide (hBD2) could act on pre-DCs, DCs and many other types of cells due to the 
peptides` dual-receptor activity. Once recruited, β-defensin also has the ability to influence and 
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augment the immune response through activation and maturation of iDCs. Enhancement by β-
defensin of the adaptive immune response including upregulation of co-stimulatory molecules 
and CCR7, and an increased Th1-polarizing proinflammatory cytokine profile was observed 
when mouse iDCs were treated with mBD2 [216]. Similarly hBD1 induced activation and 
maturation of iDCs, which included expression of CD91, a multifunctional receptor that can 
facilitate cross-presentation of antigen to the endogenous class I pathway [299],  and for which 
defensins are a known ligand [293].  
 
Previous studies with bone marrow derived DCs of mice [217] and with DCs generated from 
human bone marrow CD34
+
 cells [214], have shown that, in a species-specific manner, β-
defensin 2 is highly chemotactic for iDCs through chemokine receptor CCR6.  Biragyn et al. 
hypothesized that via CCR6, the chemo-attractive nature of β-defensins could be utilized to both 
attract iDCs and encourage uptake of antigen, and that this could be used as a strategy to improve 
effective adaptive immunity in response to DNA vaccination [217, 218].  Intradermal DNA 
immunization of mice with mBD2 fused to antigen induces mucosal CTL and high-affinity 
neutralizing antibodies to the HIV-1 envelope [218], and is effective in therapeutic treatment for 
cancerous tumors [217].  It is thought that production of β-defensin by the DNA-transfected cells 
creates a chemotactic gradient at the site of immunization that encourages migration of iDCs 
from the circulation to the tissue [217, 218].  Chemo-attraction between the iDC and the β-
defensin may bring more iDCs into the area, making it more likely that the antigen of interest is 
taken up by iDCs. Also, β-defensin-antigen fusion peptides may target antigen to these cells 
resulting in improved uptake of the antigen of interest [217]. Production of β-defensin also 
provides a “danger signal” to the cells in the surrounding area, triggering local expression of pro-
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inflammatory cytokines and chemokines [217, 235]. The influence of these substances on the 
iDC, together with antigen uptake and processing, induces effective maturation and subsequent 
migration of these “maturing” cells from the tissue to the lymph node where they present antigen 
to naïve T-cells [137]. Mature antigen presenting DCs are potent, and uniquely capable of 
initiating both humoral and cell-mediated primary immune responses through cross presentation 
of antigen on both MHC I and MHC II molecules [110, 114, 217]. Given the plethora of new 
information regarding the chemotactic effect of hBD2 on many different types of cells (above 
and reviewed in ref. [300]), one can hypothesize that the beneficial effect of defensin in these 
vaccination strategies may have been due also to the immunomodulatory contributions of in-
migrating Mo, neutrophils, and mast cells.   
 
Whether the influence of β-defensin in the micro-environment at the site of immunization is 
enough to adequately mature an iDC that has taken-up an otherwise non-antigenic peptide to 
initiate an appropriate immune response, or whether β-defensin needs to be delivered as a β-
defensin-antigen fusion, is currently unclear. The earlier studies in mice led to the conclusion 
that a non-antigenic tumor antigen needed to be targeted directly to the iDCs by physical linkage 
to mBD2 in order to elicit a protective immune response [217]. The more recent evidence that 
hBD3 activates human monocytes and myeloid DCs in a Toll-like-receptor  (TLR)1 and 2-
dependent manner [237], and that mBD2 acts directly on iDCs as an endogenous ligand for 
TLR4 causing up-regulation of costimulatory molecules and maturation of DCs [216] would 
suggest that for optimal DC maturation, antigen and defensin should be closely associated.  
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While the reports of immunomodulatory effects of human and murine β-defensins are increasing, 
little is known about defensins in large animals beyond their direct antimicrobial action. This 
represents a gap in the knowledge base that is required to confidently transfer promising 
technology such as vaccination strategies from the mouse model to application in larger species 
including humans. The effectiveness of β-defensin in attracting DCs, and its ability to elicit a 
protective response (linked or unlinked to antigen) has not been determined in cattle. To begin 
addressing these questions, the objective of this work was to describe for the first time the 
chemotactic ability of chemically synthesized and oxidized versions of fourteen bovine-β 
defensins for phenotypically and functionally immature bovine monocyte-derived DCs.  
 
3.3 Materials and Methods 
3.3.1 Synthesis and in vitro antimicrobial activity of bovine β-defensins  
Tracheal antimicrobial peptide (TAP) [199], lingual antimicrobial peptide (LAP) [200], enteric 
β-defensin (EBD) [201],  and bovine neutrophil β-defensins 1 to 13 (BNBD1-13)  [219], 
including 2 analogs of BNBD3, were chemically synthesized on a Pioneer solid-phase peptide 
synthesizer using Fmoc chemistry [301].  For pE-BNBD3, a peptide of 41 amino acids without 
the pyroglutamate was similarly synthesized, and the pyroglutamic acid residue was coupled on 
the bench. The coupling was monitored by ninhydrin analysis until completion of the reaction. 
All peptides were then isolated and purified by HPLC, with the purity and molecular weight of 
the peptides confirmed by matrix-assisted laser desorption/ionization (MALDI) –time of flight 
(TOF) mass spectrometry as has been extensively described [301]. The linear peptides were 
folded by oxidizing the cysteine residues to form three intramolecular disulfide bonds as 
described [301, 302].  The oxidized peptides were then purified by HPLC.  
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In order to determine whether folding had taken place, oxidized peptides were evaluated based 
on their MALDI data.  With the exception of BNBD10 and BNBD11, MALDI data confirmed 
the appropriate loss of 6 mass units that indicated that the correct number of disulphide bridges 
(3) had formed.  Peptides were assessed for antimicrobial activity against E. coli (ATCC 25922) 
and P. aeruginosa (ATCC 27853) using an inhibition zone assay modified from the method 
described by Zasloff [303].  Similarly modified methods have been used by others to verify 
antimicrobial activity [304-306].  Briefly, bacteria were grown overnight at 37 °C in 5 ml of 
Luria-Bertani (LB) broth. A 50 µl aliquot of the overnight culture was then grown to mid-log 
phase by incubating the cultures in 5 ml of LB broth for approximately 2 h at 37 °C or until the 
absorbance at 600 nm was 0.115 absorbance units. Forty microliters of standardized bacterial 
culture was further diluted with 160 µl of LB and then spread on Mueller-Hinton agar. The 
inoculated plates were allowed to stand at room temperature (RT) for 10 min and then 10 µl of 
sterile distilled H2O (ddH2O) as the negative control or 10  µl of bovine β-defensin (1 mg/ml) 
was pipetted onto the inoculated plate(s). Plates were again allowed to stand for at least 15 min at 
RT in order to dry the samples. Plates were then incubated overnight at 37 °C. Antimicrobial 
activity was quantified by measuring the diameter of the circular clear zones on the bacterial 
growth, and expressed as mm of clearance.  The linear peptides showed limited or no 
antimicrobial activity, whereas all of the oxidized bovine β-defensins with the exception of 
BNBD10 and BNBD11 were able to inhibit, to varying degrees, the growth of bacteria.  Zones of 
clearance showing characteristic antimicrobial activity of oxidized bovine β-defensins are 
displayed in  
 
Figure 3.1 to provide a visual reference for the antimicrobial assay.   
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Figure 3.1 Inhibition zone assay for antimicrobial activity for sythesized bovine β-
defensins. Sterile distilled H20 or synthesized bovine β-defensins (1 mg/ml) were pipetted (10 
µl) onto P. aeruginosa inoculated plates as described.  (A) Clockwise from the top: paper disk 
for plate orientation, TAP, LAP, EBD, aBNBD3, sterile distilled H20 center of the plate.  (B) 
Descending dilutions of aBNBD3. From left to right: 1, 0.75, 0.5, 0.25, 0.1 and 0 mg/ml. 
 
In conjunction with the MALDI-data, analysis of antimicrobial ability of the remaining fourteen 
peptides and the 2 analogs of BNBD3 suggest that appropriate disulfide bridges had formed 
although the connectivities of the disulfide bridges could not be unequivocally proven.   Given 
that BNBD10 and BNBD11 were not correct based on MALDI-data, had no antimicrobial 
activity, and were subsequently found to be unable to chemoattract PBMCs, monocytes or DCs 
(data not shown), these two defensins were excluded from the rest of this work.  Verification of 
A 
B 
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native disulfide connectivities was assessed by comparative HPLC of synthesized BNBD3 with 
native BNBD3 that was kindly provided by Dr. Micheal Selstead (University of California, 
Irvine, CA, United States) 
 
3.3.2 Generation of bovine monocyte-derived dendritic cells  
Peripheral blood mononuclear cells (PBMCs) were separated from heparinized (5 iu/ml) blood 
[307] by density gradient centrifugation at RT on Ficoll-Paque Plus (GE Healthcare Bio-
Sciences AB, Uppsala, Sweden, UK).  Monocytes were isolated from PBMCs following 
incubation with 100 µl per10
8
 PBMCs of anti-human CD14 paramagnetic particles (Miltenyi 
Biotech Inc., Auburn, CA, USA) and labelled cells were isolated from Midimacs LS columns 
(Miltenyi Biotech Inc.) according to the manufacturer’s instructions.  Monocytes were 
typically >97% pure by flow cytometry analysis and >99% viable by trypan blue exclusion. Cells 
were adjusted to 8 x 10
5
 cells/ml in complete RPMI (cRPMI; RPMI 1640 [Gibco, Invitrogen 
Canada Inc., Burlington, ON, Canada] supplemented with 10% fetal bovine serum (FBS), 2 mM 
L-glutamine, 100 µM non-essential amino acids, 1 mM sodium pyruvate, 50 µM 2-
mercaptoethanol, 10 µM Hepes, and 50 µg/ml gentamycin). Supernatants from bovine IL-4 and 
bovine GM-CSF transfected chinese hamster ovary (CHO) cells (kindly provided by Merial 
Limited, Lyon, France) were added at previously determined optimal dilutions of 1/100, and 3 
ml of cell suspension was added per well of six-well plates. Cells were incubated for up to 10 
days at 37 °C in 5% CO2 with one ml per well of fresh cRPMI and cytokines added every three 
days.  DCs were harvested on days three (DC3), six (DC6) and ten (DC10) and evaluated by 
flow cytometry or used for functional assays. To mature DC10, a combination consisting of 100 
ng/ml of recombinant human CD40 Ligand (Peprotech, Inc., Rocky Hill, NJ, USA), 100 ng/ml of 
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bovine TNF-α (R&D Systems Inc., Minneapolis, MN, USA) and 100 ng/ml of BNBD3 was 
added to cultures on day 7 or 8 and the subsequent “matured” cells were harvested on day 10.  
Preparatory work using these and other maturation factors, alone and in combination, showed 
that the above-described procedure resulted in DCs with increased stimulatory ability in an 
autologous antigen-specific lymphocyte proliferation assay (data not shown). 
 
3.3.3 Phenotypic Analysis 
Staining of surface antigens.  Monocytes, DCs, and responder lymphocytes used in proliferation 
assays, were washed in calcium-magnesium free phosphate-buffered saline (PBS;  pH 7.2, 
Gibco, Invitrogen Canada Inc.) with 10% added bovine serum albumin (BSA; Fraction V, 
Sigma-Aldrich Canada Ltd., Oakville, ON, Canada) and resuspended at not less than 5 x 10
6
 
cells/ml in cold fluorescence-activated cell sorting (FACs) buffer (PBS with 0.1% sodium azide 
and 10% FBS). Fifty microliters (µl) of cell suspension were added in 96-well plates to either 50 
µl of FACs buffer plus FITC- or PE-conjugated specific primary monoclonal antibody (mab) for 
direct staining, or 50 µl of pre-diluted specific primary mab for indirect staining (Table 3.1) all at 
pre-determined optimal concentrations.  Isotype-matched controls (Caltag/Invitrogen Canada 
Inc., Burlington, ON, Canada for indirect staining; BD Biosciences for direct staining) were used 
at 2-5 µl per well to detect non-specific staining. After 30 min on ice, cells were washed 
thoroughly and resuspended in 50 µl of FACs buffer.  For indirect staining, bound mab was 
detected by adding 50 µl of 0.02 µg/ml  FITC- or PE-labelled goat anti-mouse IgG1, IgG2a, 
IgG2b or IgM mab (Caltag/Invitrogen). After 10 min on ice, cells were washed, fixed with 2% 
formaldehyde and read on a FACScan flow cytometer (BD Biosciences, Mississauga, ON, 
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Canada). A minimum of 10,000 events was collected for each sample and flow cytometry data 
were analyzed with Cell Quest software (BD Biosciences). 
 
Intracellular staining.  Cells were fixed, permeablized and stained for intracellular expression of 
DC-LAMP, CD205 and mannose receptor-MMR (Table 3.1) using a BD Cytofix/Cytoperm 
fixation/permeablization kit (BD Biosciences) according to the manufacturer’s instructions. 
Stained cells were fixed with 0.05% formaldehyde, read, and analyzed as above. 
 
3.3.4 Uptake Assays 
To compare the functional ability of Mo and DCs to take up antigen, 200 µl of 1 x 10
6
 cells/ml in 
cRPMI were incubated at 37 °C (treatment) or on ice (control) with 180 µl of FITC-dextran (1 
mg/ml in PBS) for 30 min [308, 309].  The cells were washed extensively with cold PBS, fixed 
with 2% formaldehyde and read as described above.  Uptake of FITC-dextran was assessed by 
subtracting the fluorescence of the control cells from the fluorescence of the treatment cells. 
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Table 3.1 Monoclonal antibodies used for phenotypic analysis 
 
Antibody 
  
Isotype 
  
Specificity
e 
  
Source
a
 
 
MMIA 
 
  
IgG1 
  
CD3 
  
VMRD 
MCA1424G  IgG1  CD21  AbD Serotec 
MM61A  IgG1  CD14  VMRD 
IM3448  IgG1  hDC-LAMP
b
  Beckman Coulter
 
IM2741  IgG1  hCD206 (MMR)
 b
  Beckman Coulter 
CACT80C  IgG1  CD8  VMRD 
130-091-242  IgG2a  hCD 14
 c
  Miltenyi Biotech Inc.
 
TH14B  IgG2a  MHC II  VMRD 
TH97A  IgG2a  CD1 (CD1b)  VMRD 
IDAC1323  IgG2a  hCTLA4 (CD80/86)
 d
  ID Labs Inc.
 
MCA1651  IgG2b  CD 205  AbD Serotec 
MCA1651F  IgG2b  CD 205-FITC  AbD Serotec 
MCA 2041S  IgG2b  CD 172a  AbD Serotec 
BAQ153A  IgM  CD11c  VMRD 
CACT83B  IgM  CD4  VMRD 
 
a
VMRD, Veterinary Medical Research and Development, Pullman, WA, USA;  BD 
Biosciences, Mississauga, ON, Canada;  AbD Serotec, Oxford, UK;  Beckman Coulter, 
Mississauga, ON, Canada;  Miltenyi Biotech Inc., Auburn, CA, USA;  ID Labs Inc., London, 
ON, Canada. 
b
Gliddon et al., 2004. 
c
Norimatsu et al., 2004. 
d
Pinchuk et al., 2003. 
e
Human-specific antibodies/ligands are identified by an “h”. All others are bovine-specific. 
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3.3.5 Proliferation Assays 
Immunization of cattle.  Conventionally reared mixed-breed calves (~ 9 months old) were given 
a 2 ml subcutaneous (s.c.) immunization containing 50 µg of BHV-1 tgD [44, 310], 1 mg CpG 
oligonucleotide (ODN) 2007 (TCGTCGTTGTCGTTTTGTCGTT) supplied by Merial Limited 
(Lyon, France), and 30% Emulsigen (MVP Laboratories Inc., Omaha, NE, USA) in PBS (pH 7.4 
Gibco, Invitrogen Canada Inc.). All animals were handled in accordance with the guidelines of 
the Canadian Council on Animal Care.  After 14 days, sera from these animals were tested for 
tgD-specific IgG by ELISA as previously described [311].  Absorbance was read on a model 
Spectramax
®
 340 PC Microplate Spectrophotometer (Molecular Devices Corp., California, USA) 
at 405 nm, with a reference wavelength of 490 nm. 
 
Preparation of responder lymphocytes.  To compare the functional ability of Mo and DCs to 
present antigen, PBMCs from two animals with high IgG titres to tgD (bovine 39 and 84), six 
animals sensitized to tgD by one subcutaneous immunization (bovines 130, 132, 133, 134, 135, 
137), and two tgD-seronegative animals, were separated from heparinized blood as described 
above. PBMCs were suspended at 5 x 10
7
 cells/ml in fetal bovine serum (FBS) containing 10% 
DMSO [308], and stored in 1 ml aliquots at -70 C° for up to one month. On the day of the assay, 
PBMCs (5 x 10
7
 cells) were thawed quickly in a 37 °C waterbath, washed in 30 ml of pre-
warmed (37 °C) proliferation medium (PM; cRPMI with 1 ng/ml dexamethasone) and  re-
suspended in 45 ml of PM. PBMCs were depleted of Mo by plastic adhesion in a T-150 flask. 
After 2 h of incubation at 37 °C, non-adherent cells were carefully removed, washed and were 
resuspended at 1 x 10
6
 cells/ml in PM. Responder lymphocytes typically had 1 to 4% 
contaminating Mo by FACs analysis and were at least 98% viable by trypan blue exclusion. 
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Preparation of APCs.  Monocytes or DCs were suspended at 1 x 10
5
 cells/ml in PM and 100 µl 
of antigen presenting cells (APCs) were dispensed in triplicate into round-bottom 96-well plates. 
APCs were pulsed in the presence or absence of 0.3 µg tgD for 4 h at 37 °C in 5% CO2.  Control 
wells were set up in the same plates in triplicate with 100 µl aliquots of medium alone (negative 
control), and medium plus antigen as described above to quantify proliferation of responder 
lymphocytes to antigen without added APCs. After 4 h, 100 µl of autologous responder 
lymphocytes prepared as described above were added to wells of the prepared plates. After 3 or 5 
days of culture, cells were incubated with [methyl-
3
H]thymidine (Amersham Biosciences, PQ, 
Canada)
 
 at a concentration of 37 Bq (1 µCi) per well for 16 h [312].  Plates were harvested with 
a Filtermate harvester and thymidine uptake was measured by scintillation counting with a 
TopCount NXT microplate scintillation counter (Packard Instrument Company, Meriden, CT, 
USA) [313]. 
 
3.3.6 Chemotaxis assays 
Monocyte and DC chemotaxis to bovine β-defensins was performed using a 96-well disposable 
chemotaxis system with framed 5 µm polycarbonate membrane filters (ChemoTx system; 
Neuroprobe, Gaithersburg, MD, USA). The chemotaxis buffer (CB) used in these assays was 
PBS with MgCl2 (1.2mM), KCl (5mM), CaCl2 (5mM), glucose (5mM) and 0.1% BSA with an 
adjusted pH of 7.4 (personal communication; Dr. John Gordon, Dept of Vet. Micro., U. of S, 
Saskatchewan, Canada). Bovine β- defensins were diluted to 100, 10, and 1 ng/ml in CB and 29 
µl was added to triplicate wells of the bottom chamber of the plate. Triplicate wells with just CB 
served as the control for non-specific migration as per the manufacturer’s instructions. 
Monocytes and DCs suspended at 2 x 10
6
 cells/ml were labelled with 5 µg/ml of Calcein AM 
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(Molecular Probes) for 30 min at 37 °C [314]. For pertussis toxin (PTX) treatments 1 x 10
6
 
cells/ml were incubated with 100 ng/ml of PTX (Sigma-Aldrich Canada Ltd., Oakville, ON, 
Canada) for 30 min at 37° C prior to labeling. Cells were washed and resuspended at 2 x 10
6
 
cells/ml in CM and 25 µl of this suspension was added to the top of the membrane above each 
filled well. After 90 min incubation at 37 °C, the non-migrated cells were removed from the top 
of the membrane by gentle vacuum, followed by wiping with a Q-tip, and gently washing the 
filter with PBS while holding the chamber at 45
o
.  The framed membrane filter was then 
removed from the rest of the chamber, inverted and placed in a 96-well multilabel plate reader 
(Victor 3V Multilabel Counter, PerkinElmer Life And Analytical Sciences, Inc., Woodbridge, 
ON, Canada). The plate reader was set in the top read position and cells on the bottom side of the 
filter were measured using the calcein fluorescence signal (excitation 485 nm; emission 535 nm). 
Chemotactic index (CI), defined as the fold increase of cell migration in the presence of test 
factors (directed migration) over cell migration in the presence of medium (random migration) 
[214], was calculated for each well by dividing the total fluorescence of the well by the mean 
fluorescence of the medium wells.  A CI > 2 is considered statistically significant (p < 0.05) 
[315].  For each experiment, 25 µl triplicate samples of fourfold-diluted cells were placed in 
bottom wells of the plate and read as described. These data provided a standard curve of the 
linear relationship and correlation between fluorescence and number of cells [314, 316].  We 
compared the automated method with the conventional method of Falk et al. [317] and 
established a standard curve for each time point in each experiment (data not shown). The 
standard curve for both Mo and DC3 showed a strong correlation between cell number and 
fluorescence as evidenced by r
2
 values which were always greater than 0.99, validating this 
method.   
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3.3.7 Immunohistochemistry 
Cryostat sections were allowed to air dry, fixed in -20 °C ethanol for 5 min, and then incubated 
for 2 h at RT with 5% horse serum and 5% FBS to block non-specific binding.  Primary CD205-
specific mabs (Table 3.1) or an isotype-matched control mab were added and the slides were 
incubated for 1 h at RT [318].  Slides were then washed three times with tris-buffered saline 
(TBS; 0.15 M Tris, 0.02 M NaCl; pH 7.6-7.8) containing 0.025% Triton X.  The secondary 
biotinylated antibody (horse-anti-mouse IgG; Vector Laboratories (Canada) Inc., Burlington, 
ON, Canada) was diluted in TBS with 1% BSA and applied to the slides for 30 min.  Slides were 
washed as above, whereupon the conjugate (ABC solution; Vector Laboratories (Canada) was 
applied for 30 min at RT.  The slides were washed with TBS and the substrate (NovoRed; Vector 
Laboratories (Canada) Inc.) was added.  Once optimal staining was achieved, the slides were 
washed with tap H2O, counter-stained with modified Harris hematoxylin (Richard-Allan 
Scientific, Kalamazoo, MI, USA) for 30 sec, dehydrated and mounted in Cytoseal XYL 
(Richard-Allen Scientific). 
 
3.3.8 Statistical analyses 
Data were analyzed with the aid of Graphpad Prism 4.0 (San Diego, CA, USA) software.  
Differences between surface and intracellular antigen expression of Mo, DC3 and DC6, were 
analyzed by a two-way analysis of variance (ANOVA), followed by a Bonferroni t-test in case of 
a significant ANOVA.  Differences were considered significant if p<0.05.  Differences between 
uptake of FITC-dextran of Mo, DC3 and DC6 were analyzed by one-way ANOVA, followed by 
a Tukey’s multiple comparison test when ANOVA indicated significant differences (p<0.05). 
Differences in proliferation of responder lymphocytes due to antigen or APC (zero or 10% Mo, 
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DC3, DC6) were analyzed by one-way ANOVA.  When this test indicated significant differences 
(p<0.05), a Bonferroni t-test was used to compare differences between Mo, DC3 and where 
applicable, DC6.  Differences were considered significant if p<0.05.  Differences in CI of Mo, 
DC3 and where applicable, DC6 due to the effects of concentration or defensin was analyzed by 
two-way ANOVA.  When this test indicated significant differences, a Bonferroni t-test was used 
to compare differences between defensins.  Differences were considered significant if p<0.05. 
 
3.4 Results  
3.4.1 Phenotypic Characterization and Morphology of Bovine Monocyte-derived 
Dendritic Cells 
Bovine CD14+ Mo were differentiated to DCs by culture with bovine cytokines GM-CSF and 
IL-4.  By the third day of culture, plated Mo were non-adherent, and had the floating, rounded 
shape that is characteristic of human immature monocyte-derived DCs [319, 320].  
Morphological changes that occur as Mo differentiate to DCs are shown in Figure 3.2A, and 
include an increase in overall size, a change in the shape of the nucleus, and the development of 
an extensive cytoplasm that gives the cells a veiled appearance. Dendritic processes were 
observed on some of the DC6, but not on DC3.   
 
Monocytes and their subsequent DCs were stained with mabs specific for CD14, MHCII and 
CD11c, and for the DC-specific receptors CD1, CD80/86, CD205, DC-LAMP and MMR 
(mannose receptor) [308, 318, 321-325].  Since bovine DCs have not previously been described 
as immature or mature by increased or decreased expression of these receptors, and an immature 
phenotype was of most interest for use in the chemotaxis assay, receptor expression of DCs was 
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assessed on days 3 and 6, and for dendritic cell-lysosomal-associated membrane protein (DC-
LAMP) and MMR, on day 10 as well.  The numbers of cells expressing CD205, CD1, CD80/86 
and MHC II increased from 2.5%, 1%, 0.5%, and 54% in the monocyte population, to 21%, 
66%, 83% and 82% in the DC3 population, and then decreased to 13%, 60%, 75% and 75% in 
the DC6 population, respectively (Figure 3.2B). Differences between Mo and DC3 or DC6 were 
highly significant for CD1 and CD80/86 (p<0.001). The percentage of cells expressing MMR 
increased from 0.25% in Mo to 86% in DC3 (p<0.001) and 93% (p<0.001) in DC6. The 
percentage of cells expressing bovine CD11c was high in Mo at 99% and only decreased slightly 
to 93% by day 6.  Intensity of CD11c staining, however, decreased significantly (p<0.001) from 
a mean fluorescent intensity (mfi) of 460 on Mo to a mfi of 173 on DC6 (data not shown), in 
good agreement with previous reports [309]. The population expressing CD14 detected by both 
human (h) CD14- and bovine (b) CD14-specifc mabs was high (96% and 98% respectively), 
confirming the purity of the CD14+ population at the start of culture.  
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Figure 3.2  Morphology and expression of cell surface and intracellular antigens of 
monocytes and monocyte-derived DCs. Pure populations (>98%) of monocytes were 
differentiated to DCs by culture in the presence of bovine GM-CSF and bovine IL-4 for 3 -6 
days.  (A) Cytospin preparations of peripheral blood CD14+ monocytes (Ai), and monocyte-
derived DCs at day 3 (Aii) and day 6 (Aiii).  Slides were dried and stained with Diff-Quick 
(Dade Behring, Newark, DE, USA).  (B) Monocytes and DCs stained for expression of MHCII, 
CD1, CD80/86 (human CTLA4), MMR (human mannose receptor) and CD205.  Changes in (C) 
percentage, and (D) mean fluorescent intensity (MFI) of cells expressing intracellular DC-
specific antigens CD205, DC-LAMP (human CD208), and MMR.  Stained cells were analyzed 
by flow cytometry.  Experiments were conducted using bovines 39 and 84. Data are means + 
sem of four independent experiments. 
 
Staining with hCD14-specific mab decreased to 89%, and with bCD14-specific mab to 81%, in 
DC6 (data not shown). Intra-cellular expression of CD205, MMR and DC-LAMP (Figure 3.2C) 
in DCs was considerably higher than in Mo.  This increase was significant for MMR (p<0.001) 
and DC-LAMP (p<0.05). Once cells had differentiated to DCs, there was little difference in the 
percentage (ie the number) of cells that expressed these receptors from day 3 to day 6 (Figure 
3.2C) and to day 10 (data not shown). Mean fluorescent intensity (mfi) was also evaluated to 
determine whether differences could be seen in the quantity (amount) of receptor expressed by 
cells. Quantitatively, mfi of expression by DCs was increased over that of Mo for all the 
intracellular receptors, and was significantly higher for MMR (p<0.001) when DC3 were 
compared to Mo (Figure 3.2D). Also, a significant (p<0.001) reduction in mfi of MMR 
expression was observed from DC3 to DC6.  Since maturation of DCs has been previously 
associated with a reduction in mfi of MMR [308, 309, 323, 326, 327], this, combined with the 
appearance of dendritic processes on cells at day 6, suggested that DC6 were more mature than 
DC3. 
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Next, four independent experiments were conducted wherein four animals were sampled in each 
experiment.  Eight different animals were used in total.  In good agreement with the earlier 
results, flow cytometric analysis of Mo and DC3 showed that for all animals in all experiments 
expression of the DC markers CD80/86, CD205 and MMR, by DC3, was consistent and highly 
significant (Figure 3.3).  In these experiments detection of CD205 expression was much 
improved by direct staining with a fluorochrome-conjugated CD205.   Minimal variation was 
observed with respect to expression of these DC-specific markers irrespective of animal (Figure 
3.3). 
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Figure 3.3 Direct staining of DC-specific antigens.  Monocytes and DC3 from animals used in 
proliferation (Figure 3.6) and chemotaxis assays (Figure 3.7) were directly stained for surface 
expression of CD80/86, CD205 and MMR and analyzed by flow cytometry.  Experiments were 
conducted using eight animals. Data are the means + sd of at least four independent experiments 
where four animals were sampled in each experiment (n=16). 
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3.4.2 Functional Characterization of Bovine Monocyte-derived Dendritic Cells 
3.4.2.1  Endocytic ability of monocytes and DCs 
One of the main characteristics that set DCs apart from other APCs is their aptitude for antigen 
uptake [114, 135].  Since in studies with human DCs this greatly increases as Mo differentiate to 
DCs, peaks at immaturity, and then decreases as the cells mature [114, 135], functional 
characterization of bovine DCs included assessment of the cells’ ability to take up FITC-dextran.  
The percentage of cells that took up FITC-dextran increased significantly as expected (p<0.01) 
from 35% in Mo to 91% in DC3 (Figure 3.4A).   
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Figure 3.4 Uptake of FITC-dextran by monocytes, DC3, DC6 and DC10.  Monocytes or DCs 
were incubated with FITC-dextran at 37 °C and on ice (control) for 30 min and then washed, 
fixed and analyzed by flow cytometry.  Changes in uptake of dextran-FITC by monocytes and 
DCs are the values at 37 °C minus the values on ice (control) and are shown as both percentage 
(A), and fluorescent intensity (B).  Experiments were conducted using bovines 39 and 84. Data 
are means + sem of four independent experiments with the exception of DC10mf; data for which 
are from two independent experiments. 
 
This only decreased slightly through days six to ten with little difference seen even in DC10 
treated with a maturation cocktail composed of hrCD40L, bTNFα and BNBD3.  Since the 
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percentage only defines the number of cells within a population that endocytose FITC-dextran, 
but does not quantitate the amount of FITC-dextran taken up by the cells, the relative maturation 
status of DCs was evaluated quantitatively by mfi.  DC3 imbibed the largest quantity of FITC-
dextran when compared to all other cells.  Decreased mfi from day 3 to day 10 was observed 
with the lowest mfi by the matured DC10 (Figure 3.4B) as would be expected as DCs mature. 
Accordingly, these data show that DC3 have the highest capacity for antigen uptake, thus bovine 
DC3s are functionally immature at this stage of culture.  
 
3.4.2.2  Antigen-specific proliferation of lymphocytes by monocytes and DCs 
Along with the superior ability to take up and process antigen, DCs are the most capable of 
APCs at presenting antigen to, and stimulating proliferation of, lymphocytes [114, 135, 308, 309, 
321, 323, 328, 329].  To ensure that our target cell population for chemotaxis to bovine β-
defensins would be functional in this respect, autologous antigen-specific proliferation assays 
were performed with Mo and DCs as comparative APCs. Antigen-pulsed Mo or DCs were 
incubated with lymphocyte responder cells for three or five days. In agreement with other studies 
[330-332] overall proliferation was greater when cells were allowed to incubate for five days 
(data not shown). In subsequent 5-day proliferations, only DC3 and DC6, but not Mo, were able 
to significantly increase (p<0.001) proliferation above what was observed when responder cells 
alone were stimulated with tgD (Figure 3.5). DC3 and DC6 from bovine 39, and DC6 from 
bovine 84, were significantly better (p<0.001) at inducing proliferation of responder cells than 
were Mo (Figure 3.5). The greater capacity of DC6 to induce proliferation suggests that these 
cells are more mature than DC3. 
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Figure 3.5 Proliferative responses of calves to tgD presented to autologous lymphocytes by 
monocytes, DC3 , and DC6.  Autologous responder lymphocytes (10
5
 cells/well) were 
incubated with or without monocytes or DCs (10
4
 cells/well) in triplicate with tgD for 5 days.  
The animal # is indicated at the top of the graphs.  Proliferative responses were measured by the 
incorporation of [methyl-
3
H]thymidine .  Data are mean CPMs + SD of triplicate wells of two 
independent experiments with bovine #39 and two experiments with bovine #84.  Significant 
differences between the ability of monocytes and DCs to induce proliferation of responder 
lymphocytes are indicated on the graphs where ***p<0.001. 
 
To confirm these observations, six bovines previously exposed to BHV-1 were further sensitized 
to tgD. The tgD-specific IgG titres measured after 14 days ranged from 22,000 to 88,000 
indicating that the animals had been adequately sensitized (data not shown).  The two animals 
used as negative controls were confirmed BHV-1 negative.  As described above, tgD-pulsed Mo 
or DC3 from these eight animals were incubated with 
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Figure 3.6  Proliferative responses of lymphocytes induced by autologous, tgD-pulsed 
monocytes and DC3 from six tgD-sensitized and two negative control donor animals.  
Responder lymphocytes (10
5
 cells/well) from six sensitized (A-F) and two negative (G-H) 
animals were incubated with or without tgD, and with or without autologous tgD-pulsed 
monocytes or DC3 (10
4
 cells/well) in triplicate for five days.  The animal number is indicated for 
each panel.  Proliferative responses were measured by the incorporation of [methyl-
3
H]thymidine, and results are expressed as mean CPM + SD of triplicate wells.  Significant 
differences between the ability of monocytes and DCs to induce proliferation of responder 
lymphocytes are indicated on the graphs where **p<0.01 and  ***p<0.001. 
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autologous lymphocyte responder cells for five days.  Although we observed animal-to-animal 
variation in the magnitude of the proliferative response, DC3 from all sensitized animals were 
significantly more proficient (**p<0.01 and ***p<0.001) at inducing proliferation of responder 
cells than were Mo (Figure 3.6A-F), while no response (CPM<500) was seen in the negative 
animals (Figure 3.6G-H). 
 
3.4.3 Chemotaxis of monocytes and DCs to bovine β-defensins 
The concept of targeting vaccine antigens to DCs is rational as, of all APCs, DCs are the only 
ones that can stimulate naïve T-cells and induce an immune response to a previously unseen 
organism [104]. To determine whether bovine iDCs, like their human and murine counterparts 
[214, 217], would be attracted to the synthesized β-defensins, we used an in-vitro chemotaxis 
assay. 
 
In the first set of experiments 14 peptides, including TAP, LAP, EBD, BNBD 1-9 and BNBD 
12-13, were screened for chemotactic activity using a limited number of dilutions (0, 1, 10, 100 
ng/ml).  Data from four experiments with two donor animals were combined.  To compare the 
magnitude of monocyte and DC chemotaxis, the arithmetic mean for each concentration was 
calculated.  The arithmetic mean of the CI to all peptides at 0, 1, and 100 ng/ml, was 1.58, 1.45 
and 1.33 for Mo; 7.43, 7.31 and 5.66 for DC3 and 4.08, 5.1 and 4.76 for DC6, respectively.  
Overall, we observed the lowest chemotaxis by β-defensins in the monocyte population; DC6 
were more chemo-attracted than were Mo but less than DC3; and DC3 were the most chemo-
attracted.    
 89 
Since the DC3 population showed the greatest chemotactic activity, the DC3 data from each 
experiment were further examined to determine which peptide(s) had the best chemotactic 
potential for bovine iDC. The top seven β-defensins were first listed according to their “t” ratio 
and CI values. With the exception of BNBD9, defensins that were only active for one animal 
were excluded from the rest of the evaluation. The remaining six defensins, TAP, EBD, BNBD7, 
BNBD9, BND8, and aBNBD3 were then assigned a score of 7 (highest) to 1 (lowest) based on 
how they placed in terms of chemotactic ability for the DC3 in each experiment.  For each 
defensin, these scores were totalled. The total score for each peptide was then divided by the 
number of experiments (4) to give an overall index ranking of chemotactic ability. BNBD3 and 
BNBD9 had the highest CI ranking of 3.5, closely followed by EBD at 3.25, and BNBD7 at 3.  
TAP ranked fifth with a CI ranking of 1.5. Based on these results, EBD, aBNBD3 and BNBD9 
showed the most chemotactic potential and BNBD6 the least.   
 
To test the validity of these results and confirm the chemotactic ability of EBD, aBNBD3 and 
BNBD9, the chemotaxis assay was repeated with a larger number of animals. For each of the 
eight animals tested in the proliferation assay, Mo and their respectively derived DC3 were 
assayed twice for chemotaxis to EBD, aBNBD3, and BNBD9.  BNBD6, as the least chemotactic 
peptide, was included for comparison and as a control for the assay. Four independent 
experiments were conducted wherein 4 animals were sampled per experiment. When compared 
to Mo, DC3 were significantly more attracted to all concentrations of aBNBD3, BNBD9 and 
EBD; however, no differences were observed with BNBD6 (Figure 3.7). DC3 migration to all 
three concentrations of EBD, aBNBD3 and BNBD9, but not  
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Figure 3.7 Chemotaxis of bovine monocytes (DC0) and DC3 to EBD, BNBD3 and BNBD9.  
Monocytes and DC3 were labelled with Calcein AM and placed on a 5 µm pore filter membrane 
above triplicate bottom wells filled with either medium or 1, 10 or 100 ng/ml of EBD, BNBD3, 
BNBD9 or BNBD6.  Migration of cells toward medium or defensin was determined by reading 
the calcein fluorescence signal of migrated cells on the bottom of the filter after incubation at 
37 °C for 90 min.  Experiments were conducted using eight animals. Data are expressed as the 
chemotactic index (CI), and are shown as the mean values of the average CI + sem of four 
independent experiments  where four animals were sampled in each experiment (n=16).  
Significant differences between chemotaxis of monocytes and DC3 at each concentration are 
indicated on the graphs where *p<0.05, **p<0.01 and  ***p<0.001.   
 
BNBD6, was significantly greater than their migration to medium alone. As well, chemotaxis of 
DC3 to EBD and aBNBD3 at 1 ng/ml (**p<0.01 and ***p<0.001 respectively) and 10 ng/ml 
(***p<0.001 and **p<0.01 respectively) and to BNBD9 at 10 ng/ml and 100 ng/ml (*p<0.05) 
was significantly greater than DC3 migration to the same concentrations of BNBD6. As before, 
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chemotaxis by DC3 tended to be highest for EBD and aBNBD3 at the lower concentrations of 1 
ng/ml and 10 ng/ml, and at these lower concentrations, was greater than chemotaxis to BNBD9 
at any concentration. These results support the conclusion that DC3 are more chemo-attracted to 
β-defensin than are Mo and that chemotaxis of DC3 to BNBD3, EBD and BNBD9 was greater 
than to media or to BNBD6. 
 
3.4.4 Verification of native disulfide connectivities of synthesized BNBD3 
BNBD3 was one of the most chemotactic β-defensins, and thus was selected for further studies. 
Comparative HPLC and chemotaxis assays were performed to determine whether the cysteine 
pairing in synthesized BNBD3 occurred correctly during the oxidation process.  BNBD3 
peptides were synthesized and the amino acid sequences are shown in relation to EBD, BNBD9 
and human and murine β-defensins (Figure 3.8).  Sequences of the less chemotactic BNBD7, the 
poorly chemotactic BNBD2 and the least chemotactic peptide BNBD6 are also shown.  Native 
BNBD3 purified from bovine neutrophils (kindly provided by Dr M.E. Selstead) conformed to 
the sequence given for pE-BNBD3, which has pyroglutamic acid, a modified residue of 
glutamine (Q), at the N-terminus.  sBNBD3 conforms to the sequence for native and pE-
BNBD3, but with the unmodified Q at the N-terminus and aBNBD3 is an analog with glycine 
(G) replacing Q at both the N-terminus and at position 27.  MALDI-TOF analysis showed the 
correct mass of both the linear and  
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mBD2 A V G S L K S I G Y E A E L D H C H T N G G Y C V R A I C P P S A R R P G S C F P E K N P C C K Y M K
hBD1 D H Y N C V S S G G Q C L Y S A C P I F T K I Q G T C Y R G K A K C C K
hBD2 G I G D P V T C L K S G A I C H P V F C P R R Y K Q I G T C G L P G T K C C K K P
hBD3 G I I N T L Q K Y Y C R V R G G R C A V L S C L P K E E Q I G K C S T R G R K C C R R K K
BNBD2 V R N H V T C R I N R G F C V P I R C P G R T R Q I G T C F G P R I K C C R S W
BNBD6 Q G V R N H V T C R I Y G G F C V P I R C P G R T R Q I G T C F G R P V K C C R R W
BNBD7 Q G V R N F V T C R I N R G F C V P I P C P G H R R Q I G T C L G P R I K C C R
EBD N P L S C R L N R G I C V P I R C P G N L R Q I G T C F T P S V K C C R W R
BNBD9 Q G V R N F V T C R I N R G F C V P I R C P G H R R Q I G T C L G P Q I K C C R
sBNBD3 Q G V R N H V T C R I N R G F C V P I R C P G R T R Q I G T C F G P R I K C C R S W
aBNBD3 *G G V R N H V T C R I N R G F C V P I R C P G R T R *G I G T C F G P R I K C C R S W
pE-BNBD3 pE G V R N H V T C R I N R G F C V P I R C P G R T R Q I G T C F G P R I K C C R S W
Figure 8
 
Figure 3.8 Amino acid sequence alignment of the synthesized bovine β-defensins BNBD2, 
BNBD6, BNBD7, EBD, BNBD9, sBNBD3 (published sequence UniprotKB/Swiss-Prot 
accession number P46161- Glutamine in positions 1 and 27), aBNBD3 (analog, Glycine [G] 
replaces Glutamine [Q] in positions 1 and 27), pE BNBD3 (pyroglutamic acid, the modified 
residue of Glutamine at N-terminus; the sequence of Native BNBD3), aligned with 
murine(m)BD2, human(h)BD1, hBD2 and hBD3.  Aligned conserved cysteine residues are 
shown in shaded vertical bars and the  β-defensin disulfide connectivities are shown at the top. 
 
oxidised (folded) BNBD3s with a corresponding loss of 6 mass units during the folding reaction.  
Chromatograms of HPLC analyses showed the changes in the reaction products from the linear 
peptide at time 0 to the folded peptide at 72 hr during the oxidation of pE-BNBD (Figure 3.9A).  
The reaction product shifted initially to the left, but as the oxidation proceeded a defined peak 
appeared to the right.  At 72 hr this defined peak was the dominating product, and thus most 
likely to be the correct form of pE-BNBD3.  After 96 hr this fraction was isolated from the 
reaction mixture by HPLC.  The analytical chromatogram (Figure 3.9B) shows that oxidized pE-
BNBD3 elutes at a later time than the linear pE-BNBD3, showing evidence of change in 
structure during the oxidation process due to the disulphide bond formation.  Most importantly, 
pE-BNBD3 and native BNBD3 co-eluted, and their retention time was increased from that of the 
linear pE-BNBD3 (Figure 3.9B). Since β-defensin disulphide bonding is characterized by cys1-
cys5, cys2-cys4, and cys3-cys6 pairing, the native and synthesized (oxidized/folded) peptides 
only co-elute when analyzed by HPLC if they are identical [333, 334]. Accordingly, native and 
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pE-BNBD3 have identical amino acid sequences and disulphide connectivities thus 
authenticating correct folding under the oxidation conditions outlined. Since the native 
conformation usually favors that which is most thermodynamically stable [335, 336], the other 
synthetic peptides can be inferred to have the native conformation with the correct disulphide 
connectivities. 
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Figure 3.9 Oxidation of sythesized pE-BNBD3 and comparative HPLC of native BNBD3 
and synthesized/oxidized pE-BNBD3.  (A.) pE-BNBD3 oxidation reaction time course: from 
the bottom: Chromatograms of the change in the reaction profile beginning with the purified 
linear molecule at time 0 and after 1, 24, and 72 hrs.  (B) from the bottom:  chromatograms of 
the linear peptide, the synthesized/oxidized  pE-BNBD3 after oxidation reaction of 96 h and the 
native peptide. Retention times for each are shown. The native and synthesized pE-BNBD3 co-
elute.   
 
In a chemotaxis assay, only peptides with the same connectivities have the same bell-shaped 
dose-response curves and peak migration at the same concentration. Chemotaxis to five 10-fold 
dilutions (0.001-1000ng/ml) of the native and synthesized BNBD3s was examined. All four 
peptides had similar bell-shaped dose-response curves and the concentration that induced the 
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maximum cell migration was the same, at 10 ng/ml.  Migration of iDCs for all BNBD3s was 
significantly greater at 10 ng/ml (p<0.001) when compared to all other concentrations (Figure 
3.10A). This strongly supports the contention that sBNBD3 and aBNBD3 have the same 
disulfide connectivities as pE-BNBD3 and native BNBD3.  Importantly, this demonstrates that 
native BNBD3 is chemotactic for bovine iDCs while the three synthesized BNBD3s are equally 
chemotactic. 
 
To determine whether the mechanism of migration of bovine iDCs to BNBD3 might be ligand-
induced through G protein-coupled seven-transmembrane domain receptors, iDCs were treated 
with PTX (Figure 3.10A). No inhibitory effect of PTX on spontaneous migration of iDCs to CM 
was observed, thus PTX treatment did not affect migration by inhibiting cell motility. When 
compared to untreated cells; PTX pre-treament of iDCs completely abrogated migration to all 
BNBD3 peptides, and at 10 ng/ml this effect was highly significant (p<0.001). Thus, BNBD3 
likely exerts its selective chemotactic effect on bovine iDCs through a Giα receptor(s).   
 
Finally, checkerboard analysis was performed, with peptides at the optimized concentration of 10 
ng/ml, to verify that migration of iDCs to BNBD3 was directed (chemotaxis) and not random 
(chemokinesis). A 10 ng/ml concentration of peptide below the filter induced  
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Figure 3.10 Chemotaxis of bovine DC3 to native and synthesized forms of BNBD3. DC3 
were labelled with Calcein AM and migration of cells toward medium or defensin was 
determined.  Data are expressed as the chemotactic index (CI), and are shown as the mean 
values of the average CI + sem of four donor animals (n=4).  (A) Migration of DC3 pretreated 
without (PTX-) or with 100 ng/ml of pertussis toxin (PTX) at 37°C for 30 min to native BNBD3, 
and the 3 synthesized BNBD3 peptides: pE BNBD3 (pyroglutamic acid at N-terminus), 
aBNBD3 (Glycine [G] replaces Glutamine [Q] in positions 1 and 27), sBNBD3 (published 
sequence Glutamine in positions 1 and 27). (B) For checkerboard analysis the optimal 
concentration (10 ng/ml) of each BNBD3 peptide was placed in the upper (above), lower 
(below), or both compartments of the chemotactic chamber. Migration of untreated cells to each 
peptide at 10 ng/ml placed in the lower compartment was significantly greater (p<0.001) when 
compared to all other concentrations, PTX-treated cells, and placement of peptide in the upper or 
both compartments. 
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significant (p<0.001) iDC migration, whereas an equal concentration of peptide above, or above 
and below the filter of the chemotaxis chamber did not increase cell migration over that to CM 
(Figure 3.10B). Since random migration was not observed with any of the peptides, migration of 
bovine iDCs to native BNBD3 and the synthesized BNBD3s is chemotactic and not 
chemokinetic. 
 
In summary, the synthetic BNBD3 peptides, with pE-BNBD3 as an example, were properly 
folded with the correct disulphide linkages. Furthermore, the chemotactic ability of the peptides 
was dose-dependent with maximum migration at 10 ng/ml, and bovine iDC migration to the 
peptides was shown to be ligand-induced, chemotactic and not chemokinetic.  We infer from 
these findings that the synthesized bovine β-defensins preferentially folded into a biologically 
active, native conformation. 
 
3.4.5 BNBD3 increases migration of CD205+ cells with a DC-like morphology to the skin 
To ensure that bovine β-defensin is not only chemotactic for DCs in vitro, but that it would also 
be chemotactic in vivo, punch biopsies (6 mm) were taken from untreated skin and at 3 h post-
injection from bovine skin that had been injected ID with BNBD3 at 1mg/ml.  As the biological 
activity of β-defensins may be reduced by suspension in ionic media such as saline or PBS [301], 
we first we established that the tissue is unaffected by injection of double distilled (ddH2O)  into 
skin and that the number of cells in the tissue was unchanged (data not shown). Subsequently, 
BNBD3 was suspended in ddH2O and injected into the skin.    
Cryostat sections from untreated and BNBD3-treated skin were probed with the mab to CD205, 
an isotype-matched control mab, or just the secondary antibody.  When compared with sections 
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from an unvaccinated biopsy stained with mab to CD205 (Figure 3.11A) and sections from a 
BNBD3 biopsy stained with secondary antibody (Figure 3.11B) or with an isotype-matched 
primary plus secondary antibody (Figure 3.11B, Inset), sections from a BNBD3 biopsy stained 
with mab to CD205 showed more positively stained cells in the epidermis (Figure 3.11C-D), 
dermis (Figure 3.11C-D), and in the underlying lymph vessels (Figure 3.11C, E-F).  At 100x 
magnification, CD205+ cells with DC-like morphology can be clearly seen in the dermis (Figure 
3.11D).  CD205+ cells lining the lymph vessels had a veiled morphology (Figure 3.11E), and 
when viewed at 250x magnification, appeared to be moving from the surrounding tissue into the 
vessel (Figure 3.11F).  In other studies, CD205 mab stained more cells in the dermis and 
epidermis of bovine skin, with no apparent staining in lymph vessels [318].  We also observed 
higher numbers of CD205+ cells in the dermis and epidermis, and few in the lymph vessels, but 
only in sections of a biopsy taken 30 min post-injection with BNBD3 (not shown).  These results 
suggest that in vivo chemotaxis by immature or pre-cursor DCs to BNBD3 occurs in 30 min to 3 
h, and that the CD205+ cells observed in the sections from BNBD3 biopsies are, by 3 h post-
injection, already migrating to lymph vessels and draining to the LN.    
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Figure 3.11  Migration of CD205+ cells 3 h post intradermal injection with BNBD3.  
Migration of CD205+ cells with DC-like morphology was assessed by 
immunohistochemistry using anti-CD205 mab MCA1651.  (A) 10x magnification  of a 
cryostat section from an unvaccinated biopsy probed with mab to CD205-MCA1651.  (B) 10x 
magnification  of a cryostat section from a BNBD3 biopsy probed with secondary antibody 
(Inset: staining with isotype-matched primary mab plus secondary. ).  (C) 10x magnification of a 
cryostat section from a BNBD3 vaccinated biopsy probed with mab to CD205-MCA1651.  
Stained cells can be seen in the epidermis, dermis and in the underlying lymph vessels; (D) 100x 
magnification showing cells with DC-like morphology in the dermis; (E) 100x magnification of 
stained cells lining the inner surface of a lymph vessel; (F) 250x magnification of cells with a 
veiled morphology and appearing to move from the surrounding tissue into the lymph vessel. 
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3.5 Discussion 
 
Vaccination strategies for large, outbred animal species can be designed to take advantage of the 
unique APC characteristics of iDCs [275, 337]. Chemo-attracting immature bovine DCs to the 
site of antigen deposition by including a bovine β-defensin in its most effective form has the 
potential to improve the induction, magnitude and perhaps duration of adaptive immune 
responses to microbial and viral pathogens. Since little is known about bovine β-defensins, their 
potential for chemo-attracting bovine iDCs and the subsequent effect on the adaptive immune 
system of cattle, the objective of this study was to define for the first time the chemotactic ability 
of synthetic versions of 14 of the 16 known bovine β-defensins for immature bovine monocyte-
derived DCs.  
 
Since previous studies have shown that an immature phenotype and functionality is of 
importance in the ability of hBD2 and mBD2 to influence migration of iDCs and the induction of 
adaptive immune responses, we first performed a phenotypic and functional characterization of 
immature bovine monocyte-derived DCs.  After three days in culture, the cells were 
morphologically different with a phenotype that was distinct from Mo and similar to human 
iDCs [319, 320], including expression of specialized antigen uptake receptors CD205, CD1, and 
MMR [326] which along with CD80/86 were virtually not expressed by Mo.  Expression of 
CD14 and CD11c was high on Mo as would be expected in a pure positively selected population.  
Monocyte-derived bovine DCs are known to have higher expression of CD14, in contrast to 
human DCs or bovine DCs from other compartments [308, 309, 338, 339].  Thus, our 
observation that CD14 is expressed by bovine DCs does not exclude them as DCs. As well, when 
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compared to Mo, the intensity of CD11c expression by DCs was significantly reduced by day 6, 
in good agreement with previous reports of bovine monocyte-derived DCs [309].  The mab to 
human CD14 used to stain Mo and DCs for FACs analysis was the same as that used to isolate 
bovine Mo from PBMCs.  Given that both Mo and monocyte-derived DCs stain with this 
antibody it is theoretically possible that a portion of the cells isolated from PBMCs as CD14+ 
Mo could be DCs or DC-precursors.  This could explain why some Mo unexpectedly expressed 
DC-Lamp at low mfi.  Thus the health status of the donor animal on the day of isolation may 
influence the makeup of the starting cell culture population, and explain some of the variability 
in phenotype and functionality seen in different experiments with different donor animals. 
   
The mannose receptor is the major receptor for FITC-dextran [132] and highly expressed in 
iDCs. Because of its ability to repeatedly take-up and internalize FITC-dextran, and recyle to the 
cell surface, the MMR gives iDCs their hallmark endocytic characteristic and helps to 
functionally discriminate the iDC from Mo and more mature DC [132, 326].  We observed an 
increase in the number of cells that endocytosed and in the quantity of FITC-dextran taken-up by 
DC3 that was concurrent with increased surface and intra-cellular expression of MMR when 
compared to Mo.  As the cells further differentiated to DC6 and DC10, the quantity of FITC-
dextran taken up by the cells and the expression of MMR as evidenced by the decline in MFI, 
was reduced. 
 
Maturation of DCs is also associated with an increase in costimulatory molecules with a 
concurrent increase in the ability to present antigen, as evidenced by the ability to stimulate 
resting lymphocytes [307, 308, 326, 331]. The expression of CD80/86 previously used to 
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establish differentiation of bovine Mo to DCs [309, 340] was increased.  The DC3 from BHV-1 
tgD sensitized animals were significantly more proficient at inducing proliferation of responder 
cells than were Mo, though there was variation between animals in the magnitude of the 
proliferative response.  Animal to animal variation of cellular responses of outbred ruminant 
species is well documented [313, 341-343].  Typically this is attributed to MHC and cytokine 
gene polymorphisms in outbred populations [343], which could in turn influence the phenotype 
of circulating (responder) lymphocytes.  Even in calves that share the same MHC haplotype, 
large differences in the magnitude of proliferative responses can be seen [341, 344].  As well, 
marked differences in innate immune responses of individual cattle [342] were observed, and this 
suggests that animal to animal variation cannot be solely attributed to MHC and cytokine gene 
polymorphisms of outbred species. Whether variation in the proliferative response is due to 
breed or animal differences attributable to the lymphocyte or DC populations [308], or whether it 
is influenced by differences in the innate immune responses is yet to be elucidated.  Since our 
goal was to show that bovine iDCs, the target cell population for chemotaxis to bovine β-
defensins, are capable of presenting antigen to, and stimulating proliferation of, lymphocytes, the 
significantly greater proliferation of autologous lymphocytes from sensitized animals when 
incubated with tgD-pulsed DC3 fulfilled this criterion.  
 
Since antimicrobial activity is one of the most documented properties of defensins [345, 346], 
the peptides were tested prior to the chemotaxis assays.  Because native bovine β-defensin 
peptides purified from neutrophil granules have proven bactericidal activity [219], to show that 
our synthesized peptides would be similarly biologically active, and to highlight any differences 
between linear and folded, both the linear and oxidized/folded forms of the synthesized bovine 
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beta-defensins were tested.  When evaluated by plate-based assay, the linear peptides had limited 
or no antimicrobial activity.  Additionally, the oxidized forms of BNBD10 and 11 that had not 
formed 3 disulfide bonds based on the MALDI data, were unable to inhibit bacterial growth.  In 
good agreement with the findings of others, the oxidized peptides were salt-sensitive [175, 306, 
346, 347].  Currently there are conflicting reports on whether synthesized peptides can be 
oxidized to achieve native disulfide pairing and thus conformation [348].  Also being questioned 
is the requirement for disulphide bonding and/or native connectivities [175, 349-351], or even 
whether the cysteines themselves are required for antimicrobial activity [346, 352, 353]. 
Whereas Wu et al. (2003) reported that linear hBD3 did not preferentially fold into its native 
conformation [334], and in fact oxidation gave rise to numerous oxidized species regardless of 
the 3 oxidation methods used, Harder et al. (2001) and Kluver et al. (2005), upon oxidation of 
the same 45 aa linear peptide, obtained a major product with the correct native connectivities 
[351, 354].  For the majority of the β-defensins including hBD1, hBD2, hBD27, mBD7, mBD8, 
BNBD2 and BNBD12 a straightforward oxidation of the hexathiol linear precursor peptides 
leads to the correct disulphide bonded isomer as the dominating product [346].  As with hBD1 
and hBD2 [334, 355], oxidation of the synthesized linear bovine β-defensins using this method 
(with the exception of BNBD10 and 11) resulted in a dominant product that differed from the 
linear form by RP-HPLC analysis, and that could be easily purified. None of the peptides used in 
our studies gave rise to numerous forms. This is unlike hBD3, where oxidation yielded numerous 
species [334].  And although not a requirement, yields can be improved by utilization of a redox 
system such as the system used to fold the bovine β-defensin peptides in this study.  In 
contraposition to the majority of the β-defensins, there is a small group that includes hBD3, 
hBD23, and hBD28, whereby a major species of correct peptide is not obtained by oxidative 
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folding [334, 356].  BNBD10 and 11 might also belong in this “difficult to oxidize correctly” 
group although confirmation would require further study. Wu et al (2003) found that non-
natively folded forms of hBD3 had antimicrobial activity when evaluated by broth-dulution MIC 
assay [334]; whereas we found that oxidized BNBD10 and 11 had none/limited activity when 
evaluated by agar-plate assay.  The contradiction in findings could be due to true differences in 
the peptides, or they could be a function of the qualitative and comparatively insensitive nature 
of the antimicrobial assay that was used in this investigation.  With respect to antimicrobial 
activity of linear β-defensins, it has been reported in two reviews that for both bovine BNBD2 
and 12, the presence or distribution of disulfide bonds is not essential for antimicrobial activity 
[346, 348]. Thus one might conclude that the linear BNBD2 and 12 were antimicrobial.  
However, for BNBD2, only results for the carboxy-terminal segment linear and oxidized 
peptides were reported [357]. Thus it appears that neither linear nor oxidized full-length BNBD2 
was assessed for antimicrobial activity, or the results were not reported.  For synthesized 
BNBD12, antimicrobial activity of oxidized BNBD12 was compared to and found to be less than 
that of the peptide with non-native conformation (C1-3, C2-4, C5-6) but comparison with the 
linear full-length BNBD12 was either not assessed or not reported [358].  Others have similarly 
reported no loss of antimicrobial activity by a linear hBD3 [334, 350].  However, the linear 
peptide tested was unlike ours in that the cysteines were replaced with alpha-aminobutyric acid 
(Abu). Whether this substitution contributed to antimicrobial activity is unknown.  A linear 
hBD3 peptide containing six cysteines, that would be equivalent to the linear bovine beta-
defensins in this study, was not tested [334, 350].  Importantly, like our synthesized bovine β-
defensins, Routsias et al. (2010) found the linear form of hBD2 to be inactive and native 
disulfide connectivity essential for microbicidal activity of hBD2 [347].  Thus in the context of 
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the limited experimental data relating structure and antimicrobial activity, our finding that linear 
bovine beta-defensins are not antimicrobial whereas tri-disulfide folded peptides are, is not 
unreasonable. 
   
Monocytes and DCs were compared in chemotaxis experiments, which we performed to answer 
whether bovine iDCs, like their human and murine counterparts [214, 217] are attracted to β-
defensins, and if so, to which of the known bovine β-defensins they are most attracted In the 
initial screening, DCs were more chemo-attracted to bovine β-defensins than were Mo, and there 
was an overall trend for greatest chemotaxis to  defensins in DC3 compared to DC6 population. 
Since maturation of DCs has been previously associated with lower chemotactic activity, this 
finding, combined with the reduction in mfi of MMR [132, 308, 309, 323, 326, 327], lower 
endocytic ability, increased CD80/86 expression, increased ability to stimulate lymphocytes, and 
the appearance of dendritic processes on DCs at day 6, suggests that DC6 are more mature and 
by inference, that DC3 are immature.  Accordingly only DC3 were used in subsequent 
chemotaxis investigations as bovine iDC.  Migration to defensin tended to be greatest at the 
lower concentrations and marginal at the higher concentrations.  Although this effect was not 
statistically significant, chemo-attraction to the lower concentrations may be biologically 
significant, theoretically encouraging iDC to traffic from far-away to sites of injury, infection or 
vaccination in bovine skin, while protecting against influx of large numbers of iDC to highly 
inflamed areas due to their almost repulsion at higher concentrations.   
 
aBNBD3, BNBD9 and EBD had the highest CI rankings, and also have comparatively high 
homology to hBD2, although none of the bovine β-defensins share greater than 50% sequence 
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homology with this human peptide.  TAP, the bovine β-defensin with the greatest sequence 
homology to hBD2 ranked 5
th
 and this was surprising as, like EBD and hBD2, it is an inducible 
epithelial defensin [185].  What makes one defensin more chemotactic than another, and what 
determines the kind of cell attracted, is currently unclear.  Beta-defensins have a conserved 
tertiary-structure even though there is little primary structure or amino acid (aa) sequence 
similarity [306, 359, 360].  Only the six cysteines and two small residues (one is glycine, the 
other may be glycine or alanine) are highly conserved [333], although if chemically similar 
amino acids are included in the analysis, overall homology of β-defensins is increased [360].  In 
addition, the lack of connection between amino acid sequence and biological activity of the 
defensins has been well documented [345, 349].  Studies of sequence, structure and the effect (s) 
of changes on both with respect to defensin activity, have provided increased understanding of 
these relationships, but it is still not known if certain residues and/or structural features are 
required for defensin function [215, 333, 358].  Of the peptides that were tested in this study, 
BNBD6 was the least able to chemo-attract iDCs.  BNBD6 has differences in 3 aa when 
compared to the sequences of the other bovine β-defensins (Fig 3.8, changed aa’s shown in red 
letters) and these differences could account for its poor chemotactic performance. One of these is 
asparagine, an aa that is typically conserved in bovine β-defensins [227].  In BNBD6 asparagine, 
an aa with polar uncharged side chains, is substituted by tyrosine, an aa with a hydrophobic side 
chain, and a substitution that hypothetically could have unfavorable steric consequences.  Further 
highlighting BNBD6’s differences, Boniotto et al.(2003) reported a low level of homology 
between gallinacin, and BNBD6 with hBD3.  Conversely, they did not find any homology (apart 
from the conserved residues) between hBD3 and any of the other bovine β-defensins, hBD1 or 
hBD2 [359].  BNBD2 was also poorly chemotactic for iDCs, and yet it is identical in sequence to 
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nBNBD3 with the exception that it is lacking the first 2 N-terminal amino acids.   This change at 
the N-terminus could be responsible for its poor chemotactic activity compared to the highly 
chemotactic nBNBD3.  Notable reductions in chemotactic activity, particularly CCR6-mediated 
chemotaxis, have been associated with changes to the N-terminal amino acids for hBD1 [361], 
and a truncated artificial β-defensin [362].  It is also possible that at least 4 residues preceding 
Cys
1
 are needed at the N-terminus [355, 356, 362, 363].  BNBD7 was chemotactic for DC3 but 
less so than the top three.  BNBD7 had a ranking of 3 that put it just behind EBD (3.25).  The 
sequence of BNBD7 is the same as BNBD9 except BNBD7, like BNBD3, has an arginine (R) 
instead of glutamine (Q) residue at the third amino acid position preceding Cys
5
.  Why this 
single amino acid change would reduce chemotactic activity is not clear.  In human defensin 5, 
the presence of arginine residues was found to improve host cell interaction presumably as a 
function of positive charge and hydrophobicity [364].  It may be that the change from the smaller 
uncharged glutamine (BNBD9) to the larger positively charged arginine (BNBD7) interferes 
sterically with a preferred or more stable conformation [333], particularly since this occurs in 
combination with a C-terminus that is relatively short (only 1 aa after Cys
6
).  The single amino 
acid change could also be responsible for the slightly lower chemotaxis of BNBD7 as compared 
to BNBD9, if it results in a peptide with looser structure that is less stable in media containing 
serum.  The looser structure of hBD3 has been attributed to the presence of an argenine residue 
[359]; in turn, this structural characteristic has been correlated with increased degradation of 
hBD3 in serum [362].   
 
To confirm our initial chemotaxis results, migration of Mo and DC3 to the three top β-defensins 
aBNBD3, BNBD9 and EBD was repeated with additional animals and compared to BNBD6. 
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Again DC3 were significantly more chemo-attracted to BNBD3, EBD and BNBD9 than Mo. 
Thus our earlier results were confirmed in these larger studies. The poor chemotaxis of bovine 
Mo to bovine β-defensins that we observed is contradictory to the findings of Rohrl et al. (2010a) 
who reported that hBD2 was chemotactic for human Mo, but in good agreement with the 
findings of Yang et. al (1999) who observed that hBD2 was not chemotactic for Mo.  
Appropriate controls were used in all studies, thus excluding many reasons for this discrepancy. 
One possible explanation could be the effect of the isolation method on subsequent monocyte 
function.  In this and in the report by Yang et al. Mo were isolated from peripheral blood by 
Ficoll-Paque density gradient followed by immune-separation through columns, whereas Rohrl 
et al. (2010) used a Percoll gradient for the second step of the isolation.  Activation of Mo as a 
result of being isolated over a Percoll gradient has been reported [365, 366] and this or perhaps 
variances in the surface receptors of the resulting monocyte populations [366] may account for 
the discrepancy between studies.  Interestingly, we found that bovine Mo isolated using a Percoll 
gradient were unable to differentiate to DCs although whether this was due to activation or some 
other reason was not ascertained.  Our chemotaxis results suggest that whatever method, be it a 
mechanism or receptor (s), is responsible for the ability of bovine iDCs to migrate to bovine β-
defensins that these methods are not included in the monocyte repertoire.  When chemotaxis of 
just the DC3 to aBNBD3, EBD, BNBD9 and BNBD6 was compared, highly significant 
differences were observed that suggested a slight chemotactic advantage of aBNBD3 and EBD.   
 
Chemotaxis of iDCs to three synthesized forms of BNBD3s was also compared with chemotaxis 
to native BNBD3.  We first established by RP-HPLC that the synthesis method we used would 
yield correctly folded (oxidized) peptides with the defined β-defensin disulphide connectivity.  
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Chromatographically, our synthesized N-terminal pyroglutamate (pE)-BNBD3 co-eluted with 
the native BNBD3 thus authenticating correct folding under the conditions outlined [333, 334].  
Oxidation of the synthesized linear bovine β-defensins using this method resulted in a dominant 
product that differed from the linear form by RP-HPLC analysis, and that could be easily 
purified. This is unlike hBD3, where oxidation yielded numerous species [334].  None of the 
peptides gave rise to numerous forms, and the native conformation usually favors that which is 
most thermo-dynamically stable [335, 336].  It follows that the rest of our synthesized bovine β-
defensins would also adhere to the native conformation with the correct disulphide 
connectivities, although we cannot prove this unambiguously.  Chemotaxis activity offers 
another method by which to further confirm correct disulfide connectivity.  Others have shown 
that analogs with non-native disulfide connectivities show peak chemotactic activity at different 
concentrations than peptides with the native conformation [334, 361, 367].  It follows that 
synthesized peptides with native disulfide connectivities most likely have the greatest 
chemotactic activity at the same concentration as the native peptide.  We observed characteristic 
bell-shaped dose response curves [214, 306, 315, 361] with the same peak migration of 10 ng/ml 
for nBNBD3 and the three synthesized BNBD3 peptides.  Thus synthesized pE-BNBD3 and 
native BNBD3 were biochemically identical based on amino acid sequence, mass spectrometry, 
and HPLC; and were biologically identical as shown by chemotaxis assay [368].  These 
chemotaxis results strongly suggest that all three synthesized BNBD3 peptides have the native 
conformation and show that all are equally chemotactic for bovine iDCs. This means that 
aBNBD3, which is the simplest peptide to synthesize with the highest yields, can be used to 
chemo-attract bovine iDCs as equivalent to nBNBD3. Directed migration of iDC to specific sites 
in tissue is also important as a mechanism in induction of appropriate specific immune response 
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[298, 369]. Using checkerboard analysis and pretreatment of iDCs with PTX, we determined that 
nBNBD3 and the three synthetic BNBD3s are directly and specifically chemoattractant for 
bovine iDCs. All BNBD3s induced iDC chemotaxis (directed migration) as opposed to 
chemokinesis (random migration). Although the bovine iDC receptors for BNBD3 are currently 
unknown, the PTX inhibition of bovine iDC chemotaxis indicates that this mechanism involves 
at least one seven-transmembrane Giα protein coupled receptor [315] without excluding the 
possibility of other receptors or mechanisms (described in introduction).  As bovine chemokine 
receptors are discovered, and antibodies to these receptors become commercially available, 
further investigation can be done to identify the specific receptor(s) and or mechanism(s) 
involved in bovine iDC migration to bovine β-defensins. 
 
In vivo chemotaxis by bovine DCs was determined by staining sections of bovine skin with mab 
to CD205 3 h after intradermal injection of aBNBD3. Some staining of CD205+ cells was 
evident in sections from un-vaccinated skin as would be expected in a steady state of in- and out-
migration of DCs in normal skin [370].  More positively stained cells could be seen in the 
epidermis, dermis, and particularly in the underlying lymph vessels of sections from the 
BNBD3-treated skin.  Other authors have shown that CD205 is expressed at high levels on DCs 
in the afferent lymph draining from the skin [308, 323, 371, 372], so we would expect that at 
later time periods, more matured DCs would be moving out of the tissues and into the lymph 
vessels. It is theoretically possible that injection of BNBD3 resulted in not only increased in-
migration of DCs and DC-precursors from the circulation, but that it also induced migration of 
resident DCs to the site of injection [373] followed by their subsequent movement to the 
underlying lymph vessels.  This suggests that in vivo chemotaxis by immature or pre-cursor DCs 
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to BNBD3 is a relatively rapid response that can take place in under 3 h. These results 
corroborate and support our in vitro results that BNBD3 is chemotactic for immature bovine 
DCs.  
 
In conclusion, we defined phenotypically and functionally, the bovine iDC. We demonstrated 
that bovine iDCs are chemo-attracted by β-defensins and that BNBD3, BNBD9, and EBD are the 
most chemotactic. These new findings into the chemotactic nature of bovine β-defensins are a 
first step into exploration of their use in new iDC-targeting vaccination strategies.  
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Fourth Chapter Transition/Overview 
In this chapter/manuscript I built on the work of the previous chapter 3 and addressed the second 
objective of the project which was to 1) construct plasmids that expressed the iDC chemotactic 
β-defensin, BNBD3, alone and in combination with the BoHV-1 antigen tgD, and 2) assess the 
immune and protective responses induced by intradermal DNA vaccination of mice and cattle 
using the plasmids encoding BNBD3. In mice, co-administration of BNBD3 on the separate 
plasmid enhanced the tgD-induced IFN-γ response, but not the antibody response. BNBD3 fused 
to tgD did not affect the antibody levels or the number of IFN-γ secreting cells, but increased the 
induction of tgD-specific CTLs. In cattle, BNBD3 delivered with a separate plasmid did not 
enhance immune responses, while the addition of BNBD3 as a fusion construct increased CMI 
but not humoral responses. Cattle were equally protected from BoHV-1 infection by DNA 
vaccines encoding tgD alone or as a fusion with BNBD3.  
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4.1 Abstract 
 
Bovine herpesvirus-1 (BoHV-1) causes recurrent respiratory and genital infections in cattle, and 
predisposes them to lethal secondary infections. While modified-live and killed BoHV-1 
vaccines exist, these are not without problems. Development of an effective DNA vaccine for 
BoHV-1 has the potential to address these issues. As a strategy to enhance DNA vaccine 
immunity, a plasmid encoding the bovine neutrophil beta defensin-3 (BNBD3) as a fusion with 
truncated glycoprotein D (tgD) and a mix of two plasmids encoding BNBD3 and tgD were tested 
in mice and cattle. In mice, co-administration of BNBD3 on the separate plasmid enhanced the 
tgD-induced IFN-γ response, but not the antibody response. BNBD3 fused to tgD did not affect 
the antibody levels or the number of IFN-γ secreting cells, but increased the induction of tgD-
specific cytotoxic T lymphocytes (CTLs). In cattle, the addition of BNBD3 as a fusion construct 
also modified the immune response. While the IgG and virus neutralizing antibody levels were 
not affected, the number of IFN-γ secreting cells was increased; specifically the CD8+/IFN-γ+ T 
cells including CD8
+
/IFN-γ+/CD25+ CTLs after BoHV-1 challenge. While reduced virus 
shedding, rectal temperature and weight loss were observed, the level of protection was 
comparable to that observed in pMASIA-tgD-vaccinated animals. These data show that co-
administration of BNBD3 with a protective antigen as a fusion in a DNA vaccine strengthened 
the Th1 bias and increased cell-mediated immune responses, but did not enhance protection from 
BoHV-1 infection.  
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4.2 Introduction 
 
Bovine herpesvirus-1 (BoHV-1) causes recurrent respiratory and genital infections in cattle. As 
the causative agent of IBR, BoHV-1 is one of several pathogens that interact, typically during 
times of stress, to cause respiratory disease and death in calves and feedlot cattle [70, 71]. 
Economic losses associated with BRDC, of which BoHV-1 is considered a major etiological 
agent, have been approximated at 640 million annually in the United States according to a report 
in 2000 [374]. According to a study performed in 2006 an economic loss of $13.90 per animal in 
the feedlot is estimated, due to lower gains and treatment costs for BRD [375]. In the breeding 
herd, BoHV-1 infection has been implicated in reproductive diseases, poor reproductive 
performance, and in abortion [376-379]. Costs and economic losses due to BoHV-1 infection and 
reactivation are thus observed in the breeding herd, but are difficult to calculate due to a lack of 
established data. 
 
Immunization of cattle against BoHV-1 infection is currently achieved using either MLV or KV 
commercial vaccines [374]. The MLV vaccines are generally considered most effective as they 
stimulate both humoral and cell-mediated immunity [90, 278]. However, adverse effects 
associated with the use of MLV vaccines include latent infection and immune suppression [71, 
90], and abortion in pregnant animals [378, 380]; the latter effect limiting the use of MLV 
vaccines in some groups of cattle, notably bred cows and heifers. Thus, KV vaccines may be 
recommended for use in the breeding herd as they are considered safer [381]. Additionally, 
although inactivated vaccines are non-infectious and are generally stable, they have the 
disadvantage of being poorly immunogenic (unable to stimulate cellular immunity) and typically 
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require adjuvants and/or several immunizations (reviewed in [382]). As neither type of vaccine 
fully protects cattle from BoHV-1 infection and both have inherent shortcomings [98, 276, 383], 
new vaccines are being sought that would be effective, safe in all groups of cattle, and 
economical.  
 
DNA vaccines are one such type. DNA vaccines are cost-effective and can be designed, 
manufactured and stored with relative ease [241]. They also are non-infectious and do not 
promote inflammation at the site of immunization [241]. These are important factors in vaccines 
for food animals such as cattle [243], and in vaccination strategies for any virus for which the 
potential for reversion and spread of MLV vaccines is a major drawback. Furthermore, DNA 
vaccines can be used as marker vaccines to differentiate vaccinated and virus-exposed animals in 
eradication programs [243]. They also have the potential to initiate immunity in neonates born to 
immune mothers [244]. Similar to MLV vaccines and natural infection, and in a manner unique 
for a non-infectious moiety, DNA vaccines can induce MHC class I-restricted CD8 cytotoxic T 
lymphocyte (CTL) responses and produce neutralizing antibodies [246].  Since their discovery in 
1990 [247], there have been over 600 reports of successful induction of immune responses in 
animals given DNA vaccines [249]. However, in the majority of these studies mice were used as 
an experimental model. In large animals much weaker responses have been observed which were 
not always sufficient to provide protective immunity [243]. To address this, several methods 
have been employed to increase the potency of DNA vaccines and/or manipulate the immune 
response including improving cellular delivery of plasmid DNA, increasing antigen production, 
and genetic adjuvanting [384-387].  
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One method of genetic adjuvanting that has shown promise in the mouse model [217, 218] and 
also in the chicken [388] to improve the potency and/or modulate the immune response to a 
DNA vaccine is to deliver antigen as a fusion with a beta (β)-defensin. Beta-defensins are 
cationic, membrane active, antimicrobial proteins of the innate immune system that participate in 
defense against microbial pathogens [199]. In cattle, as in mice, β-defensins are found primarily 
in skin or mucosal tissues, and they are released in response to infection or injury. This suggests 
that, in a manner similar to that shown by Yang et al. [183], they are ideally positioned to recruit 
the cells of the adaptive immune system and may serve to initiate and amplify the adaptive 
immune response to invading pathogens. As such, they are an attractive target for strategies 
aimed at enhancing the antigen-specific adaptive response to a DNA vaccine. The efficacy 
and/or immunomodulatory effect of a DNA vaccine designed to express β-defensin in a large 
animal model such as cattle has not been tested. Since CMI is important in protection from viral 
infections, and this has been shown in murine and chicken models to be enhanced by the 
inclusion of β-defensin as a fusion construct in a DNA vaccine, it is logical to think that a similar 
strategy may improve efficacy of a BoHV-1 DNA vaccine for cattle.  
 
Here we describe for the first time a DNA vaccine encoding the mature form of the chemotactic 
bovine β-defensin-3 (BNBD3) peptide [389], either co-administered on a separate plasmid or 
fused with a truncated secreted form of glycoprotein D (tgD) of BoHV-1, a well-characterized 
vaccine antigen that has previously been shown to impart partial protection [44, 263] from 
BoHV-1 infection to cattle. BNBD3 was shown to modulate the type of tgD-specific immune 
response induced by DNA immunization, both in mice and in cattle.  
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4.3 Materials and Methods 
4.3.1 Construction of plasmids   
Expression plasmids encoding the mature form of the BNBD3 peptide (GenBank accession no. 
AF016396) were constructed according to the strategy shown schematically in Figure 1. BNBD3 
was inserted into pMASIA and pMASIA-tgD [390] in three pieces (Figure 4.1). Complementary 
oligonucleotide pairs, shown in Table 4.1, were synthesized (Sigma-Aldrich, St. Louis, MO, 
USA) based on the published coding sequence for the mature BNBD3 peptide (GenBank 
accession no. AF016396). The first piece was synthesized with a 5’ BamHI site (BNBD3-1), the 
second with 5’ phosphorylation (BNBD3-2) and the third with a 3’ HindIII site (BNBD3-3).  
BNBD3-3 was modified for insertion into pMASIA-tgD to create the defensin-viral antigen 
fusion construct BNBD3-tgD by removing the stop codon and adding the coding sequence for a 
defined octapeptide linker NDAQAPKS [391-393] to the 3’ end of BNBD3-3 to generate 
BNBD3-3L.  This octapeptide was used to connect the 3’ carboxy end of the BNBD3 coding 
sequence to the 5’ amino terminus of the sequence for tgD.  The coding sequence for this linker 
has been described previously as 5’-AAC GAC GCA CAA GCA CCA AAA AGC/TCA-3’ [392, 
394]. Since its use has been primarily in a mouse model, this linker gene was re-designed, 5’-
AAC GAC GCC CAG GCC CCC AAG AGC/TCA-3’, to optimize the codon bias in favor of 
expression in bovine cells (http://www.kazusa.or.jp/codon/) [395].   
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Figure 4.1 Schematic diagram of the construction of pMASIA-tgD, pMASIA-BNBD3 and 
pMASIA-BNBD3-tgD. The gene encoding BoHV-1 tgD was cloned into pMASIA to create 
pMASIA-tgD.  To construct pMASIA-BNBD3, complimentary oligonucleotides encoding the 
mature sequence of BNBD3 were synthesized as 3 sticky-ended pieces (BNBD-1, BNBD-2, 
BNBD-3) and inserted into pMASIA using the BamHI and HindIII sites.  For construction of 
pMASIA-BNBD3-tgD, BNBD3 was similarly inserted in 3 pieces into pMASIA-tgD, and only 
the 3
rd
 piece (BNBD3-3L) differed with a linker sequence at the 3’ end.   
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Synthetic oligonucleotides were suspended, and the complimentary pairs were annealed 
according to the supplier’s instructions. Then the three double-stranded sticky-ended 
oligonucleotide pieces encoding BNBD3 were ligated into the BamHI/HindIII site of pMASIA 
and pMASIA-tgD, respectively.  The ligation reactions were used to transform Escherichia coli 
strain JM109 and after selection (Kanamycin+) and amplification, the plasmids were purified 
using a QIAprep Spin Miniprep kit (Qiagen). Correctness of pMASIA-BNBD3 and pMASIA-
BNBD3-tgD was verified by restriction digestion and confirmed by DNA sequencing. Plasmids 
were amplified in Escherichia coli JM109 cells and purified with Endofree Plasmid Giga kits 
(Qiagen).   
  
Table 4.1 BNBD3-encoding complimentary synthetic oligonucleotide pairs 
Name Primer or Oligonucleotide sequence 
  
BNBD3-1 5’-GATCCATATGCAAGGAGTAAGAAATCATGTAACCTGCCGTATAAATAGAGGCT-3’ a 
BNBD3-1c 5’-CAGAAGCCTCTATTTATACGGCAGGTTACATGATTTCTTACTCCTTGCATATG-3’ a 
  
BNBD3-2 5’-TCTGTGTGCCGATCAGGTGCCCTGGACGCACGAGACAGATTGGCACCTGTTTC-3’ b 
BNBD3-2c 5’-GCCCGAAACAGGTGCCAATCTGTCTCGTGCGTCCAGGGCACCTGATCGGCACA-3’ b 
  
BNBD3nL-3 5’-GGGCCCCGAATAAAATGCTGCAGGTCGTGGTAGA-3’ c  
BNBD3nL-
3c 
5’-AGCTTCTACCACGACCTGCAGCATTTTATTCGGG-3’ c  
  
BNBD3L-3 5’-GGGCCCCGAATAAAATGCTGCAGGTCGTGGAACGACGCCCAGGCCCCCAAGAGCA-3’ d 
BNBD3L-3c 5’-AGCTTGCTCTTGGGGGCCTGGGCGTCGTTCCACGACCTGCAGCATTTTATTCGGG-3’ d 
  
 
a  First piece of BNBD3; a 5’ BamHI restriction site is underlined, and the start codon is in bold. 
b  Second  piece of BNBD3; oligonucleotides were 5’ phosphorylated, and sticky ends were made by                                     
a 4-nucleotide overhang (italics). 
c  Third piece of BNBD3 (pMASIA-BNBD3); a 3’ HindIII restriction site is underlined, and the TAG stop codon is in 
bold. 
d  Third piece of BNBD3 (pMASIA-BNBD3-tgD); the bovine codon optomised  linker is in italic, and a 3’ HindIII  
restriction site is underlined.  
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4.3.2 Expression of BNBD3 and BNBD3-tgD in vitro  
COS7 cells at 50-80% confluency were transiently transfected with pMASIA-BNBD3 or 
pMASIA-BNBD3-tgD using Lipofectamine Plus Reagent in Optimem (Life Technologies). 
After 48 h the cell supernatants were collected, clarified by centrifugation and concentrated 10X 
using an Amicon Ultra 10kDa (pMASIA-tgD, pMASIA-BNBD3-tgD) or Amicon Ultra 3kDa 
(pMASIA-BNBD3) centrifugal filter (Millipore, Bedford, MA, USA). Supernatants were divided 
to provide samples for Coomassie blue staining and Western blotting, and prepared in sodium 
dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) sample buffer in the presence 
or absence of 2-mercaptoethanol.   
 
Proteins were separated by SDS-PAGE  on a 10% acrylamide gel (pMASIA-tgD, pMASIA-
BNBD3-tgD)  according to the method of Laemmli [396] or by tricine SDS-PAGE on a 15% 
acrylamide gel (pMASIA-BNBD3) according to the method of Shagger [397, 398]. Proteins 
were transferred onto 0.45 μm nitrocellulose (pMASIA-tgD, pMASIA-BNBD3-tgD) or 0.2 μm 
PVDF (pMASIA-BNBD3) membranes. The membranes were washed in TBST (0.15M Tris, 
0.02M NaCL [pH 7.5], 0.1% Tween 20) and then incubated for 2 h at RT or overnight at 4°C in 
TBST containing 3% skim milk powder (SMP).  Membranes were probed with gD-specific 
monoclonal antibody (mAb) 3D9S diluted 1:4000 in TBST/1% SMP [399], or with BNBD3-
specific rabbit serum diluted 1:2000 in TBST/1% SMP for 2 h at RT. Polyclonal antibodies to 
BNBD3 were generated as described previously [400]. The synthetic peptide, 
QGVRNHVTCRINRGFCVPIRCPGRTRQIGTCFGPRIKCCRSW, which corresponds to the 
published amino-acid sequence for the mature form of BNBD3 (UniProtKB/Swiss-Prot 
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accession number P46161) [201, 219, 389] was used for immunization. The membranes were 
washed in TBST and then incubated with alkaline phosphatase (AP)-conjugated mouse- or 
rabbit-specific IgG (Kirkegaard and Perry Laboratories, Gaithersburg, MD, USA) at a dilution of 
1/5000 in TBST/1% SMP for 1 h at RT. The bound antibodies were visualized with 5-bromo-4-
chloro-3-indolylphosphate (BICP)/ nitroblue tetrazolium (NBT) substrate (Sigma). Images of the 
Western blots were captured and processed using a GelDoc XR imaging system (Bio-Rad 
Laboratories Ltd, Randolph, MA, USA). 
 
4.3.3 Immunizations and BoHV-1 challenge  
Six to eight week-old C56BL/6 mice (8 mice per group) were immunized twice at a 4-week 
interval intradermally (ID) at the base of the tail with 5 µg pMASIA, pMASIA-tgD, pMASIA-
BNBD3-tgD, or a mixture of pMASIA and pMASIA-tgD or pMASIA-BNBD3 and pMASIA-
tgD.  One month after the final vaccination, mice were euthanized. Serum was taken to be 
assayed for tgD-specific antibody levels and spleens were collected for analysis of tgD-specific 
CMI responses. 
 
Eight to nine month-old BoHV-1 seronegative Angus and Hereford crossbred calves were 
randomly allocated to five groups of six animals each and immunized with 750 µg pMASIA, 
pMASIA-tgD, pMASIA-BNBD3-tgD, a mixture of pMASIA and pMASIA-tgD, or a mixture of 
pMASIA-BNBD3 and pMASIA-tgD.  The plasmids were delivered three times at four-week 
intervals ID in the neck with a needle-free delivery device (Biojector Medical Technologies, 
Portland, OR).  One month after each vaccination, serum was collected for analysis of tgD-
specific antibody levels and peripheral blood was collected for analysis of tgD-specific CMI 
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responses.  
 
Calves in the groups immunized with pMASIA, pMASIA-tgD or pMASIA-BNBD3-tgD were 
challenged intranasally with 4 ml of aerosolized 10
7
 pfu/ml BoHV-1 strain 108, 52 days after the 
last immunization. Sera were collected prior to, and on days 8 and 16 after challenge. Peripheral 
blood was collected and CMI responses were measured prior to challenge and on day 8 after 
challenge by proliferation and ELISPOT assays; on day 16 by ELISPOT depletion assay; and on 
day 25 by a 4-color CTL assay. Calves were clinically assessed before challenge and for 10 days 
after challenge. Temperatures and body weights were measured and nasal swabs were collected 
every second day. All procedures were approved by the University Council for Animal Care and 
Supply in accordance with the standards stipulated by the Canadian Council on Animal Care. 
 
4.3.4 Serology  
For the enzyme-linked-immunosorbent assay (ELISA), ninety-six-well polystyrene microtiter 
plates (IMMULON® 2; Thermo Electron Corrp., Milford, MA) were coated overnight at 4°C 
with 0.05 µg of tgD per well in sodium carbonate coating buffer. Plates were washed in PBS 
with 0.05% Tween 20 (PBST) and then incubated overnight at 4°C with serially diluted mouse 
sera starting at 1:40 in four-fold dilution, with all dilutions in PBS containing 0.5% gelatin (PBS-
g). Plates were washed and bound IgG was detected using AP-conjugated goat anti-mouse IgG 
(Kirkegaard & Perry Laboratories) diluted 1:5000 in PBS-g for 1 h at room temperature (RT). 
Bovine sera were diluted four-fold in PBS-g starting at 1:10, added to plates and incubated for 2 
h at RT. The plates were then incubated for 1 h at RT with affinity-purified AP-conjugated goat 
anti-bovine IgG (Kirkegaard & Perry Laboratories) diluted 1:10,000 in PBS-g. All reactions 
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were visualized with 0.01M p-nitrophenyl phosphate (PNPP) (Sigma-Aldrich) in 0.104 M 
diethanolamine, 0.5 mM MgCl. Absorbance was read on a model 3550 Microplate Reader (Bio-
Rad Laboratories Ltd) at 405 nm, with a reference wavelength of 490 nm. ELISA titers were 
expressed as the inverse of the serum dilution that gave an absorbance (A) value two standard 
deviations above the values for serum from control naïve animals. 
Virus neutralization (VN) titers in cattle sera were determined as described previously [401]. 
Viral plaques were visualized by staining each well with 20 μl of 0.5% crystal violet in 80% 
methanol for 1 min., and then counted. Titers were expressed as the reciprocal of the highest 
dilution of serum that resulted in a 50% reduction in plaques relative to the serum-free positive 
virus control [44]. 
 
4.3.5 Enzyme-linked-immunospot assay (ELISPOT)   
Splenocytes were isolated and resuspended as previously described [402] at a concentration of 1 
x 10
7
 cells per ml in complete medium (cRPMI) made up of RPMI 1640, supplemented with 
10% fetal bovine serum (FBS), 50 μg/ml gentamycin, 1 mM L-glutamine, 10 mM Hepes, 1 mM 
non-essential amino acids, 1 mM sodium pyruvate (all Life Technologies Inc., Burlington, ON, 
Canada) and 5 x 10
-5
 M 2-mercaptoethanol (Sigma-Aldrich). Nitrocellulose plates (96-well 
Multiscreen-HA; Millipore Corp., Bedford, MA, USA) were coated overnight at 4°C with 0.2 
μg/well of anti-mouse IFN-γ or IL-5 (BD Biosciences, San Jose, CA, USA). Plates were washed 
with PBS and then blocked with 1% (w/v) bovine serum albumin (BSA; Sigma-Aldrich) for 2 h 
at 37°C. Splenocytes at 10
6
 cells/well were added to triplicate wells containing medium or tgD at 
3 μg/ml and incubated at 37°C for 20 h. Plates were washed and then incubated with 2 μg/ml 
biotinylated rat anti-mouse IFN-γ or IL-5 (BD Biosciences) in PBS with 1% BSA for 1.5 h, 
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followed by streptavidin-AP (Jackson ImmunoResearch Laboratories, West Grove, PA, USA) 
diluted 1:1000 in PBS with 1% BSA for 1.5 h.  
 
For cattle, the ELISPOT assay was performed as described above for mice, but with the 
following changes. Blood was collected into EDTA, and peripheral blood mononuclear cells 
(PBMCs) were isolated on Ficoll-Paque Plus (Pharmacia, Mississauga, ON, Canada) as 
previously described [263] and suspended at 1 x 10
7
 cells/ml in cRPMI. To assess the IFN-γ 
response attributable to the CD8 and/or CD4 subsets, the ELISPOT assay was also conducted 
with PBMCs that were first depleted of either the CD8 or CD4 T cells using magnetic-activated 
cell sorting (MACs) and subsequent flow cytometry to verify cell purity as has been previously 
described in detail [403]. Positively selected CD4 cells or CD8 cells were added back to their 
respective depleted populations as a percentage of 10
6
 cells per well. For example, in the CD4
-
 + 
5% CD4+ sample, where the number of CD4
- 
cells was 0.95 x 10
6
 cells/well (95%), 50,000 (5%) 
CD4
+
 cells were added to the well to give a total of 10
6
 cells/well. Plates were coated with a 
bovine IFN-γ-specific mAb (2-2-1) [404]. IFNγ-secreting cells were identified with 1:1500 
rabbit serum specific for bovine IFN-γ (lot 92-131) [404] followed by AP-conjugated goat anti-
rabbit IgG (Kirkegaard & Perry Laboratories).  
 
Spots representing IFN-γ or IL-5 secreting splenocytes in mice or IFN-γ secreting PBMCs in 
cattle were visualized using BCIP/NBT substrate (Sigma-Aldrich).  Stained spots were counted 
and the number of IFN-γ or IL-5 secreting cells per 1 x 106 cells was expressed as the difference 
between the number of spots in the tgD-stimulated wells and the number of spots in the control 
(medium) wells. 
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4.3.6 Proliferation:[methyl-
3
H] thymidine incorporation assay 
Bovine blood was collected, and PBMCs were isolated and suspended as described above. Cells 
were further diluted to a concentration of 3.5 x 10
6
 cells/ml in cRPMI. One hundred μl of this 
suspension was dispensed in triplicate into wells containing 100 μl of either medium or tgD at 3 
μg/ml, and then plates were incubated at 37°C. Following 72 h of restimulation, the cells were 
pulsed with 0.4 μCi/well of [methyl-3H] thymidine (Amersham Biosciences, Baie d’Urfe, PQ, 
Canada). After an additional 18 h of culture, cells were collected with a Filtermate harvester and 
thymidine uptake was measured by scintillation counting with a TopCount NXT microplate 
scintillation counter (Packard Instrument Company, Meriden, CT, USA). Proliferative responses 
were calculated as the means of triplicate wells and expressed as a stimulation index (SI) (counts 
per minute in the presence of antigen/counts per minute in the absence of antigen).  
 
4.3.7 Antigen-specific CD8
+/IFNγ+ cytotoxic T cell assay  
In mice the induction of CTLs, defined as CD8
+ 
CD3
+
 T-cells that when stimulated by recall 
antigen secrete IFN-γ [405-408], was measured by fluorescence-activated cell sorting (FACS).  
Splenocytes were isolated from each mouse as described above. Pooled splenocytes [408, 409] 
from each vaccination group were added to wells of a 96-well plate at 1 x 10
6
 cells/well, and 
then cultured at 37°C in the absence or presence of tgD at 3 μg/ml for 7 h.  GolgiPlug (BD 
Biosciences) was added 5 h before harvesting the cells. Cells were washed once with FACS 
buffer (PBS pH 7.2, 0.1% BSA, 0.05% NaNH3) supplemented with 2% FBS and cell-surface 
stained with PE anti-mouse CD3 (IgG2b; clone 17A2, BD Biosciences) and FITC anti-mouse 
CD8 (IgG2a; clone 53-6.7, BD Biosciences) at 4°C for 30 min. For intracellular cytokine 
staining of IFN-γ, cells were washed, fixed and permeablized using the Cytofix/Cytoperm kit 
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according to the manufacturer’s instruction (BD Biosciences). Intracellular IFN-γ was stained 
with APC anti-mouse IFN-γ (IgG1; clone XMG1.2, BD Biosciences).  
 
In cattle, due to difficulty doing CTL assays in outbred animals, the induction of  activated CD8
+ 
IFN-γ+ cells in the PBMCs was used as a measurement of CTL response using a FACs-based 
assay. This assay has been accepted as an alternative in other species to the standard cytolytic 
(Cr51 release) assay [410, 411], and was also selected based on a published report of CTL 
identification in cattle as activated, CD8
+, IFNγ-expressing cells [313]. Accordingly, CD8+ and 
IFN-γ+ expression, concurrent with CD25 (activation), were used as surrogate markers for CTLs 
[406, 412], and thus, cells were identified using a modification of a method that allows for 
simultaneous detection of expression of CD8
+  
and IFN-γ+ with the cell activation marker CD25 
[413-416]. Optimal conditions for cell collection and culture were determined in preliminary 
studies. Blood from two animals from the pMASIA-tgD, pMASIA-BNBD3-tgD and pMASIA 
groups was collected into heparin. PBMCs were isolated on Ficoll-Paque Plus (Pharmacia) 
[389], suspended in cRPMI and then added at 1 x 10
6
 cells per well in 250 μl volume of a 96-
well round-bottom tissue-culture microtitre plate (Corning Costar; Thermo Fisher Scientific, Life 
Technologies Inc., Burlington, ON, Canada). The cells were cultured at 37°C in the absence or 
presence of tgD at 1 μg/ml for 4 days. GolgiStop (BD Biosciences) was added for 12 h before 
harvesting the cells. Cells were washed twice with, and resuspended in, 50 μl of FACS buffer 
and surface-stained using an indirect staining method. Cells were incubated singly with mouse 
anti-bovine CD3 mAb (IgG1, MM1A, VMRD, Pullman, WA, USA), and singly or with a mAb 
mix that consisted of i) mouse anti-bovine CD8 (IgG1, CACT80C, VMRD),  mouse anti-bovine 
γδTCR (gamma-delta T cell receptor) (IgG2b, GB21A, VMRD) and mouse anti-bovine CD25 
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(IgG2a, CACT108A, VMRD), or  ii) mouse anti-bovine CD4 (IgG1, CACT138A, VMRD),  
mouse anti-bovine γδTCR and mouse anti-bovine CD25, for 30 min at 4°C. After washing twice 
with FACs buffer, cells were incubated for 30 min at 4°C either singly or with a mixture of the 
appropriate secondary reagent(s) goat F(ab’)2 anti-mouse IgG1-FITC (1072-02, Southern 
Biotech, Birmingham, AL, USA), goat anti-mouse IgG2b-TRI-COLOR® (M32406, Molecular 
Probes, Life Technologies Inc.), and goat F(ab’)2 anti-mouse IgG2a-RPE (1082-09, Southern 
Biotech). Intracellular cytokine staining of IFN-γ was accomplished with a two-step indirect 
method using the Cytofix/Cytoperm kit (BD Biosciences) according to the manufacturer’s 
instructions with the following exceptions. Cells were fixed and permeabilized by incubating at 
4°C for 1.5 h. Cells were washed twice and resuspended in 1xBD Perm/Wash for both steps. In 
the first step, 25 μl of prediluted biotinylated mouse anti-bovine IFN-γ (biotin MCA1783B, AbD 
Serotec) was added for 1 h at 4°C. In the second step, 25 μl of prediluted streptavidin-
AlexaFluor® 647 conjugate (streptavidin S-32357, Molecular Probes, Invitrogen) was added for 
30 min at 4°C.  
 
Staining specificity was controlled with the appropriate isotype-matched antibody controls. 
Samples were resuspended in Flow buffer (PBS, 1% ultrapure formaldehyde) and kept in the 
dark at 4°C until flow cytometric acquisition was performed. Single-stained samples were used 
to set compensation levels for acquisition of multi-color stained samples. Specific CTL 
responses, evaluated as the increase in the percentage of CD3
+
CD8
+IFNγ+ cells in mice and 
CD25
+
CD8
+IFNγ+ cells in cattle [313, 406, 409, 412, 417] in response to in vitro tgD stimulation 
were detected by flow cytometric analysis. Samples were acquired using a FACSCalibur flow 
cytometer and the data were analyzed with CELLQuest software (BD Biosciences).  
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 4.3.8 Statistical Analysis 
All data were analysed with the aid of GraphPad Prism 5.0 software (GraphPad Software, San 
Diego, CA, USA). For mouse and cattle pre-challenge ELISA titers and ELISPOT counts, cattle 
pre-challenge proliferation assay SIs and cattle post-challenge ELISPOT counts, differences 
among groups were examined using the non-parametric Kruskal-Wallis test. If the result of an 
analysis of variance (ANOVA) proved significant, then multiple post-test comparisons between 
medians were done using a Dunn’s test, or differences between the medians of two groups were 
examined using the Mann-Whitney U test.  Post-challenge cattle ELISA and virus neutralisation 
titers, virus shedding, weight change and temperature differences among groups over time were 
analysed by a two-way ANOVA followed by a Bonferroni t-test in case of a significant 
ANOVA. Differences between groups were considered significant if probability values of 
p<0.05 were obtained. 
 
4.4 Results  
4.4.1 In vitro expression of BNBD3 and BNBD3-tgD in COS-7 cells  
Expression of BNBD3 from pMASIA-BNBD3 was verified by Western blot analysis. A single 
band of the expected molecular mass (4.8kDa) [219] that co-migrated with the synthesized 
BNBD3 control (Figure 4.2a,c; lanes 2,3), was detected in the supernatants from pMASIA-
BNBD3 transfected cells (Figure 4.2a,c; lane 5) under both reducing (Figure 4.2a) and non-
reducing (Figure 4.2c) conditions. However, BNBD3 was not detected in the supernatants from 
pMASIA-transfected cells (Figure 4.2a,c; lane 4). A protein corresponding to the expected 
molecular mass of tgD (61kDa), was revealed by gD-specific mAb in supernatants from 
transfections with pMASIA-tgD  (Figure 4.2b,d; lane 3, right panel) or pMASIA-BNBD-tgD 
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(Figure 4.2b,d; lane 4, right panel), under both reducing (Figure 4.2b) and non-reducing (Figure 
4.2d) conditions, thus verifying expression of tgD from both plasmids. The BNBD3-specific 
rabbit serum reacted only with the supernatant from pMASIA-BNBD3-tgD transfection (Figure 
4.2b,d; lane 4; left panel) but not with the supernatant from pMASIA-tgD transfection (Figure 
4.2b,d; lane 3; left panel) under both reducing (Figure 4.2b) and non-reducing (Figure 4.2d) 
conditions.  
 Figure 2.
Reducing conditions
α-tgDα-BNBD3
1           2             3             4 1            2              3           4               
75 kDa
50 kDa
(b)
1            2              3           4               1            2              3           4               
75 kDa
50 kDa
1         2          3           4           5
α-BNBD3
6 kDa
4 kDa
(a)
Non-Reducing conditions
1         2          3           4           5
6 kDa
4 kDa
(c) (d)
pMASIA-BNBD3 pMASIA-BNBD3-tgD
 
Figure 4.2 In-vitro expression of the BNBD3-encoding constructs. (a-d) Cos-7 cells were 
transiently transfected with (a,c) pMASIA-BNBD3 or (b,d) pMASIA -BNBD3-tgD. The 
presence of BNBD3 and tgD in the supernatants of transfected cells was detected at 48 h post-
transfection by Western blotting with  rabbit anti-BNBD3 polyclonal or anti-gD monoclonal 
antibodies under (a,b) reducing and (c,d) non-reducing conditions.  (a,c) 1- molecular weight 
marker, 2-sBNBD3 peptide (1 µg),  3- sBND3 peptide (0.5 µg), 4- pMASIA supernatant, 5- 
pMASIA-BNBD3 supernatant (b,d) 1- molecular weight marker (kDa), 2- pMASIA supernatant, 
3- pMASIA-tgD supernatant , 4- pMASIA-BNBD3-tgD supernatant. (sBNBD3 = synthesized 
BNBD3). 
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As expected, there was little difference in the molecular weight of the fusion protein BNBD3-
tgD, which is approximated as 65.4 kDa, versus that of tgD (61 kDa) due to the small molecular 
mass of BNBD3 (4.8 kDa). These results verified the expression of BNBD3 and BNBD3-tgD, 
both in monomeric form, from eukaryotic cells transfected with pMASIA-BNBD3 and 
pMASIA-BNBD3-tgD, respectively.  
 
4.4.2 Immune responses induced by BNBD3-encoding DNA vaccines in mice 
The capacity of BNBD3, encoded either on a separate plasmid or as a fusion construct with tgD, 
to enhance tgD-specific immune responses was first evaluated in mice. Mice immunized with 
pMASIA + pMASIA-tgD or pMASIA-BNBD3 + pMASIA-tgD developed significantly higher 
IgG titers when compared to the animals immunized with  
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Figure 4.3 tgD-specific immune responses in mice immunized with plasmids encoding tgD 
and/or BNBD3. C57BL/6 mice (8 mice per group) were immunized twice ID with 5 µg 
plasmid.  One month after the second immunization, tgD-specific IgG titers were determined by 
ELISA (a). ELISA titers are expressed as the reciprocal of the highest dilution resulting in a 
reading of two standard deviations above the negative control. One month after the second 
immunization, the numbers of tgD-specific (b) IFN-γ or (c) IL-5 secreting cells were measured 
by ELISPOT assay. ELISPOT results are expressed as the difference between the number of 
IFN-γ or IL5 secreting cells in tgD-stimulated wells and medium-control wells per 106 cells. 
Bars represent the median values of each group with interquartile range. Significant differences 
between groups are indicated on the graphs where *p<0.05, **p<0.01 and ***p<0.001. Similar 
results were obtained in a second independent experiment. 
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pMASIA (P < 0.01), but there was no difference between these groups (Figure 4.3a).  The IgG 
titer of the group immunized with pMASIA-BNBD3-tgD appeared to be lower, but was not 
significantly different when compared to that of the pMASIA-tgD group. However, only mice 
immunized with pMASIA-tgD and not pMASIA-BNBD3-tgD, developed significantly higher 
IgG titers than the group immunized with pMASIA (P<0.05) (Figure 4.3a). These results 
demonstrate that despite these trends, BNBD3 had no significant effects on the humoral immune 
response induced by tgD.  
 
To examine the effects of BNBD3 on the CMI responses, tgD-induced secretion of IFN-γ and 
IL-5 by splenocytes was measured by ELISPOT assay. Mice immunized with pMASIA-BNBD3 
+ pMASIA-tgD had a significantly higher number (p<0.001) of IFN-γ-secreting cells upon 
restimulation with tgD when compared to the animals immunized with pMASIA and when 
compared to their control group immunized with pMASIA + pMASIA-tgD (p<0.05) (Figure 
4.3b). Immunization with pMASIA-BNBD3-tgD increased the number of IFN-γ-secreting cells 
(p<0.01) when compared with pMASIA, but there was no significant difference with pMASIA-
tgD. The number of cells expressing IL-5 was very low in all vaccinated groups (Figure 4.3c). 
These results indicate that addition of BNBD3 by separate plasmid resulted in increased numbers 
of IFN-γ secreting splenocytes, while BNBD3 added to tgD as a fusion had no effect on the IFN-
γ response in mice. 
 
In earlier DNA vaccine studies involving mBD2 in the mouse model it was found that physical 
linkage between the β-defensin and antigen was required for improvement of immune responses 
[217, 218, 391], and that this may have been particularly important for development of the CTL 
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response [218]. To investigate the influence of BNBD3 as a fusion with tgD on the induction of 
CD8
+
IFN-γ+ CTLs, the tgD-restimulated splenocytes from the mice immunized with pMASIA-
BNBD3-tgD were evaluated by FACs analysis for surface expression of CD3, CD8 and 
concurrent intracellular expression of IFN-γ. First, the live (single) cells were gated according to 
forward scattered (FSC) and side scattered (SSC) light properties (Figure 4.4a) [418]. Analysis 
of the total live cells showed that vaccination with pMASIA-BNBD3-tgD induced a greater 
percentage of tgD-specific CD8
+
 IFN-γ+ cells (8.7%. Figure 4.4c,d) than was induced in the 
group vaccinated with pMASIA-tgD (0.1%. Figure 4.4b,d) or vaccinated with pMASIA (0%, 
Figure 4.4d). Next, the live cells were further gated on surface expression of CD3 to exclude all 
non-T cells (Figure 4.4e). Analysis of this CD3
+
 population showed that vaccination with 
pMASIA-BNBD3-tgD again induced a greater percentage of tgD-specific CD8
+
 IFN-γ+ cells 
(16.1%. Figure 4.4g,h) than was induced by vaccination with pMASIA-tgD (11.7%, Figure 
4.4F,H) or with pMASIA (0%, Figure 4.4h), but the effect of BNBD3 was not as pronounced in 
this CD3
+
 T cell only population. When the frequencies of CD8
+
 IFN-γ+ cells in the total live cell 
population (Figure 4.4d) and in the CD3
+
 cell populations (Figure 4.4h) were compared, it 
appeared that vaccination with pMASIA-BNBD3-tgD induced a population of non-T cell (CD3
-
) 
IFN-γ+-secreting CD8+ cells that vaccination with pMASIA-tgD did not. Since DCs are currently 
the only known non-T CD8α+ cells in the mouse spleen, it is possible that the CD3- CD8+ IFN-γ+ 
cells that we observed were splenic DC [419]. These results demonstrate that addition of BNBD3 
as a fusion construct led to enhanced induction of tgD-specific CTL, and thus a Th1-type, 
response.  
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Figure 4.4 IFN-γ/CD8+ cells in mice immunized with plasmids encoding tgD with or 
withouot BNBD3.  C57BL/6 mice (8 mice per group) were immunized twice ID with 5 µg 
plasmid.  Splenocytes from immunized animals from each group were pooled and duplicate 
wells were restimulated in vitro without or with tgD for 7 h (in the presence of Brefeldin A for 
the last 5 h). Cells were triple-stained for surface expression of CD8 and CD3 and for 
intracellular expression of IFN-γ. Specific CD8+/ IFN-γ+ cells were detected by flow cytometry. 
(a,e) Representative dot plots show the gating strategy used to (b,c,f,g) analyze IFN-γ expression. 
(a) First, dead cells and doublets were excluded and live cells were gated in a forward scatter-
height (FSC-H) against side scatter-height (SSC-H) dot plot. (b) CD8
+
/IFN-γ+ cells in the live 
cell gate include non-T cells from mice vaccinated with pMASIA-tgD or (c) pMASIA-BNBD3-
tgD. (d) Data for CD8
+
/ IFN-γ+ cells as a % of total live cells are shown in graph form. (e) T 
cells were selected from total live cells by gating on CD3
+
 events. (f) CD8
+
/IFN-γ+ cells in the 
CD3
+
 gate include only T cells from mice vaccinated with pMASIA-tgD or (g) pMASIA-
BNBD3-tgD. (h) Data for CD8
+
/IFN-γ+ cells in the CD3 gate are shown in graph form. Results 
are expressed as the difference between the % of IFN-γ secreting cells in tgD-stimulated wells 
and non-stimulated medium-control wells. Bars represent the mean value of the duplicate wells 
of pooled cells from the 8 mice in each treatment group. Similar results were obtained in a 
second independent experiment. 
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4.4.3 Immune responses induced by BNBD3-encoding DNA vaccines in cattle 
Once it was confirmed that plasmids encoding BNBD3 induced immune responses in mice, we 
next assessed the effects of these plasmids in cattle. Calves immunized with either pMASIA-
BNBD3-tgD or pMASIA-BNBD3 + pMASIA-tgD did not develop higher IgG titers than 
animals immunized with pMASIA, whereas calves immunized with pMASIA-tgD or pMASIA + 
pMASIA-tgD (p<0.01) did have a significantly higher IgG titer (Figure 4.5a). These results 
demonstrate that addition of BNBD3, encoded either on a separate plasmid or as a fusion 
construct with tgD, did not enhance the humoral immune response induced by pMASIA-tgD in 
cattle. 
 
Proliferative responses of tgD-restimulated PBMCs from calves immunized with pMASIA-
BNBD3 + pMASIA-tgD were not significantly improved when compared to its control group 
pMASIA + pMASIA-tgD, and most importantly, neither group was able to develop significantly 
higher proliferation when compared to calves in the group immunized with pMASIA (Figure 
4.5b).In contrast, addition of BNBD3 to tgD as a fusion construct greatly improved the 
proliferative response when compared to pMASIA-tgD (P<0.01).Notably, the group immunized 
with pMASIA-BNBD3-tgD was the only one with significantly higher proliferation than the 
group immunized with pMASIA (Figure 4.5b). To further confirm activation and to characterize 
the type of immune response generated, production of IFN-γ was assessed (Figure 4.5c). Neither 
of the two-plasmid immunization strategies, pMASIA + pMASIA-tgD or pMASIA-BNBD3 + 
pMASIA-tgD, induced a significantly greater number of IFN-γ –secreting cells when compared 
to pMASIA.  In contrast, addition of  
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Figure 4.5  tgD-specific immune responses of calves immunized with plasmids encoding tgD 
and/ or BNBD3.  Eight to nine month-old BoHV-1 seronegative Angus and Hereford crossbred 
calves were immunized three times ID by needle-free injection with 0.75 mg plasmid and 
responses were determined one month after the third immunization (6 animals per group). (a) 
Serum tgD-specific IgG was measured by ELISA and the titers are expressed as the reciprocal of 
the highest dilution resulting in a reading of two standard deviations above the negative control. 
(b) tgD-specific lymphocyte proliferation of  PBMCs cultured in medium or with 3 µg/ml of tgD 
and pulsed with 0.4 μCi/well of methyl-3H] thymidine. Results are expressed as a SI. (c) The 
number of IFN-γ-secreting cells measured by ELISPOT assay. ELISPOT results are expressed as 
the difference between the number of IFN-γ secreting cells in tgD-stimulated wells and medium-
control wells per 10
6
 cells. Bars represent the median values of each group with interquartile 
range. Significant differences between groups are indicated on the graphs where *p<0.05 and 
**p<0.01. 
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BNBD3 to tgD as a fusion construct resulted in an increase in the number of IFN-γ secreting 
cells. Although this increase was not statistically significant when compared to its control group 
pMASIA-tgD, the significance of the difference observed between pMASIA and pMASIA-
BNBD3-tgD (p<0.01) was greater than that of the difference between pMASIA and pMASIA-
tgD (p<0.5).  Thus, in cattle the addition of BNBD3 as a fusion construct, but not when delivered 
by separate plasmid, enhanced the proliferative response to pMASIA-tgD.  
 
4.4.4 Immune responses of cattle after immunization with DNA vaccines and BoHV-1 
challenge 
Since BNBD3, when delivered on a separate plasmid, did not improve immune responses to tgD, 
the pMASIA-BNBD3 + pMASIA-tgD and the pMASIA + pMASIA-tgD groups were not further 
evaluated, while the groups immunized with pMASIA, pMASIA-tgD or pMASIA-BNBD3-tgD 
were subsequently challenged with BoHV-1.  Throughout the period after challenge, calves 
immunized with pMASIA-tgD (p<0.01) had higher serum tgD-specific IgG titers than calves 
immunized with pMASIA (Figure 4.6a), while the VN titers were significantly higher in both 
pMASIA-tgD and pMASIA-tgD-BNBD3 immunized groups when compared to the pMASIA 
group (Figure 4.6b).  With exception of the IgG titers on day 16-post challenge, no differences 
were observed between the pMASIA-tgD and pMASIA-tgD-BNBD3 groups.  In contrast, 
addition of BNBD3 to tgD as a fusion construct resulted in a significant increase in the number 
of IFN-γ secreting cells (p<0.05) when compared to the pMASIA-tgD group (Figure 4.6c).  
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Figure 4.6  Immune responses of calves immunized with plasmids encoding tgD and/or 
BNBD3, and challenged with BoHV-1.   Eight to nine month-old BoHV-1 seronegative Angus 
and Hereford crossbred calves were immunized three times ID by needle-free injection with 0.75 
mg plasmid followed by BoHV-1 challenge 52 days after the third immunization (6 animals per 
group). (a) Serum tgD-specific IgG was measured by ELISA on the day of challenge and then on 
days 8 and 16 post-challenge and the antibody titers were determined as described in the legend 
for Figure 4.5.  (b) Virus neutralizing antibodies in serum, expressed as a 50% endpoint using 
100 PFU of BoHV-1, were measured on the day of challenge and on days 8 and 16 post-
challenge. (c) The numbers of IFN-γ-secreting cells were measured by ELISPOT assay (as 
described in the legend for Figure 4.5 on day 8 post- challenge. Bars represent the median values 
of each group with interquartile range.. Significant differences between groups are indicated on 
each graph where *p<0.05, **p<0.01 and ***p<0.001.  
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Figure 4.7  Effect of vaccination on the phenotypes of IFN-γ-secreting T-cell 
subpopulations in PBMCs of calves vaccinated with plasmids encoding tgD and/or-BNBD3, 
and challenged with BoHV-1. PBMCs were isolated from the peripheral blood of two animals 
from each of the pMASIA-tgD, pMASIA-BNBD3-tgD and negative control groups prior to 
challenge and on days 16 and 25 after challenge (2 animals per group). CD4-depleted (CD4
-
), 
CD8-depleted (CD8
-
), CD4
+
 and CD8
+
 subsets were isolated from PBMCs by MACS and the 
homogeneity of the resulting CD4
+/-
 and CD8 
+/-
 cell populations was determined by FACS. (a-f) 
Dot plots are for one animal (96) from the pMASIA-BNBD3-tgD group on day 16 post-
challenge and are representative of all depletions. (a) PBMCs recognized by CD4 mAb. (b) CD4
- 
population recognized by CD4 mAb. (c) CD4
+
 population recognized by CD4 mAb. (d) PBMCs 
recognized by CD8 mAb. (e) CD8
- 
population recognized by CD8 mAb. (f) CD8
+
 population 
recognized by CD8 mAb. (g,i) Frequencies of IFN-γ-secreting cells in the PBMCs, CD4+, CD4- , 
and CD4
- 
+ CD4
+ 
(5, 10, 15, 20% of 10
6
/well) cells  of 2 animals from the (g) pMASIA-tgD 
vaccinated group and from the (i) pMASIA-BNBD3-tgD vaccinated group. (h,j) Frequencies of 
IFN-γ-secreting cells in the PBMCs, CD8+, CD8- , and CD8- + CD8+ (2.5 ,5, 10, 15% of 
10
6
/well) cells of 2 animals from the (h) pMASIA-tgD vaccinated group and from the (j) 
pMASIA-BNBD3-tgD vaccinated group. The number of IFN-γ –secreting cells per 106 cells was 
calculated as the difference between the number of spots in the tgD-stimulated wells and the 
number of spots in the medium-control wells. FSC=forward scatter.
 
 
 
To further characterize the effect of BNBD3 on the cellular immune response, an ELISPOT 
depletion assay was employed whereby the T cell subsets responsible for secreting IFN-γ were 
identified by isolating the CD4
+
, CD4
- 
, CD8
+
 and CD8
-
 T cell populations from the PBMCs of 
two calves from each of the groups vaccinated with pMASIA-tgD, pMASIA-BNBD3-tgD or 
pMASIA. Typical proportions of the T cell subsets in PBMCs were 24% CD4
+
 cells and 15% 
CD8
+
 cells (Figure 4.7a,d). The purity of the isolated populations was 98% for CD4
-
 and CD8
-
 
(Figure 4.7b,e) and >90% for CD4
+
 and CD8
+
 (Figure 4.7c,f). Notably, we observed five-fold 
higher numbers of IFN-γ secreting cells in the PBMCs from the calves vaccinated with 
pMASIA-BNBD3-tgD (Figure 4.7i,j) when compared to calves vaccinated with pMASIA-tgD 
(Figure 4.7g,h), suggesting that BNBD3 had a positive influence on the magnitude of the IFN-γ 
response. The CD4
+
 T cell-depleted PBMCs from calves in the pMASIA-tgD (Figure 4.7g) or 
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pMASIA-BNBD3-tgD (Figure 4.7i) groups did not secrete IFN-γ in response to restimulation 
with tgD. For both groups, when 5, 10, 15 or 20% CD4
+
 T cells were added to the CD4
+
 -
depleted PBMCs, IFN-γ secretion increased dose-dependently to an amount equal to that of the 
undepleted PBMCs (Figure 4.7g,i). Depletion of CD8
+
 T cells did not affect the number of IFN-γ 
secreting cells in the PBMCs from animals in the pMASIA-tgD group, and there was also no 
change when 2.5, 5, 10, or 15% CD8
+
 T cells were added to the CD8
+
 -depleted PBMCs (Figure 
4.7h). In contrast, when PBMCs of the pMASIA-BNBD3-tgD group were depleted of CD8
+
 T 
cells, a two-fold reduction in the number of IFN-γ secreting cells was observed and there was a 
dose-dependent increase when 2.5, 5, 10, or 15% CD8
+
 T cells were added to the CD8
+
 -depleted 
PBMCs (Figure 4.7j). These depletion studies showed that CD4
+
 T cells in the PBMCs of calves 
from both vaccinated groups produced IFN-γ, but that only calves in the pMASIA-BNBD3-tgD 
vaccinate group produced IFN-γ-secreting CD8+ T cells. Thus, the addition of BNBD3 to tgD as 
a fusion construct appeared to increase the magnitude of the IFN-γ response, and to induce tgD-
specific CD8
+
 T cells.  
 
To determine whether these CD8
+
 T cells might be CTLs, the PBMCs from the same calves were 
restimulated with tgD and then evaluated by flow cytometry. Using a multicolor flow cytometry 
assay cells were identified as CTLs that, upon restimulation with the recall antigen tgD, 
simultaneously secreted IFN-γ and expressed CD8 and the alpha-subunit of the high-affinity 
interleukin-2 receptor (IL-2Rα) on the cell surface; also known as the cell activation marker, 
CD25 [413-416]. Within the CD8
+
 T cell population, the percentage of cells positive for IFN-γ 
secretion was almost two-fold higher at 36.5% and 36.4%, after challenge in the calves  
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Table 4.2 Flow cytometric analysis of bovine CD8
+
  IFNγ+ and CD8+  IFNγ+  CD25+ CTLs  
    
 
% CTLs 
 
Animal no. 
 
 
 
 
Treatment 
CD8
+
 
IFNγ+ 
CD8
+
  IFNγ+ 
CD25
+
 
     
75  pMasia-tgD 19.7 12.5 
85  pMasia-tgD 16.3 6.9 
86  pMasia-BNBD3-tgD 36.5 22.1 
96  pMasia-BNBD3-tgD 36.4 22.7 
     
 
 
vaccinated with pMASIA-BNBD3-tgD  than the 19.7% and 16.3% positive cells observed for 
calves vaccinated with pMASIA-tgD (Table 4.2). This increased IFN-γ secretion by CD8+ T 
cells correlated well with, and may account for some of the higher numbers of IFN-γ producing 
cells observed in, the ELISPOT results (Figure 4.6c, Figure 4.7i,j) from calves in the pMASIA-
BNBD3-tgD group. To identify CTLs within this population co-expression of the CD25 
activation marker by these CD8
+
 IFN-γ+ T cells was examined. The percentage of CD8+ IFN-γ+ 
CD25
+
 cells from calves vaccinated with pMASIA-BNBD3-tgD was 22.1% and 22.7%, 
representing a greater than two-fold increase as compared to the 12.5% and 6.9% of CD8
+
/ IFN-
γ+ CD25+ cells observed for calves vaccinated with pMASIA-tgD (Table 4.2). Thus, in good 
agreement with the results in mice, in cattle the addition of BNBD3 as a fusion construct with 
tgD increased the population of what are considered CTLs, namely activated, tgD-specific CD8
+
 
T cells. No effect of vaccination with the BNBD3-encoding vaccine on the numbers of 
γδ+/IFNγ+/CD25+ T cells was observed. 
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These results demonstrate that in vaccinated, BoHV-1 challenged cattle the addition of BNBD3 
as a fusion construct increased the number of IFN-γ secreting cells, specifically the number of 
IFNγ-secreting tgD-specific CD8+ T cells, and notably the CD8+ IFN-γ+ CD25+ subset. 
 
4.4.5 Clinical observations of protection after BoHV-1 challenge 
Calves in all three groups shed virus from day 2 after challenge, with significantly less virus shed 
on day 8 by calves in the pMASIA-BNBD3-tgD (p<0.01) and pMASIA-tgD (p<0.05) groups 
when compared to the pMASIA group (Figure 4.8a). By day 10, both the pMASIA-BNBD3-tgD 
and pMASIA-tgD groups showed equal and significantly less viral shedding (p<0.05) when 
compared to the pMASIA group (Figure 4.8a). Weight loss was observed in calves from all three 
groups by day 2 to day 4 after challenge (Figure 4.8b). On day 6, weight loss was reversed for 
both the pMASIA-BNBD3-tgD and pMASIA-tgD groups, whereas calves in the pMASIA group 
continued to lose weight. Additionally, on day 6 only calves in the pMASIA-BNBD3-tgD 
(p<0.05) group had significantly less weight loss when compared to the pMASIA group, while 
by day 10 calves in both pMASIA-BNBD3-tgD and pMASIA-tgD groups had equal and 
significantly less weight loss (p<0.05) when compared to calves in the pMASIA group (Figure 
4.8b). Rectal temperatures peaked for all three groups on day 2 after challenge and then began 
falling (Figure 4.8c). Between days 8 and 10, temperatures rose in the pMASIA group, while 
they fell in the pMASIA-BNBD3-tgD and pMASIA-tgD groups. 
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Figure 4.8  Clinical signs and virus shedding after BoHV-1 challenge. Eight to nine month-
old BoHV-1 seronegative Angus and Hereford crossbred calves were immunized three times ID 
by needle-free injection with 0.75 mg plasmid followed by BoHV-1 challenge one month after 
the last immunization (6 animals per group).  (a) Mean (geometric) virus shedding in nasal 
secretions of calves challenged with BoHV-1. (b) Mean weight change. (c) Mean rectal 
temperatures. *p<0.05; **p<0.01.   
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By day 10 after challenge, rectal temperatures were significantly lower in calves from the 
pMASIA-BNBD3-tgD (p<0.05) and pMASIA-tgD (p<0.01) groups than in those from the 
pMASIA group (Figure 4.8c).  These results demonstrate that in cattle the addition of BNBD3 as 
a fusion construct was able to protect cattle from infection with BoHV-1 equally as well, but not 
better than, the control DNA vaccine, pMASIA-tgD.   
 
4.5 Discussion  
 
In this study the effect of DNA vaccines encoding an iDC chemotactic peptide BNBD3, 
separately or as a fusion construct with BoHV-1 tgD, on the immune responses was determined 
in mice and cattle. In mice, addition of pMASIA-BNBD3 to pMASIA-tgD had no effect on tgD-
specific IgG and increased the number of IFN-γ secreting cells, while in cattle this two-plasmid 
treatment did not improve either humoral or cellular immune responses. When BNBD3 was 
delivered with tgD as a fusion construct in pMASIA-BNBD3-tgD, again there was no significant 
effect on tgD-specific antibody production; however, the CMI responses were enhanced in both 
mice and cattle. The addition of BNBD3 as a fusion with tgD induced a greater number of IFN-γ 
secreting CD8
+
 T cells. In mice, this construct induced increased numbers of CD8
+
 CTLs, and 
interestingly also a population of cells identified as non-T (CD3
-)/IFNγ+/CD8+ that may have 
been CD8α+ splenic DCs. In cattle, CD8+/IFN-γ+ cells were increased and CD8+/IFN-γ+/CD25+ 
CTLs were induced only in animals immunized with pMASIA-BNBD3-tgD.  However, despite 
the fact that immunization with pMASIA-BNBD3-tgD enhanced the CMI response, protection 
from challenge was similar to that provided by immunization with pMASIA-tgD. 
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Like our results in cattle, in earlier studies in mice mixtures of free, unlinked murine chemokines 
and antigen [391], or a mixture of plasmids expressing unlinked antigen and murine β-defensin 
[217], did not induce an immune response [217, 218, 391].  In our study, segregation of BNBD3 
and tgD either physically or temporally may have occurred in cattle and not in mice; this 
phenomenon of separation has been suggested previously to account for little or no effect when 
plasmids are mixed [420]. Additionally, it has been noted that responses to mixtures of plasmids 
can result in interference, leading to dominant Th2 responses, less appropriate responses [420], 
or suppression of responses [421]. The outbred nature of cattle as a species might have also 
contributed to the lack of effect of BNBD3 in cattle when delivered as a separate plasmid, as 
immune responses to mixtures of plasmids have been found to be lower in outbred mice than in 
inbred mice [422]. 
 
Inclusion of BNBD3 in the DNA vaccine as a fusion construct pMASIA-BNBD3-tgD did not 
affect humoral responses to tgD, but increased CMI responses and appeared to strengthen the 
Th1 bias in mice. Similarly, in cattle this vaccine was unable to improve serum antibody levels, 
but it increased proliferation of PBMCs and the number of IFN-γ secreting cells. Our results are 
comparable with the findings of an earlier study in mice, where the ability of an analogous fusion 
construct comprised of mBD2 (and mBD3) in combination with idiotypic antigen (Id) expressed 
by malignant B cells, to induce protective and therapeutic immunity to lymphoma was tested 
[217]. sFv, a single chain Ig made up of the linked Vh and Vl domains of the Fv fragment of the 
Ig receptor of the malignant B cell (described in [391]) failed to elicit an Id-specific antibody 
response when the sFv-encoding DNA vaccine was delivered alone or with mBD3 on a separate 
plasmid, whereas responses were observed after vaccination with fusion constructs of either 
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mBD2, mBD3, mMIP3α or mSLC [217].  Protective immunity against an aggressive lymphoma 
(38C13) was obtained after DNA vaccination by both mBD-sFv fusion plasmids even though the 
humoral response was considerably lower with the vaccine encoding mBD2. The authors 
concluded that fusion of tumor antigen with a chemokine or defensin that targets iDCs was 
important for both tumor prevention and eradication. While humoral immunity contributed to 
protection from tumors, cellular antitumor immunity was necessary for both protection and 
therapeutic antitumor immunity [217]. In contrast to our results, this study suggests that the 
increased CMI responses induced by the defensin-antigen fusion was critical to antitumor 
efficacy. 
 
In mice the fusion construct pMASIA-BNBD3-tgD modulated the cellular immune response by 
inducing CD8
+
/IFN-γ+/ CD3+ CTLs and a population of cells that were CD8+/IFNγ+ but that 
were not T cells. It is possible that these CD8
+
/IFN-γ+/CD3- cells may have been DCs, since 
splenic CD8α+ DCs have been described.  This type of DC lacks expression of CD3 [419] and is 
a potent secretor of IFN-γ where IFN-γ is produced in an autocrine manner in response to IL-12 
secreted by the cells exposed to a  bacterial stimulus [423]. These DCs are expanded in response 
to signals from the innate immune system as a result of bacterial or viral infection [423-425]. 
They cross-prime [426], prime [425] or prime and boost CD8
+
 T cell responses and activate 
memory CD8
+
 T cells [427], trigger the development of Th1-type cells/response [428, 429], and 
cause apoptotic death of activated CD4
+
 T cells [430]. As defensins are innate immune system 
molecules, BNBD3 might have influenced induction of CD8α+ DCs in the same manner as they 
are increased by bacterial/viral infection, though this was not proven by this study. Since CD8α+ 
DCs preferentially prime CTLs this would explain the increased CTL response we observed. 
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Although the existence of these cells as a result of DNA immunization with β-defensin-antigen 
fusion constructs has not been reported yet, the presence of such cells would clarify many of the 
hitherto unexplained findings of ourselves and others. 
 
In vaccinated and BoHV-1 challenged cattle the addition of BNBD3 as a fusion construct 
modified the immune response; VN antibody levels were maintained, and the number of tgD 
specific IFN-γ-secreting cells, particularly CD8+/IFN-γ+ cells and CD8+/IFN-γ+/CD25+ CTL 
cells, were increased. Thus, BNBD3 promoted a predominantly Th1 response that included 
induction of CD8
+
 CTLs. While it is generally accepted that Th1 immune responses drive 
cellular immunity and Th2 immune responses preferentially drive humoral immunity [431, 432], 
and indeed the Th1-polarized/biased cellular response that we observed fits neatly into this 
model, in this context, it was puzzling that the VN antibody was maintained. Our data may be 
explained however, by the findings of others. Reports have suggested that while Th1 type 
cytokines exert an overall negative effect on systemic humoral responses [431, 433], they can 
have a positive effect on the magnitude of neutralizing antibody response [434] and that 
neutralizing antibody responses can occur concurrent with induction of Th1 polarized responses 
[435-437]. In particular, our results (VN antibody concurrent with induction of CTL) with this 
defensin-antigen fusion construct in cattle bears striking similarity to the results obtained when 
in the mouse model, an experimental DNA vaccine expressing murine β-defensin 2 (mBD2) as a 
fusion with the gp120 antigen of HIV-1 induced systemic and mucosal CTL and neutralizing 
antibody to the HIV-1 envelope protein in ID immunized mice [218]. Although the exact 
mechanism was not determined, the authors theorized that the immunomodulatory effect of the 
vaccine could have been due to the previously discovered chemotactic nature of mBD2 for iDCs 
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[391]. Additionally, the authors suggested that β-defensin might have targeted receptors on 
APCs, induced expression of costimulatory molecules and/or induced production of 
proinflammatory cytokines particularly by iDCs [218].    
 
More recently, a β-defensin adjuvanting strategy was evaluated in chickens whereby birds were 
immunized intramuscularly with a DNA vaccine encoding a fusion construct of the mature form 
of avian β-defensin 1 (AvBD1) with the VP2 protein of infectious bursal disease virus (IBDV) 
[388]. Unlike our results in cattle, in this study the plasmid encoding the fusion construct 
induced significantly greater antibody responses than the plasmid encoding the antigen (VP2) 
alone. The greater antibody response might have been due to the route of administration, as 
higher humoral responses have been observed when DNA vaccines have been delivered IM 
[438], or to differences in species or the two β-defensins. Comparable to the augmented cellular 
responses including increased numbers of CD8
+
 cells that we observed in cattle, in this avian 
model increased percentages of CD3, CD4 and CD8 T cells were observed in birds immunized 
with the fusion construct. After challenge with IBDV the ten chickens immunized with the 
AvBD1 fusion construct were protected, while in the group given the DNA vaccine encoding 
VP2 alone, eight out of ten were protected. Despite the modest improvements in humoral and 
cellular immunity and protection from IBDV, the authors concluded that AvBD1 in a fusion 
construct enhanced VP2-DNA vaccine immunity and protection from IBDV. The authors further 
suggested that the effect of AvBD1on improved CMI responses may have been responsible for 
the protection induced by the fusion construct; particularly since CMI and specifically T cell 
responses had been shown to be important in protection from IBDV infection. 
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In cattle, protective vaccination against BoHV-1 has been described for commercially available 
MLV or KV BoHV-1 vaccines. As such it has been defined as an observed reduction in clinical 
signs such as decreased virus shedding, lowered temperature and decreased nasal secretions 
[439]. Following challenge with BoHV-1, we observed a reduction in the clinical signs of 
infection in calves vaccinated with the fusion construct pMASIA-BNBD3-tgD. Contrary to what 
was observed in the avian model, the addition of β-defensin gave protection equivalent to, but 
not better than, what was observed in the group given the DNA vaccine encoding the antigen 
alone. This was surprising in light of the improvements seen in the avian study, and because 
protective vaccination against BoHV-1 has also been associated with increased CMI responses, 
particularly those in the form of increased IFN-γ production [439]. Given that humoral immunity 
was not enhanced in calves vaccinated with pMASIA-BNBD3-tgD when compared to those 
vaccinated with pMASIA-tgD, and that inefficient humoral immune responses have been 
implicated in a lack of protection from BoHV-1 challenge (reviewed in [440]), this does suggest 
that the humoral immune responses were not high enough and that the improved cellular 
immunity induced by BNBD3 was not sufficient to result in enhanced protection from BoHV-1.  
Here we tested our hypothesis that inclusion of an iDC chemotactic β-defensin either encoded on 
a separate plasmid or as a fusion construct with antigen in a DNA vaccine, would improve 
efficacy of a BoHV-1 DNA vaccine for cattle. In summary, delivery of BNBD3 by separate 
plasmid did not enhance immune responses in cattle, while the addition of BNBD3 as a fusion 
construct modulated the immune response to the DNA vaccine resulting in increased cell-
mediated immunity. Protection against BoHV-1 was afforded to an equal extent by DNA 
vaccines encoding tgD alone or as a fusion with BNBD3. Taken together, from our results and 
those of others regarding the effect of β-defensins on DNA vaccines, some patterns emerge that 
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are worth noting as they suggest directions where further study could be productive. With respect 
to humoral responses, systemic antigen-specific IgG responses appear to vary with the antigen, 
the route of delivery, and the species, while CMI responses appear to be improved by beta-
defensin regardless of the nature of these factors.  
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Fifth Chapter Transition/Overview 
In the previous chapter/manuscript (chapter 4) I tested my hypothesis that inclusion of the iDC 
chemotactic β-defensin BNBD3, either encoded on a separate plasmid or as a fusion construct 
with tgD, would improve efficacy of a BoHV-1 DNA vaccine for cattle.  Although the pMASIA-
BNBD3-tgD fusion construct vaccine increased CMI and afforded protection against BoHV-1, 
the vaccine was unable to improve clinical responses of BoHV-1 challenged cattle. I 
hypothesized that the lack of improvement in clinical responses may have been because the 
vaccine failed to improve the humoral response. Thus in this chapter I suggest that an ideal DNA 
vaccine strategy for BoHV-1 would increase humoral responses and maintain robust CMI. 
Accordingly, for the third objective I evaluated in mice a strategy that utilizes BNBD3 in its 
peptide form, complexed with the DNA vaccine pMASIA-tgD, for its potential to improve 
humoral immune responses while maintaining robust CMI. Vaccination with a complex 
comprised of pMASIA-tgD complexed to 0.1875 nmol aBNBD3 (125:1 nanomolar ratio) 
resulted in improved Th1 type humoral response and maintained the strong CMI response 
relative to pMASIA-tgD. This improvement may have occurred through chemotaxis of iDCs. 
Additionally, this improvement may have occurred through the effect of BNBD3 in the 
complexed vaccine on murine BMDCs as in vitro studies of the immunomodulatory effects of 
BNBD3 showed that BNBD3 activated and functionally matured these cells. Since both robust 
antibody and CMI responses of a Th1 type are desired for protection from BoHV-1 infection, 
and this strategy does result in both, the results of this chapter support my overall hypothesis that 
inclusion of an iDC chemotactic bovine β-defensin in a DNA vaccine can lead to strong humoral 
and CMI responses. 
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5.1 Abstract 
 
Protective efficacy against BoHV-1 afforded through increased cell-mediated immune responses 
was recently demonstrated by a DNA vaccine encoding the DC-chemotactic bovine beta-
defensin, BNBD3 as a fusion with the viral antigen tgD. However the vaccine was unable to 
improve clinical responses of BoHV-1 challenged cattle over what was observed in animals 
vaccinated with the DNA vaccine encoding the tgD antigen alone and this may have been 
because the vaccine failed to improve the humoral response. We hypothesized that an alternative 
vaccine design strategy that utilized the DNA vaccine pMASIA-tgD as a complex with the 
cationic peptide BNBD3 might be able to improve the humoral response while maintaining a 
robust Th1-type cell-mediated response. C57Bl/6 mice were vaccinated twice intradermally with 
pMASIA-tgD complexed with 0, 0.01875, 0.1875, or 1.875 nmol of a stable synthesized analog 
of BNBD3 (aBNBD3). The best results were seen in mice immunized with the vaccine 
comprised of pMASIA-tgD complexed to 0.1875 nmol aBNBD3. In this group the humoral 
response was improved as evidenced in increased tgD-specific IgG2a, while the strong CMI 
response, measured based on specific IFN-γ-secreting cells, was maintained relative to pMASIA-
tgD. Modulation of the immune response may have been due in part to the effect of BNBD3 on 
dendritic cells (DC). In vitro studies showed that murine bone marrow-derived DC (BMDC) pre-
treated with aBNBD3 were activated as evidenced by down-regulated CD11c and were 
functionally matured as shown by increased allostimulatory ability. Native, synthesized or 
analog BNBD3 were equally capable of inducing functional maturation of BMDCs. 
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5.2 Introduction 
 
Bovine herpesvirus-1 (BoHV-1) is an economically important veterinary pathogen. Like other 
alphaherpesviruses such as herpes simplexvirus-1,2 (HSV-1,2/HHV-1,2) in humans [441], 
pseudorabies virus (PrV/SuHV-1) in pigs and equine herpesvirus-1,4 (EHV-1,4) in horses, the 
initial infection with BoHV-1 is typically followed by the establishment of viral latency [18, 57, 
59]. Latency represents the ultimate example of immune-modulation of the host by a virus, as 
once latency is achieved, the virus can be reactivated many times throughout an animal’s 
productive lifetime causing recurrent infection, viral shedding, and spread of the virus to new 
hosts (naïve animals) [87, 442]. Along with hygienic measures, it’s quite sensible to seek 
methods that prevent infection in the first place, and since vaccination is a primary method of 
prevention, it follows that development of an effective non-infectious preventative vaccine 
would be desirable.  
 
DNA vaccines are non-infectious. Additionally, they are simple in design and economical to 
produce thus making them attractive as veterinary vaccines [242]. Immunization with a DNA 
vaccine results in endogenous host-cell expression of the antigen, with a subsequent antigen-
specific immune response [241, 443]. In mice this results in a predominantly Th1-type response 
with induction of IgG2a isotype antibody and CTL [444]. Additionally, antigen expressed by the 
host cells can be picked up by infiltrating APCs, such as DCs [269] or circulated as free antigen 
to stimulate humoral responses [445]. DNA from immunization can also be found in directly 
transfected APCs [262], as free DNA in draining lymph which can then transfect DCs in regional 
LNs [262, 446], and in transfected MΦs in the peripheral blood [447]. A major hurdle to 
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development of a DNA vaccine for herpesviruses in general and for BoHV-1 in particular, is that 
both cell-mediated and humoral responses are required [67] and need to be increased over that 
which can be obtained with naked DNA [399]. To achieve improvements in both arms of the 
immune response has proven to be a challenge and has led to many studies with attempts at 
various immune enhancing strategies including genetic adjuvanting [217, 218, 448], delivery by 
liposomes [449, 450], and adding or complexing adjuvants to the plasmid DNA [444, 451]. 
  
Recently, we evaluated the potential of a genetic adjuvanting strategy for the BoHV-1 DNA 
vaccine, pMASIA-tgD.  In cattle a DNA vaccine encoding the DC-chemotactic bovine β-
defensin BNBD3 as a fusion with the viral antigen tgD showed protective efficacy against 
BoHV-1 through increased Th1-type cell-mediated responses [452]. β-defensins are cationic, 
membrane active, antimicrobial proteins of the innate immune system that participate in defence 
against microbiological pathogens [199]. They are small peptides, 38 to 42 amino acids in 
length, characterized by an N-terminal α-helix and six conserved cysteine residues that form 
three disulfide bonds defined as Cys1-Cys5, Cys2-Cys 4, Cys3-Cys6 [175, 199, 287]. In cattle, 
sixteen β-defensins have been discovered. Thirteen are produced by neutrophils and are known 
as bovine neutrophil β-defensins 1-13 (BNBD1-13) of which BNBD3 is the most abundant 
[219]. The vaccine was unable to improve clinical responses of BoHV-1 challenged cattle over 
what was observed in animals vaccinated with the DNA vaccine encoding the tgD antigen alone 
however, and this may have been because the vaccine failed to improve the humoral response.  
 
We hypothesized that an alternative vaccine design strategy that utilized the DNA vaccine 
pMASIA-tgD as a complex with the cationic peptide BNBD3 might be able to improve the 
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humoral response while maintaining a robust Th1-type cell-mediated response. Our hypothesis 
was based on the finding by Reidle et al. (2004) that when a small cationic peptide fused to a 
short antigenic epitope was complexed with a DNA vaccine encoding for a full length antigen, 
the humoral immune response to the DNA-encoded antigen could be improved without loss of 
CMI responses; but only when the two components were complexed at the low peptide to DNA 
ratio of 125:1 [453, 454]. This phenomenon was not related to improved uptake of the DNA or 
subsequent expression of the antigen encoded by the DNA and the authors were unable to 
explain the mechanism, or whether and how it might be related to the cationic nature of the 
peptide.  
 
Enhanced serum antibody responses without loss of CTL have also been observed when the 
DNA complexing adjuvant has been in the form of a cationic microparticle [455] cationic 
emulsion [444] or contained a cationic lipid such as DOTAP [449]. Additionally, it was found 
that although macrophages could act as APCs after exposure to naked DNA, DCs could only be 
transfected with plasmid DNA and subsequently act as APCs when transfected in the presence of 
cationic lipid [456]. Thus there does appear to be a benefit when the DNA complexing adjuvant 
has been of a cationic nature.  
 
Modifying the fundamental Th1 cellular response to plasmid DNA vaccination with the BoHV-1 
antigen gD [399] to that of an improved humoral response could, however, be difficult. In a 
murine model of HSV-2/HHV-2, the gD antigen when delivered as a protein was a strong 
inducer of Th2 responses with high antibody titers, whereas the same antigen when delivered by 
DNA vaccine induced a response with a Th1 bias [431, 457]; a bias that was strengthened when 
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genetically adjuvanted with plasmid encoding the Th1 cytokine IL-12 [431, 458] and that could 
not be redirected by genetic adjuvanting with plasmid encoding Th2 cytokines IL-4 or IL-10 
[458]. 
 
 Since the use of a bovine β-defensin as the cationic component in a peptide/DNA complexed 
BoHV-1 vaccine as a way to enhance humoral responses has not been studied, in this work we 
evaluated the potential of this strategy. The DNA vaccine pMASIA-tgD was complexed with 
increasing amounts of the cationic peptide aBNBD3 and the complexed vaccine was studied for 
its capacity to stimulate immune responses in mice in vivo, and by BNBD3 for effects on murine 
BMDCs in vitro. The best results were seen in mice immunized with the vaccine comprised of 
pMASIA-tgD complexed with aBNBD3 at the medium nanomolar peptide to DNA ratio of 
125:1. Immunization with this complexed vaccine maintained robust Th1-type CMI, induced 
tgD-specific IgG, IgG1, and significantly improved IgG2a antibody responses. In vitro studies 
revealed that aBNBD3 activates and functionally matures murine BMDC.  
 
5.3  Materials and Methods 
5.3.1 Cationic peptides/BNBDs and plasmids 
BNBD3 peptides were chemically synthesized, and then folded to form the defined β-defensin 
disulfide connectivities (Cys 1-5, Cys 2-4, Cys 3-6) as described [389]. Native BNBD3, isolated 
from the bovine neutrophil [219] was kindly provided by Dr. Micheal Selsted (University of 
California, Irvine, CA, United States). The amino acid sequences of the synthesized peptides 
sBNBD3 (synthesized based on the published sequence with Glutamine [Q] in amino acid 
positions 1 and 27 (UniprotKB/Swiss-Prot accession number P46161)) and aBNBD3 (an analog 
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synthesized such that Glycine [G] replaced Glutamine [Q] in amino acid positions 1 and 27) are 
shown in relation to native BNBD3 and to human and murine β-defensin 2 (Figure 5.1).  
 
mBD2 AVGS LK SI G Y E A E L DHCHT NGGY CVRAI CP P S AR R P GS CF P E KNP CCK Y MK
hBD2 G I GD P VT CL KS GA I CHP VF CP R R YK Q I GT CGL P GT KCCK K P
sBNBD3 Q GVR N HVT CR I NR GF CVP I RCP GR T R Q I GT CF GP R I KCC R S W
aBNBD3 *GGVR N HVT CR I NR GF CVP I RCP GR T R*GI GT CF GP R I KCC R S W
nBNBD3 pE GVR N HVT CR I NR GF CVP I RCP GR T R Q I GT CF GP R I KCC R S W
Figure 1.
 
 
Figure 5.1 Amino acid sequence alignment of native and synthesized forms of BNBD3. 
sBNBD3 (published sequence UniprotKB/Swiss-Prot accession number P46161- Glutamine [Q] 
in positions 1 and 27), aBNBD3 (analog, Glycine [G] replaces Glutamine [Q] in positions 1 and 
27), nBNBD3 (the sequence of Native BNBD3; pyroglutamic acid [pE] the modified residue of 
Glutamine [Q] at N-terminus), aligned with murine(m)BD2, and human(h)BD2. Aligned 
conserved cystiene residues are shown in shaded vertical bars and the β-defensin disulfide 
connectivities (Cys 1-5, Cys 2-4, Cys 3-6) are shown at the top. 
 
The plasmids pMASIA and pMASIA-tgD, which encodes truncated glycoprotein D (tgD) of 
bovine herpesvirus-1 (BoHV-1), have been detailed previously [452]. These plasmids were 
amplified in Escherichia coli JM109 cells, purified with Endofree Plasmid Giga kits (Qiagen; 
Montreal, QC, Canada), suspended as stock solutions in water (3.12-3.5 mg/ml), and stored at -
20°C. Their application/use in cattle and mice as DNA vaccines has been described [452]. 
 
5.3.2 Chemotaxis assay 
Biological activity of the synthesized BNBD3s was confirmed using a chemotaxis assay 
described previously [389]. Briefly, chemotaxis of bovine iDC to synthesized BNBD3 was 
compared to native BNBD3 using a 96-well disposable chemotaxis system (ChemoTx system; 
Neuroprobe, Gaithersburg, MD, USA). Peptides diluted to 1000, 100, 10, 1, 0.1, 0.01 or 0 
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(buffer) ng/ml were placed in triplicate wells of the bottom chamber of the plate. Bovine Mo 
were isolated from peripheral blood mononuclear cells (PBMCs) of four donor animals and were 
cultured with supernatants from bovine IL-4 and bovine GM-CSF transfected CHO cells (kindly 
provided by Merial Limited, Lyon, France) for 3 days to generate iDCs as verified by FACs 
analysis. The monocyte-derived iDCs were labelled with Calcein AM (Molecular Probes), 
placed on the top of the membrane above each BNBD3-or buffer-filled well and the plates were 
incubated for 90 min at 37 °C. Migrated cells were identified using a 96-well multilabel plate 
reader (Victor 3V Multilabel Counter, PerkinElmer Life And Analytical Sciences, Inc., 
Woodbridge, ON, Canada). Chemotactic index (CI) was calculated for each well by dividing the 
total fluorescence of each test well by the mean fluorescence of the buffer/control wells. A CI > 
2 is considered statistically significant (p < 0.05) [315]. 
 
5.3.3 Preparation of BNBD3-DNA complexed vaccines 
Cationic peptide/DNA complexed vaccines were prepared according to the method described by 
Riedle et al. (2004) [454]. Accordingly, pMASIA-tgD (5 μg / 0.0015 nmol) was mixed with 
0.01875 nmol (Low), 0.1875 nmol (Medium), or 1.875 nmol (High) of the cationic peptide 
aBNBD3 in a Ca/Mg free PBS buffer ( pH 7.4; Gibco) in a final volume of 20 μl for 60 min at 
RT. The nanomolar ratio of peptide to DNA was thus 12.5:1 for the low dose, 125:1 for the 
medium dose and 1250:1 for the high dose. Complex formation of DNA and peptide was 
visualized by agarose gel electrophoresis in an electrophoretic mobility shift assay (EMSA). 
Samples were loaded in 10% glycerol, and were then applied to a 1% agarose gel containing 0.5 
μg/ml ethidium bromide and run for 90 min at 50V in TAE running buffer (40mM Tris-acetate, 
1mM EDTA; pH 8.3). 
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5.3.4 Immunization of mice with BNBD3-DNA complexed vaccines 
To test the ability of BNBD3, delivered as a complex with the tgD-encoding DNA vaccine 
pMASIA-tgD, to enhance tgD-specific humoral responses without reduction of specific cellular 
responses, six- to eight-week old C56BL/6 mice (n=8) were immunized twice at a 4 week 
interval. Immunizations were delivered as 2 x 10 μl intradermal injections into the base of the 
tail. Each 20 μl dose was formulated to contain 5μg pMASIA (placebo), 5μg pMASIA-tgD, 5 μg 
pMASIA-tgD (0.0015 nmol) plus 0.01875 nmol BNBD3 (Low), 5 μg pMASIA-tgD (0.0015 
nmol) plus 0.1875 nmol BNBD3 (Medium), or 5 μg pMASIA-tgD (0.0015 nmol) plus 1.875 
nmol BNBD3 (High). One month after the final vaccination, mice were euthanized. Serum was 
taken to be assayed for tgD-specific antibody levels and spleens were collected for analysis of 
tgD-specific CMI responses. 
 
5.3.5 Enzyme-linked-immunosorbent assay (ELISA)   
To measure tgD-specific IgG, IgG1, and IgG2a responses, 96-well polystyrene microtiter plates 
(IMMULON® 2; Thermo Electron Corrp., Milford, MA) were coated overnight with 0.05 μg of 
tgD per well in sodium carbonate coating buffer and then washed in PBS with 0.05% Tween 20 
(PBST). Serum was collected from each mouse, and serial dilutions starting at 1:40 in four-fold 
dilution in PBS containing 0.5% gelatin (PBS-g) were dispensed to plates. Following overnight 
incubation at 4°C, plates were washed, and bound IgG was detected using alkaline phosphatase 
(AP)-conjugated goat anti-mouse IgG (Kirkegaard & Perry Laboratories) diluted 1:5000 in PBS-
g for 1 h at RT. Bound IgG1 and IgG2a were detected using biotinylated goat anti-mouse IgG1 
and IgG2a antibodies (Caltag Laboratories, Burlingame, CA) diluted 1:5000 in PBS-g for 1 h at 
RT followed by streptavidin-AP at a dilution of 1:10,000 for 1 h at RT. All reactions were 
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visualized with 0.01M p-nitrophenyl phosphate (PNPP) (Sigma-Aldrich) in 0.104 M 
diethanolamine, 0.5 mM MgCl. Absorbance was read on a model 3550 Microplate Reader (Bio-
Rad Laboratories Ltd) at 405 nm, with a reference wavelength of 490 nm. ELISA titers were 
expressed as the inverse of the serum dilution that gave an absorbance (A) value two standard 
deviations above the values for serum from control naïve animals. 
 
5.3.6  IFN-γ and IL-5 Enzyme-linked-immunospot (ELISPOT) assay 
To measure the number of IFN-γ and IL-5 secreting cells, nitrocellulose plates (96-well 
Multiscreen-HA; Millipore Corp., Bedford, MA, USA) were coated overnight at 4°C with 0.2 
μg/well of anti-mouse IFN-γ or IL-5 (BD Biosciences, San Jose, CA, USA). Plates were washed 
with PBS and then blocked with 1% (w/v) bovine serum albumin (BSA; Sigma-Aldrich) for 2 h 
at 37°C. Splenocytes were isolated as previously described [402] and resuspended at a 
concentration of 1 x 10
7
 cells per ml in complete medium (cRPMI) made up of RPMI 1640, 
supplemented with 10% fetal bovine serum (FBS), 50 μg/ml gentamycin, 1 mM L-glutamine, 10 
mM Hepes, 1 mM non-essential amino acids, 1 mM sodium pyruvate (all Life Technologies Inc., 
Burlington, ON, Canada) and 5 x 10
-5
 M 2-mercaptoethanol (Sigma-Aldrich). Splenocytes at 10
6
 
cells/well were added to triplicate wells containing medium or tgD at 3 μg/ml and incubated at 
37°C for 20 h. Plates were washed, and then incubated with 2 μg/ml biotinylated rat anti-mouse 
IFN-γ or IL-5 (BD Biosciences) in PBS with 1% BSA for 1.5 h. Bound antibodies were detected 
using streptavidin-AP (Jackson ImmunoResearch Laboratories, West Grove, PA, USA) diluted 
1:1000 in PBS with 1% BSA for 1.5 h and visualized using BCIP/NBT substrate (Sigma-
Aldrich). Stained spots were counted and the number of IFN-γ or IL-5 secreting cells per 1 x 106 
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cells was expressed as the difference between the number of spots in the tgD-stimulated wells 
and the number of spots in the control (medium) wells. 
 
5.3.7 Murine bone marrow-derived dendritic cell (BMDC) generation and stimulation 
Changes in cell surface expression of maturation markers or in proliferative ability of BMDCs 
were used to assess the effect of BNBD3 on in vitro maturation and activation of DCs. BMDCs 
were prepared as previously described [459], with modifications. Briefly, bone marrow cells 
were flushed from femurs and tibiae of naïve C57BL/6 mice, and depleted of erythrocytes by 
lysis with Tris-ammonium chloride buffer (17 mM Tris, 144 mM NH4Cl, pH 7.2). Subsequently, 
the cells were suspended at 1 x 10
6
 cells/ml in RPMI 1640 medium supplemented with 10% 
FBS, 50 μg/ml gentamycin, 1 mM L-glutamine, 10 mM Hepes, 1 mM non-essential amino acids, 
1 mM sodium pyruvate (all Life Technologies Inc., Burlington, ON, Canada), 5 x 10
-5
 M 2-
mercaptoethanol (Sigma-Aldrich) and 20 ng/ml murine GM-CSF (PeproTech Inc., Rocky Hill, 
NJ) (DC medium). Cell suspensions of 4 ml/well were cultured in 6-well plates with non-
adherent cells (granulocytes, T and B cells) removed and fresh DC medium added on day 3. For 
the studies shown in Figure 5.6, on days 5, 7 and 9, 50% of the media was removed and replaced 
with fresh DC medium, and additionally on day 9, cells were untreated or treated for 24 h with 
lipopolysaccharide (LPS) at a final concentration of 100 ng/ml or with aBNBD3 at a final 
concentration of 10, 100 or 1000 ng/ml. On day 10, cells were harvested for FACs analysis or for 
use in proliferation assays. For the proliferation studies shown in Figure 5.7, BMDCs were 
harvested at day 5, resuspended at 1 x 10
5
 cells/ml in DC medium and dispensed (100 μl of 
cells/well) to U-bottom 96-well tissue culture plates. Cells were untreated or treated for 18 h with 
LPS at a final concentration of 100 ng/ml or with nBNBD3, sBNBD3, aBNBD3 at final 
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concentrations of 10, 100 or 1000 ng/ml or with LPS (100 ng/ml), in combination with nBNBD3 
or sBNBD3 or aBNBD3 at the above concentrations. 
 
5.3.8 Flow cytometry analysis of stimulated BMDCs 
The BMDC phenotype was examined on day 10 after 24 h incubation with the different 
treatments. Cells were washed and resuspended at 1 x 10
7
 cells/ml in FACs buffer (PBS pH 7.2, 
0.1% BSA, 0.05% NaNH3) supplemented with 2% FBS, and 100 μl aliquots were cell-surface 
stained for 30 min at 4°C with FITC anti-mouse I-A[b] (MHCII, clone AF6-120.1, BD 
Biosciences), FITC anti-mouse CD11c (clone HL3, BD Biosciences), FITC anti-mouse CD40 
(clone 3/23, BD Biosciences), or FITC anti-mouse CD86 (clone GL1, BD Biosciences). Staining 
specificity was controlled with the appropriate isotype-matched antibody controls. Cells were 
washed and resuspended in PBS. Samples were acquired using a FACSCalibur flow cytometer, 
and the data were analyzed with CELLQuest software (BD Biosciences).  
 
5.3.9 Mixed leukocyte reaction 
To assess the functional activity of BMDCs stimulated by nBNBD3, sBNBD3, or aBNBD3, 
allogeneic MLR assays were performed using mouse splenocytes as responder cells. Dendritic 
cells were cultured as described above. For Figure 5.6 the BMDCs, untreated or treated with LPS 
or aBNBD3, were harvested at day 10 and were resuspended in proliferation medium (PM) made 
up of RPMI 1640, supplemented with 1 ng/ml dexamethasone, 10% FBS, 50 μg/ml gentamycin, 
1 mM L-glutamine, 10 mM Hepes, 1 mM non-essential amino acids, 1 mM sodium pyruvate (all 
Life Technologies Inc., Burlington, ON, Canada), 5 x 10
-5
 M 2-mercaptoethanol (Sigma-Aldrich) 
and dispensed to U-bottom 96-well tissue culture plates to provide 0.5, 1, 1.5 and 2 x 10
4
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cells/well. For Figure 5.6, 100 μl of responder cells/splenocytes (2 x 106 cells/ml in PM) and for 
Figure 5.7, 100 μl of responder cells/splenocytes (1 x 106 cells/ml in PM) from BALB/C mice 
were dispensed to wells containing treated and untreated BMBDs. After 72 h in culture, the cells 
were pulsed with 0.4 μCi/well of [methyl-3H] thymidine (Amersham Biosciences, Baie d’Urfe, 
PQ, Canada). After an additional 18 h of culture, cells were collected with a Filtermate harvester 
and thymidine uptake was measured by scintillation counting with a TopCount NXT microplate 
scintillation counter (Packard Instrument Company, Meriden, CT, USA). Proliferative responses 
were reported in counts per minute.  
 
5.3.10  Statistical Analysis 
All data were analysed with the aid of GraphPad Prism 5.0 software (GraphPad Software, San 
Diego, CA, USA). For ELISA titers and ELISPOT counts, differences among groups were 
examined using the non-parametric Kruskal-Wallis test. If the result of an analysis of variance 
(ANOVA) proved significant, then multiple post-test comparisons between medians were done 
using a Dunn’s test, or differences between the medians of two groups were examined using the 
Mann-Whitney U test.  For in vitro MLR assays, differences among groups were analysed by 
ANOVA followed by Tukey’s multiple comparisons test in case of a significant ANOVA, or 
differences between the means of two groups were examined by unpaired Students t-test. 
Differences between groups were considered significant if probability values of p<0.05 were 
obtained. 
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5.4 Results  
5.4.1 Functional/biological activity of synthesized peptides 
To verify the two synthesized forms of BNBD3 prior to their use in the peptide/DNA complexed 
vaccines, both synthesized peptides were assayed to ensure that they were biologically active and 
that the native β-defensin disulfide connectivities were achieved during oxidation (folding) of the 
peptides [389]. The attraction of bovine iDC to the synthesized peptides sBNBD3 and aBNBD3 
was compared to that of native BNBD3 using a chemotaxis assay. Bovine iDCs migrated equally 
to both synthesized peptides and native BNBD3, and the data gave characteristic bell-shaped 
dose response curves with the same peak migration at 10 ng/ml (Figure 5.2).  Thus both 
synthesized peptides were deemed suitable for use in the vaccines as they were shown to be 
equivalent to the native BNBD3 in chemotactic ability for iDCs, and since maximum cell 
migration occurred at the same concentration for all, the synthesized peptides most likely had the 
native conformation. 
 
The slight changes in the amino acid sequence of sBNBD3 to that of aBNBD3 theoretically 
afforded aBNBD3 greater stability, and this may have accounted for its desirable ease of 
synthesis and greater yield when compared to that of sBNBD3.  sBNBD3 has an N-terminal 
glutamine residue, and  these residues have shown a propensity to spontaneously cyclize over 
time to become pyroglutamate [460]. This instability was reflected in a subsequent reduction in 
the yield of the purified peptide with the correct amino acid sequence, from the synthesis 
process. Since the conversion of glutamate to pyroglutamate has also been found to occur in vivo 
[460], this might also cause it to be unstable/unpredictable in an animal vaccine. Due to its 
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Figure 5.2 Chemotaxis of bovine iDC to native and synthesized forms of BNBD3. Bovine 
iDCs were labelled with Calcein AM and placed on a 5 µm pore filter membrane above triplicate 
bottom wells filled with either medium or 0.01, 0.1, 1, 10, 100 or 1,000 ng/ml of each BNBD3 
peptide. Migration of cells toward medium or defensin was determined by reading the calcein 
fluorescence signal of migrated cells on the bottom of the filter after incubation at 37 °C for 90 
min. Data are expressed as the chemotactic index (CI), and are shown as the mean values of the 
average CI + sem of four donor animals (n=4). sBNBD3 (published sequence, Glutamine [Q] in 
positions 1 and 27), aBNBD3 (Glycine [G] replaces Glutamine [Q] in positions 1 and 27). 
 
 
 
potential in vivo instability, and lower yield, sBNBD was deemed uneconomical and unsuitable 
as a vaccine component, thus only the aBNBD3-complexed vaccines were selected for 
evaluation. 
 
5.4.2 Formation of peptide/DNA complexes 
To characterize the complexing effect of the positively charged aBNBD3 peptide on the 
negatively charged pMASIA-tgD DNA vaccine, a constant amount of pMASIA-tgD (5 μg; 
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0.0015 nmol) was mixed with increasing amounts of aBNBD3 and analyzed by EMSA (Figure 
5.3). Most of the pMASIA (Figure 5.3, lane a) and pMASIA-tgD (Figure 5.3, lane b) plasmid 
migrated as supercoiled DNA that moved furthest into the gel. Addition of 0.1875 nmol 
aBNBD3 (Medium; 125:1 nanomolar peptide to DNA ratio) reduced the electrophoretic mobility 
of pMASIA-tgd (Figure 5.3, lane c) and addition of 1.875 nmols, the highest amount of aBNBD 
(High; 1250:1 ratio), reduced the electrophoretic mobility of pMASIA-tgd to the point where the 
DNA did not migrate into the gel at all (Figure 5.3, lane d). 
 
 
Figure 3.
a b c d
5 μg DNA + + + +
nmoles aBNBD3 - - 0.1875 1.875
 
 
Figure 5.3 Electrophoretic mobility shift assay (EMSA) of pMASIA-tgD and aBNBD3 
complexes. pMASIA-tgD DNA vaccine (5 μg) was complexed with a medium and a high ratio 
of aBNBD3 peptide and the DNA-aBNBD3 complexes were visualized by agarose gel 
electrophoresis in the presence of ethidium bromide. (a) pMASIA (placebo), (b) pMASIA-tgD, 
(c) pMASIA-tgD DNA complexed with 0.1875 (Medium) nmols of aBNBD3, (d) pMASIA-tgD 
DNA complexed with 1.8750 (High) nmols of aBNBD3. (aBNBD3; analog, Glycine [G] 
replaces Glutamine [Q] in positions 1 and 27).  
 
 
 169 
5.4.3 Optimization of peptide/DNA ratio based on immune responses of mice to 
complexed vaccines 
As an initial step, the optimal quantity of peptide in relation to the amount of DNA (peptide to 
DNA ratio) had to be established. To determine which peptide to DNA ratio would give the best 
results, in the first study, mice were immunized with pMASIA-tgD (5 μg; 0.0015 nmol) alone or 
complexed with 0.01875 (Low), 0.1875 (Medium) or 1.875 (High) nmol of aBNBD3 to give 
nanomolar peptide to DNA ratios of 12.5:1, 125:1 and 1250:1 respectively. The peptide 
concentrations were chosen based on the work of Riedl et al. (2004) [454], who showed a bell-
shaped dose response curve with optimal responses to the DNA-encoded antigen at a  peptide to 
DNA ratio of 125:1. 
   
With the addition of aBNBD3 to pMASIA-tgD (Figure 5.4) we observed optimal humoral and 
unchanged CMI responses to the DNA-encoded antigen at the Medium peptide to DNA ratio of 
125:1 (Figure 5.4a-d). When compared to vaccination with pMASIA-tgD alone, IgG1 (Figure 
5.4a) tended to be increased, and IgG2a was significantly increased (p<0.05) (Figure 5.4b) by 
addition of the peptide at the Medium peptide to DNA ratio; whereas addition of the peptide at 
the high peptide to DNA ratio resulted in significantly reduced IgG2a humoral responses 
(p<0.05) (Figure 5.4b) and numbers of IFNγ secreting cells (p<0.01) (Figure 5.4c).  There were 
no significant differences in the number of IFNγ (Figure 5.4c) or IL5 (Figure 5.4d) -secreting 
cells from mice in the pMASIA-tgD Low or Medium aBNBD3 complexed vaccine groups when  
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Figure 5.4 Specific (tgD) immune responses in mice immunized with aBNBD3/pMASIA-
tgD complexed vaccines. C57BL/6 mice (n=8) were immunized twice ID with 5 ug pMASIA 
(placebo) or pMASIA-tgD DNA complexed with either 0, 0.01875 (Low), 0.1875 (Medium) or 
1.8750 (High) nmols of aBNBD3 (analog, Glycine [G] replaces Glutamine [Q] in positions 1 and 
27). One month after the second immunization, tgD-specific (a) IgG1, and (b) IgG2a titers were 
determined by ELISA. ELISA titers are expressed as the reciprocal of the highest dilution 
resulting in a reading of two standard deviations above the negative control. The numbers of 
tgD-specific (c) IFN-γ or (d) IL-5 secreting cells were measured by ELISPOT assay. ELISPOT 
results are expressed as the difference between the number of IFN-γ or IL-5 secreting cells in 
tgD-stimulated wells and medium-control wells per 10
6
 cells. Bars represent the median values 
of each group with interquartile range. Significant differences between groups are indicated on 
the graphs where *p<0.05, **p<0.01 and ***p<0.001. 
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compared to mice vaccinated with pMASIA-tgD. These results suggested that aBNBD3 at the 
Medium (0.1875 nmols peptide; 125:1 ratio) nanomolar to DNA ratio, when complexed with 
pMASIA-tgD improved the specific antibody response to tgD encoded by the DNA vaccine 
while maintaining the magnitude and balance of the cellular response. 
 
5.4.4 Immune responses in mice immunized with aBNBD3-complexed vaccines  
To further explore the merits of aBNBD3/pMASIA-tgD complexed vaccine, in the second study 
mice were immunized with pMASIA-tgD (5 μg; 0.0015 nmol) alone or complexed with 0.1875 
(Medium) or 1.875 (High) nmol of aBNBD3 to give nanomolar peptide to DNA ratios of 125:1 
and 1250:1 respectively. We again observed optimal humoral and unchanged CMI responses to 
the DNA-encoded antigen at the Medium peptide to DNA ratio of 125:1 (Figure 5.5a-d). Specific 
IgG1 (Figure 5.5a) tended to be increased and IgG2a was significantly increased (p<0.001) 
(Figure 5.5b) by addition of aBNBD3 at the Medium peptide to DNA ratio when compared to 
the pMASIA-tgD group. There were no significant differences in the number of IFNγ (Figure 
5.5c) or IL5 (Figure 5.5d) -secreting cells. Interestingly only the group vaccinated with Medium 
aBNBD3/pMASIA-tgD had significantly higher numbers of IFNγ-secreting cells when 
compared to the placebo group (pMASIA) (p<0.05) (Figure 5.5c). Again we observed that 
addition of the peptide at the High peptide to DNA ratio resulted in reduced humoral responses 
(Figure 5.5a-b) and numbers of IFNγ-secreting cells (Figure 5.5c) when compared to vaccination 
with pMASIA-tgD alone. These results are consistent with those of the first study and further 
confirmed that pMASIA-tgD complexed with aBNBD3 at the Medium (0.1875 nmols peptide; 
125:1 ratio) nanomolar to DNA ratio improved the specific antibody response to tgD while 
maintaining the magnitude and balance of the cellular response. 
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Figure 5.5 Specific (tgD) immune responses in mice immunized with aBNBD3/pMASIA-
tgD complexed vaccines. C57BL/6 mice (n=8) were immunized twice ID with 5 ug pMASIA 
(placebo) or pMASIA-tgD DNA complexed with either 0, 0.1875 (Medium) or 1.8750 (High) 
nmols of aBNBD3 (analog, Glycine [G] replaces Glutamine [Q] in positions 1 and 27). One 
month after the second immunization, tgD-specific (a) IgG1, and (b) IgG2a titers were 
determined by ELISA. ELISA titers are expressed as the reciprocal of the highest dilution 
resulting in a reading of two standard deviations above the negative control. The numbers of 
tgD-specific (c) IFN-γ or (d) IL-5 secreting cells were measured by ELISPOT assay. ELISPOT 
results are expressed as the difference between the number of IFN-γ or IL5 secreting cells in 
tgD-stimulated wells and medium-control wells per 10
6
 cells. Bars represent the median values 
of each group with interquartile range. Significant differences between groups are indicated on 
the graphs where *p<0.05, **p<0.01 and ***p<0.001. 
 
 173 
5.4.5 Effect of BNBD3 on maturation and activation of murine bone marrow derived 
dendritic cells (BMDCs) 
To study the potential mechanism by which aBNBD3 increased humoral responses and 
modulated Th1-type responses as evidenced by induction of antibody of the IgG2a isotype, the 
effect of BNBD3 on maturation and functional activation of mouse BMDCs was examined. 
Phenotypic changes induced in BMDCs by different treatments were detected by analysis of DC 
markers, antigen presentation and costimulation/activation molecule expression (CD11c, MHC 
II, CD86, CD40) using flow cytometry (FACs). Mean fluorescent intensity (MFI) of expression, 
used here to measure the quantity of molecule produced in response to stimulation, was not 
affected by treatment with aBNBD3 for any marker with the exception of CD11c, where an 
increased MFI above LPS (100 ng/ml) for the aBNBD3 treated cells at 10 and 100 ng/ml 
concentrations was observed (Figure 5.6a). With respect to the effect on numbers of cells, 
treatment with LPS (100 ng/ml) or all concentrations (10, 100, 1000 ng/ml) of aBNBD3 or 
nBNBD3 resulted in equally high percentages (frequencies) of cells expressing CD11c (>80%) 
and equally moderate frequencies of cells expressing MHC II (>30%) (data not shown). 
Treatment with LPS (100 ng/ml), but not aBNBD3 or nBNBD3 at any concentration, resulted in 
strong upregulation of CD40 and CD86 costimulation/activation molecules based on a 5-10 fold 
increased percentage of cells expressing these molecules (data not shown).  
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Figure 5.6 Phenotypic and proliferative changes effected by aBNBD3 treatment of Day 9 
Mouse BMDCs. Day 9 BMDCs from C57BL/6 mice (n=3) were cultured for 24 hr in 6-well 
plates in the presence of  aBNBD3 or LPS and cells were stained for expression of CD11c, 
CD40, CD86 and MHCII. Cells were harvested for use in the assays on day 10. (a) Treatment of 
BMDC with aBNBD3 at 10, 100 or 1000 ng/ml or with LPS at 100 ng/ml increased the 
fluorescent intensity of expression of CD11c. Data are the mean MFI (mean fluorescent 
intensity) + sem of 1 well of cells from each of three mice. (b) Treatment of BMDC with 
aBNBD3 at 100 or 1000 ng/ml or with LPS at 100 ng/ml increased proliferation of mismatched 
splenocytes in an allogeneic MLR. Increasing numbers of BMDCs were incubated with 2 x 10
5
 
responder cells/well (BALB/C splenocytes) for 3 days. Proliferative responses were measured by 
the incorporation of 0.4 μCi/well [methyl-3H] thymidine for 18 hr. Data are mean CPMs + sem 
of triplicate wells. Similar results were obtained in a second independent experiment with 
nBNBD3. 
 
Functional maturation and activation as a result of treatment with BNBD3 was determined by 
measuring the changes in allostimulatory capacity of treated BMDCs. An increase in 
proliferative ability indicative of DC maturity was observed with LPS (100 ng/ml) and with 
increasing numbers of DCs which was expected (Figure 5.6b). aBNBD3 at 100 and 1000 ng/ml 
also increased proliferation; but only the higher 1000 ng/ml aBNBD3 treatment tended to induce 
greater proliferation than LPS (100 ng/ml) and this was only observed when DCs were 2 x 10
4
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/well (Figure 5.6b). These results suggest that BMDC incubation with aBNBD3 at 1000 ng/ml 
and to a lesser extent, at 100 ng/ml results in functional maturation and activation as shown by 
their increased allostimulatory ability. Additionally, from the dose response curve we observed, 
as did Yu et al. (2006) [461], that a DC to responder cell ratio of 1:10 gave the best response in 
MLR (Figure 5.6b). Thus a 1:10 DC to responder ratio was used in subsequent studies. 
 
To confirm our findings that aBNBD3 stimulated functional maturation and activation of 
BMDCs and to elucidate differences (if any) in its activity to that of nBNBD3 and sBNBD3, 
BMDCs were treated with nBNBD3 (Figure 5.7a), sBNBD3 (Figure 5.7b) and aBNBD3 (Figure 
5.7c) at 10, 100, and 1000 ng/ml with and without LPS at 100  
ng/ml. Comparable stimulation and proliferation by the DCs treated with synthesized BNBD3s 
indicated that aBNBD3 and sBNBD3 acted equally when compared to nBNBD3, and at 
concentrations of 100 ng/ml and 1000 ng/ml acted equally when compared to LPS to mature the 
DCs (Figure 5.7a-c). Proliferation was greatest (equal or better than LPS at 100 ng/ml) and 
significant relative to the medium control for: nBNBD3 at 100 ng/ml (p<0.01) and 1000 ng/ml 
(p<0.01) (Figure 5.7a); sBNBD3 at 100 ng/ml (p<0.01) and 1000 ng/ml (p<0.01) (Figure 5.7b) 
and aBNBD3 at 10 ng/ml (p<0.01), 100 ng/ml (p<0.01) and 1000 ng/ml (p<0.01) (Figure 5.7c). 
Combined stimulation by LPS and BNBD3 was tested to determine whether changes in 
maturation due to BNBD3 might be seen with a second  
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Figure 5.7 Activation/maturation measured by stimulatory ability of BMDCs in the MLR 
assay after treatment with nBNBD3, aBNBD3, and sBNBD3 with and without LPS. Day 5 
BMDCs (1 x 10
4
/well) from C56BL/6 mice (n=4) were dispensed to U-bottomed 96-well plates 
and treated for 18 hr with LPS (100 ng/ml), BNBD3 (10, 100, 1000 ng/ml) or LPS (100 ng/ml) + 
BNBD3 (1000 ng/ml). BMDCs treated with (a) native BNBD3, (b) sBNBD3 or (c) aBNBD3 
were incubated with BALB/C splenocytes (1 x 10
5
/well) for 3 days. Proliferative responses were 
measured by the incorporation of 1 μCi/well [methyl-3H] thymidine for 18 hr. Data are mean 
CPMs + sem of wells from each BMDC-donor mouse. Significant differences between groups 
are indicated on the graphs where *p<0.05, **p<0.01, ***p<0.001 and ****p<0.0001. 
 
 
stimulation, as had been noted for other peptides [235]. The combined treatment of BNBD3 at 
1000 ng/ml and LPS (100 ng/ml) tended to increase proliferation above that of LPS for all of the 
BNBD3s and this difference was significant for sBNBD3 (p<0.001) (Figure 5.7b) and aBNBD3 
(p<0.05) (Figure 5.7c). Thus, secondary stimulation may also be involved in the 
activation/maturation mechanism of BNBD3 on murine BMDCs. These results confirm our 
previous finding that aBNBD3 induces functional maturation and activation of BMDCs. There 
were no differences in the proliferations induced by BMDCs treated with nBNBD3, sBNBD3 or 
aBNBD3.  
 
5.5 Discussion  
Control of infection with BoHV-1 by infected animals is hindered by the virus’ ability to achieve 
latency and to employ other mechanisms that promote viral evasion of the immune system 
(reviewed in [59]). Induction of apoptosis of CD4
+
 T-cells, B-cells and Mo by BoHV-1 could be 
expected to have a negative consequence on antibody production and on CD4
+
 T-cell support for 
CTLs [462]. Viral interference with virus-specific antibodies can reduce the effectiveness of the 
antibody-mediated response [463]. Down-regulation of expression of MHC I would delay and 
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reduce detection of virus-infected cells [464, 465] and impair activation of CD8
+
 CTL [466, 
467]. Thus the ideal BoHV-1 vaccine that is effective and protective, yet also non-viral and non-
infectious, is sought. Responses to the ideal BoHV-1 vaccine should be broad-based [67]; and 
should stimulate both cellular and humoral arms of the immune system [468].  
 
In our quest for this “ideal” DNA vaccine we previously studied the immune response-enhancing 
capacity of BNBD3 [389], in a DNA vaccine as fusion construct with tgD of BoHV-1. This 
vaccination strategy increased cell-mediated immune responses including the induction of CTLs 
and was protective against BoHV-1, but these improvements did not result in enhanced clinical 
responses which could have been because the vaccine did not concurrently increase the humoral 
response [452]. We then hypothesized that the same cationic peptide, BNBD3, might improve 
the humoral response without loss of robust Th1-type CMI if it was formulated in a complex 
with pMASIA-tgD. This hypothesis was strongly influenced by the work of Reidle et al. (2004), 
who found that the humoral immune response to a DNA-encoded antigen could be improved, 
without loss of cellular responses when the DNA was complexed by a short cationic peptide at a 
nanomolar peptide to DNA ratio of 125:1 [453, 454]. In this current study, we showed that 
aBNBD3, when used at a nanomolar peptide to DNA ration of 125:1, enhanced the specific Th-1 
type humoral responses of mice to tgD encoded by pMASIA-tgD, with robust Th-1 type cellular 
responses maintained. In vitro we showed that aBNBD3 exerted a direct effect on murine 
BMDCs; the peptide activated BMDCs and functionally matured these cells as evidenced by 
increased allostimulatory ability. There was no effect of amino acid substitution in aBNBD3 as 
comparative studies with native, sBNBD3 and aBNBD3 showed that all three peptides were 
equally capable of inducing functional maturation of BMDCs. 
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When evaluated by chemotaxis assay for structural correctness and biological activity, the 
synthesized BNBD3 peptides were chemotactic for bovine iDCs. Chemotactic activity was 
unaffected by the amino acid substitution in aBNBD3 so this peptide was used in the complexed 
vaccine. Although chemotactic activity for bovine iDCs does not guarantee that mouse iDC 
would be attracted to aBNBD3, it is likely that they would be. Chemotactic activity of hBD2 for 
mouse and human CCR6-expressing cells [295] and of mBD4 (the mouse orthologue of hBD2) 
for human CCR2-expressing cells has been demonstrated [215].  Thus, it is possible that 
pMASIA-tgD complexed with aBNBD3 at the medium DNA: peptide ratio of 125:1 affected an 
increase in the magnitude of the humoral response by inducing chemotaxis of iDCs to the site of 
immunization. This in turn would increase the likelihood of uptake of the DNA vaccine by iDCs 
followed by expression of the tgD antigen and subsequent presentation by DCs of tgD through 
both MHCI and MHCII pathways leading to CMI and humoral responses respectively [110, 114, 
217, 218]. We have observed chemotaxis of iDCs following a bell-shaped curve in response to 
increasing concentrations of aBNBD3 in this and in a previous study [389]. It is possible that 
iDCs (and other immune cells) were optimally attracted to the concentration of aBNBD3 in the 
pMASIA-tgD vaccine complexed at the medium ratio of 125:1 and that this translated to a 
favorable improvement in the humoral response of the mice without change in the cellular 
response. In this scenario fewer cells would be attracted to the vaccine complex with the low 
concentration of peptide (12.5:1), which might explain the lower humoral and cellular response 
we observed. This would also explain the almost complete abrogation of in vivo immune 
responses in the group given the vaccine complexed to the highest peptide concentration 
(1250:1) as iDCs are so poorly chemo-attracted to high concentrations of β-defensin that they are 
almost repulsed. Also, where the concentration of aBNBD3 in the pMASIA-tgD vaccine 
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complexed at the medium nanomolar ratio of 125:1 may have made the vaccine attractive for 
uptake by infiltrating iDC, the high concentration of peptide complexing pMASIA-tgD at the 
nanomolar ratio of 1250:1 may have provided a sufficiently strong danger signal to target the 
vaccine for removal by extracellular processes [469], by endosomal or proteosomal degradation 
after cellular uptake [470] or by inducing cell death [471]. 
 
Complex formation was monitored by EMSA, and we observed a reduction or retardation, that 
increased as the amount of peptide added was increased, of electrophoretic mobility of the 
complexed DNA versus that of the naked DNA as has been described by others [472]. How 
complex formation of DNA with a cationic component translates to a benefit of the in vivo 
immune response is currently unknown. Increased transfection of cells by complexed DNA is 
one possible mechanism that would be expected to enhance the magnitude of the immune 
response. Others have reported however, that while higher peptide to DNA ratio complexes 
showed enhanced transfection efficacy in vitro as determined by cellular production of the DNA-
encoded antigen, these same complexes resulted in suppressed immunogenicity in vivo [454]. 
Our findings are in good agreement as we also observed almost complete abrogation of both 
humoral and cellular responses when pMASIA-tgD was complexed at the similarly high DNA: 
peptide ratio of 1250:1. Of the three concentrations we tested, enhanced specific humoral 
responses of mice to tgD encoded by the pMASIA-tgD DNA vaccine (with cellular responses 
maintained) were only achieved when DNA was complexed with aBNBD3 at the medium 
nanomolar peptide to DNA ratio of 125:1, but not at the low or high ratio. Others have also 
observed this critical dependency on a particular concentration of peptide in relation to DNA, 
and typically the optimal amount of peptide for the in vivo delivered complex had to be much 
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lower than the amount that gave the best transfection efficiency in vitro [454, 473]. Interestingly, 
Riedl et al. (2004) also found the cationic peptide to DNA ratio that was optimal in vivo was 
125:1 [454], thus our findings are in good agreement. Another reason for the very low response 
at the high ratio in vivo could be that after uptake of the complex by the cell, with increased 
quantity of peptide, the DNA was unable to fully release from the complex. The higher 
concentration of the peptide could either have hampered movement of DNA to the nucleus [473] 
or it could have effectively “trapped” the DNA in the endosome where ultimately the DNA 
would be degraded by lysosomal enzymes following merging of the lysosome with the late 
endosome [474]. In vivo, naked DNA can be degraded by serum nuclease before it is ever taken 
up by cells, but in a complex at the optimal ratio, aBNBD3 may have afforded protection to the 
DNA as has been observed for cationic liposomes [475], cationic copolymers [476] and cationic 
peptides such as IC30 (KLK) [477].  
 
Due to its high molecular weight and negative charge DNA does not easily cross cell membranes 
[469]. Complexing with aBNBD3 may have condensed the DNA making its size and shape more 
attractive for cellular uptake [478, 479]. An additional mechanism may have been that aBNBD3 
increased binding and entry of the DNA into cells, across the negatively charged cell 
membranes, as has been reported for cationic liposomes [480] and cationic peptides [477, 481]. 
Also, it is possible that aBNBD3 acted on iDCs as a cell-penetrating-peptide (CPP). This idea 
that aBNBD3 may act as a CPP is supported by the finding that many cationic CPPs are taken up 
with their cargo through macropinocytosis [482, 483] and the resulting macropinosomes may 
acidify but do not intersect with lysosomes and thus there is avoidance of lysosomal degradation 
[484]. It has been reported that human iDCs in the presence of hBD2 undergo actin-driven 
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plasma membrane ruffling and uptake of peptide suggestive of macropinocytosis with 
subsequent avoidance of lysosomal degradation of linked fluorophores [297]. It is possible, then, 
that aBNBD3 may use this same mechanism as described for hBD2 to gain entry to DCs and 
thus facilitate transfer of DNA into, and protection of DNA within, the cells. Following transfer, 
aBNBD3 might then carry the DNA as a passenger molecule into the nucleus [485], as has been 
described for the cationic antimicrobial peptide human LL-37 [486]. Improved trafficking into 
and through the cell and to the nucleus would be expected to result in an increase of the quantity 
of the DNA-encoded tgD protein, which in turn would have a positive effect on increasing 
antibody production.  
 
When we treated BMDCs in vitro with aBNBD3 we observed only partial phenotypic changes 
suggestive of maturation relative to LPS-treatment, but the aBNBD3-treated cells that displayed 
the lowest CD11c (comparable to LPS) were the most capable of inducing proliferation. 
Although there are conflicting reports of up- or down-regulation of CD11c with maturation [487, 
488], and up-regulation has been associated with increased DC survival [488], our results are in 
agreement with those who found down-regulation of CD11c expression to be a sign of activation 
and to be correlated with functional maturity [489]. Increased proliferative ability of DCs treated 
with aBNBD3 may provide a clue as to mechanisms for increased antibody. In analysis of allo-
MLR responses, MHC I-reactive CD4 cells function as helper cells, thus increased proliferation 
in an allo-MLR assay can indicate induction of CD4
+
 Th 1 cell responses [490]. Through 
increased CD4 Th1 cells we might expect to see increased help to B-cells that would result in 
increased antibody response of Th1-type. Thus, it is possible that in vivo, when DNA was 
complexed with aBNBD3 at the medium nanomolar peptide to DNA ratio of 125:1, aBNBD3 
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might have acted on iDCs, to increase proliferation of the CD4
+
 Th1 subset, and through help to 
B-cells, increased the specific Th1-type antibody response.  
 
In summary, we show enhanced efficacy of the humoral responses while maintaining cell-
mediated responses to a DNA vaccine by the addition, at the medium nanomolar peptide to DNA 
ration of 125:1, of the synthesized peptide aBNBD3 as a complex with the DNA vaccine. This 
characteristic of the immune response was not induced previously by vaccination with the DNA 
vaccine fusion construct encoding BNBD3 with tgD. We show induction of IFN-γ-secreting cells 
and an increase in IgG2a antibody production, both of which are desirable. Since both robust 
antibody and CMI responses of a Th1 type are desired for protection from BoHV-1 infection, 
and this strategy does result in both, the results of this study support our hypothesis and indicate 
a direction for future studies that could be undertaken for a DNA vaccination strategy to protect 
cattle from challenge with BoHV-1. 
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6. GENERAL DISCUSSION AND CONCLUSIONS 
 
Infectious diseases are a threat to the health and welfare of animals and humans. Worldwide, 
viruses that infect the respiratory tract cause the majority of human viral disease and these range 
in severity from a simple case of the sniffles (common cold) to that of severe pneumonia [491]. 
In cattle also, the most common respiratory diseases typically have a viral origin. As the 
causative agent of IBR and of an immune suppression that initiates BRDC in calves and feedlot 
cattle; as well reproductive disease causing abortion in animals of breeding age, BoHV-1 is no 
exception [90, 492]. The virus is considered a major pathogen in cattle and is responsible for 
economic loss as well as animal pain and suffering [493]. Because BoHV-1 is also able to 
establish lifelong latency following initial infection, the virus can be repeatedly reactivated 
causing recurrent infection, viral shedding, and spread of the virus [57]. Thus each animal that is 
infected becomes a possible reservoir or carrier for the virus. Vaccination is considered one of 
the best options for prevention and control of infection, but current commercial vaccines based 
on either MLV or KV vaccine technology platforms do not prevent infection and are either 1) 
safe but not sufficiently immunogenic/effective in the case of KV vaccines [494] or 2) are 
effective but potentially immunosuppressive, could establish infection and reactivate from 
latency and carry the risk of reversion to wild-type virus in the case of the MLV vaccine [382, 
495]. There is a need then, for a non-infectious, yet effective, vaccine strategy that will induce 
both the humoral and cellular arms of the adaptive immune response. Ideally, this strategy would 
provide a vaccine that would prevent infection; that is safe, does not lead to an infectious state, 
does not induce a carrier state, does not induce pathology, that imparts long-lasting protection 
and that is economical and transferable. Such a vaccine strategy would not only apply to BoHV-
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1, but could also extend to human viruses that establish latency such as HSV-1 and -2, as well as 
for high-risk viruses such as HIV, Ebola or HCV. Besides KV, current options for non-infectious 
vaccines include subunit (epitope- or protein-based) vaccines and DNA vaccines. Of the two, 
DNA vaccines mimic most closely the conditions of natural infection in that the DNA-encoded 
antigen(s) are produced by the host cell machinery, expressed within the cell and can be 
presented by MHC I, or are secreted and presented by MHC II or available for B-cell 
stimulation. DNA vaccines have great potential in their ability to generate both cellular and 
humoral immune responses [241]. The problem with DNA vaccines however, is that although 
they have inherent immunostimulatory or adjuvanting properties [496], induction of immune 
responses is slow particularly when compared to responses induced during natural viral infection 
[497]. In primates and large animals immune responses to DNA vaccines are often not of a 
magnitude sufficient to give protection from disease [252]. Many reasons have been given with 
subsequent investigations of various means to improve immune responses to DNA vaccines 
(reviewed in [498]). One most interesting strategy to improve immune responses to DNA 
vaccines is based on the central tenet that induction of immune responses to any pathogen or 
vaccine requires antigen to be presented by competent DCs [114]. Consequently, targeting 
vaccines to DCs or increasing the number of DCs at a vaccination site seems a logical approach 
to improve immune responses to DNA vaccines [135]. This approach was effective in a mouse 
model when a murine β-defensin, chemotactic for iDC, was able to improve the immune 
responses to DNA vaccines encoding otherwise non-immunogenic HIV or tumor antigen [217, 
218]. Based on the findings in mice, the work in this dissertation was undertaken to test my 
hypothesis that a bovine β-defensin, chemotactic for bovine iDCs, could act similarly to improve 
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the immune responses of cattle to DNA vaccination and ultimately afford protection from 
BoHV-1 infection.  
 
The first objective of this project was to assess the chemotactic activity of bovine β-defensins for 
bovine iDCs and select the most chemotactic (chapter 3). In order to do this, bovine DC had to 
be generated, and their maturation state characterized. Additionally, the bovine β-defensins had 
to be synthesized, validated and then screened for chemotactic activity using the defined 
immature bovine DCs. At the start of this project, there were few publications of bovine DCs, 
and in none of them had any differentiation, phenotypically or functionally, been made between 
the bovine immature or mature DC [309, 499-501]. Additionally there were no reports of 
immunological effects, including chemotaxis, for the sixteen known bovine β-defensins. Thus 
both parts of this study were novel in nature.  
 
Using phenotype and functional assays I found that bovine Mo differentiated to iDCs within as 
few as three days (DC3) and when compared to the more conventional six-day DC cultures or 
DCs cultured for ten days with and without maturation factors these DC3s were at the most 
immature stage (Chapter 3). This protocol was the first to show that bovine iDC could be 
generated in less than 5-6 days. The short culture is advantageous as it gives the greatest yield at 
the most immature stage of DCs, should help to prevent errors due to assaying with the more 
“matured” day 5-6 DC, and has an added benefit in that more studies can be conducted in a 
shorter time. Next the sixteen known β-defensins were synthesized and fourteen were correct 
(BNBDs1-9, 12, 13, EBD, TAP, LAP). These were subsequently screened for chemotactic 
activity by the bovine iDCs (DC3) and DC6. Bovine iDC were overall more chemo-attracted to 
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the bovine β-defensins than were DC6, and these results were in good agreement with those from 
the studies of mouse defensins [214, 217]. BNBD3, BNBD9 and EBD had the greatest 
chemotactic activity of the fourteen synthesized peptides for iDCs. Since the activity was equal 
for these three, but only one peptide was to be used for the rest of the project, BNBD3 was 
chosen based on its relative ease of synthesis and abundance in the bovine neutrophil, and was 
subsequently subjected to further study.  
 
Concerns that were raised regarding the correct folding and folding-related functionality of the 
synthesized peptides were addressed by synthesizing three variants of BNBD3 and comparing 
them with the native peptide using comparative HPLC and iDC chemotaxis. Of the three 
synthesized variants the one with the identical amino acid sequence as native BNBD3 
(nBNBD3) co-eluted with nBNBD3 when analyzed by HPLC, which proved our synthesized 
BNBD3 was identical to nBNBD3. This verified the native disulphide connectivities in the 
synthesized peptide and showed that the oxidation conditions and synthesis method that I used 
would produce a correctly folded peptide. Additionally, since bovine iDCs migrated equally with 
the same bell-shaped dose response curves and peak migration at the same concentration to the 
three synthesized BNBD3 variants as to the nBNBD3, and this functionality is fold-related, these 
chemotactic activity results further verified that the BNBD3 peptides were correctly folded and 
by extension that all synthesized peptides used in this study were correctly folded.  
 
Recruitment of DCs to a site of injury or infection by inflammatory molecules is the first step to 
induce an immune response to an offending pathogen and this is accomplished through co-
ordinated and orderly movement of the appropriate cells. For example, others have shown that 
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the CCR2 ligand MCP-4/CCL13 recruits CCR2-expressing DC precursors from the blood. This 
direction is very specific as MCP-4/CCL13 expression is restricted to the basal epithelium in 
contact with the blood vessels. In response to the tissue environment, these cells lose CCR2 and 
differentiate to CCR6-expressing iDC that are attracted into the tissue by the CCR6 ligand 
MIP3α/CCL20. Again this is very specific as MIP3α/CCL20 is expressed by the epithelial cells 
located at the boundary with the external environment [298]. The co-ordinate expression of 
chemokine ligands in the tissue and receptors on the cells ensures the movement of specific cells 
from circulation to the tissue where they are needed. Understanding the effect of potential 
vaccine adjuvants on DC trafficking is important because the type of DC attracted ultimately 
dictates the type of immune response that results [369]. To determine whether migration to the 
BNBD3 peptides was directed or random, the possible mechanism(s) of attraction between the 
peptides and the iDC were investigated. Migration of iDCs to BNBD3 was shown to be 
chemotactic (directed) and not chemokinetic (random) by checkerboard analysis. I further 
showed that this chemotaxis was ligand-induced through G protein-coupled seven-
transmembrane domain receptors when pre-treatment of DC3 with PTX (pertussis toxin) resulted 
in abrogation of migration to all BNBD3 peptides. This is in good agreement with the results 
from the murine studies as pre-treatment of iDC with PTX resulted in abrogation of chemotaxis 
to murine β-defensin, and subsequently the G protein-coupled seven-transmembrane domain 
receptor was identified as CCR6. Since chemokine receptors are G protein-coupled seven-
transmembrane receptors and CCR6 activation was recently found to induce changes in lipid raft 
proteins that regulate cytoskeletal dynamics of cell migration [502] my studies suggest that at 
least one of the bovine iDC receptors for BNBD3 is a chemokine receptor and/or a receptor 
involved in cell migration. Since my overall objective was to develop a DNA vaccine that could 
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be effective when delivered ID, the next step was to ensure that BNBD3 could attract iDCs in the 
skin. When BNBD3 was injected into the skin of cattle, infiltrating iDCs were identified in much 
greater numbers in response to BNBD3 injection than in naïve skin or in skin injected with a 
control solution. This showed that BNBD3 had in vivo chemotactic activity for bovine iDCs. 
Future studies could be designed to identify the specific receptor(s) and the mechanism(s) 
involved in movement of bovine iDC to the bovine β-defensins as the bovine chemokine 
receptors are discovered and as antibodies to these receptors become available. These types of 
studies are particularly important since targeting antigens to some chemokine receptors on iDCs 
has the potential to induce the undesirable effect of autoimmunity [503] in addition to inducing 
beneficial immune responses. Ultimately such studies would provide valuable information about 
how bovine β-defensins work and their subsequent potential utility in vaccine design. 
 
The point could be made that iDCs derived from Mo are too specific and do not adequately 
represent the full repertoire of DCs that might traffic to the skin and be involved in the induction, 
regulation and maintenance of the immune response. Although bovine DCs can be generated or 
isolated from a number of sources such as CD14
+
 Mo [499] or pDCs [504, 505] from PBMCs, 
bone marrow [500], afferent lymph [318, 323], or LNs [504], and other methods may result in 
more representative heterogeneous DC populations, I chose to use DCs generated from purified 
CD14+ peripheral blood Mo because use of an uncontaminated (non-DC cells) and a reasonably 
homogenous (with respect to cell size) population of DCs was important in order to obtain valid 
results in the in vitro chemotaxis assay used for screening of the bovine β-defensins. 
Additionally, since I was most interested in attracting potentially infiltrating immature cells, 
generating cells with an immature phenotype and functionality that could be verified was an 
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important aspect of the study. Also, monocyte-derived DCs have the greatest phenotypic 
similarity to dermal DCs [506] and thus perhaps represent the most likely infiltrating iDC, the 
dermal iDC. Attracting dermal iDC would be beneficial to vaccine design as these DCs are 
involved in priming for CTL responses [507], and the generation of CD4+ T cell responses [508, 
509]. Since populations of DCs going to the LN or already resident in the LN would be more 
likely to be made up of “matured” DCs, techniques that isolated DCs from afferent lymph or 
from LNs were rejected. Obtaining bone marrow typically requires euthanasia of the animal and 
in a large animal such as cattle this can be costly. Also, it may be difficult to obtain a population 
of DCs with sufficient purity using this method as additional buoyant density centrifugation to 
remove contaminating cells is needed, and to get a good yield the culture also needs to include 
Flt-3 Ligand [500], a cytokine with known stimulatory effect on DC differentiation, function and 
maturity in other species [510, 511], but undefined effects on cattle DCs. So for the purposes of 
this study, and the requirement for a pure unstimulated population of iDCs, this method of 
generating DCs from bone marrow was not used. Once the different populations generated from 
bovine bone marrow are identified and their stage of maturity/activation ascertained, future 
studies could be designed to compare chemotaxis to BNBD3 and perhaps the other bovine β-
defensins of monocyte-derived iDC versus immature bone marrow-derived DCs. Additionally it 
may prove interesting to compare chemotaxis of mouse or human iDCs to determine whether 
migration to the bovine β-defensins is also species-specific or whether one or more of the bovine 
peptides could be candidates for inclusion in vaccines for other species. 
 
Having established that BNBD3 was chemotactic for bovine iDCs, the next objective of this 
project was to construct plasmids that express BNBD3. Following successful construction of the 
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plasmids that express BNBD3 on a separate plasmid (pMASIA-BNBD3) or as a fusion construct 
with the BoHV-1 antigen tgD (pMASIA-BNBD3-tgD), I tested the effect of ID delivered 
BNBD3-encoding plasmids on immune responses of mice and cattle (chapter 4). An increase in 
the number of IFN-γ-secreting cells was seen in mice in response to BNBD3 delivered on a 
separate plasmid and in cattle when BNBD3 was delivered in the fusion construct. Additionally, 
increased proliferation indicative of CD4
+
 T cell induction was observed in the BNBD3 fusion-
vaccinated cattle. The reason for a response in mice but a lack of response with unlinked BNBD3 
in cattle is unclear although this phenomenon has been observed by others [420, 421], and 
suggests that both the BNBD3 and the tgD genes should be expressed in the vicinity of each 
other in the LN. Proximity of expression of adjuvant and antigen may be an even more important 
consideration when the vaccine is to be delivered ID. In an earlier study, improved immune 
responses to a gB DNA vaccine were observed in cattle as a result of co-administration of an IL-
12 encoding plasmid following gene-gun or IM delivery but not ID delivery [512]. The question 
of whether proximity of expression is best accomplished through coexpression by the same cell 
(that is virtually guaranteed by a fusion construct) or whether expression by individual cells in 
close proximity to each other in the LN (co-administration of separate plasmids for adjuvant and 
antigen) is sufficient, has not be answered definitively. Every study seems to offer up conflicting 
results and therefore it can’t be discounted that the encoded adjuvants and antigens themselves 
may be having some effect.  In support of the idea that adjuvant and antigen need to be linked, it 
was recently shown that co-administration of two vectors encoding distinct genes resulted in less 
than 40% coexpression of both genes by LN cells and this lack of coordinate expression 
translated to a failure of the vaccine to induce antitumor effect [513]. In cattle their size relative 
to the mouse could have resulted in greater time and distance separation of the two plasmids and 
 192 
this would have made it less likely for the plasmids encoding BNBD3 and tgD to arrive and both 
be expressed in close proximity and in the same LN. Our data showing no effect by separate 
plasmids but increased proliferation and numbers of IFNγ-secreting cells in cattle vaccinated 
with BNBD3 as a fusion construct favors the concept that both genes should be expressed by the 
same cell in order to influence T cell responses. Confounding this is the possibility that the tgD 
antigen itself may be exerting some effect on immune responses as this has been shown in 
studies with gD of HSV binding to and down-regulating a cellular receptor (HVEM) whose 
ligation can inhibit T cell function [514]. Therefore investigation of effects of tgD represents an 
area for future study. Experiments could be designed to delineate effect of antigen by comparing 
the immune responses of cattle to a mix of two plasmids encoding BNBD3 and tgD, with those 
induced by BNBD3 and a different antigen(s). Since it is simpler and more multipurpose for 
vaccine design with other antigens if the BNBD3 can be delivered on a separate plasmid, 
knowing the reason for the lack of result in a large animal would be a worthwhile undertaking.  
To further characterize the cellular response, I investigated whether BNBD3 could influence 
induction of CTLs. Greater numbers of CD8+/IFNγ+ CTLs were discovered in mice and in cattle 
due to vaccination with BNBD3 fused to tgD. This finding provides additional support that in 
order to influence T cell responses, coordinate expression of adjuvant and antigen by the same 
cell is best. My finding that BNBD3 increased the numbers of CTLs in mice is in good 
agreement with the current literature that reports a positive effect on CTL responses due to 
inclusion of β-defensin in a mouse vaccine [218, 515]. In cattle however, CTL induction was 
only evaluated after and not before BoHV-1 challenge. It has been reported that antigen targeted 
to DC receptors such as DEC-205 is cross presented but does not prime [516]. Hence DC-
targeted antigen can expand virus-specific CD8
+
 T cell responses through cross-presentation to 
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already primed CD8
+
 T cells but can’t prime for CD8+ CTL [517]. It is unlikely that the BNBD3 
fusion vaccine did not prime CTL responses in cattle given that I saw increased CTLs in mice 
without infection. However since priming of CTL T cell responses is an important consideration 
in vaccine design for viruses and intracellular bacteria, it might be helpful to determine whether 
bovine CTLs arose due to the effect of BNBD3 or whether bovine CTLs arose by priming 
through a DC receptor. Future studies could be done to determine if CTLs would be induced 
without BoHV-1 infection.  
 
Another interesting result with respect to cellular responses was observed in mice when tgD-
restimulated splenocytes were evaluated by FACs analysis for surface expression of CD3, CD8 
and concurrent intracellular expression of IFN-γ.  I found that vaccination with the BNBD3 
fusion (pMASIA-BNBD3-tgD) induced a population of cells that were negative for CD3 and 
thus were not T cells, but that nevertheless were positive for CD8
 
and  IFN-γ  (CD3- CD8+ IFN-
γ+ ). Since the antibody used in these studies to identify the CD8+ population stains specifically 
for CD8α, and DCs are currently the only known non-T CD8α+  cells in the mouse spleen, it is 
possible that the CD3
- 
CD8
+
 IFN-γ+ cells observed were splenic DCs [419]. As I discussed in 
Chapter 4, since CD8α+ DCs preferentially prime CTLs, if the cells I discovered were splenic 
DCs, this might explain the increased CTL response. Additionally, while the IgG levels were not 
significantly changed by vaccination with the fusion construct, there was a trend in both mice 
and cattle towards a lower antibody response. This might be explained by the effect of these 
CD8α+ DCs on CD4 T cells as these cells induce apoptosis and fail to provide appropriate 
signals to secondary CD4
+
 Th cells [518]. Since CD4
+
 Th cell help to B cells is critical for 
development of a robust antibody response [519, 520], such an effect on CD4
+
 Th cells could 
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ultimately lead to a weak or lowered antibody response. The existence of a CD3
- 
CD8
+
 IFN-γ+ 
cell population as a result of DNA immunization with β-defensin-antigen fusion constructs has 
not been reported previously. Given the potential for CD8α+ DC cells to influence both the 
cellular and humoral responses further studies could be designed to positively identify this 
population of interesting CD3
- 
CD8
+
 IFN-γ+ cells to determine if they are CD8α+ splenic DCs. 
 
To evaluate the effect of BNBD3 on the protective responses, cattle were then challenged with 
BoHV-1. The addition of BNBD3 to tgD as a fusion construct increased the magnitude of the 
IFN-γ response, induced tgD-specific CD8+ T cells, and increased the proportion of CTLs in the 
CD8
+
 T cell subset, but this improvement in cellular responses did not translate into improved 
protection (reduction in virus shedding, rectal temperature and weight loss) that I would have 
expected. Instead, cattle were protected equally by both tgD-encoding DNA vaccines. In looking 
for an explanation, it became apparent that since BNBD3 was unable to improve the humoral 
response and insufficient humoral immune responses can be a characteristic of DNA vaccination 
[521], and have been implicated in a lack of protection from BoHV-1 challenge, that antibody 
production may have been too low. In addition to the most important method of protection 
against BoHV-1 which is that of neutralizing the virus or blocking virus entry into cells, other 
antibody related mechanisms may also be important for early control of virus infectivity. 
Antibody-dependent uptake of virus by pDCs (plasmacytoid DCs) has been shown to be 
important in control of foot-and-mouth disease virus (FMDV). FMDV inhibits induction of 
antiviral molecules particularly type I interferons alpha/beta (IFNs α/β) as an escape mechanism. 
Virus alone stimulated little if any type I IFN, but incubations with virus-immune complexes 
(antibody coated virus) induced large quantities of type I IFN from pDCs [504]. Thus induction 
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of virus-specific antibody with subsequent triggering of IFNs α/β release by pDCs was critically 
important to the overcoming the subduing effect of the virus and to regaining the early antiviral 
response and thus early control of FMDV infection. It is not currently known whether antibody 
dependent uptake of BoHV-1 by pDCs with subsequent release of IFNs α/β occurs in BoHV-1 
infection, but since herpesviruses such as HSV-1 [522, 523] and BoHV-1 [524] have also 
devised ways to evade the antiviral effects of type I IFNs, it is sensible to think that the innate 
immune systems of cattle may use this same method to mount an antiviral IFN response to many 
viral infections. Thus in theory, improving antibody production induction as a result of 
vaccination could potentially increase antibody-dependent uptake of virus by pDCs with 
subsequent release of IFNs α/β and this might result in better early control of BoHV-1 infection 
by challenged animals. Interestingly, we often speak of the influence of the innate response on 
the subsequent development of the adaptive response, but this is an example of the reverse; how 
well-developed adaptive responses can influence induction of innate responses.  
 
There have been reports of slow, low magnitude humoral responses to DNA vaccines encoding 
the gD protein [311]. In this study I similarly observed a trend towards low antibody response. 
More importantly, I did not observe an improvement of humoral responses in mice or cattle 
regardless of whether BNBD3 was delivered separately or as a fusion. Since induction of naïve B 
cells to antigen-specific B cells is a first step in the development of humoral response, and this 
first step as well as amplification of antibody production by antigen-specific B cells requires 
sufficient good quality free or soluble antigen, the production/availability of such antigen may be 
a weakness of DNA vaccines in general and one that the addition of BNBD3 was unable to 
overcome/improve. The importance of sufficient soluble antigen in humoral responses to DNA 
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vaccine can be observed in the improvement seen in prime-boost vaccine regimens where free 
protein antigen is provided in the boost [525]. There are a number of ways in which tgD 
production by the transfected host cells may have been affected in this study. In chapter four, I 
show in a schematic overview how the plasmids were designed such that the coding sequence for 
BNBD3 could be inserted in three pieces either without or with a linker using the same BamHI 
and HindIII restriction sites for insertion into both pMASIA and the constructed pMASIA-tgD. 
Using this method I was able to reduce any potential for variability of expression due to non-
coding differences in the plasmids. Although there was a risk of negative effect on tgD 
expression by another molecule being encoded N-terminally, I decided to place the BNBD3 in 
front of tgD based on good results, particularly with respect to generation of neutralizing 
antibody that requires antigen to be in the correct structurally folded form, from mouse studies 
with placement of mBD2 in an N-terminal position to the antigen [217, 218]. I similarly 
separated BNBD3 from the antigen using a well-characterized octapeptide linker to minimize 
any potential effect of the peptide on tgD structure. Since in vitro expression of tgD from the 
constructed pMASIA-tgD and from pMASIA-BNBD3-tgD was excellent when compared to the 
standard plasmid I concluded that neither the construction of pMASIA-tgD nor the N-terminal 
addition of BNBD3 could have had a negative impact on tgD expression that would account for 
the relative lack of humoral response to vaccination. The in vivo impact of N-terminal BNBD3 
on specific tgD responses could be investigated in the future. Such a study would involve 
construction of a plasmid with the coding sequence for BNBD3 inserted at the carboxyl end of 
tgD and comparison with the plasmid that encodes BNBD3 N-terminally to tgD on 1) in vitro 
binding of the expressed tgD to mAbs specific for a number of structural neutralizing epitopes 
[526], and 2) immune responses in mice and/or cattle.  
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Another way in which tgD production by the transfected host cells may have been limited by 
BNBD3 is related to the potential for damaging effect of β-defensin on the inside of the host cell. 
HNP1, a human α-defensin, induced apoptosis of cells transfected with plasmid expressing the 
peptide. This was determined to be due to the effect of accumulation of HNP1 inside the cells 
and not from extracellular HNP1. In their study the authors constructed their plasmid to encode 
the mature or active form of the HNP1 peptide [527] that would be equivalent to our BNBD3. 
Although HNPs and BNBDs can be safely stored in the neutrophil this is thought to be due in 
part to the presence of a protective anionic propiece, and when this propiece is removed by 
proteolytic cleavage, the resulting peptide in its “mature” form is active and has the potential to 
be cytotoxic. Most of the effect of HDPs including the β-defensins has focused on the cytotoxic 
specificity of extracellular HDPs particularly in cancer research due to their specificity for 
negatively charged membrane components which differ between cancer and non-cancer cells 
[528]. Consequently, little is known of the effects of intracellular expression on DCs or on other 
populations of resident cells in skin, muscle or lymphoid tissue that one would expect to transfect 
with a DNA vaccine. In another study human aMΦ were transfected with mRNA encoding 
hBD2. After 24 h treatment, cell viability was reduced due to transfection with the hBD2 mRNA. 
In longer cultures, sadly only aMΦ cells infected with M. tuberculosis, which would have given 
the hBD2 an intracellular target and effectively distracted the peptide from targeting other 
structures inside the cell, were studied. Even so, after 2 days, the controlling effect of hBD2 on 
bacterial growth was lessened which may have been due to cytotoxic effect of the peptide [529]. 
Delineation of intracellular cytotoxicity of BNBD3 for DCs and other APCs, or for populations 
of resident cells in skin, muscle or lymphoid tissue could be a very interesting area for future 
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study. This knowledge would have a direct impact on determination of the value of BNBD3 or 
other similar peptides in subsequent DNA vaccination strategies. 
 
In chapter five, as the final objective of this project, I investigated whether humoral responses 
could be improved without loss of CMI by utilizing BNBD3 in its peptide form as a complex 
with the DNA vaccine. The observation that BNBD3 when encoded in the DNA as a fusion 
construct was able to improve cellular responses (particularly with respect to CTL), yet was 
unable to improve the humoral response had led me to investigate whether BNBD3 could be 
utilized in other ways. After review of the literature I came across some intriguing reports that 
when a small cationic peptide fused to a short antigenic epitope was complexed at a low peptide 
to DNA ratio of 125:1 with a DNA vaccine encoding for a full length antigen, the humoral 
immune response to the DNA-encoded antigen could be improved without loss of CMI 
responses. This represented an ideal in terms of response to vaccination, and since this strategy 
had not been attempted using a cationic peptide such as a β-defensin, I decided to try using the 
BNBD3 peptide in this novel way. In mice, the vaccine formulated with aBNBD3 (analog) at the 
nanomolar peptide to DNA ratio of 125:1 tended to increase IgG1 and significantly increased 
IgG2a humoral responses relative to pMASIA-tgD. There was no difference in the number of 
IFN-γ- and IL-5-secreting cells observed in mice in response to this BNBD3-complexed vaccine 
compared to pMASIA-tgD, thus using this strategy I was able to maintain the size and balance of 
the cellular response. The finding of increased antibody of the IgG2a isotype with no increase in 
the number of IL-5
+
 cells suggested that BNBD3, used in this manner, might also have 
strengthened the Th1-type response. Contrasting these positive results, I observed almost 
complete abrogation of both humoral and cellular responses when a 10X greater quantity of 
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BNBD3 (1250:1) was used. Our results agreed with the findings from the earlier study by Riedl 
et al. (2004) [454], and gave rise to two questions: 1) how might BNBD3 peptide influence the 
humoral response, and 2) why would responses be improved at one concentration and yet be 
almost completely abrogated or suppressed at another? With regard to addressing these 
questions, through in vitro investigations of effects of exogenous BNBD3 on BMDCs, I 
observed that when mBMDCs were treated with nBNBD3, sBNBD3 or aBNBD3 the cells 
acquired greater stimulatory ability indicative of functional maturation/activation. This is a 
desirable effect for a vaccine adjuvant and additionally is in good agreement with the findings 
from the mouse studies on the maturing effects of mouse β-defensins on mBMDCs [216]. Of 
relevance to our results, by increasing the proliferative ability of DCs, aBNBD3 may have 
increased the antibody response. As discussed in chapter 5, proliferation can be used as a 
measure for induction of CD4
+
 Th cells. Since CD4
+
 Th cells provide help to B-cells, an increase 
in these CD4
+
 Th cells theoretically could lead to increased antibody production by B cells [530]. 
Further in vitro studies to determine whether aBNBD3-treated mBMDCs increase induction of 
CD4
+
 Th cells and whether these cells are primarily Th1 or Th2 could be done to address 
whether this is a potential mechanism for improved antibody induction.  
 
Another possibility for how the complexed vaccine may have affected the humoral response 
could be from the action of aBNBD3 on the iDCs with subsequent effect on the NK cell subset 
[531], or from the action of aBNBD3 directly on the natural killer (NK) cell subset [532]. With 
DNA complexed to aBNBD3 at the medium nanomolar peptide to DNA ratio of 125:1 the 
vaccine in vivo may have improved the IgG2a response by increasing the number or activity of 
natural killer (NK) cells. Studies have shown that TLR-stimulated DCs increase NK cell activity 
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[533]. Interestingly, the mouse dendritic cell marker CD11c is down-regulated upon DC 
activation through TLR triggering [489]. It is provocative then, given our results whereby 
treatment of BMDC with aBNBD3 led to maturation and down-regulated CD11c expression, to 
think that aBNBD3 may have similarly triggered TLRs to activate/stimulate DCs which in turn 
acted on the NK cell subset to increase their numbers and activity. Since there is considerable 
crosstalk between NK cells and DCs or macrophages, it could be difficult to separate whether 
aBNBD3 may have acted directly on the NK cells; or whether it may have acted by first 
activating/stimulating DCs with the stimulated DCs subsequently exerting their influence on the 
NK cells; or both. Whether NK cells can be directly stimulated or whether accessory cells or 
cytokines are required for NK cell activation is currently a matter of some controversy [534].  
Regardless, since activation of NK cells has been shown to increase antigen specific IgG2a 
responses [535], the increased IgG2a that we observed might have occurred as a result of 
aBNBD3-induced activity of NK cells either by direct effect on the NK cells or indirectly 
through the effect of aBNBD3-activated DCs. 
 
I also studied in vitro chemotactic activity of BNBD3 and showed that all forms of BNBD3 were 
chemotactic for bovine DCs. Thus chemoattraction to aBNBD3 could have played a role in 
bringing iDCs to the vaccination site and this may have increased the likelihood that iDCs would 
take up the DNA vaccine. Since iDCs can uniquely utilize a direct phagosome to cytosol 
pathway [109], theoretically uptake by iDCs should result in a greater number of plasmids 
circumventing the destructive elements of the endosome/lysosome, thus increasing the 
opportunity for plasmids to reach the nucleus and subsequently resulting in higher expression of 
the tgD antigen. Increased tgD expression through improved chemotaxis and uptake of 
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pMASIA-tgD by iDCs is one way that BNBD3-complexed vaccine may have increased the 
antibody response in a concentration-dependent manner. I observed that in vitro chemotaxis by 
iDCs followed a bell-shaped curve in response to increased concentration with substantially 
lower chemotaxis by iDCs at the highest concentration of BNBD3. In vivo antibody responses 
followed a similar bell-shaped curve in response to increased concentration/amount of BNBD3 
in the complexed vaccine. If, in vivo, fewer iDCs were attracted to the higher amount of BNBD3, 
and this resulted in less migration of iDC, there would be less opportunity for uptake of 
pMASIA-tgD by iDC. Thus, low numbers of infiltrating DCs would encourage increased 
degradation of plasmid in extracellular spaces and transfected somatic cells, which would 
translate to subsequently poor expression of tgD. This poor expression of tgD could account for 
the low in vivo humoral responses to the vaccine complexed with the high amount of BNBD3. 
The potential relationship between iDC chemotaxis to BNBD3 and tgD expression could be 
confirmed by future studies of in vitro chemotaxis by murine BMDCs to BNBD3 and to the 
complexed vaccines. Additionally, studies of uptake and subsequent expression in cell lines 
versus murine BMDCs of the BNBD3 complexed vaccines might clarify whether the effect of 
the vaccine was through increased expression of tgD by DCs (an effect that may not be observed 
when using cells from cell lines), and additionally elucidate the effect of concentration of the 
peptide on subsequent expression of the DNA-encoded antigen.  
 
 Although I did not do investigations to determine receptor(s) for BNBD3, my results suggest a 
mechanism(s) for activity by BNBD3 which may be receptor-mediated and this represents an 
area that would be interesting for future studies. There are at least 40 receptors expressed by 
iDCs that function primarily in antigen capture [536]. CD205 is a type I C-type lectin containing 
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multiple calcium-dependent binding domains and a unique cytoplasmic tail. CD205 may direct 
captured antigens to specialized antigen-processing compartments [134]. Three type II C-type 
lectins that are important for receptor-mediated antigen uptake include: DC immunoreceptor 
(DCIR) [537], DC-associated C-type lectin-2 (dectin-2) [538, 539], and C-type lectin receptor 1 
(CLEC-1) [540]. DCIR contains a cytoplasmic immunoreceptor tyrosine-based inhibitory motif 
(ITIM) and can bind glycosylated ligands. Ligands for dectin-2 and CLEC-1 have not been 
identified as of yet.  The MMR and Fc receptors FcγR and FcεR, are also involved in antigen 
handling by iDCs [132, 541-544]. Chemokine receptors CCR1, CCR2, CCR5, and CCR6 are 
expressed on iDCs [296], and they are members of the CC cytokine family of G-protein-coupled 
7-transmembrane-domain receptors (GPCR). The enhanced immune response I observed after 
immunization with the BNBD3-tgD fusion (chapter 3) suggests an increased efficiency of 
antigen uptake, processing and presentation that is suggestive of chemokine binding to CC 
chemokine receptor.  
 
Other chemokine receptors are expressed by iDCs that are not strictly uptake receptors but play 
roles in antigen uptake and in regulating DC activation and may be influenced by BNBD3. These 
include two members of the immunoglobulin superfamily (IgSF); Down-Regulated by 
Activation (DORA), a receptor that is also involved in homing and recirculation of DC and is 
down-regulated following CD40L engagement [545], and  Immunoglobulin-like transcript 3 
(ILT3) that contains an ITIM in its cytoplasmic domain [546]. ILT3 is involved in antigen uptake 
and processing; it can be efficiently internalized upon cross-linking and can deliver its ligand to 
an intracellular compartment for processing. Heat-shock protein receptors are expressed at the 
cell surface where they capture hsp bound to tumor, bacterial and viral antigens [547]. Some 
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TLRs are expressed on iDCs (ie. TLR3,4); they have many ligands including microbial 
lipopeptides [548]. Additionally, some of the chemokine receptors are actually intracellular 
proteins. These could be utilized by BNBD3 and could theoretically affect the fate of BNBD3-
tgD fusion or the BNBD3: tgD complexed vaccine. The p55/fascin protein is an actin-bundling 
protein that is involved in migration through the organization of a specialized cytoskeleton that 
also promotes antigen capture [549].  Cdc42 and Rac1 are members of the Rho family of 
GTPases that are involved in regulating macropinocytosis and antigen processing [550-552]. The 
ubiquitin protein family member, di-ubiquitin, contains two ubiquitin moieties and functions to 
direct internalized antigens towards DC proteasomes for processing [553].  
 
Aside from exogenous effects on chemotaxis and uptake of DNA vaccine by iDCs, BNBD3 
peptide may have influenced the fate of the plasmid and hence antigen expression and 
subsequent antibody response by modifying intracellular processes such as release of 
intracellular DNA by transfected cells, stability of DNA in the cytoplasm and targeting of DNA 
to the nucleus. Similar studies, such as those conducted by Sandgren et al. (2004), where a 
biotinylated peptide and YOYO-1 fluorophore labelled DNA were used to track movement of 
peptide and DNA in the cells, could be done to determine whether BNBD3, like LL37 protects 
plasmid DNA from nuclease degradation and whether BNBD3 targets the plasmid DNA to the 
nucleus [486].  
 
In summary, this dissertation describes a series of studies undertaken with the overall objective 
to develop a transferable and non-infectious vaccine strategy that through targeting vaccines to 
DCs induces both the humoral and cellular arms of the adaptive immune response effective to 
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prevent infection of cattle by BoHV-1. With DC chemotaxis as a central unifying theme of all 
three studies, I show in the first study how bovine iDC are chemoattracted to BNBD3 (chapter 
3). I next show how chemoattraction by iDC to the BNBD3-tgD fusion protein expressed by 
transfected skin cells at the vaccination site could explain the increased numbers of CD8
+
/ IFN-
γ+ CTLs induced by this vaccine. I also explain how the effects of BNBD3 on the inside of the 
cell may have limited expression of the construct and thus production of the antigen resulting in 
a less than robust antibody response (chapter 4). Finally in the fifth chapter I describe how the 
same attraction of iDC to BNBD3 in a peptide/DNA complexed vaccine could have influenced 
increased transfection of iDCs with the DNA vaccine and how this may have led to increased 
antibody production while maintaining robust CMI responses (chapter 5). The information 
gained from the research presented in this thesis, as well as the current and future knowledge of 
the modulating effects of β-defensins and indeed all cationic peptides on immune responses, is 
expected to ultimately lead to the development of new effective DNA vaccines.  
 
 
 
 
 
 
 
 
 
 
 205 
7. REFERENCES 
1. Roizman, B., Pellet, P.E. (2001) The Family Herpesviridae: A Brief Introduction. In 
Fields' Virology (D. M. Knipe, P. M. Howley and et al., eds), Lippincott, Williams & 
Wilkins, Philadelphia, PA 2381-2397. 
2. Spear, P.G. (1993) Entry of alphaherpesviruses into cells. Seminars in Virology 4, 167-
180. 
3. Guo, H., Shen, S., Wang, L., Deng, H. (2010) Role of tegument proteins in herpesvirus 
assembly and egress. Protein Cell 1, 987-98. 
4. Johnson, D.C., Baines, J.D. (2011) Herpesviruses remodel host membranes for virus 
egress. Nat Rev Microbiol 9, 382-94. 
5. Roizman, B., Taddeo, B. (2007) The strategy of herpes simplex virus replication and 
takeover of the host cell. In Human Herpesviruses: Biology, Therapy and 
Immunoprophylaxis (A. Arvin, G. Campadelli-Fiume, E. Mokarski, P. S. Moore, B. 
Roizman, R. Whitley and K. Yamanishi, eds), Cambridge University Press, Cambridge. 
6. Zaichick, S.V., Bohannon, K.P., Smith, G.A. (2011) Alphaherpesviruses and the 
cytoskeleton in neuronal infections. Viruses 3, 941-81. 
7. Rock, D.L. (1993) The molecular basis of latent infections by alphaherpesviruses. 
Seminars in Virology 4, 157-165. 
8. Deruelle, M.J., Favoreel, H.W. (2011) Keep it in the subfamily: the conserved 
alphaherpesvirus US3 protein kinase. J Gen Virol 92, 18-30. 
9. Tobian, A.A., Quinn, T.C. (2009) Herpes simplex virus type 2 and syphilis infections 
with HIV: an evolving synergy in transmission and prevention. Curr Opin HIV AIDS 4, 
294-9. 
10. Liashkovich, I., Hafezi, W., Kuhn, J.M., Oberleithner, H., Shahin, V. (2011) Nuclear 
delivery mechanism of herpes simplex virus type 1 genome. J Mol Recognit 24, 414-21. 
11. (2011) Virus Taxonomy: Classification and Nomenclature of Viruses, Ninth Report of the 
International Committee on Taxonomy of Viruses. Elsevier Academic Press, San Diego, 
CA. 
12. Arvin, A., Gilden, D. (2013) Varicella-Zoster Virus. In Fields' Virology (D. M. Knipe 
and P. M. Howley, eds), Lippincott, Williams & Wilkins, Philadelphia, PA 2015-2057. 
13. Mori, I., Nishiyama, Y. (2005) Herpes simplex virus and varicella-zoster virus: why do 
these human alphaherpesviruses behave so differently from one another? Rev Med Virol 
15, 393-406. 
14. Thiry, J., Keuser, V., Muylkens, B., Meurens, F., Gogev, S., Vanderplasschen, A., Thiry, 
E. (2006) Ruminant alphaherpesviruses related to bovine herpesvirus 1. Vet Res 37, 169-
90. 
15. Pellett, P.E., Roizman, B. (2007) The Family Herpesviridae: A Brief Introduction. In 
Fields' Virology (D. M. Knipe and P. M. Howley, eds), Lippincott, Williams & Wilkins, 
New York, NY 2479-2499. 
16. Davison, A.J. (2010) Herpesvirus systematics. Vet Microbiol 143, 52-69. 
17. (2012) Virus taxonomy: classification and nomenclature of viruses, Ninth Report of the 
International Committee on Taxonomy of Viruses.  (A. M. Q. King, M. J. Adams, E. B. 
Carstens and E. J. Lefkowitz, eds), Elsevier Academic Press, San Diego, CA. 
18. Pellett, P.E., Roizman, B. (2013) Herpesviridae. In Fields' Virology (D. M. Knipe and P. 
M. Howley, eds), Lippincott, Williams & Wilkins, Philadelphia, PA 1802-1822. 
 206 
19. Deregt, D., Jordan, L.T., van Drunen Littel-van den Hurk, S., Masri, S.A., Tessaro, S.V., 
Gilbert, S.A. (2000) Antigenic and molecular characterization of a herpesvirus isolated 
from a North American elk. Am J Vet Res 61, 1614-8. 
20. Spear, P.G., Roizman, B. (1972) Proteins specified by herpes simplex virus. V. 
Purification and structural proteins of the herpesvirion. J Virol 9, 143-59. 
21. Zhou, Z.H., Chen, D.H., Jakana, J., Rixon, F.J., Chiu, W. (1999) Visualization of 
tegument-capsid interactions and DNA in intact herpes simplex virus type 1 virions. J 
Virol 73, 3210-8. 
22. Furlong, D., Swift, H., Roizman, B. (1972) Arrangement of herpesvirus deoxyribonucleic 
acid in the core. J Virol 10, 1071-4. 
23. Roizman, B., Knipe, D.M., Whitley, R. (2013) Herpes Simplex Viruses. In Fields' 
Virology (D. M. Knipe and P. M. Howley, eds), Lippincott, Williams & Wilkins, 
Philadelphia, PA 1824-1897. 
24. Liu, F., Zhou, Z.H. (2007) Comparative virion structures of human herpesviruses. In 
Human Herpesviruses: Biology, Therapy, and Immunoprophylaxis. (A. Arvin, G. 
Campadelli-Fiume and E. Mocarski, et al., eds), Cambridge University Press, Cambridge. 
25. Klupp, B.G., Granzow, H., Karger, A., Mettenleiter, T.C. (2005) Identification, subviral 
localization, and functional characterization of the pseudorabies virus UL17 protein. J 
Virol 79, 13442-53. 
26. Gibson, W. (1996) Structure and assembly of the virion. Intervirology 39, 389-400. 
27. Liu, B., Stinski, M.F. (1992) Human cytomegalovirus contains a tegument protein that 
enhances transcription from promoters with upstream ATF and AP-1 cis-acting elements. 
J Virol 66, 4434-44. 
28. Everly, D.N., Jr., Feng, P., Mian, I.S., Read, G.S. (2002) mRNA degradation by the 
virion host shutoff (Vhs) protein of herpes simplex virus: genetic and biochemical 
evidence that Vhs is a nuclease. J Virol 76, 8560-71. 
29. Gilbert, M.J., Riddell, S.R., Plachter, B., Greenberg, P.D. (1996) Cytomegalovirus 
selectively blocks antigen processing and presentation of its immediate-early gene 
product. Nature 383, 720-2. 
30. Browne, E.P., Shenk, T. (2003) Human cytomegalovirus UL83-coded pp65 virion protein 
inhibits antiviral gene expression in infected cells. Proc Natl Acad Sci U S A 100, 11439-
44. 
31. Krummenacher, C., Carfi, A., Eisenberg, R.J., Cohen, G.H. (2013) Entry of herpesviruses 
into cells: the enigma variations. Adv Exp Med Biol 790, 178-95. 
32. Spear, P.G., Longnecker, R. (2003) Herpesvirus entry: an update. J Virol 77, 10179-85. 
33. Roizman, B., Knipe, D.M. (2001) Herpes simplex viruses and their replication. In 
Virology (D. M. Knipe, P. M. Howley and E. al., eds), Lippincott, Williams & Wilkins, 
Philadelphia, PA 2399-2460. 
34. Spear, P.G., Eisenberg, R.J., Cohen, G.H. (2000) Three classes of cell surface receptors 
for alphaherpesvirus entry. Virology 275, 1-8. 
35. Reske, A., Pollara, G., Krummenacher, C., Chain, B.M., Katz, D.R. (2007) 
Understanding HSV-1 entry glycoproteins. Rev Med Virol 17, 205-15. 
36. Geraghty, R.J., Krummenacher, C., Cohen, G.H., Eisenberg, R.J., Spear, P.G. (1998) 
Entry of alphaherpesviruses mediated by poliovirus receptor-related protein 1 and 
poliovirus receptor. Science 280, 1618-20. 
 207 
37. Dasika, G.K., Letchworth, G.J., 3rd (1999) Cellular expression of bovine herpesvirus 1 
gD inhibits cell-to-cell spread of two closely related viruses without blocking their 
primary infection. Virology 254, 24-36. 
38. Gross, K.L., Porco, T.C., Grant, R.M. (2004) HIV-1 superinfection and viral diversity. 
AIDS 18, 1513-20. 
39. Fultz, P.N. (2004) HIV-1 superinfections: omens for vaccine efficacy? AIDS 18, 115-9. 
40. Smith, D.M., Richman, D.D., Little, S.J. (2005) HIV superinfection. J Infect Dis 192, 
438-44. 
41. Meurens, F., Schynts, F., Keil, G.M., Muylkens, B., Vanderplasschen, A., Gallego, P., 
Thiry, E. (2004) Superinfection prevents recombination of the alphaherpesvirus bovine 
herpesvirus 1. J Virol 78, 3872-9. 
42. Meurens, F., Keil, G.M., Muylkens, B., Gogev, S., Schynts, F., Negro, S., Wiggers, L., 
Thiry, E. (2004) Interspecific recombination between two ruminant alphaherpesviruses, 
bovine herpesviruses 1 and 5. J Virol 78, 9828-36. 
43. Dasika, G.K., Letchworth, G.J. (2000) Homologous and heterologous interference 
requires bovine herpesvirus-1 glycoprotein D at the cell surface during virus entry. J Gen 
Virol 81, 1041-9. 
44. van Drunen Littel-van den Hurk, S., Braun, R.P., Lewis, P.J., Karvonen, B.C., Baca-
Estrada, M.E., Snider, M., McCartney, D., Watts, T., Babiuk, L.A. (1998) Intradermal 
immunization with a bovine herpesvirus-1 DNA vaccine induces protective immunity in 
cattle. J Gen Virol 79 ( Pt 4), 831-9. 
45. Ligas, M.W., Johnson, D.C. (1988) A herpes simplex virus mutant in which glycoprotein 
D sequences are replaced by beta-galactosidase sequences binds to but is unable to 
penetrate into cells. J Virol 62, 1486-94. 
46. Hanon, E., Keil, G., van Drunen Littel-van den Hurk, S., Griebel, P., Vanderplasschen, 
A., Rijsewijk, F.A., Babiuk, L., Pastoret, P.P. (1999) Bovine herpesvirus 1-induced 
apoptotic cell death: role of glycoprotein D. Virology 257, 191-7. 
47. Zhu, L., Ding, X., Tao, J., Wang, J., Zhao, X., Zhu, G. (2010) Critical role of cholesterol 
in bovine herpesvirus type 1 infection of MDBK cells. Vet Microbiol 144, 51-7. 
48. Bender, F.C., Whitbeck, J.C., Ponce de Leon, M., Lou, H., Eisenberg, R.J., Cohen, G.H. 
(2003) Specific association of glycoprotein B with lipid rafts during herpes simplex virus 
entry. J Virol 77, 9542-52. 
49. Hambleton, S., Steinberg, S.P., Gershon, M.D., Gershon, A.A. (2007) Cholesterol 
dependence of varicella-zoster virion entry into target cells. J Virol 81, 7548-58. 
50. Desplanques, A.S., Nauwynck, H.J., Vercauteren, D., Geens, T., Favoreel, H.W. (2008) 
Plasma membrane cholesterol is required for efficient pseudorabies virus entry. Virology 
376, 339-45. 
51. Fraefel, C., Wirth, U.V., Vogt, B., Schwyzer, M. (1993) Immediate-early transcription 
over covalently joined genome ends of bovine herpesvirus 1: the circ gene. J Virol 67, 
1328-33. 
52. Fuchs, W., Klupp, B.G., Granzow, H., Osterrieder, N., Mettenleiter, T.C. (2002) The 
interacting UL31 and UL34 gene products of pseudorabies virus are involved in egress 
from the host-cell nucleus and represent components of primary enveloped but not 
mature virions. J Virol 76, 364-78. 
53. Mettenleiter, T.C. (2004) Budding events in herpesvirus morphogenesis. Virus Res 106, 
167-80. 
 208 
54. Loret, S., Guay, G., Lippe, R. (2008) Comprehensive characterization of extracellular 
herpes simplex virus type 1 virions. J Virol 82, 8605-18. 
55. Gibbs, E.P.J., Rweyemamu, M.M. (1977) Bovine Herpesviruses. Part 1: Bovine 
herpesvirus 1. Veterinary Bulletin 47, 317-343. 
56. Tikoo, S.K., Campos, M., Babiuk, L.A. (1995) Bovine herpesvirus 1 (BHV-1): biology, 
pathogenesis, and control. Adv Virus Res 45, 191-223. 
57. Ludwig, H. (1983) Bovine Herpesviruses. In The herpesviruses, Volume 2 (B. Roizman, 
ed) Plenum Press, New York, NY 135-214. 
58. Hammerschmidt, W., Ludwig, H., Buhk, H.J. (1988) Specificity of cleavage in 
replicative-form DNA of bovine herpesvirus 1. J Virol 62, 1355-63. 
59. Muylkens, B., Thiry, J., Kirten, P., Schynts, F., Thiry, E. (2007) Bovine herpesvirus 1 
infection and infectious bovine rhinotracheitis. Vet Res 38, 181-209. 
60. Mayfield, J.E., Good, P.J., VanOort, H.J., Campbell, A.R., Reed, D.E. (1983) Cloning 
and cleavage site mapping of DNA from bovine herpesvirus 1 (Cooper strain). J Virol 47, 
259-64. 
61. Schwyzer, M., Ackermann, M. (1996) Molecular virology of ruminant herpesviruses. Vet 
Microbiol 53, 17-29. 
62. Schynts, F., McVoy, M.A., Meurens, F., Detry, B., Epstein, A.L., Thiry, E. (2003) The 
structures of bovine herpesvirus 1 virion and concatemeric DNA: implications for 
cleavage and packaging of herpesvirus genomes. Virology 314, 326-35. 
63. Jacob, R.J., Morse, L.S., Roizman, B. (1979) Anatomy of herpes simplex virus DNA. 
XII. Accumulation of head-to-tail concatemers in nuclei of infected cells and their role in 
the generation of the four isomeric arrangements of viral DNA. J Virol 29, 448-57. 
64. Delhon, G., Moraes, M.P., Lu, Z., Afonso, C.L., Flores, E.F., Weiblen, R., Kutish, G.F., 
Rock, D.L. (2003) Genome of bovine herpesvirus 5. J Virol 77, 10339-47. 
65. Robinson, K.E., Meers, J., Gravel, J.L., McCarthy, F.M., Mahony, T.J. (2008) The 
essential and non-essential genes of Bovine herpesvirus 1. J Gen Virol 89, 2851-63. 
66. Spurzem, J.R., Raz, M., Ito, H., Kelling, C.L., Stine, L.C., Romberger, D.J., Rennard, S.I. 
(1995) Bovine herpesvirus-1 infection reduces bronchial epithelial cell migration to 
extracellular matrix proteins. Am J Physiol 268, L214-20. 
67. Babiuk, L.A., van Drunen Littel-van den Hurk, S., Tikoo, S.K. (1996) Immunology of 
bovine herpesvirus 1 infection. Vet Microbiol 53, 31-42. 
68. Baluyut, C.S., Simonson, R.R., Bemrick, W.J., Maheswaran, S.K. (1981) Interaction of 
Pasteurella haemolytica with bovine neutrophils: identification and partial 
characterization of a cytotoxin. Am J Vet Res 42, 1920-6. 
69. Haig, S.-J. (2011) Adherence of Mannheimia haemolytica to ovine bronchial epithelial 
cells. Bioscience Horizons 4, 50-60. 
70. Cusack, P.M., McMeniman, N., Lean, I.J. (2003) The medicine and epidemiology of 
bovine respiratory disease in feedlots. Aust Vet J 81, 480-7. 
71. Yates, W.D. (1982) A review of infectious bovine rhinotracheitis, shipping fever 
pneumonia and viral-bacterial synergism in respiratory disease of cattle. Can J Comp 
Med 46, 225-63. 
72. Enquist, L.W., Husak, P.J., Banfield, B.W., Smith, G.A. (1998) Infection and spread of 
alphaherpesviruses in the nervous system. Adv Virus Res 51, 237-347. 
73. Srikumaran, S., Kelling, C.L., Ambagala, A. (2007) Immune evasion by pathogens of 
bovine respiratory disease complex. Anim Health Res Rev 8, 215-29. 
 209 
74. Fuchs, M., Hubert, P., Detterer, J., Rziha, H.J. (1999) Detection of bovine herpesvirus 
type 1 in blood from naturally infected cattle by using a sensitive PCR that discriminates 
between wild-type virus and virus lacking glycoprotein E. J Clin Microbiol 37, 2498-507. 
75. Carter, J.J., Weinberg, A.D., Pollard, A., Reeves, R., Magnuson, J.A., Magnuson, N.S. 
(1989) Inhibition of T-lymphocyte mitogenic responses and effects on cell functions by 
bovine herpesvirus 1. J Virol 63, 1525-30. 
76. Hutchings, D.L., Campos, M., Qualtiere, L., Babiuk, L.A. (1990) Inhibition of antigen-
induced and interleukin-2-induced proliferation of bovine peripheral blood leukocytes by 
inactivated bovine herpes virus 1. J Virol 64, 4146-51. 
77. Winkler, M.T., Doster, A., Jones, C. (1999) Bovine herpesvirus 1 can infect CD4(+) T 
lymphocytes and induce programmed cell death during acute infection of cattle. J Virol 
73, 8657-68. 
78. Lipinska, A.D., Koppers-Lalic, D., Rychlowski, M., Admiraal, P., Rijsewijk, F.A., 
Bienkowska-Szewczyk, K., Wiertz, E.J. (2006) Bovine herpesvirus 1 UL49.5 protein 
inhibits the transporter associated with antigen processing despite complex formation 
with glycoprotein M. J Virol 80, 5822-32. 
79. Deshpande, M.S., Ambagala, T.C., Ambagala, A.P., Kehrli, M.E., Jr., Srikumaran, S. 
(2002) Bovine CD18 is necessary and sufficient to mediate Mannheimia (Pasteurella) 
haemolytica leukotoxin-induced cytolysis. Infect Immun 70, 5058-64. 
80. Hughes, H.P., Campos, M., McDougall, L., Beskorwayne, T.K., Potter, A.A., Babiuk, 
L.A. (1994) Regulation of major histocompatibility complex class II expression by 
Pasteurella haemolytica leukotoxin. Infect Immun 62, 1609-15. 
81. Chae, C.H., Gentry, M.J., Confer, A.W., Anderson, G.A. (1990) Resistance to host 
immune defense mechanisms afforded by capsular material of Pasteurella haemolytica, 
serotype 1. Vet Microbiol 25, 241-51. 
82. Cowley, D.J., Clegg, T.A., Doherty, M.L., More, S.J. (2011) Aspects of bovine 
herpesvirus-1 infection in dairy and beef herds in the Republic of Ireland. Acta Vet Scand 
53, 40. 
83. Kahrs, R.F. (1977) Infectious bovine rhinotracheitis: a review and update. J Am Vet Med 
Assoc 171, 1055-64. 
84. Straub, O.C. (1991) BHV1 infections: relevance and spread in Europe. Comp Immunol 
Microbiol Infect Dis 14, 175-86. 
85. Henderson, G., Perng, G.C., Nesburn, A.B., Wechsler, S.L., Jones, C. (2004) The 
latency-related gene encoded by bovine herpesvirus 1 can suppress caspase 3 and caspase 
9 cleavage during productive infection. J Neurovirol 10, 64-70. 
86. Inman, M., Zhou, J., Webb, H., Jones, C. (2004) Identification of a novel bovine 
herpesvirus 1 transcript containing a small open reading frame that is expressed in 
trigeminal ganglia of latently infected cattle. J Virol 78, 5438-47. 
87. Jones, C. (2003) Herpes simplex virus type 1 and bovine herpesvirus 1 latency. Clin 
Microbiol Rev 16, 79-95. 
88. Jones, C., Geiser, V., Henderson, G., Jiang, Y., Meyer, F., Perez, S., Zhang, Y. (2006) 
Functional analysis of bovine herpesvirus 1 (BHV-1) genes expressed during latency. Vet 
Microbiol 113, 199-210. 
89. Ribble, C.S., Meek, A.H., Jim, G.K., Guichon, P.T. (1995) The pattern of fatal fibrinous 
pneumonia (shipping fever) affecting calves in a large feedlot in Alberta (1985-1988). 
Can Vet J 36, 753-7. 
 210 
90. Castrucci, G., Frigeri, F., Salvatori, D., Ferrari, M., Sardonini, Q., Cassai, E., Lo, D.M., 
Rotola, A., Angelini, R. (2002) Vaccination of calves against bovine herpesvirus-1: 
assessment of the protective value of eight vaccines. Comp Immunol Microbiol Infect Dis 
25, 29-41. 
91. Gagea, M.I., Bateman, K.G., van Dreumel, T., McEwen, B.J., Carman, S., Archambault, 
M., Shanahan, R.A., Caswell, J.L. (2006) Diseases and pathogens associated with 
mortality in Ontario beef feedlots. J Vet Diagn Invest 18, 18-28. 
92. Loneragan, G.H., Dargatz, D.A., Morley, P.S., Smith, M.A. (2001) Trends in mortality 
ratios among cattle in US feedlots. J Am Vet Med Assoc 219, 1122-7. 
93. Martin, S.W., Meek, A.H., Davis, D.G., Johnson, J.A., Curtis, R.A. (1982) Factors 
associated with mortality and treatment costs in feedlot calves: the Bruce County Beef 
Project, years 1978, 1979, 1980. Can J Comp Med 46, 341-9. 
94. Strube, W., Auer, S., Block, W., Heinen, E., Kretzdorn, D., Rodenbach, C., Schmeer, N. 
(1996) A gE deleted infectious bovine rhinotracheitis marker vaccine for use in improved 
bovine herpesvirus 1 control programs. Vet Microbiol 53, 181-9. 
95. Yates, W.D., Babiuk, L.A., Jericho, K.W. (1983) Viral-bacterial pneumonia in calves: 
duration of the interaction between bovine herpesvirus 1 and Pasteurella haemolytica. 
Can J Comp Med 47, 257-64. 
96. Ackermann, M., Engels, M. (2006) Pro and contra IBR-eradication. Vet Microbiol 113, 
293-302. 
97. Thiry, E., Muylkens, B., Meurens, F., Gogev, S., Thiry, J., Vanderplasschen, A., Schynts, 
F. (2006) Recombination in the alphaherpesvirus bovine herpesvirus 1. Vet Microbiol 
113, 171-7. 
98. van Drunen Littel-van den Hurk, S., Tikoo, S.K., van den Hurk, J.V., Babiuk, L.A., Van 
Donkersgoed, J. (1997) Protective immunity in cattle following vaccination with 
conventional and marker bovine herpesvirus-1 (BHV1) vaccines. Vaccine 15, 36-44. 
99. van Drunen Littel-van den Hurk, S., Myers, D., Doig, P.A., Karvonen, B., Habermehl, 
M., Babiuk, L.A., Jelinski, M., Van Donkersgoed, J., Schlesinger, K., Rinehart, C. (2001) 
Identification of a mutant bovine herpesvirus-1 (BHV-1) in post-arrival outbreaks of IBR 
in feedlot calves and protection with conventional vaccination. Can J Vet Res 65, 81-8. 
100. Ellis, J., Waldner, C., Rhodes, C., Ricketts, V. (2005) Longevity of protective immunity 
to experimental bovine herpesvirus-1 infection following inoculation with a combination 
modified-live virus vaccine in beef calves. J Am Vet Med Assoc 227, 123-8. 
101. van Drunen Littel-van den Hurk, S., Tikoo, S.K., Liang, X., Babiuk, L.A. (1993) Bovine 
herpesvirus-1 vaccines. Immunol Cell Biol 71 ( Pt 5), 405-20. 
102. Muylkens, B., Meurens, F., Schynts, F., Farnir, F., Pourchet, A., Bardiau, M., Gogev, S., 
Thiry, J., Cuisenaire, A., Vanderplasschen, A., Thiry, E. (2006) Intraspecific bovine 
herpesvirus 1 recombinants carrying glycoprotein E deletion as a vaccine marker are 
virulent in cattle. J Gen Virol 87, 2149-54. 
103. Kalthoff, D., Konig, P., Trapp, S., Beer, M. (2010) Immunization and challenge 
experiments with a new modified live bovine herpesvirus type 1 marker vaccine 
prototype adjuvanted with a co-polymer. Vaccine 28, 5871-7. 
104. Steinman, R.M. (1991) The dendritic cell system and its role in immunogenicity. Annu 
Rev Immunol 9, 271-96. 
105. Hart, D.N. (1997) Dendritic cells: unique leukocyte populations which control the 
primary immune response. Blood 90, 3245-87. 
 211 
106. Banchereau, J., Steinman, R.M. (1998) Dendritic cells and the control of immunity. 
Nature 392, 245-52. 
107. Zitvogel, L., Mayordomo, J.I., Tjandrawan, T., DeLeo, A.B., Clarke, M.R., Lotze, M.T., 
Storkus, W.J. (1996) Therapy of murine tumors with tumor peptide-pulsed dendritic 
cells: dependence on T cells, B7 costimulation, and T helper cell 1-associated cytokines. 
J Exp Med 183, 87-97. 
108. Tuting, T., Storkus, W.J., Falo, L.D., Jr. (1998) DNA immunization targeting the skin: 
molecular control of adaptive immunity. J Invest Dermatol 111, 183-8. 
109. Rodriguez, A., Regnault, A., Kleijmeer, M., Ricciardi-Castagnoli, P., Amigorena, S. 
(1999) Selective transport of internalized antigens to the cytosol for MHC class I 
presentation in dendritic cells. Nat Cell Biol 1, 362-8. 
110. Gil-Torregrosa, B.C., Lennon-Dumenil, A.M., Kessler, B., Guermonprez, P., Ploegh, 
H.L., Fruci, D., van Endert, P., Amigorena, S. (2004) Control of cross-presentation 
during dendritic cell maturation. Eur J Immunol 34, 398-407. 
111. Albert, M.L., Sauter, B., Bhardwaj, N. (1998) Dendritic cells acquire antigen from 
apoptotic cells and induce class I-restricted CTLs. Nature 392, 86-9. 
112. Kamath, A.T., Henri, S., Battye, F., Tough, D.F., Shortman, K. (2002) Developmental 
kinetics and lifespan of dendritic cells in mouse lymphoid organs. Blood 100, 1734-41. 
113. Liu, Y.J. (2001) Dendritic cell subsets and lineages, and their functions in innate and 
adaptive immunity. Cell 106, 259-62. 
114. Banchereau, J., Briere, F., Caux, C., Davoust, J., Lebecque, S., Liu, Y.J., Pulendran, B., 
Palucka, K. (2000) Immunobiology of dendritic cells. Annu Rev Immunol 18, 767-811. 
115. Lotze, M.T., Thomson, A.W. (2001) Dendritic Cells: Biology and Clinical Applications. 
Academic Press 794. 
116. Liu, K., Nussenzweig, M.C. (2010) Development and homeostasis of dendritic cells. Eur 
J Immunol 40, 2099-102. 
117. Van de Walle, G.R., Cox, E., Nauwynck, H., Favoreel, H.W. (2009) The role of dendritic 
cells in alphaherpesvirus infections: archetypes and paradigms. Rev Med Virol 19, 338-
58. 
118. Auffray, C., Emre, Y., Geissmann, F. (2008) Homeostasis of dendritic cell pool in 
lymphoid organs. Nat Immunol 9, 584-6. 
119. Shortman, K., Liu, Y.J. (2002) Mouse and human dendritic cell subtypes. Nat Rev 
Immunol 2, 151-61. 
120. van de Ven, R., van den Hout, M.F., Lindenberg, J.J., Sluijter, B.J., van Leeuwen, P.A., 
Lougheed, S.M., Meijer, S., van den Tol, M.P., Scheper, R.J., de Gruijl, T.D. (2011) 
Characterization of four conventional dendritic cell subsets in human skin-draining 
lymph nodes in relation to T-cell activation. Blood 118, 2502-10. 
121. Shortman, K., Naik, S.H. (2007) Steady-state and inflammatory dendritic-cell 
development. Nat Rev Immunol 7, 19-30. 
122. Dalod, M., Chelbi, R., Malissen, B., Lawrence, T. (2014) Dendritic cell maturation: 
functional specialization through signaling specificity and transcriptional programming. 
EMBO J 33, 1104-1116. 
123. Richters, C.D., Mayen, I., Havenith, C.E., Beelen, R.H., Kamperdijk, E.W. (2002) Rat 
monocyte-derived dendritic cells function and migrate in the same way as isolated tissue 
dendritic cells. J Leukoc Biol 71, 582-7. 
 212 
124. Fitzgerald-Bocarsly, P., Dai, J., Singh, S. (2008) Plasmacytoid dendritic cells and type I 
IFN: 50 years of convergent history. Cytokine Growth Factor Rev 19, 3-19. 
125. Garcia-Sastre, A., Biron, C.A. (2006) Type 1 interferons and the virus-host relationship: a 
lesson in detente. Science 312, 879-82. 
126. Schmidt, S.V., Nino-Castro, A.C., Schultze, J.L. (2012) Regulatory dendritic cells: there 
is more than just immune activation. Front Immunol 3, 274. 
127. Steinman, R.M., Nussenzweig, M.C. (2002) Avoiding horror autotoxicus: the importance 
of dendritic cells in peripheral T cell tolerance. Proc Natl Acad Sci U S A 99, 351-8. 
128. Cyster, J.G. (1999) Chemokines and the homing of dendritic cells to the T cell areas of 
lymphoid organs. J Exp Med 189, 447-50. 
129. Gouwy, M., Struyf, S., Proost, P., Van Damme, J. (2005) Synergy in cytokine and 
chemokine networks amplifies the inflammatory response. Cytokine Growth Factor Rev 
16, 561-80. 
130. Svensson, M., Pfeifer, J., Stockinger, B., Wick, M.J. (1997) Bacterial antigen delivery 
systems: phagocytic processing of bacterial antigens for MHC-I and MHC-II presentation 
to T cells. Behring Inst Mitt, 197-211. 
131. Reis e Sousa, C., Stahl, P.D., Austyn, J.M. (1993) Phagocytosis of antigens by 
Langerhans cells in vitro. J Exp Med 178, 509-19. 
132. Sallusto, F., Cella, M., Danieli, C., Lanzavecchia, A. (1995) Dendritic cells use 
macropinocytosis and the mannose receptor to concentrate macromolecules in the major 
histocompatibility complex class II compartment: downregulation by cytokines and 
bacterial products. J Exp Med 182, 389-400. 
133. Kato, M., Neil, T.K., Clark, G.J., Morris, C.M., Sorg, R.V., Hart, D.N. (1998) cDNA 
cloning of human DEC-205, a putative antigen-uptake receptor on dendritic cells. 
Immunogenetics 47, 442-50. 
134. Jiang, W., Swiggard, W.J., Heufler, C., Peng, M., Mirza, A., Steinman, R.M., 
Nussenzweig, M.C. (1995) The receptor DEC-205 expressed by dendritic cells and 
thymic epithelial cells is involved in antigen processing. Nature 375, 151-5. 
135. Steinman, R.M., Pope, M. (2002) Exploiting dendritic cells to improve vaccine efficacy. 
J Clin Invest 109, 1519-26. 
136. Pardoll, D.M. (2002) Spinning molecular immunology into successful immunotherapy. 
Nat Rev Immunol 2, 227-38. 
137. Luster, A.D. (2002) The role of chemokines in linking innate and adaptive immunity. 
Curr Opin Immunol 14, 129-35. 
138. De Haes, W., Pollard, C., Vanham, G., Rejman, J. (2012) "Wrapped Up" Vaccines in the 
Context of HIV-1 Immunotherapy. In Immunodeficiency (K. Metodiev, ed) InTech. 
139. Kitajima, T., Caceres-Dittmar, G., Tapia, F.J., Jester, J., Bergstresser, P.R., Takashima, 
A. (1996) T cell-mediated terminal maturation of dendritic cells: loss of adhesive and 
phagocytotic capacities. J Immunol 157, 2340-7. 
140. Wimmers, F., Schreibelt, G., Skold, A.E., Figdor, C.G., De Vries, I.J. (2014) Paradigm 
Shift in Dendritic Cell-Based Immunotherapy: From Generated Monocyte-Derived DCs 
to Naturally Circulating DC Subsets. Front Immunol 5, 165. 
141. Summers deLuca, L., Gommerman, J.L. (2012) Fine-tuning of dendritic cell biology by 
the TNF superfamily. Nat Rev Immunol 12, 339-51. 
142. Kalinski, P., Smits, H.H., Schuitemaker, J.H., Vieira, P.L., van Eijk, M., de Jong, E.C., 
Wierenga, E.A., Kapsenberg, M.L. (2000) IL-4 is a mediator of IL-12p70 induction by 
 213 
human Th2 cells: reversal of polarized Th2 phenotype by dendritic cells. J Immunol 165, 
1877-81. 
143. Zietara, N., Lyszkiewicz, M., Puchalka, J., Pei, G., Gutierrez, M.G., Lienenklaus, S., 
Hobeika, E., Reth, M., Martins dos Santos, V.A., Krueger, A., Weiss, S. (2013) 
Immunoglobulins drive terminal maturation of splenic dendritic cells. Proc Natl Acad Sci 
U S A 110, 2282-7. 
144. Kato, K., Takaue, Y., Wakasugi, H. (2001) T-cell-conditioned medium efficiently 
induces the maturation and function of human dendritic cells. J Leukoc Biol 70, 941-9. 
145. Roitt, I., Brostoff, J., Male, D. (2001) Immunology. Mosby, Edinburgh. 
146. Kobelt, D., Lechmann, M., Steinkasserer, A. (2003) The interaction between dendritic 
cells and herpes simplex virus-1. Curr Top Microbiol Immunol 276, 145-61. 
147. de Jong, M.A., de Witte, L., Bolmstedt, A., van Kooyk, Y., Geijtenbeek, T.B. (2008) 
Dendritic cells mediate herpes simplex virus infection and transmission through the C-
type lectin DC-SIGN. J Gen Virol 89, 2398-409. 
148. Kummer, M., Turza, N.M., Muhl-Zurbes, P., Lechmann, M., Boutell, C., Coffin, R.S., 
Everett, R.D., Steinkasserer, A., Prechtel, A.T. (2007) Herpes simplex virus type 1 
induces CD83 degradation in mature dendritic cells with immediate-early kinetics via the 
cellular proteasome. J Virol 81, 6326-38. 
149. Esser, M.T., Marchese, R.D., Kierstead, L.S., Tussey, L.G., Wang, F., Chirmule, N., 
Washabaugh, M.W. (2003) Memory T cells and vaccines. Vaccine 21, 419-30. 
150. Seya, T. (2008) Toll-like receptor and pattern sensing for evoking immune response. Adv 
Drug Deliv Rev 60, 779-81. 
151. Asselin-Paturel, C., Boonstra, A., Dalod, M., Durand, I., Yessaad, N., Dezutter-
Dambuyant, C., Vicari, A., O'Garra, A., Biron, C., Briere, F., Trinchieri, G. (2001) 
Mouse type I IFN-producing cells are immature APCs with plasmacytoid morphology. 
Nat Immunol 2, 1144-50. 
152. Pirhonen, J., Sareneva, T., Kurimoto, M., Julkunen, I., Matikainen, S. (1999) Virus 
infection activates IL-1 beta and IL-18 production in human macrophages by a caspase-1-
dependent pathway. J Immunol 162, 7322-9. 
153. Bjorck, P. (2004) Dendritic cells exposed to herpes simplex virus in vivo do not produce 
IFN-alpha after rechallenge with virus in vitro and exhibit decreased T cell alloreactivity. 
J Immunol 172, 5396-404. 
154. Eisemann, J., Muhl-Zurbes, P., Steinkasserer, A., Kummer, M. (2007) Infection of 
mature dendritic cells with herpes simplex virus type 1 interferes with the interferon 
signaling pathway. Immunobiology 212, 877-86. 
155. Prechtel, A.T., Turza, N.M., Kobelt, D.J., Eisemann, J.I., Coffin, R.S., McGrath, Y., 
Hacker, C., Ju, X., Zenke, M., Steinkasserer, A. (2005) Infection of mature dendritic cells 
with herpes simplex virus type 1 dramatically reduces lymphoid chemokine-mediated 
migration. J Gen Virol 86, 1645-57. 
156. Mandelboim, O., Lieberman, N., Lev, M., Paul, L., Arnon, T.I., Bushkin, Y., Davis, 
D.M., Strominger, J.L., Yewdell, J.W., Porgador, A. (2001) Recognition of 
haemagglutinins on virus-infected cells by NKp46 activates lysis by human NK cells. 
Nature 409, 1055-60. 
157. Pollara, G., Speidel, K., Samady, L., Rajpopat, M., McGrath, Y., Ledermann, J., Coffin, 
R.S., Katz, D.R., Chain, B. (2003) Herpes simplex virus infection of dendritic cells: 
balance among activation, inhibition, and immunity. J Infect Dis 187, 165-78. 
 214 
158. Nopora, K., Bernhard, C.A., Ried, C., Castello, A.A., Murphy, K.M., Marconi, P., 
Koszinowski, U., Brocker, T. (2012) MHC class I cross-presentation by dendritic cells 
counteracts viral immune evasion. Front Immunol 3, 348. 
159. Piqueras, B., Connolly, J., Freitas, H., Palucka, A.K., Banchereau, J. (2006) Upon viral 
exposure, myeloid and plasmacytoid dendritic cells produce 3 waves of distinct 
chemokines to recruit immune effectors. Blood 107, 2613-8. 
160. Schwartz, R.H. (2003) T cell anergy. Annu Rev Immunol 21, 305-34. 
161. Schiavo, R., Baatar, D., Olkhanud, P., Indig, F.E., Restifo, N., Taub, D., Biragyn, A. 
(2006) Chemokine receptor targeting efficiently directs antigens to MHC class I 
pathways and elicits antigen-specific CD8+ T-cell responses. Blood 107, 4597-605. 
162. Dubois, B., Massacrier, C., Vanbervliet, B., Fayette, J., Briere, F., Banchereau, J., Caux, 
C. (1998) Critical role of IL-12 in dendritic cell-induced differentiation of naive B 
lymphocytes. J Immunol 161, 2223-31. 
163. Dubois, B., Vanbervliet, B., Fayette, J., Massacrier, C., Van Kooten, C., Briere, F., 
Banchereau, J., Caux, C. (1997) Dendritic cells enhance growth and differentiation of 
CD40-activated B lymphocytes. J Exp Med 185, 941-51. 
164. Moore, P.A., Belvedere, O., Orr, A., Pieri, K., LaFleur, D.W., Feng, P., Soppet, D., 
Charters, M., Gentz, R., Parmelee, D., Li, Y., Galperina, O., Giri, J., Roschke, V., 
Nardelli, B., Carrell, J., Sosnovtseva, S., Greenfield, W., Ruben, S.M., Olsen, H.S., Fikes, 
J., Hilbert, D.M. (1999) BLyS: member of the tumor necrosis factor family and B 
lymphocyte stimulator. Science 285, 260-3. 
165. Schneider, P., MacKay, F., Steiner, V., Hofmann, K., Bodmer, J.L., Holler, N., Ambrose, 
C., Lawton, P., Bixler, S., Acha-Orbea, H., Valmori, D., Romero, P., Werner-Favre, C., 
Zubler, R.H., Browning, J.L., Tschopp, J. (1999) BAFF, a novel ligand of the tumor 
necrosis factor family, stimulates B cell growth. J Exp Med 189, 1747-56. 
166. Thomma, B.P., Cammue, B.P., Thevissen, K. (2002) Plant defensins. Planta 216, 193-
202. 
167. Lay, F.T., Anderson, M.A. (2005) Defensins--components of the innate immune system 
in plants. Curr Protein Pept Sci 6, 85-101. 
168. Hoffmann, J.A., Hetru, C. (1992) Insect defensins: inducible antibacterial peptides. 
Immunol Today 13, 411-5. 
169. Froy, O., Gurevitz, M. (2003) Arthropod and mollusk defensins--evolution by exon-
shuffling. Trends Genet 19, 684-7. 
170. Bulet, P., Stocklin, R., Menin, L. (2004) Anti-microbial peptides: from invertebrates to 
vertebrates. Immunol Rev 198, 169-84. 
171. Boman, H.G. (1998) Gene-encoded peptide antibiotics and the concept of innate 
immunity: an update review. Scand J Immunol 48, 15-25. 
172. Hilchie, A.L., Wuerth, K., Hancock, R.E. (2013) Immune modulation by multifaceted 
cationic host defense (antimicrobial) peptides. Nat Chem Biol 9, 761-8. 
173. Mookherjee, N., Hancock, R.E. (2007) Cationic host defence peptides: innate immune 
regulatory peptides as a novel approach for treating infections. Cell Mol Life Sci 64, 922-
33. 
174. Mulder, K.C., Lima, L.A., Miranda, V.J., Dias, S.C., Franco, O.L. (2013) Current 
scenario of peptide-based drugs: the key roles of cationic antitumor and antiviral 
peptides. Front Microbiol 4, 321. 
 215 
175. Selsted, M.E., Ouellette, A.J. (2005) Mammalian defensins in the antimicrobial immune 
response. Nat Immunol 6, 551-7. 
176. Lehrer, R.I. (2004) Primate defensins. Nat Rev Microbiol 2, 727-38. 
177. Lehrer, R.I., Ganz, T. (2002) Cathelicidins: a family of endogenous antimicrobial 
peptides. Curr Opin Hematol 9, 18-22. 
178. Durr, U.H., Sudheendra, U.S., Ramamoorthy, A. (2006) LL-37, the only human member 
of the cathelicidin family of antimicrobial peptides. Biochim Biophys Acta 1758, 1408-
25. 
179. Nizet, V., Gallo, R.L. (2003) Cathelicidins and innate defense against invasive bacterial 
infection. Scand J Infect Dis 35, 670-6. 
180. Zanetti, M. (2004) Cathelicidins, multifunctional peptides of the innate immunity. J 
Leukoc Biol 75, 39-48. 
181. Tran, D., Tran, P.A., Tang, Y.Q., Yuan, J., Cole, T., Selsted, M.E. (2002) Homodimeric 
theta-defensins from rhesus macaque leukocytes: isolation, synthesis, antimicrobial 
activities, and bacterial binding properties of the cyclic peptides. J Biol Chem 277, 3079-
84. 
182. Kaiser, V., Diamond, G. (2000) Expression of mammalian defensin genes. J Leukoc Biol 
68, 779-84. 
183. Yang, D., Biragyn, A., Hoover, D.M., Lubkowski, J., Oppenheim, J.J. (2004) Multiple 
roles of antimicrobial defensins, cathelicidins, and eosinophil-derived neurotoxin in host 
defense. Annu Rev Immunol 22, 181-215. 
184. Ganz, T. (2003) Defensins: antimicrobial peptides of innate immunity. Nat Rev Immunol 
3, 710-20. 
185. Diamond, G., Bevins, C.L. (1998) beta-Defensins: endogenous antibiotics of the innate 
host defense response. Clin Immunol Immunopathol 88, 221-5. 
186. Patterson-Delafield, J., Martinez, R.J., Lehrer, R.I. (1980) Microbicidal cationic proteins 
in rabbit alveolar macrophages: a potential host defense mechanism. Infect Immun 30, 
180-92. 
187. Lehrer, R.I., Daher, K., Ganz, T., Selsted, M.E. (1985) Direct inactivation of viruses by 
MCP-1 and MCP-2, natural peptide antibiotics from rabbit leukocytes. J Virol 54, 467-
72. 
188. Lehrer, R.I., Lu, W. (2012) alpha-Defensins in human innate immunity. Immunol Rev 
245, 84-112. 
189. Selsted, M.E., Brown, D.M., DeLange, R.J., Harwig, S.S., Lehrer, R.I. (1985) Primary 
structures of six antimicrobial peptides of rabbit peritoneal neutrophils. J Biol Chem 260, 
4579-84. 
190. Ganz, T., Selsted, M.E., Szklarek, D., Harwig, S.S., Daher, K., Bainton, D.F., Lehrer, R.I. 
(1985) Defensins. Natural peptide antibiotics of human neutrophils. J Clin Invest 76, 
1427-35. 
191. Cunliffe, R.N. (2003) Alpha-defensins in the gastrointestinal tract. Mol Immunol 40, 463-
7. 
192. Quayle, A.J., Porter, E.M., Nussbaum, A.A., Wang, Y.M., Brabec, C., Yip, K.P., Mok, 
S.C. (1998) Gene expression, immunolocalization, and secretion of human defensin-5 in 
human female reproductive tract. Am J Pathol 152, 1247-58. 
193. Eisenhauer, P.B., Harwig, S.S., Lehrer, R.I. (1992) Cryptdins: antimicrobial defensins of 
the murine small intestine. Infect Immun 60, 3556-65. 
 216 
194. Ouellette, A.J., Hsieh, M.M., Nosek, M.T., Cano-Gauci, D.F., Huttner, K.M., Buick, 
R.N., Selsted, M.E. (1994) Mouse Paneth cell defensins: primary structures and 
antibacterial activities of numerous cryptdin isoforms. Infect Immun 62, 5040-7. 
195. Eisenhauer, P.B., Lehrer, R.I. (1992) Mouse neutrophils lack defensins. Infect Immun 60, 
3446-7. 
196. Ouellette, A.J., Miller, S.I., Henschen, A.H., Selsted, M.E. (1992) Purification and 
primary structure of murine cryptdin-1, a Paneth cell defensin. FEBS Lett 304, 146-8. 
197. Ouellette, A.J. (1997) Paneth cells and innate immunity in the crypt microenvironment. 
Gastroenterology 113, 1779-84. 
198. Fjell, C.D., Jenssen, H., Fries, P., Aich, P., Griebel, P., Hilpert, K., Hancock, R.E., 
Cherkasov, A. (2008) Identification of novel host defense peptides and the absence of 
alpha-defensins in the bovine genome. Proteins 73, 420-30. 
199. Diamond, G., Zasloff, M., Eck, H., Brasseur, M., Maloy, W.L., Bevins, C.L. (1991) 
Tracheal antimicrobial peptide, a cysteine-rich peptide from mammalian tracheal mucosa: 
peptide isolation and cloning of a cDNA. Proc Natl Acad Sci U S A 88, 3952-6. 
200. Schonwetter, B.S., Stolzenberg, E.D., Zasloff, M.A. (1995) Epithelial antibiotics induced 
at sites of inflammation. Science 267, 1645-8. 
201. Tarver, A.P., Clark, D.P., Diamond, G., Russell, J.P., Erdjument-Bromage, H., Tempst, 
P., Cohen, K.S., Jones, D.E., Sweeney, R.W., Wines, M., Hwang, S., Bevins, C.L. (1998) 
Enteric beta-defensin: molecular cloning and characterization of a gene with inducible 
intestinal epithelial cell expression associated with Cryptosporidium parvum infection. 
Infect Immun 66, 1045-56. 
202. Michaelson, D., Rayner, J., Couto, M., Ganz, T. (1992) Cationic defensins arise from 
charge-neutralized propeptides: a mechanism for avoiding leukocyte autocytotoxicity? J 
Leukoc Biol 51, 634-9. 
203. Schutte, B.C., McCray, P.B., Jr. (2002) [beta]-defensins in lung host defense. Annu Rev 
Physiol 64, 709-48. 
204. Patil, A., Hughes, A.L., Zhang, G. (2004) Rapid evolution and diversification of 
mammalian alpha-defensins as revealed by comparative analysis of rodent and primate 
genes. Physiol Genomics 20, 1-11. 
205. Lynn, D.J., Lloyd, A.T., Fares, M.A., O'Farrelly, C. (2004) Evidence of positively 
selected sites in mammalian alpha-defensins. Mol Biol Evol 21, 819-27. 
206. Jia, H.P., Schutte, B.C., Schudy, A., Linzmeier, R., Guthmiller, J.M., Johnson, G.K., 
Tack, B.F., Mitros, J.P., Rosenthal, A., Ganz, T., McCray, P.B., Jr. (2001) Discovery of 
new human beta-defensins using a genomics-based approach. Gene 263, 211-8. 
207. Ali, R.S., Falconer, A., Ikram, M., Bissett, C.E., Cerio, R., Quinn, A.G. (2001) 
Expression of the peptide antibiotics human beta defensin-1 and human beta defensin-2 
in normal human skin. J Invest Dermatol 117, 106-11. 
208. Pazgier, M., Hoover, D.M., Yang, D., Lu, W., Lubkowski, J. (2006) Human beta-
defensins. Cell Mol Life Sci 63, 1294-313. 
209. Huang, L., Ching, C.B., Jiang, R., Leong, S.S. (2008) Production of bioactive human 
beta-defensin 5 and 6 in Escherichia coli by soluble fusion expression. Protein Expr Purif 
61, 168-74. 
210. Yamaguchi, Y., Nagase, T., Makita, R., Fukuhara, S., Tomita, T., Tominaga, T., 
Kurihara, H., Ouchi, Y. (2002) Identification of multiple novel epididymis-specific beta-
defensin isoforms in humans and mice. J Immunol 169, 2516-23. 
 217 
211. Sun, L., Finnegan, C.M., Kish-Catalone, T., Blumenthal, R., Garzino-Demo, P., La Terra 
Maggiore, G.M., Berrone, S., Kleinman, C., Wu, Z., Abdelwahab, S., Lu, W., Garzino-
Demo, A. (2005) Human beta-defensins suppress human immunodeficiency virus 
infection: potential role in mucosal protection. J Virol 79, 14318-29. 
212. Quinones-Mateu, M.E., Lederman, M.M., Feng, Z., Chakraborty, B., Weber, J., Rangel, 
H.R., Marotta, M.L., Mirza, M., Jiang, B., Kiser, P., Medvik, K., Sieg, S.F., Weinberg, A. 
(2003) Human epithelial beta-defensins 2 and 3 inhibit HIV-1 replication. Aids 17, F39-
48. 
213. Ferris, L.K., Mburu, Y.K., Mathers, A.R., Fluharty, E.R., Larregina, A.T., Ferris, R.L., 
Falo, L.D., Jr. (2013) Human beta-defensin 3 induces maturation of human langerhans 
cell-like dendritic cells: an antimicrobial peptide that functions as an endogenous 
adjuvant. J Invest Dermatol 133, 460-8. 
214. Yang, D., Chertov, O., Bykovskaia, S.N., Chen, Q., Buffo, M.J., Shogan, J., Anderson, 
M., Schroder, J.M., Wang, J.M., Howard, O.M., Oppenheim, J.J. (1999) Beta-defensins: 
linking innate and adaptive immunity through dendritic and T cell CCR6. Science 286, 
525-8. 
215. Rohrl, J., Yang, D., Oppenheim, J.J., Hehlgans, T. (2010) Human beta-defensin 2 and 3 
and their mouse orthologs induce chemotaxis through interaction with CCR2. J Immunol 
184, 6688-94. 
216. Biragyn, A., Ruffini, P.A., Leifer, C.A., Klyushnenkova, E., Shakhov, A., Chertov, O., 
Shirakawa, A.K., Farber, J.M., Segal, D.M., Oppenheim, J.J., Kwak, L.W. (2002) Toll-
like receptor 4-dependent activation of dendritic cells by beta-defensin 2. Science 298, 
1025-9. 
217. Biragyn, A., Surenhu, M., Yang, D., Ruffini, P.A., Haines, B.A., Klyushnenkova, E., 
Oppenheim, J.J., Kwak, L.W. (2001) Mediators of innate immunity that target immature, 
but not mature, dendritic cells induce antitumor immunity when genetically fused with 
nonimmunogenic tumor antigens. J Immunol 167, 6644-53. 
218. Biragyn, A., Belyakov, I.M., Chow, Y.H., Dimitrov, D.S., Berzofsky, J.A., Kwak, L.W. 
(2002) DNA vaccines encoding human immunodeficiency virus-1 glycoprotein 120 
fusions with proinflammatory chemoattractants induce systemic and mucosal immune 
responses. Blood 100, 1153-9. 
219. Selsted, M.E., Tang, Y.Q., Morris, W.L., McGuire, P.A., Novotny, M.J., Smith, W., 
Henschen, A.H., Cullor, J.S. (1993) Purification, primary structures, and antibacterial 
activities of beta-defensins, a new family of antimicrobial peptides from bovine 
neutrophils. J Biol Chem 268, 6641-8. 
220. Mallow, E.B., Harris, A., Salzman, N., Russell, J.P., DeBerardinis, R.J., Ruchelli, E., 
Bevins, C.L. (1996) Human enteric defensins. Gene structure and developmental 
expression. J Biol Chem 271, 4038-45. 
221. Huttner, K.M., Lambeth, M.R., Burkin, H.R., Burkin, D.J., Broad, T.E. (1998) 
Localization and genomic organization of sheep antimicrobial peptide genes. Gene 206, 
85-91. 
222. Diamond, G., Russell, J.P., Bevins, C.L. (1996) Inducible expression of an antibiotic 
peptide gene in lipopolysaccharide-challenged tracheal epithelial cells. Proc Natl Acad 
Sci U S A 93, 5156-60. 
223. Diamond, G., Bevins, C.L. (1994) Endotoxin upregulates expression of an antimicrobial 
peptide gene in mammalian airway epithelial cells. Chest 105, 51S-52S. 
 218 
224. Russell, J.P., Diamond, G., Tarver, A.P., Scanlin, T.F., Bevins, C.L. (1996) Coordinate 
induction of two antibiotic genes in tracheal epithelial cells exposed to the inflammatory 
mediators lipopolysaccharide and tumor necrosis factor alpha. Infect Immun 64, 1565-8. 
225. Ganz, T., Lehrer, R.I. (1994) Defensins. Curr Opin Immunol 6, 584-9. 
226. Stolzenberg, E.D., Anderson, G.M., Ackermann, M.R., Whitlock, R.H., Zasloff, M. 
(1997) Epithelial antibiotic induced in states of disease. Proc Natl Acad Sci U S A 94, 
8686-90. 
227. Luenser, K., Ludwig, A. (2005) Variability and evolution of bovine beta-defensin genes. 
Genes Immun 6, 115-22. 
228. Aono, S., Li, C., Zhang, G., Kemppainen, R.J., Gard, J., Lu, W., Hu, X., Schwartz, D.D., 
Morrison, E.E., Dykstra, C., Shi, J. (2006) Molecular and functional characterization of 
bovine beta-defensin-1. Vet Immunol Immunopathol 113, 181-90. 
229. Cole, A.M., Ganz, T., Liese, A.M., Burdick, M.D., Liu, L., Strieter, R.M. (2001) Cutting 
edge: IFN-inducible ELR- CXC chemokines display defensin-like antimicrobial activity. 
J Immunol 167, 623-7. 
230. Niyonsaba, F., Someya, A., Hirata, M., Ogawa, H., Nagaoka, I. (2001) Evaluation of the 
effects of peptide antibiotics human beta-defensins-1/-2 and LL-37 on histamine release 
and prostaglandin D(2) production from mast cells. Eur J Immunol 31, 1066-75. 
231. Niyonsaba, F., Iwabuchi, K., Matsuda, H., Ogawa, H., Nagaoka, I. (2002) Epithelial cell-
derived human beta-defensin-2 acts as a chemotaxin for mast cells through a pertussis 
toxin-sensitive and phospholipase C-dependent pathway. Int Immunol 14, 421-6. 
232. Niyonsaba, F., Ogawa, H., Nagaoka, I. (2004) Human beta-defensin-2 functions as a 
chemotactic agent for tumour necrosis factor-alpha-treated human neutrophils. 
Immunology 111, 273-81. 
233. Chen, X., Niyonsaba, F., Ushio, H., Hara, M., Yokoi, H., Matsumoto, K., Saito, H., 
Nagaoka, I., Ikeda, S., Okumura, K., Ogawa, H. (2007) Antimicrobial peptides human 
beta-defensin (hBD)-3 and hBD-4 activate mast cells and increase skin vascular 
permeability. Eur J Immunol 37, 434-44. 
234. Seo, E.S., Blaum, B.S., Vargues, T., De Cecco, M., Deakin, J.A., Lyon, M., Barran, P.E., 
Campopiano, D.J., Uhrin, D. (2010) Interaction of human beta-defensin 2 (HBD2) with 
glycosaminoglycans. Biochemistry 49, 10486-95. 
235. Lillard, J.W., Jr., Boyaka, P.N., Chertov, O., Oppenheim, J.J., McGhee, J.R. (1999) 
Mechanisms for induction of acquired host immunity by neutrophil peptide defensins. 
Proc Natl Acad Sci U S A 96, 651-6. 
236. Niyonsaba, F., Ushio, H., Nakano, N., Ng, W., Sayama, K., Hashimoto, K., Nagaoka, I., 
Okumura, K., Ogawa, H. (2007) Antimicrobial Peptides Human beta-Defensins Stimulate 
Epidermal Keratinocyte Migration, Proliferation and Production of Proinflammatory 
Cytokines and Chemokines. J Invest Dermatol 127, 594-604. 
237. Funderburg, N., Lederman, M.M., Feng, Z., Drage, M.G., Jadlowsky, J., Harding, C.V., 
Weinberg, A., Sieg, S.F. (2007) Human -defensin-3 activates professional antigen-
presenting cells via Toll-like receptors 1 and 2. Proc Natl Acad Sci U S A 104, 18631-5. 
238. Lai, Y., Adhikarakunnathu, S., Bhardwaj, K., Ranjith-Kumar, C.T., Wen, Y., Jordan, 
J.L., Wu, L.H., Dragnea, B., San Mateo, L., Kao, C.C. (2011) LL37 and cationic peptides 
enhance TLR3 signaling by viral double-stranded RNAs. PLoS One 6, e26632. 
 219 
239. Davey, G.M., Wojtasiak, M., Proietto, A.I., Carbone, F.R., Heath, W.R., Bedoui, S. 
(2010) Cutting edge: priming of CD8 T cell immunity to herpes simplex virus type 1 
requires cognate TLR3 expression in vivo. J Immunol 184, 2243-6. 
240. Steinman, R.M., Turley, S., Mellman, I., Inaba, K. (2000) The induction of tolerance by 
dendritic cells that have captured apoptotic cells. J Exp Med 191, 411-6. 
241. Gurunathan, S., Klinman, D.M., Seder, R.A. (2000) DNA vaccines: immunology, 
application, and optimization*. Annu Rev Immunol 18, 927-74. 
242. Davis, H.L., McCluskie, M.J. (1999) DNA vaccines for viral diseases. Microbes Infect 1, 
7-21. 
243. Babiuk, L.A., van Drunen Littel-van den, H., Babiuk, S.L. (1999) Immunization of 
animals: from DNA to the dinner plate. Vet Immunol Immunopathol 72, 189-202. 
244. Van Drunen Littel-van den Hurk, S., Braun, R.P., Lewis, P.J., Karvonen, B.C., Babiuk, 
L.A., Griebel, P.J. (1999) Immunization of neonates with DNA encoding a bovine 
herpesvirus glycoprotein is effective in the presence of maternal antibodies. Viral 
Immunol 12, 67-77. 
245. Ulmer, J.B., Donnelly, J.J., Parker, S.E., Rhodes, G.H., Felgner, P.L., Dwarki, V.J., 
Gromkowski, S.H., Deck, R.R., DeWitt, C.M., Friedman, A., et al. (1993) Heterologous 
protection against influenza by injection of DNA encoding a viral protein. Science 259, 
1745-9. 
246. Donnelly, J.J., Martinez, D., Jansen, K.U., Ellis, R.W., Montgomery, D.L., Liu, M.A. 
(1996) Protection against papillomavirus with a polynucleotide vaccine. J Infect Dis 173, 
314-20. 
247. Wolff, J.A., Malone, R.W., Williams, P., Chong, W., Acsadi, G., Jani, A., Felgner, P.L. 
(1990) Direct gene transfer into mouse muscle in vivo. Science 247, 1465-8. 
248. Tang, D.C., DeVit, M., Johnston, S.A. (1992) Genetic immunization is a simple method 
for eliciting an immune response. Nature 356, 152-4. 
249. Babiuk, L.A., van Drunen Littel-van den Hurk, S., Loehr, B.I., Uwiera, R. (2000) 
Veterinary applications of DNA vaccines. Dev Biol (Basel) 104, 73-81. 
250. Babiuk, L.A., Lewis, J., van den Hurk, S., Braun, R. (1999) DNA immunization: present 
and future. Adv Vet Med 41, 163-79. 
251. van Drunen Littel-van den Hurk, S., Loehr, B.I., Babiuk, L.A. (2001) Immunization of 
livestock with DNA vaccines: current studies and future prospects. Vaccine 19, 2474-9. 
252. Ulmer, J.B., Wahren, B., Liu, M.A. (2006) Gene-based vaccines: recent technical and 
clinical advances. Trends Mol Med 12, 216-22. 
253. Boyle, J.S., Koniaras, C., Lew, A.M. (1997) Influence of cellular location of expressed 
antigen on the efficacy of DNA vaccination: cytotoxic T lymphocyte and antibody 
responses are suboptimal when antigen is cytoplasmic after intramuscular DNA 
immunization. Int Immunol 9, 1897-906. 
254. Drew, D.R., Lightowlers, M., Strugnell, R.A. (2000) Humoral immune responses to DNA 
vaccines expressing secreted, membrane bound and non-secreted forms of the Tania ovis 
45W antigen. Vaccine 18, 2522-32. 
255. Dyer, C.M., Zhan, Y., Brady, J.L., Carbone, F.R., Smyth, M.J., Lew, A.M. (2004) 
Unexpectedly, induction of cytotoxic T lymphocytes enhances the humoral response after 
DNA immunization. Blood 103, 3073-5. 
256. Roy, M.J., Wu, M.S., Barr, L.J., Fuller, J.T., Tussey, L.G., Speller, S., Culp, J., 
Burkholder, J.K., Swain, W.F., Dixon, R.M., Widera, G., Vessey, R., King, A., Ogg, G., 
 220 
Gallimore, A., Haynes, J.R., Heydenburg Fuller, D. (2000) Induction of antigen-specific 
CD8+ T cells, T helper cells, and protective levels of antibody in humans by particle-
mediated administration of a hepatitis B virus DNA vaccine. Vaccine 19, 764-78. 
257. Justewicz, D.M., Webster, R.G. (1996) Long-term maintenance of B cell immunity to 
influenza virus hemagglutinin in mice following DNA-based immunization. Virology 
224, 10-7. 
258. Deck, R.R., DeWitt, C.M., Donnelly, J.J., Liu, M.A., Ulmer, J.B. (1997) Characterization 
of humoral immune responses induced by an influenza hemagglutinin DNA vaccine. 
Vaccine 15, 71-8. 
259. Kang, Y., Calvo, P.A., Daly, T.M., Long, C.A. (1998) Comparison of humoral immune 
responses elicited by DNA and protein vaccines based on merozoite surface protein-1 
from Plasmodium yoelii, a rodent malaria parasite. J Immunol 161, 4211-9. 
260. Feltquate, D.M., Heaney, S., Webster, R.G., Robinson, H.L. (1997) Different T helper 
cell types and antibody isotypes generated by saline and gene gun DNA immunization. J 
Immunol 158, 2278-84. 
261. Leitner, W.W., Seguin, M.C., Ballou, W.R., Seitz, J.P., Schultz, A.M., Sheehy, M.J., 
Lyon, J.A. (1997) Immune responses induced by intramuscular or gene gun injection of 
protective deoxyribonucleic acid vaccines that express the circumsporozoite protein from 
Plasmodium berghei malaria parasites. J Immunol 159, 6112-9. 
262. Torres, C.A., Iwasaki, A., Barber, B.H., Robinson, H.L. (1997) Differential dependence 
on target site tissue for gene gun and intramuscular DNA immunizations. J Immunol 158, 
4529-32. 
263. Braun, R.P., Babiuk, L.A., Loehr, B.I., van Drunen Littel-van den, H. (1999) Particle-
mediated DNA immunization of cattle confers long-lasting immunity against bovine 
herpesvirus-1. Virology 265, 46-56. 
264. Loehr, B.I., Pontarollo, R., Rankin, R., Latimer, L., Willson, P., Babiuk, L.A., van 
Drunen Littel-van den Hurk, S. (2001) Priming by DNA immunization augments T-cell 
responses induced by modified live bovine herpesvirus vaccine. J Gen Virol 82, 3035-43. 
265. Loehr, B.I., Willson, P., Babiuk, L.A., van Drunen Littel-van den, H. (2000) Gene gun-
mediated DNA immunization primes development of mucosal immunity against bovine 
herpesvirus 1 in cattle. J Virol 74, 6077-86. 
266. Corr, M., Lee, D.J., Carson, D.A., Tighe, H. (1996) Gene vaccination with naked plasmid 
DNA: mechanism of CTL priming. J Exp Med 184, 1555-60. 
267. Doe, B., Selby, M., Barnett, S., Baenziger, J., Walker, C.M. (1996) Induction of cytotoxic 
T lymphocytes by intramuscular immunization with plasmid DNA is facilitated by bone 
marrow-derived cells. Proc Natl Acad Sci U S A 93, 8578-83. 
268. Cho, J.H., Youn, J.W., Sung, Y.C. (2001) Cross-priming as a predominant mechanism 
for inducing CD8(+) T cell responses in gene gun DNA immunization. J Immunol 167, 
5549-57. 
269. Casares, S., Inaba, K., Brumeanu, T.D., Steinman, R.M., Bona, C.A. (1997) Antigen 
presentation by dendritic cells after immunization with DNA encoding a major 
histocompatibility complex class II-restricted viral epitope. J Exp Med 186, 1481-6. 
270. Whitton, J.L., Zhang, J. (1995) Principles of cytotoxic T lymphocyte induction and 
recognition. Curr Top Microbiol Immunol 202, 247-59. 
 221 
271. Porgador, A., Irvine, K.R., Iwasaki, A., Barber, B.H., Restifo, N.P., Germain, R.N. 
(1998) Predominant role for directly transfected dendritic cells in antigen presentation to 
CD8+ T cells after gene gun immunization. J Exp Med 188, 1075-82. 
272. Fonteneau, J.F., Kavanagh, D.G., Lirvall, M., Sanders, C., Cover, T.L., Bhardwaj, N., 
Larsson, M. (2003) Characterization of the MHC class I cross-presentation pathway for 
cell-associated antigens by human dendritic cells. Blood 102, 4448-55. 
273. Kleijmeer, M.J., Escola, J.M., UytdeHaag, F.G., Jakobson, E., Griffith, J.M., Osterhaus, 
A.D., Stoorvogel, W., Melief, C.J., Rabouille, C., Geuze, H.J. (2001) Antigen loading of 
MHC class I molecules in the endocytic tract. Traffic 2, 124-37. 
274. Wakim, L.M., Bevan, M.J. (2011) Cross-dressed dendritic cells drive memory CD8+ T-
cell activation after viral infection. Nature 471, 629-32. 
275. Condon, C., Watkins, S.C., Celluzzi, C.M., Thompson, K., Falo, L.D., Jr. (1996) DNA-
based immunization by in vivo transfection of dendritic cells. Nat Med 2, 1122-8. 
276. van Donkersgoed, J., Klassen, P. (1995) Serological study of a modified-live virus IBR 
vaccine given to feedlot calves after arrival. Can Vet J 36, 394. 
277. Castrucci, G., Frigeri, F., Salvatori, D., Ferrari, M., Dico, M.L., Rotola, A., Sardonini, Q., 
Petrini, S., Cassai, E. (2002) A study on latency in calves by five vaccines against bovine 
herpesvirus-1 infection. Comp Immunol Microbiol Infect Dis 25, 205-15. 
278. van Donkersgoed, J. (1991) Diagnosing and managing the respiratory form of infectious 
bovine rhinotracheitis. Veterinary Medicine 1, 86. 
279. Radostits, O.M., et. al. (2000) Bovine Herpesviruses. In Veterinary Medicine: a textbook 
of the diseases of cattle, sheep, pigs, goats and horses (O. M. Radostits, ed) W. B. 
Saunders Co. Ltd., New York, NY. 1173. 
280. Manickan, E., Kanangat, S., Rouse, R.J., Yu, Z., Rouse, B.T. (1997) Enhancement of 
immune response to naked DNA vaccine by immunization with transfected dendritic 
cells. J Leukoc Biol 61, 125-32. 
281. Steinman, R.M., Hemmi, H. (2006) Dendritic cells: translating innate to adaptive 
immunity. Curr Top Microbiol Immunol 311, 17-58. 
282. Pantel, A., Cheong, C., Dandamudi, D., Shrestha, E., Mehandru, S., Brane, L., Ruane, D., 
Teixeira, A., Bozzacco, L., Steinman, R.M., Longhi, M.P. (2012) A new synthetic TLR4 
agonist, GLA, allows dendritic cells targeted with antigen to elicit Th1 T-cell immunity 
in vivo. Eur J Immunol 42, 101-9. 
283. Steinman, R.M. (2012) Decisions about dendritic cells: past, present, and future. Annu 
Rev Immunol 30, 1-22. 
284. Desmet, C.J., Ishii, K.J. (2012) Nucleic acid sensing at the interface between innate and 
adaptive immunity in vaccination. Nat Rev Immunol 12, 479-91. 
285. Sparwasser, T., Koch, E.S., Vabulas, R.M., Heeg, K., Lipford, G.B., Ellwart, J.W., 
Wagner, H. (1998) Bacterial DNA and immunostimulatory CpG oligonucleotides trigger 
maturation and activation of murine dendritic cells. Eur J Immunol 28, 2045-54. 
286. Bachmann, M.F., Kopf, M., Marsland, B.J. (2006) Chemokines: more than just road 
signs. Nat Rev Immunol 6, 159-64. 
287. Hoover, D.M., Chertov, O., Lubkowski, J. (2001) The structure of human beta-defensin-
1: new insights into structural properties of beta-defensins. J Biol Chem 276, 39021-6. 
288. Bell, D., Young, J.W., Banchereau, J. (1999) Dendritic cells. Adv Immunol 72, 255-324. 
289. Caminschi, I., Lahoud, M.H., Shortman, K. (2009) Enhancing immune responses by 
targeting antigen to DC. Eur J Immunol 39, 931-8. 
 222 
290. Sallusto, F., Schaerli, P., Loetscher, P., Schaniel, C., Lenig, D., Mackay, C.R., Qin, S., 
Lanzavecchia, A. (1998) Rapid and coordinated switch in chemokine receptor expression 
during dendritic cell maturation. Eur J Immunol 28, 2760-9. 
291. Dieu, M.C., Vanbervliet, B., Vicari, A., Bridon, J.M., Oldham, E., Ait-Yahia, S., Briere, 
F., Zlotnik, A., Lebecque, S., Caux, C. (1998) Selective recruitment of immature and 
mature dendritic cells by distinct chemokines expressed in different anatomic sites. J Exp 
Med 188, 373-86. 
292. Tacken, P.J., Torensma, R., Figdor, C.G. (2006) Targeting antigens to dendritic cells in 
vivo. Immunobiology 211, 599-608. 
293. Presicce, P., Giannelli, S., Taddeo, A., Villa, M.L., Della Bella, S. (2009) Human 
defensins activate monocyte-derived dendritic cells, promote the production of 
proinflammatory cytokines, and up-regulate the surface expression of CD91. J Leukoc 
Biol 86, 941-8. 
294. Rohrl, J., Yang, D., Oppenheim, J.J., Hehlgans, T. (2008) Identification and Biological 
Characterization of Mouse beta-defensin 14, the orthologue of human beta-defensin 3. J 
Biol Chem 283, 5414-9. 
295. Rohrl, J., Yang, D., Oppenheim, J.J., Hehlgans, T. (2010) Specific binding and 
chemotactic activity of mBD4 and its functional orthologue hBD2 to CCR6-expressing 
cells. J Biol Chem 285, 7028-34. 
296. Sallusto, F., Palermo, B., Lenig, D., Miettinen, M., Matikainen, S., Julkunen, I., Forster, 
R., Burgstahler, R., Lipp, M., Lanzavecchia, A. (1999) Distinct patterns and kinetics of 
chemokine production regulate dendritic cell function. Eur J Immunol 29, 1617-25. 
297. Morgera, F., Pacor, S., Creatti, L., Antcheva, N., Vaccari, L., Tossi, A. (2011) Effects on 
APC antigen presenting cells of short-term interaction with the human human host 
defense peptide beta-defensin 2. Biochem J 436, 537-46. 
298. Vanbervliet, B., Homey, B., Durand, I., Massacrier, C., Ait-Yahia, S., de Bouteiller, O., 
Vicari, A., Caux, C. (2002) Sequential involvement of CCR2 and CCR6 ligands for 
immature dendritic cell recruitment: possible role at inflamed epithelial surfaces. Eur J 
Immunol 32, 231-42. 
299. Stebbing, J., Savage, P., Patterson, S., Gazzard, B. (2004) All for CD91 and CD91 for all. 
J Antimicrob Chemother 53, 1-3. 
300. Oppenheim, J.J., Yang, D. (2005) Alarmins: chemotactic activators of immune responses. 
Curr Opin Immunol 17, 359-65. 
301. Elahi, S., Buchanan, R.M., Attah-Poku, S., Townsend, H.G., Babiuk, L.A., Gerdts, V. 
(2006) The host defense peptide beta-defensin 1 confers protection against Bordetella 
pertussis in newborn piglets. Infect Immun 74, 2338-52. 
302. Hiratsuka, T., Nakazato, M., Date, Y., Ashitani, J., Minematsu, T., Chino, N., Matsukura, 
S. (1998) Identification of human beta-defensin-2 in respiratory tract and plasma and its 
increase in bacterial pneumonia. Biochem Biophys Res Commun 249, 943-7. 
303. Zasloff, M. (1987) Magainins, a class of antimicrobial peptides from Xenopus skin: 
isolation, characterization of two active forms, and partial cDNA sequence of a precursor. 
Proc Natl Acad Sci U S A 84, 5449-53. 
304. Good, L., Nielsen, P.E. (1998) Inhibition of translation and bacterial growth by peptide 
nucleic acid targeted to ribosomal RNA. Proc Natl Acad Sci U S A 95, 2073-6. 
 223 
305. Shen, Y., Liu, J., Estiu, G., Isin, B., Ahn, Y.Y., Lee, D.S., Barabasi, A.L., Kapatral, V., 
Wiest, O., Oltvai, Z.N. (2010) Blueprint for antimicrobial hit discovery targeting 
metabolic networks. Proc Natl Acad Sci U S A 107, 1082-7. 
306. Garcia, J.R., Krause, A., Schulz, S., Rodriguez-Jimenez, F.J., Kluver, E., Adermann, K., 
Forssmann, U., Frimpong-Boateng, A., Bals, R., Forssmann, W.G. (2001) Human beta-
defensin 4: a novel inducible peptide with a specific salt-sensitive spectrum of 
antimicrobial activity. Faseb J 15, 1819-21. 
307. Norimatsu, M., Harris, J., Chance, V., Dougan, G., Howard, C.J., Villarreal-Ramos, B. 
(2003) Differential response of bovine monocyte-derived macrophages and dendritic 
cells to infection with Salmonella typhimurium in a low-dose model in vitro. Immunology 
108, 55-61. 
308. Howard, C.J., Sopp, P., Brownlie, J., Kwong, L.S., Parsons, K.R., Taylor, G. (1997) 
Identification of two distinct populations of dendritic cells in afferent lymph that vary in 
their ability to stimulate T cells. J Immunol 159, 5372-82. 
309. Werling, D., Hope, J.C., Chaplin, P., Collins, R.A., Taylor, G., Howard, C.J. (1999) 
Involvement of caveolae in the uptake of respiratory syncytial virus antigen by dendritic 
cells. J Leukoc Biol 66, 50-8. 
310. van Drunen Littel-van den Hurk, S., Van Donkersgoed, J., Kowalski, J., van den Hurk, 
J.V., Harland, R., Babiuk, L.A., Zamb, T.J. (1994) A subunit gIV vaccine, produced by 
transfected mammalian cells in culture, induces mucosal immunity against bovine 
herpesvirus-1 in cattle. Vaccine 12, 1295-302. 
311. Manoj, S., Griebel, P.J., Babiuk, L.A., van Drunen Littel-van den Hurk, S. (2004) 
Modulation of immune responses to bovine herpesvirus-1 in cattle by immunization with 
a DNA vaccine encoding glycoprotein D as a fusion protein with bovine CD154. 
Immunology 112, 328-38. 
312. Glew, E.J., Carr, B.V., Brackenbury, L.S., Hope, J.C., Charleston, B., Howard, C.J. 
(2003) Differential effects of bovine viral diarrhoea virus on monocytes and dendritic 
cells. J Gen Virol 84, 1771-80. 
313. Huang, Y., Babiuk, L.A., van Drunen Littel-van den Hurk, S. (2005) Immunization with 
a bovine herpesvirus 1 glycoprotein B DNA vaccine induces cytotoxic T-lymphocyte 
responses in mice and cattle. J Gen Virol 86, 887-98. 
314. Frevert, C.W., Wong, V.A., Goodman, R.B., Goodwin, R., Martin, T.R. (1998) Rapid 
fluorescence-based measurement of neutrophil migration in vitro. J Immunol Methods 
213, 41-52. 
315. Yang, D., Chen, Q., Chertov, O., Oppenheim, J.J. (2000) Human neutrophil defensins 
selectively chemoattract naive T and immature dendritic cells. J Leukoc Biol 68, 9-14. 
316. Nagase, H., Yamaguchi, M., Jibiki, S., Yamada, H., Ohta, K., Kawasaki, H., Yoshie, O., 
Yamamoto, K., Morita, Y., Hirai, K. (1999) Eosinophil chemotaxis by chemokines: a 
study by a simple photometric assay. Allergy 54, 944-50. 
317. Falk, W., Goodwin, R.H., Jr., Leonard, E.J. (1980) A 48-well micro chemotaxis assembly 
for rapid and accurate measurement of leukocyte migration. J Immunol Methods 33, 239-
47. 
318. Gliddon, D.R., Hope, J.C., Brooke, G.P., Howard, C.J. (2004) DEC-205 expression on 
migrating dendritic cells in afferent lymph. Immunology 111, 262-72. 
 224 
319. Landi, A., Babiuk, L.A., van Drunen Littel-van den Hurk, S. (2007) High transfection 
efficiency, gene expression, and viability of monocyte-derived human dendritic cells after 
nonviral gene transfer. J Leukoc Biol 82, 849-60. 
320. Riegler, S., Hebart, H., Einsele, H., Brossart, P., Jahn, G., Sinzger, C. (2000) Monocyte-
derived dendritic cells are permissive to the complete replicative cycle of human 
cytomegalovirus. J Gen Virol 81, 393-9. 
321. Howard, C.J., Brooke, G.P., Werling, D., Sopp, P., Hope, J.C., Parsons, K.R., Collins, 
R.A. (1999) Dendritic cells in cattle: phenotype and function. Vet Immunol 
Immunopathol 72, 119-24. 
322. Howard, C.J., Hope, J.C., Villarreal-Ramos, B. (2004) Contribution of in vivo and ex 
vivo studies to understanding the role of antigen-presenting cells and T cell subsets in 
immunity to cattle diseases. Anim Health Res Rev 5, 1-13. 
323. Howard, C.J., Sopp, P., Brownlie, J., Parsons, K.R., Kwong, L.S., Collins, R.A. (1996) 
Afferent lymph veiled cells stimulate proliferative responses in allogeneic CD4+ and 
CD8+ T cells but not gamma delta TCR+ T cells. Immunology 88, 558-64. 
324. Mirkovitch, J., Konig, A., Sauter, K.S., Brcic, M., Hope, J.C., Howard, C.J., Jungi, T.W. 
(2006) Single-cell analysis divides bovine monocyte-derived dendritic cells into subsets 
expressing either high or low levels of inducible nitric oxide synthase. Vet Immunol 
Immunopathol 114, 1-14. 
325. MacHugh, N.D., Bensaid, A., Davis, W.C., Howard, C.J., Parsons, K.R., Jones, B., 
Kaushal, A. (1988) Characterization of a bovine thymic differentiation antigen analogous 
to CD1 in the human. Scand J Immunol 27, 541-7. 
326. Cella, M., Sallusto, F., Lanzavecchia, A. (1997) Origin, maturation and antigen 
presenting function of dendritic cells. Curr Opin Immunol 9, 10-6. 
327. Gliddon, D.R., Howard, C.J. (2002) CD26 is expressed on a restricted subpopulation of 
dendritic cells in vivo. Eur J Immunol 32, 1472-81. 
328. Howard, C.J., Charleston, B., Stephens, S.A., Sopp, P., Hope, J.C. (2004) The role of 
dendritic cells in shaping the immune response. Anim Health Res Rev 5, 191-5. 
329. Howard, C.J., Collins, R.A., Sopp, P., Brooke, G.P., Kwong, L.S., Parsons, K.R., 
Weynants, V., Letesson, J.J., Bembridge, G.P. (1999) T-cell responses and the influence 
of dendritic cells in cattle. Adv Vet Med 41, 275-88. 
330. Hope, J.C., Whelan, A.O., Hewinson, R.G., Vordermeier, M., Howard, C.J. (2003) 
Maturation of bovine dendritic cells by lipopeptides. Vet Immunol Immunopathol 95, 21-
31. 
331. Norimatsu, M., Chance, V., Dougan, G., Howard, C.J., Villarreal-Ramos, B. (2004) Live 
Salmonella enterica serovar Typhimurium (S. Typhimurium) elicit dendritic cell 
responses that differ from those induced by killed S. Typhimurium. Vet Immunol 
Immunopathol 98, 193-201. 
332. Werling, D., Collins, R.A., Taylor, G., Howard, C.J. (2002) Cytokine responses of bovine 
dendritic cells and T cells following exposure to live or inactivated bovine respiratory 
syncytial virus. J Leukoc Biol 72, 297-304. 
333. Bauer, F., Schweimer, K., Kluver, E., Conejo-Garcia, J.R., Forssmann, W.G., Rosch, P., 
Adermann, K., Sticht, H. (2001) Structure determination of human and murine beta-
defensins reveals structural conservation in the absence of significant sequence similarity. 
Protein Sci 10, 2470-9. 
 225 
334. Wu, Z., Hoover, D.M., Yang, D., Boulegue, C., Santamaria, F., Oppenheim, J.J., 
Lubkowski, J., Lu, W. (2003) Engineering disulfide bridges to dissect antimicrobial and 
chemotactic activities of human beta-defensin 3. Proc Natl Acad Sci U S A 100, 8880-5. 
335. Ahmed, A.K., Schaffer, S.W., Wetlaufer, D.B. (1975) Nonenzymic reactivation of 
reduced bovine pancreatic ribonuclease by air oxidation and by glutathione 
oxidoreduction buffers. J Biol Chem 250, 8477-82. 
336. Ferrer, M., Woodward, C., Barany, G. (1992) Solid-phase synthesis of bovine pancreatic 
trypsin inhibitor (BPTI) and two analogues. A chemical approach for evaluating the role 
of disulfide bridges in protein folding and stability. Int J Pept Protein Res 40, 194-207. 
337. Tuting, T. (1999) The immunology of cutaneous DNA immunization. Curr Opin Mol 
Ther 1, 216-25. 
338. Mwangi, W., Brown, W.C., Splitter, G.A., Zhuang, Y., Kegerreis, K., Palmer, G.H. 
(2005) Enhancement of antigen acquisition by dendritic cells and MHC class II-restricted 
epitope presentation to CD4+ T cells using VP22 DNA vaccine vectors that promote 
intercellular spreading following initial transfection. J Leukoc Biol 78, 401-11. 
339. Zhuang, Y., Mwangi, W., Brown, W.C., Davis, W.C., Hope, J.C., Palmer, G.H. (2006) 
Characterization of a phenotypically unique population of CD13+ dendritic cells resident 
in the spleen. Clin Vaccine Immunol 13, 1064-9. 
340. Pinchuk, L.M., Boyd, B.L., Kruger, E.F., Roditi, I., Furger, A. (2003) Bovine dendritic 
cells generated from monocytes and bone marrow progenitors regulate immunoglobulin 
production in peripheral blood B cells. Comp Immunol Microbiol Infect Dis 26, 233-49. 
341. Mwangi, W., Brown, W.C., Splitter, G.A., Davies, C.J., Howard, C.J., Hope, J.C., Aida, 
Y., Zhuang, Y., Hunter, B.J., Palmer, G.H. (2007) DNA vaccine construct incorporating 
intercellular trafficking and intracellular targeting motifs effectively primes and induces 
memory B- and T-cell responses in outbred animals. Clin Vaccine Immunol 14, 304-11. 
342. Mena, A., Nichani, A.K., Popowych, Y., Ioannou, X.P., Godson, D.L., Mutwiri, G.K., 
Hecker, R., Babiuk, L.A., Griebel, P. (2003) Bovine and ovine blood mononuclear 
leukocytes differ markedly in innate immune responses induced by Class A and Class B 
CpG-oligodeoxynucleotide. Oligonucleotides 13, 245-59. 
343. Wattegedera, S., Sills, K., Howard, C.J., Hope, J.C., McInnes, C.J., Entrican, G. (2004) 
Variability in cytokine production and cell proliferation by mitogen-activated ovine 
peripheral blood mononuclear cells: modulation by interleukin (IL)-10 and IL-12. Vet 
Immunol Immunopathol 102, 67-76. 
344. Mwangi, W., Brown, W.C., Lewin, H.A., Howard, C.J., Hope, J.C., Baszler, T.V., 
Caplazi, P., Abbott, J., Palmer, G.H. (2002) DNA-encoded fetal liver tyrosine kinase 3 
ligand and granulocyte macrophage-colony-stimulating factor increase dendritic cell 
recruitment to the inoculation site and enhance antigen-specific CD4+ T cell responses 
induced by DNA vaccination of outbred animals. J Immunol 169, 3837-46. 
345. Dhople, V., Krukemeyer, A., Ramamoorthy, A. (2006) The human beta-defensin-3, an 
antibacterial peptide with multiple biological functions. Biochim Biophys Acta 1758, 
1499-512. 
346. Kluver, E., Adermann, K., Schulz, A. (2006) Synthesis and structure-activity relationship 
of beta-defensins, multi-functional peptides of the immune system. J Pept Sci 12, 243-57. 
347. Routsias, J.G., Karagounis, P., Parvulesku, G., Legakis, N.J., Tsakris, A. (2010) In vitro 
bactericidal activity of human beta-defensin 2 against nosocomial strains. Peptides 31, 
1654-60. 
 226 
348. Taylor, K., Barran, P.E., Dorin, J.R. (2008) Structure-activity relationships in beta-
defensin peptides. Biopolymers 90, 1-7. 
349. Scudiero, O., Galdiero, S., Cantisani, M., Di Noto, R., Vitiello, M., Galdiero, M., 
Naclerio, G., Cassiman, J.J., Pedone, C., Castaldo, G., Salvatore, F. (2010) Novel 
synthetic, salt-resistant analogs of human beta-defensins 1 and 3 endowed with enhanced 
antimicrobial activity. Antimicrob Agents Chemother 54, 2312-22. 
350. Hoover, D.M., Wu, Z., Tucker, K., Lu, W., Lubkowski, J. (2003) Antimicrobial 
characterization of human beta-defensin 3 derivatives. Antimicrob Agents Chemother 47, 
2804-9. 
351. Kluver, E., Schulz-Maronde, S., Scheid, S., Meyer, B., Forssmann, W.G., Adermann, K. 
(2005) Structure-activity relation of human beta-defensin 3: influence of disulfide bonds 
and cysteine substitution on antimicrobial activity and cytotoxicity. Biochemistry 44, 
9804-16. 
352. Circo, R., Skerlavaj, B., Gennaro, R., Amoroso, A., Zanetti, M. (2002) Structural and 
functional characterization of hBD-1(Ser35), a peptide deduced from a DEFB1 
polymorphism. Biochem Biophys Res Commun 293, 586-92. 
353. Taylor, K., McCullough, B., Clarke, D.J., Langley, R.J., Pechenick, T., Hill, A., 
Campopiano, D.J., Barran, P.E., Dorin, J.R., Govan, J.R. (2007) Covalent dimer species 
of beta-defensin Defr1 display potent antimicrobial activity against multidrug-resistant 
bacterial pathogens. Antimicrob Agents Chemother 51, 1719-24. 
354. Harder, J., Bartels, J., Christophers, E., Schroder, J.M. (2001) Isolation and 
characterization of human beta -defensin-3, a novel human inducible peptide antibiotic. J 
Biol Chem 276, 5707-13. 
355. Kluver, E., Schulz, A., Forssmann, W.G., Adermann, K. (2002) Chemical synthesis of 
beta-defensins and LEAP-1/hepcidin. J Pept Res 59, 241-8. 
356. Schulz, A., Kluver, E., Schulz-Maronde, S., Adermann, K. (2005) Engineering disulfide 
bonds of the novel human beta-defensins hBD-27 and hBD-28: differences in disulfide 
formation and biological activity among human beta-defensins. Biopolymers 80, 34-49. 
357. Krishnakumari, V., Sharadadevi, A., Singh, S., Nagaraj, R. (2003) Single disulfide and 
linear analogues corresponding to the carboxy-terminal segment of bovine beta-defensin-
2: effects of introducing the beta-hairpin nucleating sequence d-pro-gly on antibacterial 
activity and Biophysical properties. Biochemistry 42, 9307-15. 
358. Mandal, M., Jagannadham, M.V., Nagaraj, R. (2002) Antibacterial activities and 
conformations of bovine beta-defensin BNBD-12 and analogs:structural and disulfide 
bridge requirements for activity. Peptides 23, 413-8. 
359. Boniotto, M., Antcheva, N., Zelezetsky, I., Tossi, A., Palumbo, V., Verga Falzacappa, 
M.V., Sgubin, S., Braida, L., Amoroso, A., Crovella, S. (2003) A study of host defence 
peptide beta-defensin 3 in primates. Biochem J 374, 707-14. 
360. Bensch, K.W., Raida, M., Magert, H.J., Schulz-Knappe, P., Forssmann, W.G. (1995) 
hBD-1: a novel beta-defensin from human plasma. FEBS Lett 368, 331-5. 
361. Pazgier, M., Prahl, A., Hoover, D.M., Lubkowski, J. (2007) Studies of the biological 
properties of human beta -defensin 1. J Biol Chem 282, 1819-29. 
362. Antcheva, N., Morgera, F., Creatti, L., Vaccari, L., Pag, U., Pacor, S., Shai, Y., Sahl, 
H.G., Tossi, A. (2009) Artificial beta-defensin based on a minimal defensin template. 
Biochem J 421, 435-47. 
 227 
363. Zhao, C., Nguyen, T., Liu, L., Sacco, R.E., Brogden, K.A., Lehrer, R.I. (2001) 
Gallinacin-3, an inducible epithelial beta-defensin in the chicken. Infect Immun 69, 2684-
91. 
364. de Leeuw, E., Rajabi, M., Zou, G., Pazgier, M., Lu, W. (2009) Selective arginines are 
important for the antibacterial activity and host cell interaction of human alpha-defensin 
5. FEBS Lett 583, 2507-12. 
365. Wakefield, J.S., Gale, J.S., Berridge, M.V., Jordan, T.W., Ford, H.C. (1982) Is Percoll 
innocuous to cells? Biochem J 202, 795-7. 
366. Graziani-Bowering, G.M., Graham, J.M., Filion, L.G. (1997) A quick, easy and 
inexpensive method for the isolation of human peripheral blood monocytes. J Immunol 
Methods 207, 157-68. 
367. Taylor, K., Clarke, D.J., McCullough, B., Chin, W., Seo, E., Yang, D., Oppenheim, J., 
Uhrin, D., Govan, J.R., Campopiano, D.J., MacMillan, D., Barran, P., Dorin, J.R. (2008) 
Analysis and separation of residues important for the chemoattractant and antimicrobial 
activities of beta-defensin 3. J Biol Chem 283, 6631-9. 
368. Struyf, S., Proost, P., Lenaerts, J.P., Stoops, G., Wuyts, A., Van Damme, J. (2001) 
Identification of a blood-derived chemoattractant for neutrophils and lymphocytes as a 
novel CC chemokine, Regakine-1. Blood 97, 2197-204. 
369. Caux, C., Vanbervliet, B., Massacrier, C., Ait-Yahia, S., Vaure, C., Chemin, K., Dieu, N., 
Mc, Vicari, A. (2002) Regulation of dendritic cell recruitment by chemokines. 
Transplantation 73, S7-11. 
370. Wilson, N.S., Young, L.J., Kupresanin, F., Naik, S.H., Vremec, D., Heath, W.R., Akira, 
S., Shortman, K., Boyle, J., Maraskovsky, E., Belz, G.T., Villadangos, J.A. (2007) 
Normal proportion and expression of maturation markers in migratory dendritic cells in 
the absence of germs or Toll-like receptor signaling. Immunol Cell Biol. 
371. Dutia, B.M., Ross, A.J., Hopkins, J. (1993) Analysis of the monoclonal antibodies 
comprising WC6. Vet Immunol Immunopathol 39, 193-9. 
372. McKeever, D.J., MacHugh, N.D., Goddeeris, B.M., Awino, E., Morrison, W.I. (1991) 
Bovine afferent lymph veiled cells differ from blood monocytes in phenotype and 
accessory function. J Immunol 147, 3703-9. 
373. Le Borgne, M., Dubois, B., Kaiserlian, D. (2007) [Dendritic cells of mucosa and skin: 
"recruited for vaccination"]. Med Sci (Paris) 23, 819-25. 
374. Bowland, S.L., Shewen, P.E. (2000) Bovine respiratory disease: commercial vaccines 
currently available in Canada. Can Vet J 41, 33-48. 
375. Snowder, G.D., Van Vleck, L.D., Cundiff, L.V., Bennett, G.L. (2006) Bovine respiratory 
disease in feedlot cattle: environmental, genetic, and economic factors. J Anim Sci 84, 
1999-2008. 
376. Kahrs, R.F. (1981) Viral disease of cattle. Iowa State University Press, Ames, Iowa 135-
136. 
377. Raaperi, K., Bougeard, S., Aleksejev, A., Orro, T., Viltrop, A. (2012) Association of herd 
BRSV and BHV-1 seroprevalence with respiratory disease and reproductive performance 
in adult dairy cattle. Acta Vet Scand 54, 4. 
378. van Drunen Littel-van den Hurk, S., Parker, M.D., Massie, B., van den Hurk, J.V., 
Harland, R., Babiuk, L.A., Zamb, T.J. (1993) Protection of cattle from BHV-1 infection 
by immunization with recombinant glycoprotein gIV. Vaccine 11, 25-35. 
 228 
379. Wyler, R., Engels, M., Schwyzer, M. (1989) Infectious bovine 
rhinotracheitis/vulvovaginitis (BHV-1). In Herpesvirus disease of cattle, horses and pigs. 
Developments in veterinary virology. (G. Wittman, ed) Kluwer Academic Publishers, 
Boston 1-72. 
380. Zimmerman, A.D., Buterbaugh, R.E., Herbert, J.M., Hass, J.M., Frank, N.E., Luempert 
Iii, L.G., Chase, C.C. (2007) Efficacy of bovine herpesvirus-1 inactivated vaccine against 
abortion and stillbirth in pregnant heifers. J Am Vet Med Assoc 231, 1386-9. 
381. Pospisil, Z., Krejci, J., Jinek, P., Lany, P., Zendulkova, D., Cihal, P. (1996) Development 
of a disease control programme based on the use of an inactivated vaccine against 
infectious bovine rhinotracheitis. Vet Microbiol 53, 199-206. 
382. Meeusen, E.N., Walker, J., Peters, A., Pastoret, P.P., Jungersen, G. (2007) Current status 
of veterinary vaccines. Clin Microbiol Rev 20, 489-510, table of contents. 
383. van Drunen Littel-van den Hurk, S., Myers, D., Doig, P.A., Karvonen, B., Habermehl, 
M., Babiuk, L.A., Jelinski, M., Van Donkersgoed, J., Schlesinger, K., Rinehart, C. (2001) 
Identification of a mutant bovine herpesvirus-1 (BHV-1) in post-arrival outbreaks of IBR 
in feedlot calves and protection with conventional vaccination. Can J Vet Res 65, 81-8. 
384. Lowe, D.B., Shearer, M.H., Kennedy, R.C. (2006) DNA vaccines: successes and 
limitations in cancer and infectious disease. J Cell Biochem 98, 235-42. 
385. Kutzler, M.A., Weiner, D.B. (2008) DNA vaccines: ready for prime time? Nat Rev Genet 
9, 776-88. 
386. Kutzler, M.A., Weiner, D.B. (2004) Developing DNA vaccines that call to dendritic cells. 
J Clin Invest 114, 1241-4. 
387. Ivory, C., Chadee, K. (2004) DNA vaccines: designing strategies against parasitic 
infections. Genet Vaccines Ther 2, 17. 
388. Zhang, H.H., Yang, X.M., Xie, Q.M., Ma, J.Y., Luo, Y.N., Cao, Y.C., Chen, F., Bi, Y.Z. 
(2010) The potent adjuvant effects of chicken beta-defensin-1 when genetically fused 
with infectious bursal disease virus VP2 gene. Vet Immunol Immunopathol 136, 92-7. 
389. Mackenzie-Dyck, S., Attah-Poku, S., Juillard, V., Babiuk, L.A., van Drunen Littel-van 
den Hurk, S. (2011) The synthetic peptides bovine enteric beta-defensin (EBD), bovine 
neutrophil beta-defensin (BNBD) 9 and BNBD 3 are chemotactic for immature bovine 
dendritic cells. Vet Immunol Immunopathol 143, 87-107. 
390. Pontarollo, R.A., Babiuk, L.A., Hecker, R., Van Drunen Littel-Van Den Hurk, S. (2002) 
Augmentation of cellular immune responses to bovine herpesvirus-1 glycoprotein D by 
vaccination with CpG-enhanced plasmid vectors. J Gen Virol 83, 2973-81. 
391. Biragyn, A., Tani, K., Grimm, M.C., Weeks, S., Kwak, L.W. (1999) Genetic fusion of 
chemokines to a self tumor antigen induces protective, T-cell dependent antitumor 
immunity. Nat Biotechnol 17, 253-8. 
392. Tang, Y., Zhang, L., Yuan, J., Akbulut, H., Maynard, J., Linton, P.J., Deisseroth, A. 
(2004) Multistep process through which adenoviral vector vaccine overcomes anergy to 
tumor-associated antigens. Blood 104, 2704-13. 
393. Kwak, L.W., Biragyn, A. (2010) Defensin-Antigen Fusion Proteins. The Govt. of USA. 
as represented by the Secretary of the Dept. of Health and Human Services Office of 
Technology Transfer, National Institutes of Health, United States. 
394. Tang, Y., Deisseroth, A. (2006) Methods for immunotherapy of cancer. United States. 
 229 
395. Nakamura, Y., Gojobori, T., Ikemura, T. (2000) Codon usage tabulated from 
international DNA sequence databases: status for the year 2000. Nucleic Acids Res 28, 
292. 
396. Laemmli, U.K. (1970) Cleavage of structural proteins during the assembly of the head of 
bacteriophage T4. Nature 227, 680-5. 
397. Schagger, H., von Jagow, G. (1987) Tricine-sodium dodecyl sulfate-polyacrylamide gel 
electrophoresis for the separation of proteins in the range from 1 to 100 kDa. Anal 
Biochem 166, 368-79. 
398. Yount, N.Y., Yuan, J., Tarver, A., Castro, T., Diamond, G., Tran, P.A., Levy, J.N., 
McCullough, C., Cullor, J.S., Bevins, C.L., Selsted, M.E. (1999) Cloning and expression 
of bovine neutrophil beta-defensins. Biosynthetic profile during neutrophilic maturation 
and localization of mature peptide to novel cytoplasmic dense granules. J Biol Chem 274, 
26249-58. 
399. Manoj, S., Griebel, P.J., Babiuk, L.A., van Drunen Littel-van den Hurk, S. (2003) 
Targeting with bovine CD154 enhances humoral immune responses induced by a DNA 
vaccine in sheep. J Immunol 170, 989-96. 
400. Labiuk, S.L., Babiuk, L.A., van Drunen Littel-van den Hurk, S. (2009) Major tegument 
protein VP8 of bovine herpesvirus 1 is phosphorylated by viral US3 and cellular CK2 
protein kinases. J Gen Virol 90, 2829-39. 
401. Babiuk, L.A., Wardley, R.C., Rouse, B.T. (1975) Defense mechanisms against bovine 
herpesvirus: relationship of virus-host cell events to susceptibility to antibody-
complement cell lysis. Infect Immun 12, 958-63. 
402. Mapletoft, J.W., Oumouna, M., Kovacs-Nolan, J., Latimer, L., Mutwiri, G., Babiuk, 
L.A., van Drunen Littel-van den Hurk, S. (2008) Intranasal immunization of mice with a 
formalin-inactivated bovine respiratory syncytial virus vaccine co-formulated with CpG 
oligodeoxynucleotides and polyphosphazenes results in enhanced protection. J Gen Virol 
89, 250-60. 
403. Liang, R., van den Hurk, J.V., Landi, A., Lawman, Z., Deregt, D., Townsend, H., Babiuk, 
L.A., van Drunen Littel-van den Hurk, S. (2008) DNA prime protein boost strategies 
protect cattle from bovine viral diarrhea virus type 2 challenge. J Gen Virol 89, 453-66. 
404. Raggo, C., Habermehl, M., Babiuk, L.A., Griebel, P. (2000) The in vivo effects of 
recombinant bovine herpesvirus-1 expressing bovine interferon-gamma. J Gen Virol 81, 
2665-73. 
405. Nakamoto, Y., Kaneko, S. (2006) Analysis of intrahepatic lymphocyte subsets in a 
transgenic mouse model of immune-mediated hepatocarcinogenesis. J Exp Clin Cancer 
Res 25, 55-7. 
406. Ghanekar, S.A., Nomura, L.E., Suni, M.A., Picker, L.J., Maecker, H.T., Maino, V.C. 
(2001) Gamma interferon expression in CD8(+) T cells is a marker for circulating 
cytotoxic T lymphocytes that recognize an HLA A2-restricted epitope of human 
cytomegalovirus phosphoprotein pp65. Clin Diagn Lab Immunol 8, 628-31. 
407. Jacobson, M.A., Maecker, H.T., Orr, P.L., D'Amico, R., Van Natta, M., Li, X.D., Pollard, 
R.B., Bredt, B.M. (2004) Results of a cytomegalovirus (CMV)-specific CD8+/interferon- 
gamma+ cytokine flow cytometry assay correlate with clinical evidence of protective 
immunity in patients with AIDS with CMV retinitis. J Infect Dis 189, 1362-73. 
 230 
408. Peng, S., Monie, A., Pang, X., Hung, C.F., Wu, T.C. (2011) Vascular disrupting agent 
DMXAA enhances the antitumor effects generated by therapeutic HPV DNA vaccines. J 
Biomed Sci 18, 21. 
409. Zhang, W., Lin, Y., Bai, Y., Tong, T., Wang, Q., Liu, N., Liu, G., Xiao, Y., Yang, T., Bu, 
Z., Tong, G., Wu, D. (2011) Identification of CD8+ cytotoxic T lymphocyte epitopes 
from porcine reproductive and respiratory syndrome virus matrix protein in BALB/c 
mice. Virol J 8, 263. 
410. Horton, H., Russell, N., Moore, E., Frank, I., Baydo, R., Havenar-Daughton, C., Lee, D., 
Deers, M., Hudgens, M., Weinhold, K., McElrath, M.J. (2004) Correlation between 
interferon- gamma secretion and cytotoxicity, in virus-specific memory T cells. J Infect 
Dis 190, 1692-6. 
411. Betts, M.R., Brenchley, J.M., Price, D.A., De Rosa, S.C., Douek, D.C., Roederer, M., 
Koup, R.A. (2003) Sensitive and viable identification of antigen-specific CD8+ T cells 
by a flow cytometric assay for degranulation. J Immunol Methods 281, 65-78. 
412. Badovinac, V.P., Harty, J.T. (2000) Intracellular staining for TNF and IFN-gamma 
detects different frequencies of antigen-specific CD8(+) T cells. J Immunol Methods 238, 
107-17. 
413. Quade, M.J., Roth, J.A. (1999) Antigen-specific in vitro activation of T-lymphocyte 
subsets of cattle immunized with a modified live bovine herpesvirus 1 vaccine. Viral 
Immunol 12, 9-21. 
414. Endsley, J.J., Quade, M.J., Terhaar, B., Roth, J.A. (2002) BHV-1-Specific CD4+, CD8+, 
and gammadelta T cells in calves vaccinated with one dose of a modified live BHV-1 
vaccine. Viral Immunol 15, 385-93. 
415. Platt, R., Burdett, W., Roth, J.A. (2006) Induction of antigen-specific T-cell subset 
activation to bovine respiratory disease viruses by a modified-live virus vaccine. Am J 
Vet Res 67, 1179-84. 
416. Platt, R., Roth, J.A., Royer, R.L., Thoen, C.O. (2006) Monitoring responses by use of 
five-color flow cytometry in subsets of peripheral T cells obtained from cattle inoculated 
with a killed Mycobacterium avium subsp paratuberculosis vaccine. Am J Vet Res 67, 
2050-8. 
417. Gaddum, R.M., Cook, R.S., Furze, J.M., Ellis, S.A., Taylor, G. (2003) Recognition of 
bovine respiratory syncytial virus proteins by bovine CD8+ T lymphocytes. Immunology 
108, 220-9. 
418. Schinnerling, K., Moos, V., Geelhaar, A., Allers, K., Loddenkemper, C., Friebel, J., 
Conrad, K., Kuhl, A.A., Erben, U., Schneider, T. (2011) Regulatory T cells in patients 
with Whipple's disease. J Immunol 187, 4061-7. 
419. Vremec, D., Zorbas, M., Scollay, R., Saunders, D.J., Ardavin, C.F., Wu, L., Shortman, K. 
(1992) The surface phenotype of dendritic cells purified from mouse thymus and spleen: 
investigation of the CD8 expression by a subpopulation of dendritic cells. J Exp Med 176, 
47-58. 
420. Braun, R., Babiuk, L.A., van Drunen Littel-van den, H. (1998) Compatibility of plasmids 
expressing different antigens in a single DNA vaccine formulation. J Gen Virol 79 ( Pt 
12), 2965-70. 
421. Sedegah, M., Charoenvit, Y., Minh, L., Belmonte, M., Majam, V.F., Abot, S., Ganeshan, 
H., Kumar, S., Bacon, D.J., Stowers, A., Narum, D.L., Carucci, D.J., Rogers, W.O. 
 231 
(2004) Reduced immunogenicity of DNA vaccine plasmids in mixtures. Gene Ther 11, 
448-56. 
422. Sedegah, M., Charoenvit, Y., Aguiar, J., Sacci, J., Hedstrom, R., Kumar, S., Belmonte, 
A., Lanar, D.E., Jones, T.R., Abot, E., Druilhe, P., Corradin, G., Epstein, J.E., Richie, 
T.L., Carucci, D.J., Hoffman, S.L. (2004) Effect on antibody and T-cell responses of 
mixing five GMP-produced DNA plasmids and administration with plasmid expressing 
GM-CSF. Genes Immun 5, 553-61. 
423. Ohteki, T., Fukao, T., Suzue, K., Maki, C., Ito, M., Nakamura, M., Koyasu, S. (1999) 
Interleukin 12-dependent interferon gamma production by CD8alpha+ lymphoid 
dendritic cells. J Exp Med 189, 1981-6. 
424. Dunne, P.J., Moran, B., Cummins, R.C., Mills, K.H. (2009) CD11c+CD8alpha+ dendritic 
cells promote protective immunity to respiratory infection with Bordetella pertussis. J 
Immunol 183, 400-10. 
425. Smith, C.M., Belz, G.T., Wilson, N.S., Villadangos, J.A., Shortman, K., Carbone, F.R., 
Heath, W.R. (2003) Cutting edge: conventional CD8 alpha+ dendritic cells are 
preferentially involved in CTL priming after footpad infection with herpes simplex virus-
1. J Immunol 170, 4437-40. 
426. den Haan, J.M., Lehar, S.M., Bevan, M.J. (2000) CD8(+) but not CD8(-) dendritic cells 
cross-prime cytotoxic T cells in vivo. J Exp Med 192, 1685-96. 
427. Behboudi, S., Moore, A., Hill, A.V. (2004) Splenic dendritic cell subsets prime and boost 
CD8 T cells and are involved in the generation of effector CD8 T cells. Cell Immunol 
228, 15-9. 
428. Maldonado-Lopez, R., De Smedt, T., Pajak, B., Heirman, C., Thielemans, K., Leo, O., 
Urbain, J., Maliszewski, C.R., Moser, M. (1999) Role of CD8alpha+ and CD8alpha- 
dendritic cells in the induction of primary immune responses in vivo. J Leukoc Biol 66, 
242-6. 
429. Maldonado-Lopez, R., De Smedt, T., Michel, P., Godfroid, J., Pajak, B., Heirman, C., 
Thielemans, K., Leo, O., Urbain, J., Moser, M. (1999) CD8alpha+ and CD8alpha- 
subclasses of dendritic cells direct the development of distinct T helper cells in vivo. J 
Exp Med 189, 587-92. 
430. Suss, G., Shortman, K. (1996) A subclass of dendritic cells kills CD4 T cells via Fas/Fas-
ligand-induced apoptosis. J Exp Med 183, 1789-96. 
431. Sin, J.I., Kim, J.J., Arnold, R.L., Shroff, K.E., McCallus, D., Pachuk, C., McElhiney, 
S.P., Wolf, M.W., Pompa-de Bruin, S.J., Higgins, T.J., Ciccarelli, R.B., Weiner, D.B. 
(1999) IL-12 gene as a DNA vaccine adjuvant in a herpes mouse model: IL-12 enhances 
Th1-type CD4+ T cell-mediated protective immunity against herpes simplex virus-2 
challenge. J Immunol 162, 2912-21. 
432. Clerici, M., Shearer, G.M. (1994) The Th1-Th2 hypothesis of HIV infection: new 
insights. Immunol Today 15, 575-81. 
433. Kidd, P. (2003) Th1/Th2 balance: the hypothesis, its limitations, and implications for 
health and disease. Altern Med Rev 8, 223-46. 
434. Agrawal, L., Haq, W., Hanson, C.V., Rao, D.N. (2003) Generating neutralizing 
antibodies, Th1 response and MHC non restricted immunogenicity of HIV-I env and gag 
peptides in liposomes and ISCOMs with in-built adjuvanticity. J Immune Based Ther 
Vaccines 1, 5. 
 232 
435. Mascarell, L., Fayolle, C., Bauche, C., Ladant, D., Leclerc, C. (2005) Induction of 
neutralizing antibodies and Th1-polarized and CD4-independent CD8+ T-cell responses 
following delivery of human immunodeficiency virus type 1 Tat protein by recombinant 
adenylate cyclase of Bordetella pertussis. J Virol 79, 9872-84. 
436. Bielinska, A.U., Janczak, K.W., Landers, J.J., Markovitz, D.M., Montefiori, D.C., Baker, 
J.R., Jr. (2008) Nasal immunization with a recombinant HIV gp120 and nanoemulsion 
adjuvant produces Th1 polarized responses and neutralizing antibodies to primary HIV 
type 1 isolates. AIDS Res Hum Retroviruses 24, 271-81. 
437. Liu, L., Wan, Y., Wu, L., Sun, J., Li, H., Ma, L., Shao, Y. (2010) Broader HIV-1 
neutralizing antibody responses induced by envelope glycoprotein mutants based on the 
EIAV attenuated vaccine. Retrovirology 7, 71. 
438. McCluskie, M.J., Brazolot Millan, C.L., Gramzinski, R.A., Robinson, H.L., Santoro, J.C., 
Fuller, J.T., Widera, G., Haynes, J.R., Purcell, R.H., Davis, H.L. (1999) Route and 
method of delivery of DNA vaccine influence immune responses in mice and non-human 
primates. Mol Med 5, 287-300. 
439. Woolums, A.R., Siger, L., Johnson, S., Gallo, G., Conlon, J. (2003) Rapid onset of 
protection following vaccination of calves with multivalent vaccines containing 
modified-live or modified-live and killed BHV-1 is associated with virus-specific 
interferon gamma production. Vaccine 21, 1158-64. 
440. Ioannou, X.P., Griebel, P., Hecker, R., Babiuk, L.A., van Drunen Littel-van den Hurk, S. 
(2002) The immunogenicity and protective efficacy of bovine herpesvirus 1 glycoprotein 
D plus Emulsigen are increased by formulation with CpG oligodeoxynucleotides. J Virol 
76, 9002-10. 
441. Rouse, B.T., Kaistha, S.D. (2006) A tale of 2 alpha-herpesviruses: lessons for 
vaccinologists. Clin Infect Dis 42, 810-7. 
442. Jones, C. (1998) Alphaherpesvirus latency: its role in disease and survival of the virus in 
nature. Adv Virus Res 51, 81-133. 
443. Weiner, D.B., Kennedy, R.C. (1999) Genetic vaccines. Sci Am 281, 50-7. 
444. Ott, G., Singh, M., Kazzaz, J., Briones, M., Soenawan, E., Ugozzoli, M., O'Hagan, D.T. 
(2002) A cationic sub-micron emulsion (MF59/DOTAP) is an effective delivery system 
for DNA vaccines. J Control Release 79, 1-5. 
445. Michel, M.L., Davis, H.L., Schleef, M., Mancini, M., Tiollais, P., Whalen, R.G. (1995) 
DNA-mediated immunization to the hepatitis B surface antigen in mice: aspects of the 
humoral response mimic hepatitis B viral infection in humans. Proc Natl Acad Sci U S A 
92, 5307-11. 
446. Davis, H.L. (1997) Plasmid DNA expression systems for the purpose of immunization. 
Curr Opin Biotechnol 8, 635-46. 
447. Chattergoon, M.A., Robinson, T.M., Boyer, J.D., Weiner, D.B. (1998) Specific immune 
induction following DNA-based immunization through in vivo transfection and 
activation of macrophages/antigen-presenting cells. J Immunol 160, 5707-18. 
448. Sin, J.I., Kim, J.J., Ugen, K.E., Ciccarelli, R.B., Higgins, T.J., Weiner, D.B. (1998) 
Enhancement of protective humoral (Th2) and cell-mediated (Th1) immune responses 
against herpes simplex virus-2 through co-delivery of granulocyte-macrophage colony-
stimulating factor expression cassettes. Eur J Immunol 28, 3530-40. 
449. Perrie, Y., Frederik, P.M., Gregoriadis, G. (2001) Liposome-mediated DNA vaccination: 
the effect of vesicle composition. Vaccine 19, 3301-10. 
 233 
450. Commander, N.J., Brewer, J.M., Wren, B.W., Spencer, S.A., Macmillan, A.P., Stack, 
J.A. (2010) Liposomal delivery of p-ialB and p-omp25 DNA vaccines improves 
immunogenicity but fails to provide full protection against B. melitensis challenge. Genet 
Vaccines Ther 8, 5. 
451. Greenland, J.R., Letvin, N.L. (2007) Chemical adjuvants for plasmid DNA vaccines. 
Vaccine 25, 3731-41. 
452. Mackenzie-Dyck, S., Kovacs-Nolan, J., Snider, M., Babiuk, L.A., van Drunen Littel-van 
den Hurk, S. (2014) Inclusion of the bovine neutrophil beta-defensin 3 with glycoprotein 
D of Bovine herpesvirus-1 in a DNA vaccine modulates immune responses of mice and 
cattle. Clin Vaccine Immunol 21, 463-477. 
453. Riedl, P., Reimann, J., Schirmbeck, R. (2006) Complexes of DNA vaccines with cationic, 
antigenic peptides are potent, polyvalent CD8(+) T-cell-stimulating immunogens. 
Methods Mol Med 127, 159-69. 
454. Riedl, P., Reimann, J., Schirmbeck, R. (2004) Peptides containing antigenic and cationic 
domains have enhanced, multivalent immunogenicity when bound to DNA vaccines. J 
Mol Med 82, 144-52. 
455. Singh, M., Briones, M., Ott, G., O'Hagan, D. (2000) Cationic microparticles: A potent 
delivery system for DNA vaccines. Proc Natl Acad Sci U S A 97, 811-6. 
456. Rouse, R.J., Nair, S.K., Lydy, S.L., Bowen, J.C., Rouse, B.T. (1994) Induction in vitro of 
primary cytotoxic T-lymphocyte responses with DNA encoding herpes simplex virus 
proteins. J Virol 68, 5685-9. 
457. Sin, J.I., Ayyavoo, V., Boyer, J., Kim, J., Ciccarelli, R.B., Weiner, D.B. (1999) Protective 
immune correlates can segregate by vaccine type in a murine herpes model system. Int 
Immunol 11, 1763-73. 
458. Sin, J.I., Kim, J.J., Boyer, J.D., Ciccarelli, R.B., Higgins, T.J., Weiner, D.B. (1999) In 
vivo modulation of vaccine-induced immune responses toward a Th1 phenotype 
increases potency and vaccine effectiveness in a herpes simplex virus type 2 mouse 
model. J Virol 73, 501-9. 
459. Yu, H., Babiuk, L.A., van Drunen Littel-van den Hurk, S. (2008) Strategies for loading 
dendritic cells with hepatitis C NS5a antigen and inducing protective immunity. J Viral 
Hepat 15, 459-70. 
460. Liu, Y.D., Goetze, A.M., Bass, R.B., Flynn, G.C. (2011) N-terminal glutamate to 
pyroglutamate conversion in vivo for human IgG2 antibodies. J Biol Chem 286, 11211-7. 
461. Yu, H., Huang, H., Xiang, J., Babiuk, L.A., van Drunen Littel-van den Hurk, S. (2006) 
Dendritic cells pulsed with hepatitis C virus NS3 protein induce immune responses and 
protection from infection with recombinant vaccinia virus expressing NS3. J Gen Virol 
87, 1-10. 
462. Wiesel, M., Walton, S., Richter, K., Oxenius, A. (2009) Virus-specific CD8 T cells: 
activation, differentiation and memory formation. APMIS 117, 356-81. 
463. Favoreel, H.W., Van Minnebruggen, G., Van de Walle, G.R., Ficinska, J., Nauwynck, 
H.J. (2006) Herpesvirus interference with virus-specific antibodies: bridging antibodies, 
internalizing antibodies, and hiding from antibodies. Vet Microbiol 113, 257-63. 
464. Hewitt, E.W. (2003) The MHC class I antigen presentation pathway: strategies for viral 
immune evasion. Immunology 110, 163-9. 
 234 
465. Wei, H., Wang, Y., Chowdhury, S.I. (2011) Bovine herpesvirus type 1 (BHV-1) UL49.5 
luminal domain residues 30 to 32 are critical for MHC-I down-regulation in virus-
infected cells. PLoS One 6, e25742. 
466. Gao, G.F., Jakobsen, B.K. (2000) Molecular interactions of coreceptor CD8 and MHC 
class I: the molecular basis for functional coordination with the T-cell receptor. Immunol 
Today 21, 630-6. 
467. Wang, B., Norbury, C.C., Greenwood, R., Bennink, J.R., Yewdell, J.W., Frelinger, J.A. 
(2001) Multiple paths for activation of naive CD8+ T cells: CD4-independent help. J 
Immunol 167, 1283-9. 
468. Manoj, S., Babiuk, L.A., van Drunen Littel-van den Hurk, S. (2003) Immunization with a 
dicistronic plasmid expressing a truncated form of bovine herpesvirus-1 glycoprotein D 
and the amino-terminal subunit of glycoprotein B results in reduced gB-specific immune 
responses. Virology 313, 296-307. 
469. Kawabata, K., Takakura, Y., Hashida, M. (1995) The fate of plasmid DNA after 
intravenous injection in mice: involvement of scavenger receptors in its hepatic uptake. 
Pharm Res 12, 825-30. 
470. Martin, M.E., Rice, K.G. (2007) Peptide-guided gene delivery. AAPS J 9, E18-29. 
471. Gerashchenko, O.L., Zhuravel, E.V., Skachkova, O.V., Khranovska, N.N., Filonenko, 
V.V., Pogrebnoy, P.V., Soldatkina, M.A. (2013) Biologic activities of recombinant 
human-beta-defensin-4 toward cultured human cancer cells. Exp Oncol 35, 76-82. 
472. Licciardi, M., Campisi, M., Cavallaro, G., Cervello, M., Azzolina, A., Giammona, G. 
(2006) Synthesis and characterization of polyaminoacidic polycations for gene delivery. 
Biomaterials 27, 2066-75. 
473. Lehto, T., Simonson, O.E., Mager, I., Ezzat, K., Sork, H., Copolovici, D.M., Viola, J.R., 
Zaghloul, E.M., Lundin, P., Moreno, P.M., Mae, M., Oskolkov, N., Suhorutsenko, J., 
Smith, C.I., Andaloussi, S.E. (2011) A peptide-based vector for efficient gene transfer in 
vitro and in vivo. Mol Ther 19, 1457-67. 
474. Wattiaux, R., Laurent, N., Wattiaux-De Coninck, S., Jadot, M. (2000) Endosomes, 
lysosomes: their implication in gene transfer. Adv Drug Deliv Rev 41, 201-8. 
475. Zelphati, O., Szoka, F.C., Jr. (1996) Mechanism of oligonucleotide release from cationic 
liposomes. Proc Natl Acad Sci U S A 93, 11493-8. 
476. Pedone, E., Cavallaro, G., Richardson, S.C., Duncan, R., Giammona, G. (2001) 
alpha,beta-poly(asparthylhydrazide)-glycidyltrimethylammonium chloride copolymers 
(PAHy-GTA): novel polymers with potential for DNA delivery. J Control Release 77, 
139-53. 
477. Lingnau, K., Riedl, K., von Gabain, A. (2007) IC31 and IC30, novel types of vaccine 
adjuvant based on peptide delivery systems. Expert Rev Vaccines 6, 741-6. 
478. Niidome, T., Takaji, K., Urakawa, M., Ohmori, N., Wada, A., Hirayama, T., Aoyagi, H. 
(1999) Chain length of cationic alpha-helical peptide sufficient for gene delivery into 
cells. Bioconjug Chem 10, 773-80. 
479. Haines, A.M., Irvine, A.S., Mountain, A., Charlesworth, J., Farrow, N.A., Husain, R.D., 
Hyde, H., Ketteringham, H., McDermott, R.H., Mulcahy, A.F., Mustoe, T.L., Reid, S.C., 
Rouquette, M., Shaw, J.C., Thatcher, D.R., Welsh, J.H., Williams, D.E., Zauner, W., 
Phillips, R.O. (2001) CL22 - a novel cationic peptide for efficient transfection of 
mammalian cells. Gene Ther 8, 99-110. 
 235 
480. Foged, C., Arigita, C., Sundblad, A., Jiskoot, W., Storm, G., Frokjaer, S. (2004) 
Interaction of dendritic cells with antigen-containing liposomes: effect of bilayer 
composition. Vaccine 22, 1903-13. 
481. Wyman, T.B., Nicol, F., Zelphati, O., Scaria, P.V., Plank, C., Szoka, F.C., Jr. (1997) 
Design, synthesis, and characterization of a cationic peptide that binds to nucleic acids 
and permeabilizes bilayers. Biochemistry 36, 3008-17. 
482. Wadia, J.S., Stan, R.V., Dowdy, S.F. (2004) Transducible TAT-HA fusogenic peptide 
enhances escape of TAT-fusion proteins after lipid raft macropinocytosis. Nat Med 10, 
310-5. 
483. Heitz, F., Morris, M.C., Divita, G. (2009) Twenty years of cell-penetrating peptides: from 
molecular mechanisms to therapeutics. Br J Pharmacol 157, 195-206. 
484. Conner, S.D., Schmid, S.L. (2003) Regulated portals of entry into the cell. Nature 422, 
37-44. 
485. Zanta, M.A., Belguise-Valladier, P., Behr, J.P. (1999) Gene delivery: a single nuclear 
localization signal peptide is sufficient to carry DNA to the cell nucleus. Proc Natl Acad 
Sci U S A 96, 91-6. 
486. Sandgren, S., Wittrup, A., Cheng, F., Jonsson, M., Eklund, E., Busch, S., Belting, M. 
(2004) The human antimicrobial peptide LL-37 transfers extracellular DNA plasmid to 
the nuclear compartment of mammalian cells via lipid rafts and proteoglycan-dependent 
endocytosis. J Biol Chem 279, 17951-6. 
487. Labeur, M.S., Roters, B., Pers, B., Mehling, A., Luger, T.A., Schwarz, T., Grabbe, S. 
(1999) Generation of tumor immunity by bone marrow-derived dendritic cells correlates 
with dendritic cell maturation stage. J Immunol 162, 168-75. 
488. Rivas-Caicedo, A., Soldevila, G., Fortoul, T.I., Castell-Rodriguez, A., Flores-Romo, L., 
Garcia-Zepeda, E.A. (2009) Jak3 is involved in dendritic cell maturation and CCR7-
dependent migration. PLoS One 4, e7066. 
489. Singh-Jasuja, H., Thiolat, A., Ribon, M., Boissier, M.C., Bessis, N., Rammensee, H.G., 
Decker, P. (2013) The mouse dendritic cell marker CD11c is down-regulated upon cell 
activation through Toll-like receptor triggering. Immunobiology 218, 28-39. 
490. Asano, Y., Komuro, T., Tada, T. (1990) Synergistic T-T cell interaction present in 
alloreactivity: determination of 'MLR helper' T cell subsets. Int Immunol 2, 1203-11. 
491. Peltola, V., Ruuskanen, O. (2008) Editorial commentary: Respiratory viral infections in 
developing countries: common, severe, and unrecognized. Clin Infect Dis 46, 58-60. 
492. Graham, D.A. (2013) Bovine herpes virus-1 (BoHV-1) in cattle-a review with emphasis 
on reproductive impacts and the emergence of infection in Ireland and the United 
Kingdom. Ir Vet J 66, 15. 
493. Hartel, H., Nikunen, S., Neuvonen, E., Tanskanen, R., Kivela, S.L., Aho, R., Soveri, T., 
Saloniemi, H. (2004) Viral and bacterial pathogens in bovine respiratory disease in 
Finland. Acta Vet Scand 45, 193-200. 
494. Deshpande, M.S., Ambagala, T.C., Hegde, N.R., Hariharan, M.J., Navaratnam, M., 
Srikumaran, S. (2002) Induction of cytotoxic T-lymphocytes specific for bovine 
herpesvirus-1 by DNA immunization. Vaccine 20, 3744-51. 
495. Whetstone, C.A., Miller, J.M., Seal, B.S., Bello, L.J., Lawrence, W.C. (1992) Latency 
and reactivation of a thymidine kinase-negative bovine herpesvirus 1 deletion mutant. 
Arch Virol 122, 207-14. 
 236 
496. Coban, C., Kobiyama, K., Jounai, N., Tozuka, M., Ishii, K.J. (2013) DNA vaccines: a 
simple DNA sensing matter? Hum Vaccin Immunother 9, 2216-21. 
497. Bins, A.D., Jorritsma, A., Wolkers, M.C., Hung, C.F., Wu, T.C., Schumacher, T.N., 
Haanen, J.B. (2005) A rapid and potent DNA vaccination strategy defined by in vivo 
monitoring of antigen expression. Nat Med 11, 899-904. 
498. Coban, C., Kobiyama, K., Aoshi, T., Takeshita, F., Horii, T., Akira, S., Ishii, K.J. Novel 
strategies to improve DNA vaccine immunogenicity. Curr Gene Ther 11, 479-84. 
499. Bajer, A.A., Garcia-Tapia, D., Jordan, K.R., Haas, K.M., Werling, D., Howard, C.J., 
Estes, D.M. (2003) Peripheral blood-derived bovine dendritic cells promote IgG1-
restricted B cell responses in vitro. J Leukoc Biol 73, 100-6. 
500. Hope, J.C., Werling, D., Collins, R.A., Mertens, B., Howard, C.J. (2000) Flt-3 ligand, in 
combination with bovine granulocyte-macrophage colony-stimulating factor and 
interleukin-4, promotes the growth of bovine bone marrow derived dendritic cells. Scand 
J Immunol 51, 60-6. 
501. Howard, C.J., Hope, J.C. (2000) Dendritic cells, implications on function from studies of 
the afferent lymph veiled cell. Vet Immunol Immunopathol 77, 1-13. 
502. Lin, S.L., Chien, C.W., Han, C.L., Chen, E.S., Kao, S.H., Chen, Y.J., Liao, F. (2010) 
Temporal proteomics profiling of lipid rafts in CCR6-activated T cells reveals the 
integration of actin cytoskeleton dynamics. J Proteome Res 9, 283-97. 
503. Oppenheim, J.J., Yang, D., Biragyn, A., Howard, O.M., Plotz, P. (2002) Chemokine 
receptors on dendritic cells promote autoimmune reactions. Arthritis Res 4 Suppl 3, 
S183-8. 
504. Reid, E., Juleff, N., Gubbins, S., Prentice, H., Seago, J., Charleston, B. (2011) Bovine 
plasmacytoid dendritic cells are the major source of type I interferon in response to foot-
and-mouth disease virus in vitro and in vivo. J Virol 85, 4297-308. 
505. Gibson, A., Miah, S., Griebel, P., Brownlie, J., Werling, D. (2012) Identification of a 
lineage negative cell population in bovine peripheral blood with the ability to mount a 
strong type I interferon response. Dev Comp Immunol 36, 332-41. 
506. Grassi, F., Dezutter-Dambuyant, C., McIlroy, D., Jacquet, C., Yoneda, K., Imamura, S., 
Boumsell, L., Schmitt, D., Autran, B., Debre, P., Hosmalin, A. (1998) Monocyte-derived 
dendritic cells have a phenotype comparable to that of dermal dendritic cells and display 
ultrastructural granules distinct from Birbeck granules. J Leukoc Biol 64, 484-93. 
507. He, Y., Zhang, J., Donahue, C., Falo, L.D., Jr. (2006) Skin-derived dendritic cells induce 
potent CD8(+) T cell immunity in recombinant lentivector-mediated genetic 
immunization. Immunity 24, 643-56. 
508. Allenspach, E.J., Lemos, M.P., Porrett, P.M., Turka, L.A., Laufer, T.M. (2008) Migratory 
and lymphoid-resident dendritic cells cooperate to efficiently prime naive CD4 T cells. 
Immunity 29, 795-806. 
509. Mount, A.M., Smith, C.M., Kupresanin, F., Stoermer, K., Heath, W.R., Belz, G.T. (2008) 
Multiple dendritic cell populations activate CD4+ T cells after viral stimulation. PLoS 
One 3, e1691. 
510. Harada, S., Kimura, T., Fujiki, H., Nakagawa, H., Ueda, Y., Itoh, T., Yamagishi, H., 
Sonoda, Y. (2007) Flt3 ligand promotes myeloid dendritic cell differentiation of human 
hematopoietic progenitor cells: possible application for cancer immunotherapy. Int J 
Oncol 30, 1461-8. 
 237 
511. Miller, G., Pillarisetty, V.G., Shah, A.B., Lahrs, S., DeMatteo, R.P. (2003) Murine Flt3 
ligand expands distinct dendritic cells with both tolerogenic and immunogenic properties. 
J Immunol 170, 3554-64. 
512. Huang, Y., Babiuk, L.A., van Drunen Littel-van den Hurk, S. (2006) The cell-mediated 
immune response induced by plasmid encoding bovine herpesvirus 1 glycoprotein B is 
enhanced by plasmid encoding IL-12 when delivered intramuscularly or by gene gun, but 
not after intradermal injection. Vaccine 24, 5349-59. 
513. Kemnade, J.O., Seethammagari, M., Narayanan, P., Levitt, J.M., McCormick, A.A., 
Spencer, D.M. (2012) Off-the-shelf adenoviral-mediated immunotherapy via bicistronic 
expression of tumor antigen and iMyD88/CD40 adjuvant. Mol Ther 20, 1462-71. 
514. Stiles, K.M., Whitbeck, J.C., Lou, H., Cohen, G.H., Eisenberg, R.J., Krummenacher, C. 
(2010) Herpes simplex virus glycoprotein D interferes with binding of herpesvirus entry 
mediator to its ligands through downregulation and direct competition. J Virol 84, 11646-
60. 
515. Mei, H.F., Jin, X.B., Zhu, J.Y., Zeng, A.H., Wu, Q., Lu, X.M., Li, X.B., Shen, J. (2012) 
beta-defensin 2 as an adjuvant promotes anti-melanoma immune responses and inhibits 
the growth of implanted murine melanoma in vivo. PLoS One 7, e31328. 
516. Idoyaga, J., Lubkin, A., Fiorese, C., Lahoud, M.H., Caminschi, I., Huang, Y., Rodriguez, 
A., Clausen, B.E., Park, C.G., Trumpfheller, C., Steinman, R.M. (2011) Comparable T 
helper 1 (Th1) and CD8 T-cell immunity by targeting HIV gag p24 to CD8 dendritic cells 
within antibodies to Langerin, DEC205, and Clec9A. Proc Natl Acad Sci U S A 108, 
2384-9. 
517. Bozzacco, L., Trumpfheller, C., Siegal, F.P., Mehandru, S., Markowitz, M., Carrington, 
M., Nussenzweig, M.C., Piperno, A.G., Steinman, R.M. (2007) DEC-205 receptor on 
dendritic cells mediates presentation of HIV gag protein to CD8+ T cells in a spectrum of 
human MHC I haplotypes. Proc Natl Acad Sci U S A 104, 1289-94. 
518. Kronin, V., Fitzmaurice, C.J., Caminschi, I., Shortman, K., Jackson, D.C., Brown, L.E. 
(2001) Differential effect of CD8(+) and CD8(-) dendritic cells in the stimulation of 
secondary CD4(+) T cells. Int Immunol 13, 465-73. 
519. Parker, D.C. (1993) T cell-dependent B cell activation. Annu Rev Immunol 11, 331-60. 
520. Mozdzanowska, K., Furchner, M., Zharikova, D., Feng, J., Gerhard, W. (2005) Roles of 
CD4+ T-cell-independent and -dependent antibody responses in the control of influenza 
virus infection: evidence for noncognate CD4+ T-cell activities that enhance the 
therapeutic activity of antiviral antibodies. J Virol 79, 5943-51. 
521. Otten, G.R., Doe, B., Schaefer, M., Chen, M., Selby, M.J., Goldbeck, C., Hong, M., Xu, 
F., Ulmer, J.B. (2000) Relative potency of cellular and humoral immune responses 
induced by DNA vaccination. Intervirology 43, 227-32. 
522. Melroe, G.T., DeLuca, N.A., Knipe, D.M. (2004) Herpes simplex virus 1 has multiple 
mechanisms for blocking virus-induced interferon production. J Virol 78, 8411-20. 
523. Xing, J., Ni, L., Wang, S., Wang, K., Lin, R., Zheng, C. (2013) Herpes simplex virus 1-
encoded tegument protein VP16 abrogates the production of beta interferon (IFN) by 
inhibiting NF-kappaB activation and blocking IFN regulatory factor 3 to recruit its 
coactivator CBP. J Virol 87, 9788-801. 
524. Saira, K., Zhou, Y., Jones, C. (2007) The infected cell protein 0 encoded by bovine 
herpesvirus 1 (bICP0) induces degradation of interferon response factor 3 and, 
consequently, inhibits beta interferon promoter activity. J Virol 81, 3077-86. 
 238 
525. Dai, Y., Zhu, Y., Harn, D.A., Wang, X., Tang, J., Zhao, S., Lu, F., Guan, X. (2009) DNA 
vaccination by electroporation and boosting with recombinant proteins enhances the 
efficacy of DNA vaccines for Schistosomiasis japonica. Clin Vaccine Immunol 16, 1796-
803. 
526. Hughes, G., Babiuk, L.A., van Drunen Littel-van den Hurk, S. (1988) Functional and 
topographical analyses of epitopes on bovine herpesvirus type 1 glycoprotein IV. Arch 
Virol 103, 47-60. 
527. Xu, N., Wang, Y.S., Pan, W.B., Xiao, B., Wen, Y.J., Chen, X.C., Chen, L.J., Deng, H.X., 
You, J., Kan, B., Fu, A.F., Li, D., Zhao, X., Wei, Y.Q. (2008) Human alpha-defensin-1 
inhibits growth of human lung adenocarcinoma xenograft in nude mice. Mol Cancer Ther 
7, 1588-97. 
528. Riedl, S., Zweytick, D., Lohner, K. (2011) Membrane-active host defense peptides--
challenges and perspectives for the development of novel anticancer drugs. Chem Phys 
Lipids 164, 766-81. 
529. Kisich, K.O., Heifets, L., Higgins, M., Diamond, G. (2001) Antimycobacterial agent 
based on mRNA encoding human beta-defensin 2 enables primary macrophages to 
restrict growth of Mycobacterium tuberculosis. Infect Immun 69, 2692-9. 
530. Alberts, B., Jonhnson, A., Lewis, J., al., e. (2002) Helper T cells and Lymphocyte 
Activation. In Molecular Biology of the CellGarland Science, New York. 
531. Amakata, Y., Fujiyama, Y., Andoh, A., Hodohara, K., Bamba, T. (2001) Mechanism of 
NK cell activation induced by coculture with dendritic cells derived from peripheral 
blood monocytes. Clin Exp Immunol 124, 214-22. 
532. Chalifour, A., Jeannin, P., Gauchat, J.F., Blaecke, A., Malissard, M., N'Guyen, T., 
Thieblemont, N., Delneste, Y. (2004) Direct bacterial protein PAMP recognition by 
human NK cells involves TLRs and triggers alpha-defensin production. Blood 104, 1778-
83. 
533. Michel, T., Poli, A., Domingues, O., Mauffray, M., Theresine, M., Brons, N.H., Hentges, 
F., Zimmer, J. (2012) Mouse lung and spleen natural killer cells have phenotypic and 
functional differences, in part influenced by macrophages. PLoS One 7, e51230. 
534. Adib-Conquy, M., Scott-Algara, D., Cavaillon, J.M., Souza-Fonseca-Guimaraes, F. 
(2014) TLR-mediated activation of NK cells and their role in bacterial/viral immune 
responses in mammals. Immunol Cell Biol 92, 256-62. 
535. Koh, C.Y., Yuan, D. (2000) The functional relevance of NK-cell-mediated upregulation 
of antigen-specific IgG2a responses. Cell Immunol 204, 135-42. 
536. Cruse, J.M., Lewis, R.E., Wang, H. (2004) Immunology Guidebook. Elsevier Academic 
Press, San Diego 516. 
537. Bates, E.E., Fournier, N., Garcia, E., Valladeau, J., Durand, I., Pin, J.J., Zurawski, S.M., 
Patel, S., Abrams, J.S., Lebecque, S., Garrone, P., Saeland, S. (1999) APCs express 
DCIR, a novel C-type lectin surface receptor containing an immunoreceptor tyrosine-
based inhibitory motif. J Immunol 163, 1973-83. 
538. Ariizumi, K., Shen, G.L., Shikano, S., Ritter, R., 3rd, Zukas, P., Edelbaum, D., Morita, 
A., Takashima, A. (2000) Cloning of a second dendritic cell-associated C-type lectin 
(dectin-2) and its alternatively spliced isoforms. J Biol Chem 275, 11957-63. 
539. Ariizumi, K., Shen, G.L., Shikano, S., Xu, S., Ritter, R., 3rd, Kumamoto, T., Edelbaum, 
D., Morita, A., Bergstresser, P.R., Takashima, A. (2000) Identification of a novel, 
 239 
dendritic cell-associated molecule, dectin-1, by subtractive cDNA cloning. J Biol Chem 
275, 20157-67. 
540. Colonna, M., Samaridis, J., Angman, L. (2000) Molecular characterization of two novel 
C-type lectin-like receptors, one of which is selectively expressed in human dendritic 
cells. Eur J Immunol 30, 697-704. 
541. Sallusto, F., Lanzavecchia, A. (1994) Efficient presentation of soluble antigen by cultured 
human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor 
plus interleukin 4 and downregulated by tumor necrosis factor alpha. J Exp Med 179, 
1109-18. 
542. Jordens, R., Thompson, A., Amons, R., Koning, F. (1999) Human dendritic cells shed a 
functional, soluble form of the mannose receptor. Int Immunol 11, 1775-80. 
543. Regnault, A., Lankar, D., Lacabanne, V., Rodriguez, A., Thery, C., Rescigno, M., Saito, 
T., Verbeek, S., Bonnerot, C., Ricciardi-Castagnoli, P., Amigorena, S. (1999) Fcgamma 
receptor-mediated induction of dendritic cell maturation and major histocompatibility 
complex class I-restricted antigen presentation after immune complex internalization. J 
Exp Med 189, 371-80. 
544. Maurer, D., Fiebiger, E., Reininger, B., Ebner, C., Petzelbauer, P., Shi, G.P., Chapman, 
H.A., Stingl, G. (1998) Fc epsilon receptor I on dendritic cells delivers IgE-bound 
multivalent antigens into a cathepsin S-dependent pathway of MHC class II presentation. 
J Immunol 161, 2731-9. 
545. Bates, E.E., Dieu, M.C., Ravel, O., Zurawski, S.M., Patel, S., Bridon, J.M., Ait-Yahia, S., 
Vega, F., Jr., Banchereau, J., Lebecque, S. (1998) CD40L activation of dendritic cells 
down-regulates DORA, a novel member of the immunoglobulin superfamily. Mol 
Immunol 35, 513-24. 
546. Cella, M., Dohring, C., Samaridis, J., Dessing, M., Brockhaus, M., Lanzavecchia, A., 
Colonna, M. (1997) A novel inhibitory receptor (ILT3) expressed on monocytes, 
macrophages, and dendritic cells involved in antigen processing. J Exp Med 185, 1743-
51. 
547. Colaco, C.A. (1998) Towards a unified theory of immunity: dendritic cells, stress 
proteins and antigen capture. Cell Mol Biol (Noisy-le-grand) 44, 883-90. 
548. Hertz, C.J., Kiertscher, S.M., Godowski, P.J., Bouis, D.A., Norgard, M.V., Roth, M.D., 
Modlin, R.L. (2001) Microbial lipopeptides stimulate dendritic cell maturation via Toll-
like receptor 2. J Immunol 166, 2444-50. 
549. Mosialos, G., Birkenbach, M., Ayehunie, S., Matsumura, F., Pinkus, G.S., Kieff, E., 
Langhoff, E. (1996) Circulating human dendritic cells differentially express high levels 
of a 55-kd actin-bundling protein. Am J Pathol 148, 593-600. 
550. Nobes, C., Marsh, M. (2000) Dendritic cells: new roles for Cdc42 and Rac in antigen 
uptake? Curr Biol 10, R739-41. 
551. Garrett, W.S., Chen, L.M., Kroschewski, R., Ebersold, M., Turley, S., Trombetta, S., 
Galan, J.E., Mellman, I. (2000) Developmental control of endocytosis in dendritic cells 
by Cdc42. Cell 102, 325-34. 
552. West, M.A., Prescott, A.R., Eskelinen, E.L., Ridley, A.J., Watts, C. (2000) Rac is 
required for constitutive macropinocytosis by dendritic cells but does not control its 
downregulation. Curr Biol 10, 839-48. 
553. Bates, E.E., Ravel, O., Dieu, M.C., Ho, S., Guret, C., Bridon, J.M., Ait-Yahia, S., Briere, 
F., Caux, C., Banchereau, J., Lebecque, S. (1997) Identification and analysis of a novel 
 240 
member of the ubiquitin family expressed in dendritic cells and mature B cells. Eur J 
Immunol 27, 2471-7. 
 
 
